<!DOCTYPE html>
<html lang="en" class="grade-c">
<head>
    <title>Therapeutic advances in COVID-19 | Nature Reviews Nephrology</title>
    
        
<link rel="alternate" type="application/rss+xml" href="https://www.nature.com/nrneph.rss"/>


    
        

        <script id="save-data-connection-testing">
            function hasConnection() {
                return navigator.connection || navigator.mozConnection || navigator.webkitConnection || navigator.msConnection;
            }

            function createLink(src) {
                var preloadLink = document.createElement("link");
                preloadLink.rel = "preload";
                preloadLink.href = src;
                preloadLink.as = "font";
                preloadLink.type = "font/woff2";
                preloadLink.crossOrigin = "";
                document.head.insertBefore(preloadLink, document.head.firstChild);
            }

            var connectionDetail = {
                saveDataEnabled: false,
                slowConnection: false
            };

            var connection = hasConnection();
            if (connection) {
                connectionDetail.saveDataEnabled = connection.saveData;
                if (/\slow-2g|2g/.test(connection.effectiveType)) {
                    connectionDetail.slowConnection = true;
                }
            }

            if (!(connectionDetail.saveDataEnabled || connectionDetail.slowConnection)) {
                createLink("/static/fonts/HardingText-Regular-Web-cecd90984f.woff2");
            } else {
                document.documentElement.classList.add('save-data');
            }
        </script>
    

<link rel="preconnect" href="https://cmp.nature.com" crossorigin>

<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="applicable-device" content="pc,mobile">
<meta name="viewport" content="width=device-width,initial-scale=1.0,maximum-scale=5,user-scalable=yes">
<meta name="360-site-verification" content="5a2dc4ab3fcb9b0393241ffbbb490480" />

<script data-test="dataLayer">
    window.dataLayer = [{"content":{"category":{"contentType":"review article","legacy":{"webtrendsPrimaryArticleType":"reviews","webtrendsSubjectTerms":"end-stage-renal-disease;molecular-targeted-therapy;organ-transplantation;sars-cov-2","webtrendsContentCategory":null,"webtrendsContentCollection":"COVID-19 and nephrology","webtrendsContentGroup":"Nature Reviews Nephrology","webtrendsContentGroupType":null,"webtrendsContentSubGroup":"Review Article"}},"article":{"doi":"10.1038/s41581-022-00642-4"},"attributes":{"cms":null,"deliveryPlatform":"oscar","copyright":{"open":false,"legacy":{"webtrendsLicenceType":null}}},"contentInfo":{"authors":["Naoka Murakami","Robert Hayden","Thomas Hills","Hanny Al-Samkari","Jonathan Casey","Lorenzo Del Sorbo","Patrick R. Lawler","Meghan E. Sise","David E. Leaf"],"publishedAt":1665964800,"publishedAtString":"2022-10-17","title":"Therapeutic advances in COVID-19","legacy":null,"publishedAtTime":null,"documentType":"aplusplus"},"journal":{"pcode":"nrneph","title":"nature reviews nephrology","volume":"19","issue":"1"},"authorization":{"status":true},"features":[{"name":"furtherReadingSection","present":true}],"collection":{"id":"gggidgechf"}},"page":{"category":{"pageType":"article"},"attributes":{"template":"mosaic","featureFlags":[{"name":"nature-onwards-journey","active":false},{"name":"getftr-entitled","active":false},{"name":"paywall_recommendations","active":false}],"testGroup":null},"search":null},"privacy":{},"version":"1.0.0","product":null,"session":null,"user":null,"backHalfContent":true,"country":"TR","hasBody":true,"uneditedManuscript":false,"twitterId":["o3xnx","o43y9","o3ef7"],"baiduId":"d38bce82bcb44717ccc29a90c4b781ea","japan":false}];
    window.dataLayer.push({
        ga4MeasurementId: 'G-ERRNTNZ807',
        ga360TrackingId: 'UA-71668177-1',
        twitterId: ['3xnx', 'o43y9', 'o3ef7'],
        baiduId: 'd38bce82bcb44717ccc29a90c4b781ea',
        ga4ServerUrl: 'https://collect.nature.com',
        imprint: 'nature'
    });
</script>

<script>
    (function(w, d) {
        w.config = w.config || {};
        w.config.mustardcut = false;

        
        if (w.matchMedia && w.matchMedia('only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)').matches) {
            w.config.mustardcut = true;
            d.classList.add('js');
            d.classList.remove('grade-c');
            d.classList.remove('no-js');
        }
    })(window, document.documentElement);
</script>
 



     
    
    
        
    
    <style>@media only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark) {  .c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card--major .c-card__title,.c-card__title,.u-h2,.u-h3,h2,h3{-webkit-font-smoothing:antialiased;font-family:Harding,Palatino,serif;font-weight:700;letter-spacing:-.0117156rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card__title,.u-h3,h3{font-size:1.25rem;line-height:1.4rem}.c-reading-companion__figure-title,.u-h4,h4{-webkit-font-smoothing:antialiased;font-weight:700;line-height:1.4rem}html{text-size-adjust:100%;box-sizing:border-box;font-size:100%;height:100%;line-height:1.15;overflow-y:scroll}body{background:#eee;color:#222;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.125rem;line-height:1.76;margin:0;min-height:100%}details,main{display:block}h1{font-size:2em;margin:.67em 0}a,sup{vertical-align:baseline}a{background-color:transparent;color:#069;overflow-wrap:break-word;text-decoration:underline;text-decoration-skip-ink:auto;word-break:break-word}b{font-weight:bolder}sup{font-size:75%;line-height:0;position:relative;top:-.5em}img{border:0;height:auto;max-width:100%;vertical-align:middle}button,input,select{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=submit],button{-webkit-appearance:button}[type=checkbox]{box-sizing:border-box;padding:0}summary{display:list-item}[hidden]{display:none}button{border-radius:0;cursor:pointer;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}h1{-webkit-font-smoothing:antialiased;font-family:Harding,Palatino,serif;font-size:2rem;font-weight:700;letter-spacing:-.0390625rem;line-height:2.25rem}.c-card--major .c-card__title,.u-h2,.u-h3,h2{font-family:Harding,Palatino,serif;letter-spacing:-.0117156rem}.c-card--major .c-card__title,.u-h2,h2{-webkit-font-smoothing:antialiased;font-size:1.5rem;font-weight:700;line-height:1.6rem}.u-h3{font-size:1.25rem}.c-card__title,.c-reading-companion__figure-title,.u-h3,.u-h4,h4,h5,h6{-webkit-font-smoothing:antialiased;font-weight:700;line-height:1.4rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card__title,h3{font-family:Harding,Palatino,serif;font-size:1.25rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,h3{-webkit-font-smoothing:antialiased;font-weight:700;letter-spacing:-.0117156rem;line-height:1.4rem}.c-reading-companion__figure-title,.u-h4,h4{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.125rem;letter-spacing:-.0117156rem}button:focus{outline:3px solid #fece3e;will-change:transform}input+label{padding-left:.5em}nav ol,nav ul{list-style:none none}p:empty{display:none}.sans-serif{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.article-page{background:#fff}.c-article-header{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;margin-bottom:40px}.c-article-identifiers{color:#6f6f6f;display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3;list-style:none;margin:0 0 8px;padding:0}.c-article-identifiers__item{border-right:1px solid #6f6f6f;list-style:none;margin-right:8px;padding-right:8px}.c-article-identifiers__item:last-child{border-right:0;margin-right:0;padding-right:0}.c-article-title{font-size:1.5rem;line-height:1.25;margin:0 0 16px}@media only screen and (min-width:768px){.c-article-title{font-size:1.875rem;line-height:1.2}}.c-article-author-list{display:inline;font-size:1rem;list-style:none;margin:0 8px 0 0;padding:0;width:100%}.c-article-author-list__item{display:inline;padding-right:0}.c-article-author-list svg{margin-left:4px}.c-article-author-list__show-more{display:none;margin-right:4px}.c-article-author-list__button,.js .c-article-author-list__item--hide,.js .c-article-author-list__show-more{display:none}.js .c-article-author-list--long .c-article-author-list__show-more,.js .c-article-author-list--long+.c-article-author-list__button{display:inline}@media only screen and (max-width:539px){.js .c-article-author-list__item--hide-small-screen{display:none}.js .c-article-author-list--short .c-article-author-list__show-more,.js .c-article-author-list--short+.c-article-author-list__button{display:inline}}#uptodate-client,.js .c-article-author-list--expanded .c-article-author-list__show-more{display:none!important}.js .c-article-author-list--expanded .c-article-author-list__item--hide-small-screen{display:inline!important}.c-article-author-list__button,.c-button-author-list{background:#ebf1f5;border:4px solid #ebf1f5;border-radius:20px;color:#666;font-size:.875rem;line-height:1.4;padding:2px 11px 2px 8px;text-decoration:none}.c-article-author-list__button svg,.c-button-author-list svg{margin:1px 4px 0 0}.c-article-author-list__button:hover,.c-button-author-list:hover{background:#069;border-color:transparent;color:#fff}.c-article-info-details{font-size:1rem;margin-bottom:8px;margin-top:16px}.c-article-info-details__cite-as{border-left:1px solid #6f6f6f;margin-left:8px;padding-left:8px}.c-article-metrics-bar{display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3}.c-article-metrics-bar__wrapper{margin:16px 0}.c-article-metrics-bar__item{align-items:baseline;border-right:1px solid #6f6f6f;margin-right:8px}.c-article-metrics-bar__item:last-child{border-right:0}.c-article-metrics-bar__count{font-weight:700;margin:0}.c-article-metrics-bar__label{color:#626262;font-style:normal;font-weight:400;margin:0 10px 0 5px}.c-article-metrics-bar__details{margin:0}.c-article-main-column{font-family:Harding,Palatino,serif;margin-right:8.6%;width:60.2%}@media only screen and (max-width:1023px){.c-article-main-column{margin-right:0;width:100%}}.c-article-extras{float:left;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;width:31.2%}@media only screen and (max-width:1023px){.c-article-extras{display:none}}.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{border-bottom:2px solid #d5d5d5;font-size:1.25rem;margin:0;padding-bottom:8px}@media only screen and (min-width:768px){.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{font-size:1.5rem;line-height:1.24}}.c-article-associated-content__container .c-article-associated-content__title{margin-bottom:8px}.c-article-body p{margin-bottom:24px;margin-top:0}.c-article-section{clear:both}.c-article-section__content{margin-bottom:40px;padding-top:8px}@media only screen and (max-width:1023px){.c-article-section__content{padding-left:0}}.c-article-authors-search{margin-bottom:24px;margin-top:0}.c-article-authors-search__item,.c-article-authors-search__title{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.c-article-authors-search__title{color:#626262;font-size:1.05rem;font-weight:700;margin:0;padding:0}.c-article-authors-search__item{font-size:1rem}.c-article-authors-search__text{margin:0}.c-article-license__badge,c-card__section{margin-top:8px}.c-code-block{border:1px solid #eee;font-family:monospace;margin:0 0 24px;padding:20px}.c-code-block__heading{font-weight:400;margin-bottom:16px}.c-code-block__line{display:block;overflow-wrap:break-word;white-space:pre-wrap}.c-article-share-box__no-sharelink-info{font-size:.813rem;font-weight:700;margin-bottom:24px;padding-top:4px}.c-article-share-box__only-read-input{border:1px solid #d5d5d5;box-sizing:content-box;display:inline-block;font-size:.875rem;font-weight:700;height:24px;margin-bottom:8px;padding:8px 10px}.c-article-share-box__button--link-like{background-color:transparent;border:0;color:#069;cursor:pointer;font-size:.875rem;margin-bottom:8px;margin-left:10px}.c-article-editorial-summary__container{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem}.c-article-editorial-summary__container .c-article-editorial-summary__content p:last-child{margin-bottom:0}.c-article-editorial-summary__container .c-article-editorial-summary__content--less{max-height:9.5rem;overflow:hidden}.c-article-editorial-summary__container .c-article-editorial-summary__button{background-color:#fff;border:0;color:#069;font-size:.875rem;margin-bottom:16px}.c-article-editorial-summary__container .c-article-editorial-summary__button.active,.c-article-editorial-summary__container .c-article-editorial-summary__button.hover,.c-article-editorial-summary__container .c-article-editorial-summary__button:active,.c-article-editorial-summary__container .c-article-editorial-summary__button:hover{text-decoration:underline;text-decoration-skip-ink:auto}.c-article-associated-content__container .c-article-associated-content__collection-label{font-size:.875rem;line-height:1.4}.c-article-associated-content__container .c-article-associated-content__collection-title{line-height:1.3}.c-context-bar{box-shadow:0 0 10px 0 rgba(51,51,51,.2);position:relative;width:100%}.c-context-bar__title{display:none}.c-reading-companion{clear:both;min-height:389px}.c-reading-companion__sticky{max-width:389px}.c-reading-companion__scroll-pane{margin:0;min-height:200px;overflow:hidden auto}.c-reading-companion__tabs{display:flex;flex-flow:row nowrap;font-size:1rem;list-style:none;margin:0 0 8px;padding:0}.c-reading-companion__tabs>li{flex-grow:1}.c-reading-companion__tab{background-color:#eee;border:1px solid #d5d5d5;border-image:initial;border-left-width:0;color:#069;font-size:1rem;padding:8px 8px 8px 15px;text-align:left;width:100%}.c-reading-companion__tabs li:first-child .c-reading-companion__tab{border-left-width:1px}.c-reading-companion__tab--active{background-color:#fff;border-bottom:1px solid #fff;color:#222;font-weight:700}.c-reading-companion__sections-list{list-style:none;padding:0}.c-reading-companion__figures-list,.c-reading-companion__references-list{list-style:none;min-height:389px;padding:0}.c-reading-companion__references-list--numeric{list-style:decimal inside}.c-reading-companion__sections-list{margin:0 0 8px;min-height:50px}.c-reading-companion__section-item{font-size:1rem;padding:0}.c-reading-companion__section-item a{display:block;line-height:1.5;overflow:hidden;padding:8px 0 8px 16px;text-overflow:ellipsis;white-space:nowrap}.c-reading-companion__figure-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:16px 8px 16px 0}.c-reading-companion__figure-item:first-child{border-top:none;padding-top:8px}.c-reading-companion__reference-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:8px 8px 8px 16px}.c-reading-companion__reference-item:first-child{border-top:none}.c-reading-companion__reference-item a{word-break:break-word}.c-reading-companion__reference-citation{display:inline}.c-reading-companion__reference-links{font-size:.813rem;font-weight:700;list-style:none;margin:8px 0 0;padding:0;text-align:right}.c-reading-companion__reference-links>a{display:inline-block;padding-left:8px}.c-reading-companion__reference-links>a:first-child{display:inline-block;padding-left:0}.c-reading-companion__figure-title{display:block;margin:0 0 8px}.c-reading-companion__figure-links{display:flex;justify-content:space-between;margin:8px 0 0}.c-reading-companion__figure-links>a{align-items:center;display:flex}.c-reading-companion__figure-full-link svg{height:.8em;margin-left:2px}.c-reading-companion__panel{border-top:none;display:none;margin-top:0;padding-top:0}.c-cod,.c-reading-companion__panel--active{display:block}.c-cod{font-size:1rem;width:100%}.c-cod__form{background:#ebf0f3}.c-cod__prompt{font-size:1.125rem;line-height:1.3;margin:0 0 24px}.c-cod__label{display:block;margin:0 0 4px}.c-cod__row{display:flex;margin:0 0 16px}.c-cod__row:last-child{margin:0}.c-cod__input{border:1px solid #d5d5d5;border-radius:2px;flex-basis:75%;flex-shrink:0;margin:0;padding:13px}.c-cod__input--submit{background-color:#069;border:1px solid #069;color:#fff;flex-shrink:1;margin-left:8px;transition:background-color .2s ease-out 0s,color .2s ease-out 0s}.c-cod__input--submit-single{flex-basis:100%;flex-shrink:0;margin:0}.c-cod__input--submit:focus,.c-cod__input--submit:hover{background-color:#fff;color:#069}.c-pdf-download__link .u-icon{padding-top:2px}.c-pdf-download{display:flex;margin-bottom:16px;max-height:48px}@media only screen and (min-width:540px){.c-pdf-download{max-height:none}}@media only screen and (min-width:1024px){.c-pdf-download{max-height:48px}}.c-pdf-download__link{display:flex;flex:1 1 0%}.c-pdf-download__link:hover{text-decoration:none}.c-pdf-download__text{padding-right:4px}@media only screen and (max-width:539px){.c-pdf-download__text{text-transform:capitalize}}@media only screen and (min-width:540px){.c-pdf-download__text{padding-right:8px}}.c-context-bar--sticky .c-pdf-download{display:block;margin-bottom:0;white-space:nowrap}@media only screen and (max-width:539px){.c-pdf-download .u-sticky-visually-hidden{clip:rect(0,0,0,0);border:0;height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}}.c-pdf-container{display:flex;justify-content:flex-end}@media only screen and (max-width:539px){.c-pdf-container .c-pdf-download{display:flex;flex-basis:100%}}.c-pdf-container .c-pdf-download+.c-pdf-download{margin-left:16px}.c-article-extras .c-pdf-container .c-pdf-download{width:100%}.c-article-extras .c-pdf-container .c-pdf-download+.c-pdf-download{margin-left:0}@media only screen and (min-width:540px){.c-context-bar--sticky .c-pdf-download__link{align-items:center;flex:1 1 183px}}@media only screen and (max-width:320px){.c-context-bar--sticky .c-pdf-download__link{padding:16px}}.article-page--commercial .c-article-main-column .c-pdf-button__container .c-pdf-download{display:none}@media only screen and (max-width:1023px){.article-page--commercial .c-article-main-column .c-pdf-button__container .c-pdf-download{display:block}}.c-status-message--success{border-bottom:2px solid #00b8b0;justify-content:center;margin-bottom:16px;padding-bottom:8px}.c-recommendations-list__item .c-card{flex-basis:100%}.c-recommendations-list__item .c-card__image{align-items:baseline;flex:1 1 40%;margin:0 0 0 16px;max-width:150px}.c-recommendations-list__item .c-card__image img{border:1px solid #cedbe0;height:auto;min-height:0;position:static}@media only screen and (max-width:1023px){.c-recommendations-list__item .c-card__image{display:none}}.c-card__layout{display:flex;flex:1 1 auto;justify-content:space-between}.c-card__title-recommendation{-webkit-box-orient:vertical;-webkit-line-clamp:4;display:-webkit-box;font-size:1rem;font-weight:700;line-height:1.4;margin:0 0 8px;max-height:5.6em;overflow:hidden!important;text-overflow:ellipsis}.c-card__title-recommendation .c-card__link{color:inherit}.c-card__title-recommendation .c-card__link:hover{text-decoration:underline}.c-card__title-recommendation .MathJax_Display{display:inline!important}.c-card__link:not(.c-card__link--no-block-link):before{z-index:1}.c-article-metrics__heading a,.c-article-metrics__posts .c-card__title a,.c-article-recommendations-card__link{color:inherit}.c-recommendations-column-switch .c-meta{margin-top:auto}.c-article-recommendations-card__meta-type,.c-meta .c-meta__item:first-child{font-weight:700}.c-article-body .c-article-recommendations-card__authors{display:none;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;line-height:1.5;margin:0 0 8px}@media only screen and (max-width:539px){.c-article-body .c-article-recommendations-card__authors{display:block;margin:0}}.c-article-metrics__posts .c-card__title{font-size:1.05rem}.c-article-metrics__posts .c-card__title+span{color:#6f6f6f;font-size:1rem}p{overflow-wrap:break-word;word-break:break-word}.c-ad{text-align:center}@media only screen and (min-width:320px){.c-ad{padding:8px}}.c-ad--728x90{background-color:#ccc;display:none}.c-ad--728x90 .c-ad__inner{min-height:calc(1.5em + 94px)}@media only screen and (min-width:768px){.js .c-ad--728x90{display:none}}.c-ad__label{color:#333;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;font-weight:400;line-height:1.5;margin-bottom:4px}.c-author-list{color:#6f6f6f;font-family:inherit;font-size:1rem;line-height:inherit;list-style:none;margin:0;padding:0}.c-author-list>li,.c-breadcrumbs>li,.c-footer__links>li,.js .c-author-list,.u-list-comma-separated>li,.u-list-inline>li{display:inline}.c-author-list>li:not(:first-child):not(:last-child):before{content:", "}.c-author-list>li:not(:only-child):last-child:before{content:" & "}.c-author-list--compact{font-size:.875rem;line-height:1.4}.c-author-list--truncated>li:not(:only-child):last-child:before{content:" ... "}.js .c-author-list__hide{display:none;visibility:hidden}.js .c-author-list__hide:first-child+*{margin-block-start:0}.c-meta{color:inherit;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;line-height:1.4;list-style:none;margin:0;padding:0}.c-meta--large{font-size:1rem}.c-meta--large .c-meta__item{margin-bottom:8px}.c-meta__item{display:inline-block;margin-bottom:4px}.c-meta__item:not(:last-child){border-right:1px solid #d5d5d5;margin-right:4px;padding-right:4px}@media only screen and (max-width:539px){.c-meta__item--block-sm-max{display:block}.c-meta__item--block-sm-max:not(:last-child){border-right:none;margin-right:0;padding-right:0}}@media only screen and (min-width:1024px){.c-meta__item--block-at-lg{display:block}.c-meta__item--block-at-lg:not(:last-child){border-right:none;margin-right:0;padding-right:0}}.c-meta__type{font-weight:700;text-transform:none}.c-skip-link{background:#069;bottom:auto;color:#fff;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;padding:8px;position:absolute;text-align:center;transform:translateY(-100%);z-index:9999}@media (prefers-reduced-motion:reduce){.c-skip-link{transition:top .3s ease-in-out 0s}}@media print{.c-skip-link{display:none}}.c-skip-link:link{color:#fff}.c-status-message{align-items:center;box-sizing:border-box;display:flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;position:relative;width:100%}.c-card__summary>p:last-child,.c-status-message :last-child{margin-bottom:0}.c-status-message--boxed{background-color:#fff;border:1px solid #eee;border-radius:2px;line-height:1.4;padding:16px}.c-status-message__heading{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;font-weight:700}.c-status-message__icon{fill:currentcolor;display:inline-block;flex:0 0 auto;height:1.5em;margin-right:8px;transform:translate(0);vertical-align:text-top;width:1.5em}.c-status-message__icon--top{align-self:flex-start}.c-status-message--info .c-status-message__icon{color:#003f8d}.c-status-message--boxed.c-status-message--info{border-bottom:4px solid #003f8d}.c-status-message--error .c-status-message__icon{color:#c40606}.c-status-message--boxed.c-status-message--error{border-bottom:4px solid #c40606}.c-status-message--success .c-status-message__icon{color:#00b8b0}.c-status-message--boxed.c-status-message--success{border-bottom:4px solid #00b8b0}.c-status-message--warning .c-status-message__icon{color:#edbc53}.c-status-message--boxed.c-status-message--warning{border-bottom:4px solid #edbc53}.c-breadcrumbs{color:#000;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;list-style:none;margin:0;padding:0}.c-breadcrumbs__link{color:#666}svg.c-breadcrumbs__chevron{fill:#888;height:10px;margin:4px 4px 0;width:10px}@media only screen and (max-width:539px){.c-breadcrumbs .c-breadcrumbs__item{display:none}.c-breadcrumbs .c-breadcrumbs__item:last-child,.c-breadcrumbs .c-breadcrumbs__item:nth-last-child(2){display:inline}}.c-card{background-color:transparent;border:0;box-shadow:none;display:flex;flex-direction:column;font-size:14px;min-width:0;overflow:hidden;padding:0;position:relative}.c-card--no-shape{background:0 0;border:0;box-shadow:none}.c-card__image{display:flex;justify-content:center;overflow:hidden;padding-bottom:56.25%;position:relative}@supports (aspect-ratio:1/1){.c-card__image{padding-bottom:0}}.c-card__image img{left:0;min-height:100%;min-width:100%;position:absolute}@supports ((-o-object-fit:cover) or (object-fit:cover)){.c-card__image img{height:100%;object-fit:cover;width:100%}}.c-card__body{flex:1 1 auto;padding:16px}.c-card--no-shape .c-card__body{padding:0}.c-card--no-shape .c-card__body:not(:first-child){padding-top:16px}.c-card__title{letter-spacing:-.01875rem;margin-bottom:8px;margin-top:0}[lang=de] .c-card__title{hyphens:auto}.c-card__summary{line-height:1.4}.c-card__summary>p{margin-bottom:5px}.c-card__summary a{text-decoration:underline}.c-card__link:not(.c-card__link--no-block-link):before{bottom:0;content:"";left:0;position:absolute;right:0;top:0}.c-card--flush .c-card__body{padding:0}.c-card--major{font-size:1rem}.c-card--dark{background-color:#29303c;border-width:0;color:#e3e4e5}.c-card--dark .c-card__title{color:#fff}.c-card--dark .c-card__link,.c-card--dark .c-card__summary a{color:inherit}.c-header{background-color:#fff;border-bottom:5px solid #000;font-size:1rem;line-height:1.4;margin-bottom:16px}.c-header__row{padding:0;position:relative}.c-header__row:not(:last-child){border-bottom:1px solid #eee}.c-header__split{align-items:center;display:flex;justify-content:space-between}.c-header__logo-container{flex:1 1 0px;line-height:0;margin:8px 24px 8px 0}.c-header__logo{transform:translateZ(0)}.c-header__logo img{max-height:32px}.c-header__container{margin:0 auto;max-width:1280px}.c-header__menu{align-items:center;display:flex;flex:0 1 auto;flex-wrap:wrap;font-weight:700;gap:8px 8px;line-height:1.4;list-style:none;margin:0 -8px;padding:0}@media print{.c-header__menu{display:none}}@media only screen and (max-width:1023px){.c-header__menu--hide-lg-max{display:none;visibility:hidden}}.c-header__menu--global{font-weight:400;justify-content:flex-end}.c-header__menu--global svg{display:none;visibility:hidden}.c-header__menu--global svg:first-child+*{margin-block-start:0}@media only screen and (min-width:540px){.c-header__menu--global svg{display:block;visibility:visible}}.c-header__menu--journal{font-size:.875rem;margin:8px 0 8px -8px}@media only screen and (min-width:540px){.c-header__menu--journal{flex-wrap:nowrap;font-size:1rem}}.c-header__item{padding-bottom:0;padding-top:0;position:static}.c-header__item--pipe{border-left:2px solid #eee;padding-left:8px}.c-header__item--padding{padding-bottom:8px;padding-top:8px}@media only screen and (min-width:540px){.c-header__item--dropdown-menu{position:relative}}@media only screen and (min-width:1024px){.c-header__item--hide-lg{display:none;visibility:hidden}}@media only screen and (max-width:767px){.c-header__item--hide-md-max{display:none;visibility:hidden}.c-header__item--hide-md-max:first-child+*{margin-block-start:0}}.c-header__link{align-items:center;color:inherit;display:inline-flex;gap:4px 4px;padding:8px;white-space:nowrap}.c-header__link svg{transition-duration:.2s}.c-header__show-text{display:none;visibility:hidden}.has-tethered .c-header__heading--js-hide:first-child+*{margin-block-start:0}@media only screen and (min-width:540px){.c-header__show-text{display:inline;visibility:visible}}.c-header__dropdown{background-color:#000;border-bottom:1px solid #2f2f2f;color:#eee;font-size:.875rem;line-height:1.2;padding:16px 0}@media print{.c-header__dropdown{display:none}}.c-header__heading{display:inline-block;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.25rem;font-weight:400;line-height:1.4;margin-bottom:8px}.c-header__heading--keyline{border-top:1px solid;border-color:#2f2f2f;margin-top:16px;padding-top:16px;width:100%}.c-header__list{display:flex;flex-wrap:wrap;gap:0 16px;list-style:none;margin:0 -8px}.c-header__flush{margin:0 -8px}.c-header__visually-hidden{clip:rect(0,0,0,0);border:0;height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.c-header__search-form{margin-bottom:8px}.c-header__search-layout{display:flex;flex-wrap:wrap;gap:16px 16px}.c-header__search-layout>:first-child{flex:999 1 auto}.c-header__search-layout>*{flex:1 1 auto}.c-header__search-layout--max-width{max-width:720px}.c-header__search-button{align-items:center;background-color:transparent;background-image:none;border:1px solid #fff;border-radius:2px;color:#fff;cursor:pointer;display:flex;font-family:sans-serif;font-size:1rem;justify-content:center;line-height:1.15;margin:0;padding:8px 16px;position:relative;text-decoration:none;transition:all .25s ease 0s,color .25s ease 0s,border-color .25s ease 0s;width:100%}.u-button svg,.u-button--primary svg{fill:currentcolor}.c-header__input,.c-header__select{border:1px solid;border-radius:3px;box-sizing:border-box;font-size:1rem;padding:8px 16px;width:100%}.c-header__select{-webkit-appearance:none;background-image:url("data:image/svg+xml,%3Csvg height='16' viewBox='0 0 16 16' width='16' xmlns='http://www.w3.org/2000/svg'%3E%3Cpath d='m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z' fill='%23333' fill-rule='evenodd' transform='matrix(0 1 -1 0 11 3)'/%3E%3C/svg%3E");background-position:right .7em top 50%;background-repeat:no-repeat;background-size:1em;box-shadow:0 1px 0 1px rgba(0,0,0,.04);display:block;margin:0;max-width:100%;min-width:150px}@media only screen and (min-width:540px){.c-header__menu--journal .c-header__item--dropdown-menu:last-child .c-header__dropdown.has-tethered{left:auto;right:0}}@media only screen and (min-width:768px){.c-header__menu--journal .c-header__item--dropdown-menu:last-child .c-header__dropdown.has-tethered{left:0;right:auto}}.c-header__dropdown.has-tethered{border-bottom:0;border-radius:0 0 2px 2px;left:0;position:absolute;top:100%;transform:translateY(5px);width:100%;z-index:1}@media only screen and (min-width:540px){.c-header__dropdown.has-tethered{transform:translateY(8px);width:auto}}@media only screen and (min-width:768px){.c-header__dropdown.has-tethered{min-width:225px}}.c-header__dropdown--full-width.has-tethered{padding:32px 0 24px;transform:none;width:100%}.has-tethered .c-header__heading--js-hide{display:none;visibility:hidden}.has-tethered .c-header__list--js-stack{flex-direction:column}.has-tethered .c-header__item--keyline,.has-tethered .c-header__list~.c-header__list .c-header__item:first-child{border-top:1px solid #d5d5d5;margin-top:8px;padding-top:8px}.c-header__item--snid-account-widget{display:flex}.c-header__container{padding:0 4px}.c-header__list{padding:0 12px}.c-header__menu .c-header__link{font-size:14px}.c-header__item--snid-account-widget .c-header__link{padding:8px}.c-header__menu--journal{margin-left:0}@media only screen and (min-width:540px){.c-header__container{padding:0 16px}.c-header__menu--journal{margin-left:-8px}.c-header__menu .c-header__link{font-size:16px}.c-header__link--search{gap:13px 13px}}.u-button{align-items:center;background-color:transparent;background-image:none;border:1px solid #069;border-radius:2px;color:#069;cursor:pointer;display:inline-flex;font-family:sans-serif;font-size:1rem;justify-content:center;line-height:1.3;margin:0;padding:8px;position:relative;text-decoration:none;transition:all .25s ease 0s,color .25s ease 0s,border-color .25s ease 0s;width:auto}.u-button--primary{background-color:#069;background-image:none;border:1px solid #069;color:#fff}.u-button--full-width{display:flex;width:100%}.u-display-none{display:none}.js .u-js-hide,.u-hide{display:none;visibility:hidden}.u-hide:first-child+*{margin-block-start:0}.u-visually-hidden{clip:rect(0,0,0,0);border:0;height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}@media print{.u-hide-print{display:none}}@media only screen and (min-width:1024px){.u-hide-at-lg{display:none;visibility:hidden}.u-hide-at-lg:first-child+*{margin-block-start:0}}.u-clearfix:after,.u-clearfix:before{content:"";display:table}.u-clearfix:after{clear:both}.u-color-open-access{color:#b74616}.u-float-left{float:left}.u-icon{fill:currentcolor;display:inline-block;height:1em;transform:translate(0);vertical-align:text-top;width:1em}.u-full-height{height:100%}.u-list-reset{list-style:none;margin:0;padding:0}.u-sans-serif{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.u-container{margin:0 auto;max-width:1280px;padding:0 16px}.u-justify-content-space-between{justify-content:space-between}.u-mt-32{margin-top:32px}.u-mb-8{margin-bottom:8px}.u-mb-16{margin-bottom:16px}.u-mb-24{margin-bottom:24px}.u-mb-32{margin-bottom:32px}.c-nature-box svg+.c-article__button-text,.u-ml-8{margin-left:8px}.u-pa-16{padding:16px}html *,html :after,html :before{box-sizing:inherit}.c-article-section__title,.c-article-title{font-weight:700}.c-card__title{line-height:1.4em}.c-article__button{background-color:#069;border:1px solid #069;border-radius:2px;color:#fff;display:flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;line-height:1.4;margin-bottom:16px;padding:13px;transition:background-color .2s ease-out 0s,color .2s ease-out 0s}.c-article__button,.c-article__button:hover{text-decoration:none}.c-article__button--inverted,.c-article__button:hover{background-color:#fff;color:#069}.c-article__button--inverted:hover{background-color:#069;color:#fff}.c-header__link{text-decoration:inherit}.grade-c-hide{display:block}.u-lazy-ad-wrapper{background-color:#ccc;display:none;min-height:137px}@media only screen and (min-width:768px){.u-lazy-ad-wrapper{display:block}}.c-nature-box{background-color:#fff;border:1px solid #d5d5d5;border-radius:2px;box-shadow:0 0 5px 0 rgba(51,51,51,.1);line-height:1.3;margin-bottom:24px;padding:16px 16px 3px}.c-nature-box__text{font-size:1rem;margin-bottom:16px}.c-nature-box .c-pdf-download{margin-bottom:16px!important}.c-nature-box--version{background-color:#eee}.c-nature-box__wrapper{transform:translateZ(0)}.c-nature-box__wrapper--placeholder{min-height:165px}.c-pdf-download__link{padding:13px 24px} } </style>




    
        <link data-test="critical-css-handler" data-inline-css-source="critical-css" rel="stylesheet" href="/static/css/enhanced-article-nature-branded-f53307b6d2.css" media="print" onload="this.media='only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)';this.onload=null">
    
    <noscript>
        <link rel="stylesheet" type="text/css" href="/static/css/enhanced-article-nature-branded-f53307b6d2.css" media="only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)">
    </noscript>

<link rel="stylesheet" type="text/css" href="/static/css/article-print-122346e276.css" media="print">
    



<link rel="apple-touch-icon" sizes="180x180" href=/static/images/favicons/nature/apple-touch-icon-f39cb19454.png>
<link rel="icon" type="image/png" sizes="32x32" href=/static/images/favicons/nature/favicon-32x32-3fe59ece92.png>
<link rel="icon" type="image/png" sizes="16x16" href=/static/images/favicons/nature/favicon-16x16-951651ab72.png>
<link rel="manifest" href=/static/manifest.json crossorigin="use-credentials">
<link rel="mask-icon" href=/static/images/favicons/nature/safari-pinned-tab-69bff48fe6.svg color="#000000">
<link rel="shortcut icon" href=/static/images/favicons/nature/favicon.ico>
<meta name="msapplication-TileColor" content="#000000">
<meta name="msapplication-config" content=/static/browserconfig.xml>
<meta name="theme-color" content="#000000">
<meta name="application-name" content="Nature">


<script>
    (function () {
        if ( typeof window.CustomEvent === "function" ) return false;
        function CustomEvent ( event, params ) {
            params = params || { bubbles: false, cancelable: false, detail: null };
            var evt = document.createEvent( 'CustomEvent' );
            evt.initCustomEvent( event, params.bubbles, params.cancelable, params.detail );
            return evt;
        }

        CustomEvent.prototype = window.Event.prototype;

        window.CustomEvent = CustomEvent;
    })();
</script>



<!-- Google Tag Manager -->
<script data-test="gtm-head">
    window.initGTM = function() {
        if (window.config.mustardcut) {
            (function (w, d, s, l, i) {
                w[l] = w[l] || [];
                w[l].push({'gtm.start': new Date().getTime(), event: 'gtm.js'});
                var f = d.getElementsByTagName(s)[0],
                        j = d.createElement(s),
                        dl = l != 'dataLayer' ? '&l=' + l : '';
                j.async = true;
                j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl;
                f.parentNode.insertBefore(j, f);
            })(window, document, 'script', 'dataLayer', 'GTM-MRVXSHQ');
        }
    }
</script>
<!-- End Google Tag Manager -->

    <script>
    (function(w,d,t) {
        function cc() {
            var h = w.location.hostname;
            if (h.indexOf('preview-www.nature.com') > -1) return;

            var e = d.createElement(t),
                    s = d.getElementsByTagName(t)[0];

            if (h.indexOf('nature.com') > -1) {
                if (h.indexOf('test-www.nature.com') > -1) {
                    e.src = 'https://cmp.nature.com/production_live/en/consent-bundle-8-54.js';
                    e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')");
                } else {
                    e.src = 'https://cmp.nature.com/production_live/en/consent-bundle-8-54.js';
                    e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')");
                }
            } else {
                e.src = '/static/js/cookie-consent-es5-bundle-26e142e9c6.js';
                e.setAttribute('data-consent', h);
            }
            s.insertAdjacentElement('afterend', e);
        }

        cc();
    })(window,document,'script');
</script>


<script id="js-position0">
    (function(w, d) {
        w.idpVerifyPrefix = 'https://verify.nature.com';
        w.ra21Host = 'https://wayf.springernature.com';
        var moduleSupport = (function() {
            return 'noModule' in d.createElement('script');
        })();

        if (w.config.mustardcut === true) {
            w.loader = {
                index: 0,
                registered: [],
                scripts: [
                    
                        {src: '/static/js/global-article-es6-bundle-f5393c8c3e.js', test: 'global-article-js', module: true},
                        {src: '/static/js/global-article-es5-bundle-ef62ceaff5.js', test: 'global-article-js', nomodule: true},
                        {src: '/static/js/shared-es6-bundle-e677fdfe83.js', test: 'shared-js', module: true},
                        {src: '/static/js/shared-es5-bundle-cf3fb71324.js', test: 'shared-js', nomodule: true},
                        {src: '/static/js/header-150-es6-bundle-5bb959eaa1.js', test: 'header-150-js', module: true},
                        {src: '/static/js/header-150-es5-bundle-1fe07484e5.js', test: 'header-150-js', nomodule: true}
                    
                ].filter(function (s) {
                    if (s.src === null) return false;
                    if (moduleSupport && s.nomodule) return false;
                    return !(!moduleSupport && s.module);
                }),

                register: function (value) {
                    this.registered.push(value);
                },

                ready: function () {
                    if (this.registered.length === this.scripts.length) {
                        this.registered.forEach(function (fn) {
                            if (typeof fn === 'function') {
                                setTimeout(fn, 0); 
                            }
                        });
                        this.ready = function () {};
                    }
                },

                insert: function (s) {
                    var t = d.getElementById('js-position' + this.index);
                    if (t && t.insertAdjacentElement) {
                        t.insertAdjacentElement('afterend', s);
                    } else {
                        d.head.appendChild(s);
                    }
                    ++this.index;
                },

                createScript: function (script, beforeLoad) {
                    var s = d.createElement('script');
                    s.id = 'js-position' + (this.index + 1);
                    s.setAttribute('data-test', script.test);
                    if (beforeLoad) {
                        s.defer = 'defer';
                        s.onload = function () {
                            if (script.noinit) {
                                loader.register(true);
                            }
                            if (d.readyState === 'interactive' || d.readyState === 'complete') {
                                loader.ready();
                            }
                        };
                    } else {
                        s.async = 'async';
                    }
                    s.src = script.src;
                    return s;
                },

                init: function () {
                    this.scripts.forEach(function (s) {
                        loader.insert(loader.createScript(s, true));
                    });

                    d.addEventListener('DOMContentLoaded', function () {
                        loader.ready();
                        var conditionalScripts;
                        
                            conditionalScripts = [
                                {match: 'div[data-pan-container]', src: '/static/js/pan-zoom-es6-bundle-464a2af269.js', test: 'pan-zoom-js',  module: true },
                                {match: 'div[data-pan-container]', src: '/static/js/pan-zoom-es5-bundle-8fc1a30809.js', test: 'pan-zoom-js',  nomodule: true },
                                {match: 'math,span.mathjax-tex', src: '/static/js/math-es6-bundle-d8f48a7381.js', test: 'math-js', module: true},
                                {match: 'math,span.mathjax-tex', src: '/static/js/math-es5-bundle-b4dea43f0b.js', test: 'math-js', nomodule: true}
                            ];
                        

                        if (conditionalScripts) {
                            conditionalScripts.filter(function (script) {
                                return !!document.querySelector(script.match) && !((moduleSupport && script.nomodule) || (!moduleSupport && script.module));
                            }).forEach(function (script) {
                                loader.insert(loader.createScript(script));
                            });
                        }
                    }, false);
                }
            };
            loader.init();
        }
    })(window, document);
</script>










<meta name="robots" content="noarchive">
<meta name="access" content="Yes">


<link rel="search" href="https://www.nature.com/search">
<link rel="search" href="https://www.nature.com/opensearch/opensearch.xml" type="application/opensearchdescription+xml" title="nature.com">
<link rel="search" href="https://www.nature.com/opensearch/request" type="application/sru+xml" title="nature.com">





    
    <script type="application/ld+json">{"mainEntity":{"headline":"Therapeutic advances in COVID-19","description":"Over 2 years have passed since the start of the COVID-19 pandemic, which has claimed millions of lives. Unlike the early days of the pandemic, when management decisions were based on extrapolations from in vitro data, case reports and case series, clinicians are now equipped with an armamentarium of therapies based on high-quality evidence. These treatments are spread across seven main therapeutic categories: anti-inflammatory agents, antivirals, antithrombotics, therapies for acute hypoxaemic respiratory failure, anti-SARS-CoV-2 (neutralizing) antibody therapies, modulators of the renin–angiotensin–aldosterone system and vitamins. For each of these treatments, the patient population characteristics and clinical settings in which they were studied are important considerations. Although few direct comparisons have been performed, the evidence base and magnitude of benefit for anti-inflammatory and antiviral agents clearly outweigh those of other therapeutic approaches such as vitamins. The emergence of novel variants has further complicated the interpretation of much of the available evidence, particularly for antibody therapies. Importantly, patients with acute and chronic kidney disease were under-represented in many of the COVID-19 clinical trials, and outcomes in this population might differ from those reported in the general population. Here, we examine the clinical evidence for these therapies through a kidney medicine lens. The COVID-19 pandemic was met with large-scale efforts to assess novel and repurposed therapeutic interventions that could reduce patient morbidity and mortality. Here, the authors discuss the different types of therapies available to treat COVID-19, including their relevance to patients with kidney failure and kidney transplant recipients. \n                \n                  \n                \n               \n                \n                  \n                \n                \n                  \n                \n                \n                  \n                \n              ","datePublished":"2022-10-17T00:00:00Z","dateModified":"2023-02-06T00:00:00Z","pageStart":"38","pageEnd":"52","sameAs":"https://doi.org/10.1038/s41581-022-00642-4","keywords":["End-stage renal disease","Molecularly targeted therapy","Organ transplantation","SARS-CoV-2","Medicine/Public Health","general","Nephrology"],"image":["https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41581-022-00642-4/MediaObjects/41581_2022_642_Fig1_HTML.png","https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41581-022-00642-4/MediaObjects/41581_2022_642_Fig2_HTML.png","https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41581-022-00642-4/MediaObjects/41581_2022_642_Fig3_HTML.png"],"isPartOf":{"name":"Nature Reviews Nephrology","issn":["1759-507X","1759-5061"],"volumeNumber":"19","@type":["Periodical","PublicationVolume"]},"publisher":{"name":"Nature Publishing Group UK","logo":{"url":"https://www.springernature.com/app-sn/public/images/logo-springernature.png","@type":"ImageObject"},"@type":"Organization"},"author":[{"name":"Naoka Murakami","affiliation":[{"name":"Brigham and Women’s Hospital","address":{"name":"Division of Renal Medicine, Brigham and Women’s Hospital, Boston, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Harvard Medical School","address":{"name":"Harvard Medical School, Boston, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Robert Hayden","affiliation":[{"name":"Brigham and Women’s Hospital","address":{"name":"Division of Renal Medicine, Brigham and Women’s Hospital, Boston, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Harvard Medical School","address":{"name":"Harvard Medical School, Boston, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Thomas Hills","url":"http://orcid.org/0000-0003-0322-5822","affiliation":[{"name":"Medical Research Institute of New Zealand","address":{"name":"Medical Research Institute of New Zealand, Wellington, New Zealand","@type":"PostalAddress"},"@type":"Organization"},{"name":"Auckland District Health Board","address":{"name":"Auckland District Health Board, Auckland, New Zealand","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Hanny Al-Samkari","url":"http://orcid.org/0000-0001-6175-1383","affiliation":[{"name":"Harvard Medical School","address":{"name":"Harvard Medical School, Boston, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Massachusetts General Hospital","address":{"name":"Division of Hematology, Massachusetts General Hospital, Boston, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Jonathan Casey","affiliation":[{"name":"Vanderbilt University Medical Center","address":{"name":"Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Lorenzo Del Sorbo","affiliation":[{"name":"University Health Network, Interdepartmental Division of Critical Care Medicine, University of Toronto","address":{"name":"Department of Medicine, University Health Network, Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Canada","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Patrick R. Lawler","affiliation":[{"name":"University Health Network, Interdepartmental Division of Critical Care Medicine, University of Toronto","address":{"name":"Department of Medicine, University Health Network, Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Canada","@type":"PostalAddress"},"@type":"Organization"},{"name":"University Health Network, University of Toronto","address":{"name":"Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto, Canada","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Meghan E. Sise","affiliation":[{"name":"Harvard Medical School","address":{"name":"Harvard Medical School, Boston, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Massachusetts General Hospital","address":{"name":"Division of Nephrology, Massachusetts General Hospital, Boston, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"David E. Leaf","url":"http://orcid.org/0000-0001-7875-090X","affiliation":[{"name":"Brigham and Women’s Hospital","address":{"name":"Division of Renal Medicine, Brigham and Women’s Hospital, Boston, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Harvard Medical School","address":{"name":"Harvard Medical School, Boston, USA","@type":"PostalAddress"},"@type":"Organization"}],"email":"deleaf@bwh.harvard.edu","@type":"Person"}],"isAccessibleForFree":true,"@type":"ScholarlyArticle"},"@context":"https://schema.org","@type":"WebPage"}</script>




    
    
    


    
    <link rel="canonical" href="https://www.nature.com/articles/s41581-022-00642-4">
    
    
    <meta name="journal_id" content="41581"/>
    <meta name="dc.title" content="Therapeutic advances in COVID-19"/>
    <meta name="dc.source" content="Nature Reviews Nephrology 2022 19:1"/>
    <meta name="dc.format" content="text/html"/>
    <meta name="dc.publisher" content="Nature Publishing Group"/>
    <meta name="dc.date" content="2022-10-17"/>
    <meta name="dc.type" content="ReviewPaper"/>
    <meta name="dc.language" content="En"/>
    <meta name="dc.copyright" content="2022 Springer Nature Limited"/>
    <meta name="dc.rights" content="2022 Springer Nature Limited"/>
    <meta name="dc.rightsAgent" content="journalpermissions@springernature.com"/>
    <meta name="dc.description" content="Over 2 years have passed since the start of the COVID-19 pandemic, which has claimed millions of lives. Unlike the early days of the pandemic, when management decisions were based on extrapolations from in vitro data, case reports and case series, clinicians are now equipped with an armamentarium of therapies based on high-quality evidence. These treatments are spread across seven main therapeutic categories: anti-inflammatory agents, antivirals, antithrombotics, therapies for acute hypoxaemic respiratory failure, anti-SARS-CoV-2 (neutralizing) antibody therapies, modulators of the renin&#8211;angiotensin&#8211;aldosterone system and vitamins. For&amp;nbsp;each of these treatments, the patient population characteristics and clinical settings in which they were studied&amp;nbsp;are important considerations. Although few direct comparisons have been performed, the evidence base and magnitude of benefit for anti-inflammatory and antiviral agents clearly outweigh those of other therapeutic approaches such as vitamins. The emergence of novel variants has further complicated the interpretation of much of the available evidence, particularly for antibody therapies. Importantly, patients with acute and chronic kidney disease were under-represented in many of the COVID-19 clinical trials, and outcomes in this population might differ from those reported in the general population. Here, we examine the clinical evidence for these therapies through a kidney medicine lens. The COVID-19 pandemic was met with large-scale efforts to assess novel and repurposed therapeutic interventions that could reduce patient morbidity and mortality. Here, the authors discuss the different types of therapies available to treat COVID-19, including their relevance to patients with kidney failure and kidney transplant recipients."/>
    <meta name="prism.issn" content="1759-507X"/>
    <meta name="prism.publicationName" content="Nature Reviews Nephrology"/>
    <meta name="prism.publicationDate" content="2022-10-17"/>
    <meta name="prism.volume" content="19"/>
    <meta name="prism.number" content="1"/>
    <meta name="prism.section" content="ReviewPaper"/>
    <meta name="prism.startingPage" content="38"/>
    <meta name="prism.endingPage" content="52"/>
    <meta name="prism.copyright" content="2022 Springer Nature Limited"/>
    <meta name="prism.rightsAgent" content="journalpermissions@springernature.com"/>
    <meta name="prism.url" content="https://www.nature.com/articles/s41581-022-00642-4"/>
    <meta name="prism.doi" content="doi:10.1038/s41581-022-00642-4"/>
    <meta name="citation_pdf_url" content="https://www.nature.com/articles/s41581-022-00642-4.pdf"/>
    <meta name="citation_fulltext_html_url" content="https://www.nature.com/articles/s41581-022-00642-4"/>
    <meta name="citation_journal_title" content="Nature Reviews Nephrology"/>
    <meta name="citation_journal_abbrev" content="Nat Rev Nephrol"/>
    <meta name="citation_publisher" content="Nature Publishing Group"/>
    <meta name="citation_issn" content="1759-507X"/>
    <meta name="citation_title" content="Therapeutic advances in COVID-19"/>
    <meta name="citation_volume" content="19"/>
    <meta name="citation_issue" content="1"/>
    <meta name="citation_publication_date" content="2023/01"/>
    <meta name="citation_online_date" content="2022/10/17"/>
    <meta name="citation_firstpage" content="38"/>
    <meta name="citation_lastpage" content="52"/>
    <meta name="citation_article_type" content="Review Article"/>
    <meta name="citation_fulltext_world_readable" content=""/>
    <meta name="citation_language" content="en"/>
    <meta name="dc.identifier" content="doi:10.1038/s41581-022-00642-4"/>
    <meta name="DOI" content="10.1038/s41581-022-00642-4"/>
    <meta name="size" content="368769"/>
    <meta name="citation_doi" content="10.1038/s41581-022-00642-4"/>
    <meta name="citation_springer_api_url" content="http://api.springer.com/xmldata/jats?q=doi:10.1038/s41581-022-00642-4&amp;api_key="/>
    <meta name="description" content="Over 2 years have passed since the start of the COVID-19 pandemic, which has claimed millions of lives. Unlike the early days of the pandemic, when management decisions were based on extrapolations from in vitro data, case reports and case series, clinicians are now equipped with an armamentarium of therapies based on high-quality evidence. These treatments are spread across seven main therapeutic categories: anti-inflammatory agents, antivirals, antithrombotics, therapies for acute hypoxaemic respiratory failure, anti-SARS-CoV-2 (neutralizing) antibody therapies, modulators of the renin&#8211;angiotensin&#8211;aldosterone system and vitamins. For&amp;nbsp;each of these treatments, the patient population characteristics and clinical settings in which they were studied&amp;nbsp;are important considerations. Although few direct comparisons have been performed, the evidence base and magnitude of benefit for anti-inflammatory and antiviral agents clearly outweigh those of other therapeutic approaches such as vitamins. The emergence of novel variants has further complicated the interpretation of much of the available evidence, particularly for antibody therapies. Importantly, patients with acute and chronic kidney disease were under-represented in many of the COVID-19 clinical trials, and outcomes in this population might differ from those reported in the general population. Here, we examine the clinical evidence for these therapies through a kidney medicine lens. The COVID-19 pandemic was met with large-scale efforts to assess novel and repurposed therapeutic interventions that could reduce patient morbidity and mortality. Here, the authors discuss the different types of therapies available to treat COVID-19, including their relevance to patients with kidney failure and kidney transplant recipients."/>
    <meta name="dc.creator" content="Murakami, Naoka"/>
    <meta name="dc.creator" content="Hayden, Robert"/>
    <meta name="dc.creator" content="Hills, Thomas"/>
    <meta name="dc.creator" content="Al-Samkari, Hanny"/>
    <meta name="dc.creator" content="Casey, Jonathan"/>
    <meta name="dc.creator" content="Del Sorbo, Lorenzo"/>
    <meta name="dc.creator" content="Lawler, Patrick R."/>
    <meta name="dc.creator" content="Sise, Meghan E."/>
    <meta name="dc.creator" content="Leaf, David E."/>
    <meta name="dc.subject" content="End-stage renal disease"/>
    <meta name="dc.subject" content="Molecularly targeted therapy"/>
    <meta name="dc.subject" content="Organ transplantation"/>
    <meta name="dc.subject" content="SARS-CoV-2"/>
    <meta name="citation_reference" content="citation_journal_title=Lancet; citation_title=Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic; citation_author=SSA Karim, QA Karim; citation_volume=398; citation_publication_date=2021; citation_pages=2126-2128; citation_doi=10.1016/S0140-6736(21)02758-6; citation_id=CR1"/>
    <meta name="citation_reference" content="citation_journal_title=Am. J. Kidney Dis.; citation_title=Characteristics and outcomes of individuals with pre-existing kidney disease and COVID-19 admitted to intensive care units in the United States; citation_author=JE Flythe; citation_volume=77; citation_publication_date=2021; citation_pages=190-203.e1; citation_doi=10.1053/j.ajkd.2020.09.003; citation_id=CR2"/>
    <meta name="citation_reference" content="citation_journal_title=Am. J. Transplant.; citation_title=Quantifying excess deaths among solid organ transplant recipients in the COVID-19 era; citation_author=AB Massie; citation_volume=22; citation_publication_date=2022; citation_pages=2077-2082; citation_doi=10.1111/ajt.17036; citation_id=CR3"/>
    <meta name="citation_reference" content="citation_journal_title=J. Am. Soc. Nephrol.; citation_title=AKI in hospitalized patients with COVID-19; citation_author=L Chan; citation_volume=32; citation_publication_date=2021; citation_pages=151-160; citation_doi=10.1681/ASN.2020050615; citation_id=CR4"/>
    <meta name="citation_reference" content="citation_journal_title=J. Am. Soc. Nephrol.; citation_title=AKI treated with renal replacement therapy in critically ill patients with COVID-19; citation_author=S Gupta; citation_volume=32; citation_publication_date=2021; citation_pages=161-176; citation_doi=10.1681/ASN.2020060897; citation_id=CR5"/>
    <meta name="citation_reference" content="citation_journal_title=Lancet; citation_title=COVID-19: consider cytokine storm syndromes and immunosuppression; citation_author=P Mehta; citation_volume=395; citation_publication_date=2020; citation_pages=1033-1034; citation_doi=10.1016/S0140-6736(20)30628-0; citation_id=CR6"/>
    <meta name="citation_reference" content="citation_journal_title=JAMA Intern. Med.; citation_title=Factors associated with death in critically ill patients with coronavirus disease 2019 in the US; citation_author=S Gupta; citation_volume=180; citation_publication_date=2020; citation_pages=1436-1447; citation_doi=10.1001/jamainternmed.2020.3596; citation_id=CR7"/>
    <meta name="citation_reference" content="citation_journal_title=Nat. Med.; citation_title=An inflammatory cytokine signature predicts COVID-19 severity and survival; citation_author=DM Valle; citation_volume=26; citation_publication_date=2020; citation_pages=1636-1643; citation_doi=10.1038/s41591-020-1051-9; citation_id=CR8"/>
    <meta name="citation_reference" content="citation_journal_title=Crit. Care Med.; citation_title=d-dimer and death in critically ill patients with coronavirus disease 2019; citation_author=SAP Short; citation_volume=49; citation_publication_date=2021; citation_pages=e500-e511; citation_doi=10.1097/CCM.0000000000004917; citation_id=CR9"/>
    <meta name="citation_reference" content="citation_journal_title=JCI Insight; citation_title=Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis; citation_author=JG Wilson; citation_volume=5; citation_publication_date=2020; citation_pages=140289; citation_doi=10.1172/jci.insight.140289; citation_id=CR10"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Dexamethasone in hospitalized patients with Covid-19; citation_author=; citation_volume=384; citation_publication_date=2021; citation_pages=693-704; citation_doi=10.1056/NEJMoa2021436; citation_id=CR11"/>
    <meta name="citation_reference" content="citation_journal_title=JAMA; citation_title=Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis; citation_author=; citation_volume=324; citation_publication_date=2020; citation_pages=1330-1341; citation_doi=10.1001/jama.2020.17023; citation_id=CR12"/>
    <meta name="citation_reference" content="citation_journal_title=JAMA Intern. Med.; citation_title=Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19; citation_author=S Gupta; citation_volume=181; citation_publication_date=2021; citation_pages=41-51; citation_doi=10.1001/jamainternmed.2020.6252; citation_id=CR13"/>
    <meta name="citation_reference" content="citation_journal_title=Lancet Rheumatol.; citation_title=Tocilizumab in patients with severe COVID-19: a retrospective cohort study; citation_author=G Guaraldi; citation_volume=2; citation_publication_date=2020; citation_pages=e474-e484; citation_doi=10.1016/S2665-9913(20)30173-9; citation_id=CR14"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Efficacy of tocilizumab in patients hospitalized with Covid-19; citation_author=JH Stone; citation_volume=383; citation_publication_date=2020; citation_pages=2333-2344; citation_doi=10.1056/NEJMoa2028836; citation_id=CR15"/>
    <meta name="citation_reference" content="citation_journal_title=JAMA Intern. Med.; citation_title=Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial; citation_author=C Salvarani; citation_volume=181; citation_publication_date=2021; citation_pages=24-31; citation_doi=10.1001/jamainternmed.2020.6615; citation_id=CR16"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Tocilizumab in covid-19; citation_author=DE Leaf, S Gupta, W Wang; citation_volume=384; citation_publication_date=2021; citation_pages=86-87; citation_doi=10.1056/NEJMc2032911; citation_id=CR17"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Interleukin-6 receptor antagonists in critically ill patients with covid-19; citation_author=; citation_volume=384; citation_publication_date=2021; citation_pages=1491-1502; citation_doi=10.1056/NEJMoa2100433; citation_id=CR18"/>
    <meta name="citation_reference" content="citation_journal_title=Lancet; citation_title=Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial; citation_author=; citation_volume=397; citation_publication_date=2021; citation_pages=1637-1645; citation_doi=10.1016/S0140-6736(21)00676-0; citation_id=CR19"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=The RECOVERY platform; citation_author=SLT Normand; citation_volume=384; citation_publication_date=2021; citation_pages=757-758; citation_doi=10.1056/NEJMe2025674; citation_id=CR20"/>
    <meta name="citation_reference" content="citation_journal_title=JAMA; citation_title=Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis; citation_author=; citation_volume=326; citation_publication_date=2021; citation_pages=499-518; citation_doi=10.1001/jama.2021.11330; citation_id=CR21"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Baricitinib plus remdesivir for hospitalized adults with Covid-19; citation_author=AC Kalil; citation_volume=384; citation_publication_date=2021; citation_pages=795-807; citation_doi=10.1056/NEJMoa2031994; citation_id=CR22"/>
    <meta name="citation_reference" content="citation_journal_title=Lancet Respir. Med.; citation_title=Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial; citation_author=VC Marconi; citation_volume=9; citation_publication_date=2021; citation_pages=1407-1418; citation_doi=10.1016/S2213-2600(21)00331-3; citation_id=CR23"/>
    <meta name="citation_reference" content="citation_journal_title=Lancet Respir. Med.; citation_title=Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial; citation_author=EW Ely; citation_volume=10; citation_publication_date=2022; citation_pages=327-336; citation_doi=10.1016/S2213-2600(22)00006-6; citation_id=CR24"/>
    <meta name="citation_reference" content="citation_journal_title=Lancet; citation_title=Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis; citation_author=; citation_volume=400; citation_publication_date=2022; citation_pages=359-368; citation_doi=10.1016/S0140-6736(22)01109-6; citation_id=CR25"/>
    <meta name="citation_reference" content="citation_journal_title=Nat. Commun.; citation_title=Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials; citation_author=C Axfors; citation_volume=12; citation_publication_date=2021; citation_doi=10.1038/s41467-021-22446-z; citation_id=CR26"/>
    <meta name="citation_reference" content="citation_journal_title=Intensive Care Med.; citation_title=Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial; citation_author=YM Arabi; citation_volume=47; citation_publication_date=2021; citation_pages=867-886; citation_doi=10.1007/s00134-021-06448-5; citation_id=CR27"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Effect of early treatment with ivermectin among patients with Covid-19; citation_author=G Reis; citation_volume=386; citation_publication_date=2022; citation_pages=1721-1731; citation_doi=10.1056/NEJMoa2115869; citation_id=CR28"/>
    <meta name="citation_reference" content="citation_journal_title=Sci. Transl Med.; citation_title=Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses; citation_author=TP Sheahan; citation_volume=9; citation_publication_date=2017; citation_pages=eaal3653; citation_doi=10.1126/scitranslmed.aal3653; citation_id=CR29"/>
    <meta name="citation_reference" content="citation_journal_title=Cell Res.; citation_title=Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro; citation_author=M Wang; citation_volume=30; citation_publication_date=2020; citation_pages=269-271; citation_doi=10.1038/s41422-020-0282-0; citation_id=CR30"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Early remdesivir to prevent progression to severe Covid-19 in outpatients; citation_author=RL Gottlieb; citation_volume=386; citation_publication_date=2022; citation_pages=305-315; citation_doi=10.1056/NEJMoa2116846; citation_id=CR31"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Remdesivir for the treatment of Covid-19 &#8212; final report; citation_author=JH Beigel; citation_volume=383; citation_publication_date=2020; citation_pages=1813-1826; citation_doi=10.1056/NEJMoa2007764; citation_id=CR32"/>
    <meta name="citation_reference" content="citation_journal_title=Lancet; citation_title=Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses; citation_author=; citation_volume=399; citation_publication_date=2022; citation_pages=1941-1953; citation_doi=10.1016/S0140-6736(22)00519-0; citation_id=CR33"/>
    <meta name="citation_reference" content="citation_journal_title=Science; citation_title=An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19; citation_author=DR Owen; citation_volume=374; citation_publication_date=2021; citation_pages=1586-1593; citation_doi=10.1126/science.abl4784; citation_id=CR34"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19; citation_author=J Hammond; citation_volume=386; citation_publication_date=2022; citation_pages=1397-1408; citation_doi=10.1056/NEJMoa2118542; citation_id=CR35"/>
    <meta name="citation_reference" content="citation_journal_title=Sci. Transl Med.; citation_title=An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice; citation_author=TP Sheahan; citation_volume=12; citation_publication_date=2020; citation_pages=eabb5883; citation_doi=10.1126/scitranslmed.abb5883; citation_id=CR36"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients; citation_author=A Jayk Bernal; citation_volume=386; citation_publication_date=2022; citation_pages=509-520; citation_doi=10.1056/NEJMoa2116044; citation_id=CR37"/>
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Pharmacol.; citation_title=Clinical pharmacokinetics of sulfobutylether-&#946;-cyclodextrin in patients with varying degrees of renal impairment; citation_author=RK Hoover; citation_volume=58; citation_publication_date=2018; citation_pages=814-822; citation_doi=10.1002/jcph.1077; citation_id=CR38"/>
    <meta name="citation_reference" content="citation_journal_title=Kidney Int. Rep.; citation_title=Remdesivir in patients with estimated GFR &lt;30 ml/min per 1.73 m2 or on renal replacement therapy; citation_author=C Estiverne; citation_volume=6; citation_publication_date=2021; citation_pages=835-838; citation_doi=10.1016/j.ekir.2020.11.025; citation_id=CR39"/>
    <meta name="citation_reference" content="citation_journal_title=Kidney Int. Rep.; citation_title=Safety of remdesivir in patients with acute kidney injury or CKD; citation_author=S Thakare; citation_volume=6; citation_publication_date=2021; citation_pages=206-210; citation_doi=10.1016/j.ekir.2020.10.005; citation_id=CR40"/>
    <meta name="citation_reference" content="citation_journal_title=Clin. Infect. Dis.; citation_title=Remdesivir use in the setting of severe renal impairment: a theoretical concern or real risk?; citation_author=NN Pettit; citation_volume=73; citation_publication_date=2021; citation_pages=e3990-e3995; citation_doi=10.1093/cid/ciaa1851; citation_id=CR41"/>
    <meta name="citation_reference" content="citation_journal_title=CPT Pharmacomet. Syst. Pharmacol.; citation_title=Population pharmacokinetic modeling of GS-441524, the active metabolite of remdesivir, in Japanese COVID-19 patients with renal dysfunction; citation_author=A Sukeishi; citation_volume=11; citation_publication_date=2022; citation_pages=94-103; citation_doi=10.1002/psp4.12736; citation_id=CR42"/>
    <meta name="citation_reference" content="citation_journal_title=Kidney360; citation_title=A propensity score-matched observational study of remdesivir in patients with COVID-19 and severe kidney disease; citation_author=R Seethapathy, S Zhao, JD Long, IA Strohbehn, ME Sise; citation_volume=3; citation_publication_date=2022; citation_pages=269-278; citation_doi=10.34067/KID.0006152021; citation_id=CR43"/>
    <meta name="citation_reference" content="US National Library of Medicine. ClinicalTrials.gov 
                  https://clinicaltrials.gov/ct2/show/NCT04745351
                  
                 (2022)."/>
    <meta name="citation_reference" content="US Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for paxlovid. FDA 
                  https://www.fda.gov/media/155050/download
                  
                 (2022)."/>
    <meta name="citation_reference" content="citation_journal_title=Am. J. Transplant.; citation_title=Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients; citation_author=DM Salerno; citation_volume=22; citation_publication_date=2022; citation_pages=2083-2088; citation_doi=10.1111/ajt.17027; citation_id=CR46"/>
    <meta name="citation_reference" content="citation_journal_title=Science; citation_title=Lethal mutagenesis as an antiviral strategy; citation_author=R Swanstrom, RF Schinazi; citation_volume=375; citation_publication_date=2022; citation_pages=497-498; citation_doi=10.1126/science.abn0048; citation_id=CR47"/>
    <meta name="citation_reference" content="citation_journal_title=Ann. Intern. Med.; citation_title=Thrombosis, bleeding, and the observational effect of early therapeutic anticoagulation on survival in critically ill patients with COVID-19; citation_author=H Al-Samkari; citation_volume=174; citation_publication_date=2021; citation_pages=622-632; citation_doi=10.7326/M20-6739; citation_id=CR48"/>
    <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection; citation_author=H Al-Samkari; citation_volume=136; citation_publication_date=2020; citation_pages=489-500; citation_doi=10.1182/blood.2020006520; citation_id=CR49"/>
    <meta name="citation_reference" content="citation_journal_title=Inflamm. Res.; citation_title=The coagulopathy, endotheliopathy, and vasculitis of COVID-19; citation_author=T Iba, JM Connors, JH Levy; citation_volume=69; citation_publication_date=2020; citation_pages=1181-1189; citation_doi=10.1007/s00011-020-01401-6; citation_id=CR50"/>
    <meta name="citation_reference" content="citation_journal_title=Lancet Haematol.; citation_title=Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study; citation_author=G Goshua; citation_volume=7; citation_publication_date=2020; citation_pages=e575-e582; citation_doi=10.1016/S2352-3026(20)30216-7; citation_id=CR51"/>
    <meta name="citation_reference" content="citation_journal_title=Am. J. Hematol.; citation_title=Evaluation of the prothrombin fragment 1.2 in patients with coronavirus disease 2019 (COVID-19); citation_author=H Al-Samkari, F Song, EM Cott, DJ Kuter, R Rosovsky; citation_volume=95; citation_publication_date=2020; citation_pages=1479-1485; citation_doi=10.1002/ajh.25962; citation_id=CR52"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19; citation_author=; citation_volume=385; citation_publication_date=2021; citation_pages=790-802; citation_doi=10.1056/NEJMoa2105911; citation_id=CR53"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Therapeutic anticoagulation with heparin in critically ill patients with Covid-19; citation_author=; citation_volume=385; citation_publication_date=2021; citation_pages=777-789; citation_doi=10.1056/NEJMoa2103417; citation_id=CR54"/>
    <meta name="citation_reference" content="citation_journal_title=JAMA; citation_title=Finding the optimal thromboprophylaxis dose in patients with COVID-19; citation_author=H Al-Samkari; citation_volume=325; citation_publication_date=2021; citation_pages=1613-1615; citation_doi=10.1001/jama.2021.4295; citation_id=CR55"/>
    <meta name="citation_reference" content="citation_journal_title=Blood Adv.; citation_title=American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19; citation_author=A Cuker; citation_volume=5; citation_publication_date=2021; citation_pages=872-888; citation_doi=10.1182/bloodadvances.2020003763; citation_id=CR56"/>
    <meta name="citation_reference" content="National Institutes of Health. COVID-19 treatment guidelines: antithrombotic therapy in patients with COVID-19. NIH 
                  https://www.covid19treatmentguidelines.nih.gov/therapies/antithrombotic-therapy/
                  
                 (2022)."/>
    <meta name="citation_reference" content="American Society of Hematology. ASH clinical practice guidelines on venous thromboembolism. ASH 
                  https://www.hematology.org/education/clinicians/guidelines-and-quality-care/clinical-practice-guidelines/venous-thromboembolism-guidelines/ash-guidelines-on-use-of-anticoagulation-in-patients-with-covid-19
                  
                 (2022)."/>
    <meta name="citation_reference" content="citation_journal_title=JAMA Intern. Med.; citation_title=Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial; citation_author=AC Spyropoulos; citation_volume=181; citation_publication_date=2021; citation_pages=1612-1620; citation_doi=10.1001/jamainternmed.2021.6203; citation_id=CR59"/>
    <meta name="citation_reference" content="citation_journal_title=BMJ; citation_title=Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial; citation_author=M Sholzberg; citation_volume=375; citation_publication_date=2021; citation_pages=n2400; citation_doi=10.1136/bmj.n2400; citation_id=CR60"/>
    <meta name="citation_reference" content="citation_journal_title=Lancet; citation_title=Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial; citation_author=RD Lopes; citation_volume=397; citation_publication_date=2021; citation_pages=2253-2263; citation_doi=10.1016/S0140-6736(21)01203-4; citation_id=CR61"/>
    <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry; citation_author=D Giannis; citation_volume=137; citation_publication_date=2021; citation_pages=2838-2847; citation_doi=10.1182/blood.2020010529; citation_id=CR62"/>
    <meta name="citation_reference" content="citation_journal_title=Lancet; citation_title=Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial; citation_author=E Ramacciotti; citation_volume=399; citation_publication_date=2022; citation_pages=50-59; citation_doi=10.1016/S0140-6736(21)02392-8; citation_id=CR63"/>
    <meta name="citation_reference" content="citation_journal_title=J. Am. Coll. Cardiol.; citation_title=Post-discharge prophylaxis with rivaroxaban reduces fatal and major thromboembolic events in medically ill patients; citation_author=AC Spyropoulos; citation_volume=75; citation_publication_date=2020; citation_pages=3140-3147; citation_doi=10.1016/j.jacc.2020.04.071; citation_id=CR64"/>
    <meta name="citation_reference" content="citation_journal_title=Lancet; citation_title=Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial; citation_author=; citation_volume=399; citation_publication_date=2022; citation_pages=143-151; citation_doi=10.1016/S0140-6736(21)01825-0; citation_id=CR65"/>
    <meta name="citation_reference" content="citation_journal_title=JAMA; citation_title=Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial; citation_author=JM Connors; citation_volume=326; citation_publication_date=2021; citation_pages=1703-1712; citation_doi=10.1001/jama.2021.17272; citation_id=CR66"/>
    <meta name="citation_reference" content="citation_journal_title=JAMA; citation_title=Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: a randomized clinical trial; citation_author=; citation_volume=327; citation_publication_date=2022; citation_pages=1247-1259; citation_doi=10.1001/jama.2022.2910; citation_id=CR67"/>
    <meta name="citation_reference" content="US National Library of Medicine. ClinicalTrials.gov 
                  https://clinicaltrials.gov/ct2/show/NCT04505774
                  
                 (2022)."/>
    <meta name="citation_reference" content="citation_journal_title=Semin. Dial.; citation_title=Platelet dysfunction and end-stage renal disease; citation_author=D Kaw, D Malhotra; citation_volume=19; citation_publication_date=2006; citation_pages=317-322; citation_doi=10.1111/j.1525-139X.2006.00179.x; citation_id=CR69"/>
    <meta name="citation_reference" content="citation_journal_title=J. Am. Soc. Nephrol.; citation_title=Chronic kidney disease increases risk for venous thromboembolism; citation_author=K Wattanakit, M Cushman, C Stehman-Breen, SR Heckbert, AR Folsom; citation_volume=19; citation_publication_date=2008; citation_pages=135-140; citation_doi=10.1681/ASN.2007030308; citation_id=CR70"/>
    <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis; citation_author=N Martel, J Lee, PS Wells; citation_volume=106; citation_publication_date=2005; citation_pages=2710-2715; citation_doi=10.1182/blood-2005-04-1546; citation_id=CR71"/>
    <meta name="citation_reference" content="citation_journal_title=Chest; citation_title=Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines; citation_author=DA Garcia, TP Baglin, JI Weitz, MM Samama; citation_volume=141; citation_publication_date=2012; citation_pages=e24S-e43S; citation_doi=10.1378/chest.11-2291; citation_id=CR72"/>
    <meta name="citation_reference" content="citation_journal_title=J. Thromb. Thrombolysis; citation_title=Filter clotting with continuous renal replacement therapy in COVID-19; citation_author=P Endres; citation_volume=51; citation_publication_date=2021; citation_pages=966-970; citation_doi=10.1007/s11239-020-02301-6; citation_id=CR73"/>
    <meta name="citation_reference" content="citation_journal_title=BMC Nephrol.; citation_title=Comparison of different anticoagulation strategies for renal replacement therapy in critically ill patients with COVID-19: a cohort study; citation_author=F Arnold; citation_volume=21; citation_publication_date=2020; citation_pages=486; citation_doi=10.1186/s12882-020-02150-8; citation_id=CR74"/>
    <meta name="citation_reference" content="citation_journal_title=Thrombosis Update; citation_title=Intervention in COVID-19 linked hypercoagulable states characterized by circuit thrombosis utilizing a direct thrombin inhibitor; citation_author=M Seshadri, J Ahamed, J Laurence; citation_volume=1; citation_publication_date=2020; citation_pages=100009; citation_doi=10.1016/j.tru.2020.100009; citation_id=CR75"/>
    <meta name="citation_reference" content="citation_journal_title=Thromb. Res.; citation_title=Acquired antithrombin deficiency is a risk factor for venous thromboembolism after major trauma; citation_author=E Rahbar, BA Cotton, CE Wade, JC Cardenas; citation_volume=204; citation_publication_date=2021; citation_pages=9-12; citation_doi=10.1016/j.thromres.2021.05.015; citation_id=CR76"/>
    <meta name="citation_reference" content="citation_journal_title=Nat. Rev. Nephrol.; citation_title=Pathophysiology of COVID-19-associated acute kidney injury; citation_author=M Legrand; citation_volume=17; citation_publication_date=2021; citation_pages=751-764; citation_doi=10.1038/s41581-021-00452-0; citation_id=CR77"/>
    <meta name="citation_reference" content="citation_journal_title=EClinicalMedicine; citation_title=Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series; citation_author=AV Rapkiewicz; citation_volume=24; citation_publication_date=2020; citation_pages=100434; citation_doi=10.1016/j.eclinm.2020.100434; citation_id=CR78"/>
    <meta name="citation_reference" content="citation_journal_title=Dig. Dis. Sci.; citation_title=Anticoagulant pretreatment attenuates production of cytokine-induced neutrophil chemoattractant following ischemia-reperfusion of rat liver; citation_author=N Hisama; citation_volume=41; citation_publication_date=1996; citation_pages=1481-1486; citation_doi=10.1007/BF02088576; citation_id=CR79"/>
    <meta name="citation_reference" content="citation_journal_title=JAMA; citation_title=Management of COVID-19 respiratory distress; citation_author=JJ Marini, L Gattinoni; citation_volume=323; citation_publication_date=2020; citation_pages=2329-2330; citation_doi=10.1001/jama.2020.6825; citation_id=CR80"/>
    <meta name="citation_reference" content="citation_journal_title=Crit. Care; citation_title=Siempos II. Effect of timing of intubation on clinical outcomes of critically ill patients with COVID-19: a systematic review and meta-analysis of non-randomized cohort studies; citation_author=E Papoutsi, VG Giannakoulis, E Xourgia, C Routsi, A Kotanidou; citation_volume=25; citation_publication_date=2021; citation_doi=10.1186/s13054-021-03540-6; citation_id=CR81"/>
    <meta name="citation_reference" content="citation_journal_title=Am. J. Respir. Crit. Care Med.; citation_title=Respiratory pathophysiology of mechanically ventilated patients with COVID-19: a cohort study; citation_author=DR Ziehr; citation_volume=201; citation_publication_date=2020; citation_pages=1560-1564; citation_doi=10.1164/rccm.202004-1163LE; citation_id=CR82"/>
    <meta name="citation_reference" content="citation_journal_title=Ann. Intern. Med.; citation_title=Characteristics, outcomes, and trends of patients with COVID-19-related critical illness at a learning health system in the United States; citation_author=GL Anesi; citation_volume=174; citation_publication_date=2021; citation_pages=613-621; citation_doi=10.7326/M20-5327; citation_id=CR83"/>
    <meta name="citation_reference" content="citation_journal_title=Am. J. Respir. Crit. Care Med.; citation_title=Aerosol generation from the respiratory tract with various modes of oxygen delivery; citation_author=NT Gaeckle; citation_volume=202; citation_publication_date=2020; citation_pages=1115-1124; citation_doi=10.1164/rccm.202006-2309OC; citation_id=CR84"/>
    <meta name="citation_reference" content="citation_journal_title=JAMA; citation_title=Effect of noninvasive respiratory strategies on intubation or mortality among patients with acute hypoxemic respiratory failure and COVID-19: the RECOVERY-RS randomized clinical trial; citation_author=GD Perkins; citation_volume=327; citation_publication_date=2022; citation_pages=546-558; citation_doi=10.1001/jama.2022.0028; citation_id=CR85"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Prone positioning in severe acute respiratory distress syndrome; citation_author=C Gu&#233;rin; citation_volume=368; citation_publication_date=2013; citation_pages=2159-2168; citation_doi=10.1056/NEJMoa1214103; citation_id=CR86"/>
    <meta name="citation_reference" content="citation_journal_title=Crit. Care Med.; citation_title=Prone positioning and survival in mechanically ventilated patients with coronavirus disease 2019-related respiratory failure; citation_author=KS Mathews; citation_volume=49; citation_publication_date=2021; citation_pages=1026-1037; citation_id=CR87"/>
    <meta name="citation_reference" content="citation_journal_title=Lancet Respir. Med.; citation_title=Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial; citation_author=S Ehrmann; citation_volume=9; citation_publication_date=2021; citation_pages=1387-1395; citation_doi=10.1016/S2213-2600(21)00356-8; citation_id=CR88"/>
    <meta name="citation_reference" content="citation_journal_title=JAMA; citation_title=Effect of awake prone positioning on endotracheal intubation in patients with COVID-19 and acute respiratory failure: a randomized clinical trial; citation_author=AW Alhazzani; citation_volume=327; citation_publication_date=2022; citation_pages=2104-2113; citation_doi=10.1001/jama.2022.7993; citation_id=CR89"/>
    <meta name="citation_reference" content="citation_journal_title=JAMA Intern. Med.; citation_title=Assessment of awake prone positioning in hospitalized adults with COVID-19: a nonrandomized controlled trial; citation_author=ET Qian; citation_volume=182; citation_publication_date=2022; citation_pages=612-621; citation_doi=10.1001/jamainternmed.2022.1070; citation_id=CR90"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Early neuromuscular blockade in the acute respiratory distress syndrome; citation_author=M Moss; citation_volume=380; citation_publication_date=2019; citation_pages=1997-2008; citation_doi=10.1056/NEJMoa1901686; citation_id=CR91"/>
    <meta name="citation_reference" content="citation_journal_title=Intensive Care Med.; citation_title=Extracorporeal membrane oxygenation in patients with severe respiratory failure from COVID-19; citation_author=S Shaefi; citation_volume=47; citation_publication_date=2021; citation_pages=208-221; citation_doi=10.1007/s00134-020-06331-9; citation_id=CR92"/>
    <meta name="citation_reference" content="citation_journal_title=BMJ; citation_title=Venovenous extracorporeal membrane oxygenation in patients with acute covid-19 associated respiratory failure: comparative effectiveness study; citation_author=M Urner; citation_volume=377; citation_publication_date=2022; citation_doi=10.1136/bmj-2021-068723; citation_id=CR93"/>
    <meta name="citation_reference" content="citation_journal_title=JAMA; citation_title=Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome and posterior probability of mortality benefit in a post hoc Bayesian analysis of a randomized clinical trial; citation_author=EC Goligher; citation_volume=320; citation_publication_date=2018; citation_pages=2251-2259; citation_doi=10.1001/jama.2018.14276; citation_id=CR94"/>
    <meta name="citation_reference" content="citation_journal_title=Am. J. Respir. Crit. Care Med.; citation_title=Association between availability of ECMO and mortality in COVID-19 patients eligible for ECMO: a natural experiment; citation_author=WD Gannon; citation_volume=205; citation_publication_date=2022; citation_pages=1354-1357; citation_doi=10.1164/rccm.202110-2399LE; citation_id=CR95"/>
    <meta name="citation_reference" content="citation_journal_title=Clin. J. Am. Soc. Nephrol.; citation_title=Acute respiratory distress syndrome and risk of AKI among critically ill patients; citation_author=M Darmon; citation_volume=9; citation_publication_date=2014; citation_pages=1347-1353; citation_doi=10.2215/CJN.08300813; citation_id=CR96"/>
    <meta name="citation_reference" content="citation_journal_title=Semin. Nephrol.; citation_title=Pulmonary consequences of acute kidney injury; citation_author=JP Teixeira, S Ambruso, BR Griffin, S Faubel; citation_volume=39; citation_publication_date=2019; citation_pages=3-16; citation_doi=10.1016/j.semnephrol.2018.10.001; citation_id=CR97"/>
    <meta name="citation_reference" content="citation_journal_title=Nat. Rev. Drug Discov.; citation_title=Antibodies to combat viral infections: development strategies and progress; citation_author=G Pantaleo, B Correia, C Fenwick, VS Joo, L Perez; citation_volume=21; citation_publication_date=2022; citation_pages=676-696; citation_doi=10.1038/s41573-022-00495-3; citation_id=CR98"/>
    <meta name="citation_reference" content="citation_journal_title=JAMA; citation_title=Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis; citation_author=P Janiaud; citation_volume=325; citation_publication_date=2021; citation_pages=1185-1195; citation_doi=10.1001/jama.2021.2747; citation_id=CR99"/>
    <meta name="citation_reference" content="citation_journal_title=Nat. Med.; citation_title=Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial; citation_author=P B&#233;gin; citation_volume=27; citation_publication_date=2021; citation_pages=2012-2024; citation_doi=10.1038/s41591-021-01488-2; citation_id=CR100"/>
    <meta name="citation_reference" content="citation_journal_title=Lancet; citation_title=Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial; citation_author=; citation_volume=397; citation_publication_date=2021; citation_pages=2049-2059; citation_doi=10.1016/S0140-6736(21)00897-7; citation_id=CR101"/>
    <meta name="citation_reference" content="citation_journal_title=JAMA; citation_title=Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial; citation_author=; citation_volume=326; citation_publication_date=2021; citation_pages=1690-1702; citation_doi=10.1001/jama.2021.18178; citation_id=CR102"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Early outpatient treatment for Covid-19 with convalescent plasma; citation_author=DJ Sullivan; citation_volume=386; citation_publication_date=2022; citation_pages=1700-1711; citation_doi=10.1056/NEJMoa2119657; citation_id=CR103"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Early high-titer plasma therapy to prevent severe Covid-19 in older adults; citation_author=R Libster; citation_volume=384; citation_publication_date=2021; citation_pages=610-618; citation_doi=10.1056/NEJMoa2033700; citation_id=CR104"/>
    <meta name="citation_reference" content="citation_journal_title=Lancet Respir. Med.; citation_title=High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial; citation_author=A Alemany; citation_volume=10; citation_publication_date=2022; citation_pages=278-288; citation_doi=10.1016/S2213-2600(21)00545-2; citation_id=CR105"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Early convalescent plasma for high-risk outpatients with Covid-19; citation_author=FK Korley; citation_volume=385; citation_publication_date=2021; citation_pages=1951-1960; citation_doi=10.1056/NEJMoa2103784; citation_id=CR106"/>
    <meta name="citation_reference" content="citation_journal_title=Nat. Commun.; citation_title=Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients; citation_author=P Millat-Martinez; citation_volume=13; citation_publication_date=2022; citation_doi=10.1038/s41467-022-29911-3; citation_id=CR107"/>
    <meta name="citation_reference" content="National Institutes of Health. Anti-SARS-CoV-2 antibody products summary recommendations: COVID-19 treatment guidelines. NIH 
                  https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/summary-recommendations/
                  
                 (2022)."/>
    <meta name="citation_reference" content="citation_journal_title=Nat. Rev. Immunol.; citation_title=Neutralizing monoclonal antibodies for treatment of COVID-19; citation_author=PC Taylor; citation_volume=21; citation_publication_date=2021; citation_pages=382-393; citation_doi=10.1038/s41577-021-00542-x; citation_id=CR109"/>
    <meta name="citation_reference" content="citation_journal_title=Lancet; citation_title=Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial; citation_author=; citation_volume=399; citation_publication_date=2022; citation_pages=665-676; citation_doi=10.1016/S0140-6736(22)00163-5; citation_id=CR110"/>
    <meta name="citation_reference" content="citation_journal_title=Clin. Infect. Dis.; citation_title=A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load; citation_author=M Dougan; citation_volume=75; citation_publication_date=2021; citation_pages=e440-e449; citation_doi=10.1093/cid/ciab912; citation_id=CR111"/>
    <meta name="citation_reference" content="citation_journal_title=JAMA; citation_title=Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial; citation_author=A Gupta; citation_volume=327; citation_publication_date=2022; citation_pages=1236-1246; citation_doi=10.1001/jama.2022.2832; citation_id=CR112"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=REGEN-COV antibody combination and outcomes in outpatients with Covid-19; citation_author=DM Weinreich; citation_volume=385; citation_publication_date=2021; citation_doi=10.1056/NEJMoa2108163; citation_id=CR113"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Efficacy of antibodies and antiviral drugs against Covid-19 Omicron variant; citation_author=E Takashita; citation_volume=386; citation_publication_date=2022; citation_pages=995-998; citation_doi=10.1056/NEJMc2119407; citation_id=CR114"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19; citation_author=MJ Levin; citation_volume=386; citation_publication_date=2022; citation_pages=2188-2200; citation_doi=10.1056/NEJMoa2116620; citation_id=CR115"/>
    <meta name="citation_reference" content="citation_journal_title=Am. J. Transpl.; citation_title=Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States; citation_author=MZ Molnar; citation_volume=20; citation_publication_date=2020; citation_pages=3061-3071; citation_doi=10.1111/ajt.16280; citation_id=CR116"/>
    <meta name="citation_reference" content="citation_journal_title=Transplantation; citation_title=Efficacy of convalescent plasma to treat mild to moderate COVID-19 in kidney transplant patients: a propensity score matching analysis; citation_author=MP Cristelli; citation_volume=106; citation_publication_date=2022; citation_pages=e92-e94; citation_doi=10.1097/TP.0000000000003962; citation_id=CR117"/>
    <meta name="citation_reference" content="citation_journal_title=Transpl. Infect. Dis.; citation_title=Convalescent plasma treatment for early post-kidney transplant acquired COVID-19; citation_author=MA Kluger; citation_volume=23; citation_publication_date=2021; citation_doi=10.1111/tid.13685; citation_id=CR118"/>
    <meta name="citation_reference" content="citation_journal_title=Lancet Microbe; citation_title=Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19; citation_author=RN Rodionov; citation_volume=2; citation_publication_date=2021; citation_doi=10.1016/S2666-5247(21)00030-6; citation_id=CR119"/>
    <meta name="citation_reference" content="citation_journal_title=JAMA Oncol.; citation_title=Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19; citation_author=MA Thompson; citation_volume=7; citation_publication_date=2021; citation_pages=1167-1175; citation_doi=10.1001/jamaoncol.2021.1799; citation_id=CR120"/>
    <meta name="citation_reference" content="citation_journal_title=Clin. Exp. Nephrol.; citation_title=Effectiveness of neutralizing antibody cocktail in hemodialysis patients: a case series of 20 patients treated with or without REGN-COV2; citation_author=S Arikawa; citation_volume=26; citation_publication_date=2022; citation_pages=476-485; citation_doi=10.1007/s10157-021-02151-3; citation_id=CR121"/>
    <meta name="citation_reference" content="citation_journal_title=Kidney Int. Rep.; citation_title=Early administration of anti-SARS-CoV-2 monoclonal antibodies prevents severe Covid-19 in kidney transplant patients; citation_author=J Gueguen; citation_volume=7; citation_publication_date=2022; citation_pages=1241-1247; citation_doi=10.1016/j.ekir.2022.03.020; citation_id=CR122"/>
    <meta name="citation_reference" content="citation_journal_title=Kidney Int.; citation_title=Efficacy of anti-SARS-CoV-2 monoclonal antibody prophylaxis and vaccination on the Omicron variant of COVID-19 in kidney transplant recipients; citation_author=D Bertrand; citation_volume=102; citation_publication_date=2022; citation_pages=440-442; citation_doi=10.1016/j.kint.2022.05.007; citation_id=CR123"/>
    <meta name="citation_reference" content="citation_journal_title=Am. J. Transplant.; citation_title=Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave; citation_author=A Al Jurdi; citation_publication_date=2022; citation_doi=10.1111/ajt.17128; citation_id=CR124"/>
    <meta name="citation_reference" content="US Food and Drug Administration. Fact sheet for health care providers emergency use authorization (EUA) of bamlanivimab and etesevimab. FDA 
                  https://www.fda.gov/media/145802/download
                  
                 (2020)."/>
    <meta name="citation_reference" content="US Food and Drug Administration. Fact sheet for health care providers emergency use authorization (EUA) of REGEN-COV. FDA 
                  https://www.fda.gov/media/145611/download
                  
                 (2020)."/>
    <meta name="citation_reference" content="US Food and Drug Administration. Fact sheet for healthcare providers emergency use authorization (EUA) of sotrovimab. FDA 
                  https://www.fda.gov/media/149534/download
                  
                 (2020)."/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19; citation_author=M Vaduganathan; citation_volume=382; citation_publication_date=2020; citation_pages=1653-1659; citation_doi=10.1056/NEJMsr2005760; citation_id=CR128"/>
    <meta name="citation_reference" content="citation_journal_title=Front. Immunol.; citation_title=Intoxication with endogenous angiotensin II: a COVID-19 hypothesis; citation_author=A Sfera; citation_volume=11; citation_publication_date=2020; citation_pages=1472; citation_doi=10.3389/fimmu.2020.01472; citation_id=CR129"/>
    <meta name="citation_reference" content="citation_journal_title=Cell; citation_title=SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor; citation_author=M Hoffmann; citation_volume=181; citation_publication_date=2020; citation_pages=271-280.e8; citation_doi=10.1016/j.cell.2020.02.052; citation_id=CR130"/>
    <meta name="citation_reference" content="citation_journal_title=J. Pathol.; citation_title=Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis; citation_author=I Hamming; citation_volume=203; citation_publication_date=2004; citation_pages=631-637; citation_doi=10.1002/path.1570; citation_id=CR131"/>
    <meta name="citation_reference" content="citation_journal_title=Nat. Rev. Cardiol.; citation_title=Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets; citation_author=F Jiang; citation_volume=11; citation_publication_date=2014; citation_pages=413-426; citation_doi=10.1038/nrcardio.2014.59; citation_id=CR132"/>
    <meta name="citation_reference" content="citation_journal_title=Nature; citation_title=Angiotensin-converting enzyme 2 protects from severe acute lung failure; citation_author=Y Imai; citation_volume=436; citation_publication_date=2005; citation_pages=112-116; citation_doi=10.1038/nature03712; citation_id=CR133"/>
    <meta name="citation_reference" content="citation_journal_title=Intensive Care Med.; citation_title=Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target; citation_author=H Zhang, JM Penninger, Y Li, N Zhong, AS Slutsky; citation_volume=46; citation_publication_date=2020; citation_pages=586-590; citation_doi=10.1007/s00134-020-05985-9; citation_id=CR134"/>
    <meta name="citation_reference" content="citation_journal_title=Nat. Commun.; citation_title=COVID-19 pathophysiology may be driven by an imbalance in the renin-angiotensin-aldosterone system; citation_author=S Rysz; citation_volume=12; citation_publication_date=2021; citation_doi=10.1038/s41467-021-22713-z; citation_id=CR135"/>
    <meta name="citation_reference" content="citation_journal_title=Crit. Care Med.; citation_title=The renin-angiotensin system in acute lung injury; citation_author=PR Lawler, LPG Derde, B Verry, JA Russell, F Veerdonk; citation_volume=50; citation_publication_date=2022; citation_pages=1411-1415; citation_doi=10.1097/CCM.0000000000005567; citation_id=CR136"/>
    <meta name="citation_reference" content="citation_journal_title=BMJ; citation_title=Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis; citation_author=D Caldeira, J Alarc&#227;o, A Vaz-Carneiro, J Costa; citation_volume=345; citation_publication_date=2012; citation_doi=10.1136/bmj.e4260; citation_id=CR137"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Association between angiotensin blockade and incidence of influenza in the United Kingdom; citation_author=SC Chung, R Providencia, R Sofat; citation_volume=383; citation_publication_date=2020; citation_pages=397-400; citation_doi=10.1056/NEJMc2005396; citation_id=CR138"/>
    <meta name="citation_reference" content="citation_journal_title=Crit. Care Med.; citation_title=Effect of antihypertensive medications on sepsis-related outcomes: a population-based cohort study; citation_author=J Kim; citation_volume=47; citation_publication_date=2019; citation_pages=e386-e393; citation_doi=10.1097/CCM.0000000000003654; citation_id=CR139"/>
    <meta name="citation_reference" content="citation_journal_title=JAMA Netw. Open; citation_title=Association between renin-angiotensin-aldosterone system inhibitors and clinical outcomes in patients with COVID-19: a systematic review and meta-analysis; citation_author=R Baral; citation_volume=4; citation_publication_date=2021; citation_doi=10.1001/jamanetworkopen.2021.3594; citation_id=CR140"/>
    <meta name="citation_reference" content="citation_journal_title=JAMA; citation_title=Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial; citation_author=RD Lopes; citation_volume=325; citation_publication_date=2021; citation_pages=254-264; citation_doi=10.1001/jama.2020.25864; citation_id=CR141"/>
    <meta name="citation_reference" content="citation_journal_title=EClinicalMedicine; citation_title=Telmisartan for treatment of Covid-19 patients: an open multicenter randomized clinical trial; citation_author=M Duarte; citation_volume=37; citation_publication_date=2021; citation_pages=100962; citation_doi=10.1016/j.eclinm.2021.100962; citation_id=CR142"/>
    <meta name="citation_reference" content="citation_journal_title=EClinicalMedicine; citation_title=A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19; citation_author=MA Puskarich; citation_volume=37; citation_publication_date=2021; citation_pages=100957; citation_doi=10.1016/j.eclinm.2021.100957; citation_id=CR143"/>
    <meta name="citation_reference" content="citation_journal_title=Genome Res.; citation_title=A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution; citation_author=SV Ramagopalan; citation_volume=20; citation_publication_date=2010; citation_pages=1352-1360; citation_doi=10.1101/gr.107920.110; citation_id=CR144"/>
    <meta name="citation_reference" content="citation_journal_title=Science; citation_title=Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response; citation_author=PT Liu; citation_volume=311; citation_publication_date=2006; citation_pages=1770-1773; citation_doi=10.1126/science.1123933; citation_id=CR145"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Early high-dose vitamin D3 for critically ill, vitamin D-deficient patients; citation_author=AA Ginde; citation_volume=381; citation_publication_date=2019; citation_pages=2529-2540; citation_doi=10.1056/NEJMoa1911124; citation_id=CR146"/>
    <meta name="citation_reference" content="citation_journal_title=JAMA; citation_title=Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency: the VITdAL-ICU randomized clinical trial; citation_author=K Amrein; citation_volume=312; citation_publication_date=2014; citation_pages=1520-1530; citation_doi=10.1001/jama.2014.13204; citation_id=CR147"/>
    <meta name="citation_reference" content="citation_journal_title=JAMA; citation_title=Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial; citation_author=IH Murai; citation_volume=325; citation_publication_date=2021; citation_pages=1053-1060; citation_doi=10.1001/jama.2020.26848; citation_id=CR148"/>
    <meta name="citation_reference" content="citation_journal_title=JAMA; citation_title=Vitamin D3 to treat COVID-19: different disease, same answer; citation_author=DE Leaf, AA Ginde; citation_volume=325; citation_publication_date=2021; citation_pages=1047-1048; citation_doi=10.1001/jama.2020.26850; citation_id=CR149"/>
    <meta name="citation_reference" content="US National Library of Medicine. ClinicalTrials.gov 
                  https://clinicaltrials.gov/ct2/show/NCT04536298
                  
                 (2022)."/>
    <meta name="citation_reference" content="citation_journal_title=Nature; citation_title=PGC1&#945; drives NAD biosynthesis linking oxidative metabolism to renal protection; citation_author=MT Tran; citation_volume=531; citation_publication_date=2016; citation_pages=528-532; citation_doi=10.1038/nature17184; citation_id=CR151"/>
    <meta name="citation_reference" content="citation_journal_title=Nat. Med.; citation_title=De novo NAD+ biosynthetic impairment in acute kidney injury in humans; citation_author=A Poyan Mehr; citation_volume=24; citation_publication_date=2018; citation_pages=1351-1359; citation_doi=10.1038/s41591-018-0138-z; citation_id=CR152"/>
    <meta name="citation_reference" content="US National Library of Medicine. ClinicalTrials.gov 
                  https://clinicaltrials.gov/ct2/show/NCT04342975
                  
                 (2022)."/>
    <meta name="citation_reference" content="US National Library of Medicine. ClinicalTrials.gov 
                  https://clinicaltrials.gov/ct2/show/NCT04589546
                  
                 (2021)."/>
    <meta name="citation_reference" content="citation_journal_title=Kidney360; citation_title=Niacinamide may be associated with improved outcomes in COVID-19-related acute kidney injury: an observational study; citation_author=NH Raines; citation_volume=2; citation_publication_date=2021; citation_pages=33-41; citation_doi=10.34067/KID.0006452020; citation_id=CR155"/>
    <meta name="citation_reference" content="US National Library of Medicine. ClinicalTrials.gov 
                  https://clinicaltrials.gov/ct2/show/NCT05038488
                  
                 (2021)."/>
    <meta name="citation_reference" content="US National Library of Medicine. ClinicalTrials.gov 
                  https://clinicaltrials.gov/ct2/show/NCT04809974
                  
                 (2022)."/>
    <meta name="citation_reference" content="citation_journal_title=Crit. Care Med.; citation_title=Effect of IV high-dose vitamin c on mortality in patients with sepsis: a systematic review and meta-analysis of randomized controlled trials; citation_author=R Sato; citation_volume=49; citation_publication_date=2021; citation_pages=2121-2130; citation_id=CR158"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Intravenous vitamin C in adults with sepsis in the intensive care unit; citation_author=F Lamontagne; citation_volume=386; citation_publication_date=2022; citation_pages=2387-2398; citation_doi=10.1056/NEJMoa2200644; citation_id=CR159"/>
    <meta name="citation_reference" content="citation_journal_title=JAMA Netw. Open; citation_title=Effect of high-dose zinc and ascorbic acid supplementation vs usual care on symptom length and reduction among ambulatory patients with SARS-CoV-2 infection: the COVID A to Z randomized clinical trial; citation_author=S Thomas; citation_volume=4; citation_publication_date=2021; citation_doi=10.1001/jamanetworkopen.2021.0369; citation_id=CR160"/>
    <meta name="citation_reference" content="citation_journal_title=Ann. Intensive Care; citation_title=Pilot trial of high-dose vitamin C in critically ill COVID-19 patients; citation_author=J Zhang; citation_volume=11; citation_publication_date=2021; citation_doi=10.1186/s13613-020-00792-3; citation_id=CR161"/>
    <meta name="citation_reference" content="Johns Hopkins University &amp; Medicine. Coronavirus Resource Center. JHU 
                  https://coronavirus.jhu.edu/
                  
                 (2022)."/>
    <meta name="citation_reference" content="citation_journal_title=JAMA; citation_title=Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial; citation_author=; citation_volume=325; citation_publication_date=2021; citation_pages=1620-1630; citation_doi=10.1001/jama.2021.4152; citation_id=CR163"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=A neutralizing monoclonal antibody for hospitalized patients with Covid-19; citation_author=; citation_volume=384; citation_publication_date=2021; citation_pages=905-914; citation_doi=10.1056/NEJMoa2033130; citation_id=CR164"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Bamlanivimab plus etesevimab in mild or moderate Covid-19; citation_author=M Dougan; citation_volume=385; citation_publication_date=2021; citation_pages=1382-1392; citation_doi=10.1056/NEJMoa2102685; citation_id=CR165"/>
    <meta name="citation_author" content="Murakami, Naoka"/>
    <meta name="citation_author_institution" content="Division of Renal Medicine, Brigham and Women&#8217;s Hospital, Boston, USA"/>
    <meta name="citation_author_institution" content="Harvard Medical School, Boston, USA"/>
    <meta name="citation_author" content="Hayden, Robert"/>
    <meta name="citation_author_institution" content="Division of Renal Medicine, Brigham and Women&#8217;s Hospital, Boston, USA"/>
    <meta name="citation_author_institution" content="Harvard Medical School, Boston, USA"/>
    <meta name="citation_author" content="Hills, Thomas"/>
    <meta name="citation_author_institution" content="Medical Research Institute of New Zealand, Wellington, New Zealand"/>
    <meta name="citation_author_institution" content="Auckland District Health Board, Auckland, New Zealand"/>
    <meta name="citation_author" content="Al-Samkari, Hanny"/>
    <meta name="citation_author_institution" content="Harvard Medical School, Boston, USA"/>
    <meta name="citation_author_institution" content="Division of Hematology, Massachusetts General Hospital, Boston, USA"/>
    <meta name="citation_author" content="Casey, Jonathan"/>
    <meta name="citation_author_institution" content="Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, USA"/>
    <meta name="citation_author" content="Del Sorbo, Lorenzo"/>
    <meta name="citation_author_institution" content="Department of Medicine, University Health Network, Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Canada"/>
    <meta name="citation_author" content="Lawler, Patrick R."/>
    <meta name="citation_author_institution" content="Department of Medicine, University Health Network, Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Canada"/>
    <meta name="citation_author_institution" content="Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto, Canada"/>
    <meta name="citation_author" content="Sise, Meghan E."/>
    <meta name="citation_author_institution" content="Harvard Medical School, Boston, USA"/>
    <meta name="citation_author_institution" content="Division of Nephrology, Massachusetts General Hospital, Boston, USA"/>
    <meta name="citation_author" content="Leaf, David E."/>
    <meta name="citation_author_institution" content="Division of Renal Medicine, Brigham and Women&#8217;s Hospital, Boston, USA"/>
    <meta name="citation_author_institution" content="Harvard Medical School, Boston, USA"/>
    <meta name="access_endpoint" content="https://www.nature.com/platform/readcube-access"/>
    <meta name="twitter:site" content="@NatRevNeph"/>
    <meta name="twitter:card" content="summary_large_image"/>
    <meta name="twitter:image:alt" content="Content cover image"/>
    <meta name="twitter:title" content="Therapeutic advances in COVID-19"/>
    <meta name="twitter:description" content="Nature Reviews Nephrology - The COVID-19 pandemic was met with large-scale efforts to assess novel and repurposed therapeutic interventions that could reduce patient morbidity and mortality. Here,..."/>
    <meta name="twitter:image" content="https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41581-022-00642-4/MediaObjects/41581_2022_642_Fig1_HTML.png"/>
    

    
    
    <meta property="og:url" content="https://www.nature.com/articles/s41581-022-00642-4"/>
    <meta property="og:type" content="article"/>
    <meta property="og:site_name" content="Nature"/>
    <meta property="og:title" content="Therapeutic advances in COVID-19 - Nature Reviews Nephrology"/>
    <meta property="og:description" content="The COVID-19 pandemic was met with large-scale efforts to assess novel and repurposed therapeutic interventions that could reduce patient morbidity and mortality. Here, the authors discuss the different types of therapies available to treat COVID-19, including their relevance to patients with kidney failure and kidney transplant recipients."/>
    <meta property="og:image" content="https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41581-022-00642-4/MediaObjects/41581_2022_642_Fig1_HTML.png"/>
    

    <script>
        window.eligibleForRa21 = 'false'; 
    </script>
</head>
<body class="article-page">

<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-MRVXSHQ"
                  height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>



<div class="position-relative cleared z-index-50 background-white" data-test="top-containers">
    <a class="c-skip-link" href="#content">Skip to main content</a>



<div class="c-grade-c-banner u-hide">
    <div class="c-grade-c-banner__container">
        
        <p>Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
            the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
            Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
            and JavaScript.</p>

    </div>
</div>

    

    <div class="u-lazy-ad-wrapper u-mbs-0">
            <div class="deferred-placeholder" data-replace="true"
                 data-placeholder="/placeholder/v1/institutionalBanner?bpids=[bpids] #institutional-banner-container"></div>
            <aside class="c-ad c-ad--728x90">
                <div class="c-ad__inner" data-container-type="banner-advert">
                    <p class="c-ad__label">Advertisement</p>
                    
        
            
    <div id="div-gpt-ad-top-1"
         class="div-gpt-ad advert leaderboard js-ad text-center hide-print grade-c-hide"
         data-ad-type="top"
         data-test="top-ad"
         data-pa11y-ignore
         data-gpt
         data-gpt-unitpath="/285/naturereviews.nephrology/article"
         data-gpt-sizes="728x90"
         data-gpt-targeting="type=article;pos=top;artid=s41581-022-00642-4;doi=10.1038/s41581-022-00642-4;subjmeta=104,1436,1585,1586,2185,326,402,4022,4130,545,565,576,596,631,692,700;kwrd=End-stage+renal+disease,Molecularly+targeted+therapy,Organ+transplantation,SARS-CoV-2">
        <noscript>
            <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/285/naturereviews.nephrology/article&amp;sz=728x90&amp;c=-1468343717&amp;t=pos%3Dtop%26type%3Darticle%26artid%3Ds41581-022-00642-4%26doi%3D10.1038/s41581-022-00642-4%26subjmeta%3D104,1436,1585,1586,2185,326,402,4022,4130,545,565,576,596,631,692,700%26kwrd%3DEnd-stage+renal+disease,Molecularly+targeted+therapy,Organ+transplantation,SARS-CoV-2">
                <img data-test="gpt-advert-fallback-img"
                     src="//pubads.g.doubleclick.net/gampad/ad?iu=/285/naturereviews.nephrology/article&amp;sz=728x90&amp;c=-1468343717&amp;t=pos%3Dtop%26type%3Darticle%26artid%3Ds41581-022-00642-4%26doi%3D10.1038/s41581-022-00642-4%26subjmeta%3D104,1436,1585,1586,2185,326,402,4022,4130,545,565,576,596,631,692,700%26kwrd%3DEnd-stage+renal+disease,Molecularly+targeted+therapy,Organ+transplantation,SARS-CoV-2"
                     alt="Advertisement"
                     width="728"
                     height="90"></a>
        </noscript>
    </div>

        
    
                </div>
            </aside>
        </div>
    <header class="c-header" id="header" data-header data-track-component="nature-150-split-header" style="border-color:#006eb7">
        <div class="c-header__row">
            <div class="c-header__container">
                <div class="c-header__split">
                    
                    
                    <div class="c-header__logo-container">
                        
                        <a href="/nrneph"
                           data-track="click" data-track-action="home" data-track-label="image">
                            <picture class="c-header__logo">
                                <source srcset="https://media.springernature.com/full/nature-cms/uploads/product/nrneph/header-f24a2f19dbb97a44a49fe2a4e6a8ee65.svg" media="(min-width: 875px)">
                                <img src="https://media.springernature.com/full/nature-cms/uploads/product/nrneph/header-f24a2f19dbb97a44a49fe2a4e6a8ee65.svg" height="32" alt="Nature Reviews Nephrology">
                            </picture>
                        </a>
                    
                    </div>
                    
                    <ul class="c-header__menu c-header__menu--global">
                        <li class="c-header__item c-header__item--padding c-header__item--hide-md-max">
                            <a class="c-header__link" href="https://www.nature.com/siteindex" data-test="siteindex-link"
                               data-track="click" data-track-action="open nature research index" data-track-label="link">
                                <span>View all journals</span>
                            </a>
                        </li>
                        <li class="c-header__item c-header__item--padding c-header__item--pipe">
                            <a class="c-header__link c-header__link--search"
                                href="#search-menu"
                                data-header-expander
                                data-test="search-link" data-track="click" data-track-action="open search tray" data-track-label="button">
                                <svg role="img" aria-hidden="true" focusable="false" height="22" width="22" viewBox="0 0 18 18" xmlns="http://www.w3.org/2000/svg"><path d="M16.48 15.455c.283.282.29.749.007 1.032a.738.738 0 01-1.032-.007l-3.045-3.044a7 7 0 111.026-1.026zM8 14A6 6 0 108 2a6 6 0 000 12z"/></svg><span>Search</span>
                            </a>
                        </li>
                        <li class="c-header__item c-header__item--padding c-header__item--snid-account-widget c-header__item--pipe">
                            
                                <a class="c-header__link eds-c-header__link" id="identity-account-widget" href='https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41581-022-00642-4'><span class="eds-c-header__widget-fragment-title">Log in</span></a>
                            
                        </li>
                    </ul>
                </div>
            </div>
        </div>
        
            <div class="c-header__row">
                <div class="c-header__container" data-test="navigation-row">
                    <div class="c-header__split">
                        <ul class="c-header__menu c-header__menu--journal">
                            
                                <li class="c-header__item c-header__item--dropdown-menu" data-test="explore-content-button">
                                    <a href="#explore"
                                       class="c-header__link"
                                       data-header-expander
                                       data-test="menu-button--explore"
                                       data-track="click" data-track-action="open explore expander" data-track-label="button">
                                        <span><span class="c-header__show-text">Explore</span> content</span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"/></svg>
                                    </a>
                                </li>
                            
                            
                                <li class="c-header__item c-header__item--dropdown-menu">
                                    <a href="#about-the-journal"
                                       class="c-header__link"
                                       data-header-expander
                                       data-test="menu-button--about-the-journal"
                                       data-track="click" data-track-action="open about the journal expander" data-track-label="button">
                                        <span>About <span class="c-header__show-text">the journal</span></span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"/></svg>
                                    </a>
                                </li>
                                
                                    <li class="c-header__item c-header__item--dropdown-menu" data-test="publish-with-us-button">
                                        <a href="#publish-with-us"
                                           class="c-header__link c-header__link--dropdown-menu"
                                           data-header-expander
                                           data-test="menu-button--publish"
                                           data-track="click" data-track-action="open publish with us expander" data-track-label="button">
                                            <span>Publish <span class="c-header__show-text">with us</span></span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"/></svg>
                                        </a>
                                    </li>
                                
                            
                            
                        </ul>
                        <ul class="c-header__menu c-header__menu--hide-lg-max">
                            
                                <li class="c-header__item">
                                    <a class="c-header__link"
                                       href="https://www.nature.com/my-account/alerts/subscribe-journal?list-id&#x3D;110"
                                       rel="nofollow"
                                       data-track="click"
                                       data-track-action="Sign up for alerts"
                                       data-track-label="link (desktop site header)"
                                       data-track-external>
                                        <span>Sign up for alerts</span><svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill="#222"/></svg>
                                    </a>
                                </li>
                            
                            
                                <li class="c-header__item c-header__item--pipe">
                                    <a class="c-header__link"
                                       href="https://www.nature.com/nrneph.rss"
                                       data-track="click"
                                       data-track-action="rss feed"
                                       data-track-label="link">
                                            <span>RSS feed</span>
                                    </a>
                                </li>
                            
                        </ul>
                    </div>
                </div>
            </div>
        
    </header>


    
    
        <nav class="u-mb-16" aria-label="breadcrumbs">
            <div class="u-container">
                <ol class="c-breadcrumbs" itemscope itemtype="https://schema.org/BreadcrumbList">
                    <li class="c-breadcrumbs__item" id="breadcrumb0" itemprop="itemListElement" itemscope itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link"
                               href="/" itemprop="item"
                               data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:nature"><span itemprop="name">nature</span></a><meta itemprop="position" content="1">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10"
                                         xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z"
                                              fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"/>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb1" itemprop="itemListElement" itemscope itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link"
                               href="/nrneph" itemprop="item"
                               data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:nature reviews nephrology"><span itemprop="name">nature reviews nephrology</span></a><meta itemprop="position" content="2">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10"
                                         xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z"
                                              fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"/>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb2" itemprop="itemListElement" itemscope itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link"
                               href="/nrneph/articles?type&#x3D;review-article" itemprop="item"
                               data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:review articles"><span itemprop="name">review articles</span></a><meta itemprop="position" content="3">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10"
                                         xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z"
                                              fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"/>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb3" itemprop="itemListElement" itemscope itemtype="https://schema.org/ListItem">
                                    <span itemprop="name">article</span><meta itemprop="position" content="4"></li>
                </ol>
            </div>
        </nav>
    



    

</div>


<div class="u-container u-mt-32 u-mb-32 u-clearfix" id="content" data-component="article-container"  data-container-type="article">
    <main class="c-article-main-column u-float-left js-main-column" data-track-component="article body">
        
            <div class="c-context-bar u-hide"
                 data-test="context-bar"
                 data-context-bar
                 aria-hidden="true">
                <div class="c-context-bar__container u-container">
                    <div class="c-context-bar__title">
                        Therapeutic advances in COVID-19
                    </div>
                    
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41581-022-00642-4.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="click" data-track-action="download pdf" data-track-label="link" data-track-external download>
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"/></svg>
            </a>
        </div>
    

                </div>
            </div>
        
        <article lang="en">
            
                <div class="c-pdf-button__container u-mb-16 u-hide-at-lg js-context-bar-sticky-point-mobile">
                    <div class="c-pdf-container">
                        
                            
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41581-022-00642-4.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="click" data-track-action="download pdf" data-track-label="link" data-track-external download>
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"/></svg>
            </a>
        </div>
    

                        
                    </div>
                </div>
            
            <div class="c-article-header">
                <header>
                    <ul class="c-article-identifiers" data-test="article-identifier">
                        
        <li class="c-article-identifiers__item" data-test="article-category">Review Article</li>
    
    

                        <li class="c-article-identifiers__item"><a href="#article-info" data-track="click" data-track-action="publication date" data-track-label="link">Published: <time datetime="2022-10-17">17 October 2022</time></a></li>
                    </ul>

                    <h1 class="c-article-title" data-test="article-title" data-article-title="">Therapeutic advances in COVID-19</h1>
                    <ul class="c-article-author-list c-article-author-list--short" data-test="authors-list" data-component-authors-activator="authors-list"><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Naoka-Murakami-Aff1-Aff2" data-author-popup="auth-Naoka-Murakami-Aff1-Aff2" data-author-search="Murakami, Naoka">Naoka Murakami</a><sup class="u-js-hide"><a href="#Aff1">1</a>,<a href="#Aff2">2</a></sup>, </li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Robert-Hayden-Aff1-Aff2" data-author-popup="auth-Robert-Hayden-Aff1-Aff2" data-author-search="Hayden, Robert">Robert Hayden</a><sup class="u-js-hide"><a href="#Aff1">1</a>,<a href="#Aff2">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Thomas-Hills-Aff3-Aff4" data-author-popup="auth-Thomas-Hills-Aff3-Aff4" data-author-search="Hills, Thomas">Thomas Hills</a><span class="u-js-hide"> 
            <a class="js-orcid" href="http://orcid.org/0000-0003-0322-5822"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-0322-5822</a></span><sup class="u-js-hide"><a href="#Aff3">3</a>,<a href="#Aff4">4</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Hanny-Al_Samkari-Aff2-Aff5" data-author-popup="auth-Hanny-Al_Samkari-Aff2-Aff5" data-author-search="Al-Samkari, Hanny">Hanny Al-Samkari</a><span class="u-js-hide"> 
            <a class="js-orcid" href="http://orcid.org/0000-0001-6175-1383"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0001-6175-1383</a></span><sup class="u-js-hide"><a href="#Aff2">2</a>,<a href="#Aff5">5</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Jonathan-Casey-Aff6" data-author-popup="auth-Jonathan-Casey-Aff6" data-author-search="Casey, Jonathan">Jonathan Casey</a><sup class="u-js-hide"><a href="#Aff6">6</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Lorenzo-Sorbo-Aff7" data-author-popup="auth-Lorenzo-Sorbo-Aff7" data-author-search="Del Sorbo, Lorenzo">Lorenzo Del Sorbo</a><sup class="u-js-hide"><a href="#Aff7">7</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Patrick_R_-Lawler-Aff7-Aff8" data-author-popup="auth-Patrick_R_-Lawler-Aff7-Aff8" data-author-search="Lawler, Patrick R.">Patrick R. Lawler</a><sup class="u-js-hide"><a href="#Aff7">7</a>,<a href="#Aff8">8</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Meghan_E_-Sise-Aff2-Aff9" data-author-popup="auth-Meghan_E_-Sise-Aff2-Aff9" data-author-search="Sise, Meghan E.">Meghan E. Sise</a><sup class="u-js-hide"><a href="#Aff2">2</a>,<a href="#Aff9">9</a></sup> &amp; </li><li class="c-article-author-list__show-more" aria-label="Show all 9 authors for this article" title="Show all 9 authors for this article">…</li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-David_E_-Leaf-Aff1-Aff2" data-author-popup="auth-David_E_-Leaf-Aff1-Aff2" data-author-search="Leaf, David E." data-corresp-id="c1">David E. Leaf<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-mail-medium"></use></svg></a><span class="u-js-hide"> 
            <a class="js-orcid" href="http://orcid.org/0000-0001-7875-090X"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0001-7875-090X</a></span><sup class="u-js-hide"><a href="#Aff1">1</a>,<a href="#Aff2">2</a></sup> </li></ul><button aria-expanded="false" class="c-article-author-list__button"><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-down-medium"></use></svg><span>Show authors</span></button>

                    

                    <p class="c-article-info-details" data-container-section="info">
                        
    <a data-test="journal-link" href="/nrneph" data-track="click" data-track-action="journal homepage" data-track-category="article body" data-track-label="link"><i data-test="journal-title">Nature Reviews Nephrology</i></a>

                        <b data-test="journal-volume"><span class="u-visually-hidden">volume</span> 19</b>, <span class="u-visually-hidden">pages </span>38–52 (<span data-test="article-publication-year">2023</span>)<a href="#citeas" class="c-article-info-details__cite-as u-hide-print" data-track="click" data-track-action="cite this article" data-track-label="link">Cite this article</a>
                    </p>
                    
        <div class="c-article-metrics-bar__wrapper u-clear-both">
            <ul class="c-article-metrics-bar u-list-reset">
                
                    <li class=" c-article-metrics-bar__item">
                        <p class="c-article-metrics-bar__count">21k <span class="c-article-metrics-bar__label">Accesses</span></p>
                    </li>
                
                
                    <li class="c-article-metrics-bar__item">
                        <p class="c-article-metrics-bar__count">57 <span class="c-article-metrics-bar__label">Citations</span></p>
                    </li>
                
                
                    
                        <li class="c-article-metrics-bar__item">
                            <p class="c-article-metrics-bar__count">389 <span class="c-article-metrics-bar__label">Altmetric</span></p>
                        </li>
                    
                
                <li class="c-article-metrics-bar__item">
                    <p class="c-article-metrics-bar__details"><a href="/articles/s41581-022-00642-4/metrics" data-track="click" data-track-action="view metrics" data-track-label="link" rel="nofollow">Metrics <span class="u-visually-hidden">details</span></a></p>
                </li>
            </ul>
        </div>
    
                    
                </header>

                
    <div class="u-js-hide" data-component="article-subject-links">
        <h3 class="c-article__sub-heading">Subjects</h3>
        <ul class="c-article-subject-list">
            <li class="c-article-subject-list__subject"><a href="/subjects/end-stage-renal-disease" data-track="click" data-track-action="view subject" data-track-label="link">End-stage renal disease</a></li><li class="c-article-subject-list__subject"><a href="/subjects/molecular-targeted-therapy" data-track="click" data-track-action="view subject" data-track-label="link">Molecularly targeted therapy</a></li><li class="c-article-subject-list__subject"><a href="/subjects/organ-transplantation" data-track="click" data-track-action="view subject" data-track-label="link">Organ transplantation</a></li><li class="c-article-subject-list__subject"><a href="/subjects/sars-cov-2" data-track="click" data-track-action="view subject" data-track-label="link">SARS-CoV-2</a></li>
        </ul>
    </div>

                
    
    
        <div class="u-mb-8 c-status-message c-status-message--boxed c-status-message--info">
            
                <span class="c-status-message__icon">
                    <svg class="u-icon" width="18" height="18" aria-hidden="true" focusable="false">
                        <use xlink:href="#icon-eds-i-info-filled-medium"></use>
                    </svg>
                </span>
            
            
                
                    <p class="u-mt-0">An <a href="https://doi.org/10.1038/s41581-023-00686-0" class="relation-link" data-track="click" data-track-action="view linked article" data-track-label="link">Author Correction</a> to this article was published on 06 February 2023</p>
                
            
        </div>
    

    
        <div class="u-mb-8 c-status-message c-status-message--boxed c-status-message--info">
            
                <span class="c-status-message__icon">
                    <svg class="u-icon" width="18" height="18" aria-hidden="true" focusable="false">
                        <use xlink:href="#icon-eds-i-info-filled-medium"></use>
                    </svg>
                </span>
            
            <p class="u-mt-0">This article has been <a href="#change-history">updated</a></p>
        </div>
    
    

                
            </div>

        <div class="c-article-body">
            <section aria-labelledby="Abs1" data-title="Abstract" lang="en"><div class="c-article-section" id="Abs1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Abs1">Abstract</h2><div class="c-article-section__content" id="Abs1-content"><p>Over 2 years have passed since the start of the COVID-19 pandemic, which has claimed millions of lives. Unlike the early days of the pandemic, when management decisions were based on extrapolations from in vitro data, case reports and case series, clinicians are now equipped with an armamentarium of therapies based on high-quality evidence. These treatments are spread across seven main therapeutic categories: anti-inflammatory agents, antivirals, antithrombotics, therapies for acute hypoxaemic respiratory failure, anti-SARS-CoV-2 (neutralizing) antibody therapies, modulators of the renin–angiotensin–aldosterone system and vitamins. For each of these treatments, the patient population characteristics and clinical settings in which they were studied are important considerations. Although few direct comparisons have been performed, the evidence base and magnitude of benefit for anti-inflammatory and antiviral agents clearly outweigh those of other therapeutic approaches such as vitamins. The emergence of novel variants has further complicated the interpretation of much of the available evidence, particularly for antibody therapies. Importantly, patients with acute and chronic kidney disease were under-represented in many of the COVID-19 clinical trials, and outcomes in this population might differ from those reported in the general population. Here, we examine the clinical evidence for these therapies through a kidney medicine lens.</p></div></div></section><section aria-labelledby="Abs3" data-title="Key points" lang="en"><div class="c-article-section" id="Abs3-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Abs3">Key points</h2><div class="c-article-section__content" id="Abs3-content"><ul class="u-list-style-bullet">
                <li>
                  <p>Multiple effective and safe therapeutics for COVID-19 have been developed since the start of the pandemic in early 2020, with several agents now approved for use across the spectrum of disease severity.</p>
                </li>
              </ul><ul class="u-list-style-bullet">
                <li>
                  <p>COVID-19 therapeutics investigated to date include anti-inflammatory agents, antivirals, antithrombotics, therapies for acute hypoxaemic respiratory failure, anti-SARS-CoV-2 (neutralizing) antibody therapies, modulators of the renin–angiotensin–aldosterone system and vitamins.</p>
                </li>
                <li>
                  <p>Patients with underlying kidney disease represent a vulnerable population at high risk of adverse outcomes from COVID-19, yet they were excluded or under-represented in many COVID-19 clinical trials.</p>
                </li>
                <li>
                  <p>Additional data on the efficacy and safety of COVID-19 therapeutics in patients with chronic kidney disease are needed, as well as data on therapeutics for the prevention and treatment of COVID-19-associated acute kidney injury.</p>
                </li>
              </ul></div></div></section>

            <noscript>
                
            </noscript>

            

            
                
                    
        
            <section aria-labelledby="inline-recommendations" data-title="Inline Recommendations" class="c-article-recommendations" data-track-component="inline-recommendations">
                <h3 class="c-article-recommendations-title" id="inline-recommendations">Similar content being viewed by others</h3>
                <div class="c-article-recommendations-list">
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41579-022-00846-2/MediaObjects/41579_2022_846_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link"
                                           itemprop="url"
                                           href="https://www.nature.com/articles/s41579-022-00846-2?fromPaywallRec=true"
                                           data-track="click"
                                           data-track-action="click recommendations inline - 1"
                                           data-track-label="10.1038/s41579-022-00846-2">Long COVID: major findings, mechanisms and recommendations
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                        
                                         <span class="c-article-meta-recommendations__date">13 January 2023</span>
                                    </div>
                                </div>
                                <p class="c-article-recommendations-card__authors u-sans-serif">Hannah E. Davis, Lisa McCorkell, … Eric J. Topol</p>
                            </article>
                        </div>
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41590-024-01754-8/MediaObjects/41590_2024_1754_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link"
                                           itemprop="url"
                                           href="https://www.nature.com/articles/s41590-024-01754-8?fromPaywallRec=true"
                                           data-track="click"
                                           data-track-action="click recommendations inline - 2"
                                           data-track-label="10.1038/s41590-024-01754-8">Iron dysregulation and inflammatory stress erythropoiesis associates with long-term outcome of COVID-19
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">01 March 2024</span>
                                    </div>
                                </div>
                                <p class="c-article-recommendations-card__authors u-sans-serif">Aimee L. Hanson, Matthew P. Mulè, … Kenneth G. C. Smith</p>
                            </article>
                        </div>
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41573-023-00859-3/MediaObjects/41573_2023_859_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link"
                                           itemprop="url"
                                           href="https://www.nature.com/articles/s41573-023-00859-3?fromPaywallRec=true"
                                           data-track="click"
                                           data-track-action="click recommendations inline - 3"
                                           data-track-label="10.1038/s41573-023-00859-3">Strategies to reduce the risks of mRNA drug and vaccine toxicity
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                        
                                         <span class="c-article-meta-recommendations__date">23 January 2024</span>
                                    </div>
                                </div>
                                <p class="c-article-recommendations-card__authors u-sans-serif">Dimitrios Bitounis, Eric Jacquinet, … Mansoor M. Amiji</p>
                            </article>
                        </div>
                    
                </div>
            </section>
        
            <script>
                window.dataLayer = window.dataLayer || [];
                window.dataLayer.push({
                    recommendations: {
                        recommender: 'topic',
                        model: 'visits_v2',
                        policy_id: 'speedy-BootstrappedUCB',
                        timestamp: 1710277731,
                        embedded_user: 'null'
                    }
                });
            </script>
        
    
                
                
                <div class="main-content">
                    <section data-title="Introduction"><div class="c-article-section" id="Sec1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec1">Introduction</h2><div class="c-article-section__content" id="Sec1-content"><p>Since the beginning of the COVID-19 pandemic in March 2020, SARS-CoV-2 has claimed the lives of millions of people worldwide, and the number of deaths continues to rise with the emergence of new variants<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 1" title="Karim, S. S. A. &amp; Karim, Q. A. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet 398, 2126–2128 (2021)." href="/articles/s41581-022-00642-4#ref-CR1" id="ref-link-section-d17524587e718">1</a></sup>. During this time, therapeutics against COVID-19 have also advanced at an astounding pace, and clinicians are now equipped with an armamentarium of treatment options for patients across the spectrum of COVID-19 severity, ranging from mild to critical illness.</p><p>Therapeutic agents investigated during the pandemic include medications with diverse mechanisms of action, such as antiviral therapies that inhibit viral replication directly, recombinant neutralizing monoclonal antibodies that block viral entry into host cells, adjunct therapies that target the host immune response (for example, anti-inflammatory and antithrombotic therapies), and therapies targeting the renin–angiotensin–aldosterone system (RAAS) (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41581-022-00642-4#Fig1">1</a>). Numerous randomized clinical trials (RCTs) have tested the safety and efficacy of these agents (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41581-022-00642-4#Fig2">2</a>), which include both novel and repurposed drugs. Multiple therapies have obtained emergency-use authorization (EUA) and, in some cases, approval from regulatory agencies, including the FDA and the EMA (Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41581-022-00642-4#Tab1">1</a>).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-1" data-title="Classes of therapies for COVID-19."><figure><figcaption><b id="Fig1" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 1: Classes of therapies for COVID-19.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41581-022-00642-4/figures/1" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41581-022-00642-4/MediaObjects/41581_2022_642_Fig1_HTML.png?as=webp"><img aria-describedby="Fig1" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41581-022-00642-4/MediaObjects/41581_2022_642_Fig1_HTML.png" alt="figure 1" loading="lazy" width="685" height="297"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-1-desc"><p>Therapies for COVID-19 can be broadly categorized as targeting the host response to infection (including inflammation, thrombosis, acute respiratory distress syndrome (ARDS) and renin–angiotensin–aldosterone system (RAAS) activation) or targeting the virus directly (including direct antivirals and antibody-based therapies). SARS-CoV-2 infection can lead to hyperinflammation characterized by abundant circulating levels of pro-inflammatory cytokines such as IL-6. Therapies targeting inflammation include immunosuppressive drugs such as glucocorticoids (for example, dexamethasone) and anti-IL-6 receptor antibodies (for example, tocilizumab). Several antithrombotic therapies have also been trialled to address the haemostatic and thrombotic complications associated with COVID-19, whereas different methods of oxygen delivery and intubation can be employed to treat patients with ARDS. COVID-19 can also disrupt RAAS homeostasis and drugs such as angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers are being investigated as potential therapies. Finally, therapies targeting SARS-CoV-2 directly include antivirals that disrupt viral replication and neutralizing antibody therapies that prevent virus entry into host cells.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41581-022-00642-4/figures/1" data-track-dest="link:Figure1 Full size image" aria-label="Full size image figure 1" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-2" data-title="Timeline of publication of pivotal phase III randomized clinical trials of COVID-19 therapies."><figure><figcaption><b id="Fig2" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 2: Timeline of publication of pivotal phase III randomized clinical trials of COVID-19 therapies.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41581-022-00642-4/figures/2" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41581-022-00642-4/MediaObjects/41581_2022_642_Fig2_HTML.png?as=webp"><img aria-describedby="Fig2" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41581-022-00642-4/MediaObjects/41581_2022_642_Fig2_HTML.png" alt="figure 2" loading="lazy" width="685" height="564"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-2-desc"><p>Timeline of publication and key features of pivotal phase III randomized clinical trials of COVID-19 therapies. These trials are categorized into six treatment categories: anti-inflammatory agents, antivirals, renin–angiotensin–aldosterone system (RAAS) modification, antithrombotic agents, convalescent plasma and monoclonal antibody therapies. AC, anticoagulation; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; d, days; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; IMV, invasive mechanical ventilation; NIV, noninvasive ventilation; outpts, outpatients; pts, patients. This timeline reflects published data as of 29 May 2022.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41581-022-00642-4/figures/2" data-track-dest="link:Figure2 Full size image" aria-label="Full size image figure 2" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><div class="c-article-table" data-test="inline-table" data-container-section="table" id="table-1"><figure><figcaption class="c-article-table__figcaption"><b id="Tab1" data-test="table-caption">Table 1 Authorized or approved therapeutics for COVID-19</b></figcaption><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="table-link" data-track="click" data-track-action="view table" data-track-label="button" rel="nofollow" href="/articles/s41581-022-00642-4/tables/1" aria-label="Full size table 1"><span>Full size table</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>In this Review, we discuss the therapeutic advances in the treatment of COVID-19 since the start of the pandemic. We also emphasize their relevance to patients with kidney disease, including chronic kidney disease (CKD) and kidney failure requiring kidney replacement therapy (KRT), as well as kidney transplant recipients, who are all at increased risk of adverse COVID-19 outcomes<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 2" title="Flythe, J. E. et al. Characteristics and outcomes of individuals with pre-existing kidney disease and COVID-19 admitted to intensive care units in the United States. Am. J. Kidney Dis. 77, 190–203.e1 (2021)." href="/articles/s41581-022-00642-4#ref-CR2" id="ref-link-section-d17524587e1337">2</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 3" title="Massie, A. B. et al. Quantifying excess deaths among solid organ transplant recipients in the COVID-19 era. Am. J. Transplant. 22, 2077–2082 (2022)." href="/articles/s41581-022-00642-4#ref-CR3" id="ref-link-section-d17524587e1340">3</a></sup>. These patient populations were excluded or under-represented in many of the RCTs of novel therapies for COVID-19, presumably owing to concerns regarding altered pharmacokinetics and the potential for increased toxicity. We also discuss the role of these therapies in the prevention and treatment of COVID-19-associated acute kidney injury (AKI), which is a common and important complication of COVID-19 among hospitalized<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 4" title="Chan, L. et al. AKI in hospitalized patients with COVID-19. J. Am. Soc. Nephrol. 32, 151–160 (2021)." href="/articles/s41581-022-00642-4#ref-CR4" id="ref-link-section-d17524587e1344">4</a></sup> and critically ill patients<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5" title="Gupta, S. et al. AKI treated with renal replacement therapy in critically ill patients with COVID-19. J. Am. Soc. Nephrol. 32, 161–176 (2021)." href="/articles/s41581-022-00642-4#ref-CR5" id="ref-link-section-d17524587e1348">5</a></sup>.</p></div></div></section><section data-title="Therapies targeting inflammation"><div class="c-article-section" id="Sec2-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec2">Therapies targeting inflammation</h2><div class="c-article-section__content" id="Sec2-content"><p>From the early stages of the COVID-19 pandemic, hyperinflammation has been proposed to have an important role in the pathophysiology of severe COVID-19 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 6" title="Mehta, P. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395, 1033–1034 (2020)." href="/articles/s41581-022-00642-4#ref-CR6" id="ref-link-section-d17524587e1360">6</a></sup>). Compared with healthy individuals, hospitalized patients with COVID-19 have elevated circulating concentrations of acute phase reactants (for example, ferritin)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 7" title="Gupta, S. et al. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern. Med. 180, 1436–1447 (2020)." href="/articles/s41581-022-00642-4#ref-CR7" id="ref-link-section-d17524587e1364">7</a></sup>, pro-inflammatory cytokines (for example, IL-6)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 8" title="Del Valle, D. M. et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 26, 1636–1643 (2020)." href="/articles/s41581-022-00642-4#ref-CR8" id="ref-link-section-d17524587e1368">8</a></sup> and markers of coagulation and fibrinolysis (for example, D-dimer)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 9" title="Short, S. A. P. et al. d-dimer and death in critically ill patients with coronavirus disease 2019. Crit. Care Med. 49, e500–e511 (2021)." href="/articles/s41581-022-00642-4#ref-CR9" id="ref-link-section-d17524587e1372">9</a></sup>. Moreover, higher levels of these markers have been consistently associated with an increased risk of death in patients with COVID-19 (refs. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 8" title="Del Valle, D. M. et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 26, 1636–1643 (2020)." href="/articles/s41581-022-00642-4#ref-CR8" id="ref-link-section-d17524587e1376">8</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 9" title="Short, S. A. P. et al. d-dimer and death in critically ill patients with coronavirus disease 2019. Crit. Care Med. 49, e500–e511 (2021)." href="/articles/s41581-022-00642-4#ref-CR9" id="ref-link-section-d17524587e1379">9</a></sup>). Although subsequent studies found that the severity of inflammation in COVID-19 might be similar to that observed in patients with sepsis or acute respiratory distress syndrome (ARDS) but without COVID-19 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 10" title="Wilson, J. G. et al. Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis. JCI Insight 5, 140289 (2020)." href="/articles/s41581-022-00642-4#ref-CR10" id="ref-link-section-d17524587e1384">10</a></sup>), the association between inflammatory markers and outcome severity prompted a series of trials of interventions that targeted inflammatory pathways.</p><h3 class="c-article__sub-heading" id="Sec3">Dexamethasone</h3><p>The Randomized Evaluation of COVID-19 Therapy (RECOVERY) group conducted the largest RCT to date of glucocorticoids in patients with COVID-19 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 11" title="RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 384, 693–704 (2021)." href="/articles/s41581-022-00642-4#ref-CR11" id="ref-link-section-d17524587e1395">11</a></sup>). RECOVERY randomly assigned 6,425 hospitalized adult patients with COVID-19 to receive oral or intravenous (i.v.) dexamethasone 6 mg daily for up to 10 days, or usual care. The primary outcome of mortality at 28 days was lower in the dexamethasone group (22.9% versus 25.7%; rate ratio (RR) 0.83, 95% CI 0.75–0.93). Pre-specified analyses of the primary outcome revealed significant heterogeneity according to the level of oxygen support (<i>P</i> &lt; 0.001) — the mortality benefit with dexamethasone was greatest in patients receiving invasive mechanical ventilation (IMV) at randomization (RR, 0.64, 95% CI 0.51–0.81), whereas a trend towards harm was observed in patients not receiving oxygen at randomization (RR 1.19, 95% CI 0.92–1.55). These findings were corroborated by a meta-analysis conducted by the WHO Rapid Evidence Appraisal for COVID-19 (REACT) Working Group, which pooled data from seven RCTs of glucocorticoids in 1,703 critically ill patients with COVID-19 and found the odds ratio (OR) for 28-day mortality to be 0.66 (95% CI 0.53–0.82)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 324, 1330–1341 (2020)." href="/articles/s41581-022-00642-4#ref-CR12" id="ref-link-section-d17524587e1402">12</a></sup>.</p><h3 class="c-article__sub-heading" id="Sec4">Tocilizumab</h3><p>Tocilizumab is a humanized monoclonal antibody against the IL-6 receptor. Early observational data suggested a survival benefit in hospitalized patients with COVID-19 treated with tocilizumab<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Gupta, S. et al. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern. Med. 181, 41–51 (2021)." href="/articles/s41581-022-00642-4#ref-CR13" id="ref-link-section-d17524587e1414">13</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 14" title="Guaraldi, G. et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2, e474–e484 (2020)." href="/articles/s41581-022-00642-4#ref-CR14" id="ref-link-section-d17524587e1417">14</a></sup>, particularly if administered early in the disease course. These data conflict with those of initial RCTs<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 15" title="Stone, J. H. et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N. Engl. J. Med. 383, 2333–2344 (2020)." href="/articles/s41581-022-00642-4#ref-CR15" id="ref-link-section-d17524587e1421">15</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 16" title="Salvarani, C. et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern. Med. 181, 24–31 (2021)." href="/articles/s41581-022-00642-4#ref-CR16" id="ref-link-section-d17524587e1424">16</a></sup>, which were largely negative but were also underpowered to rule out a significant clinical benefit<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Leaf, D. E., Gupta, S. &amp; Wang, W. Tocilizumab in covid-19. N. Engl. J. Med. 384, 86–87 (2021)." href="/articles/s41581-022-00642-4#ref-CR17" id="ref-link-section-d17524587e1428">17</a></sup>. Subsequently, two large pragmatic RCTs demonstrated a mortality benefit.</p><p>The Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) randomly assigned 755 critically ill adult patients with COVID-19 to receive tocilizumab or usual care<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with covid-19. N. Engl. J. Med. 384, 1491–1502 (2021)." href="/articles/s41581-022-00642-4#ref-CR18" id="ref-link-section-d17524587e1435">18</a></sup>. Tocilizumab was administered at a median of 1.2 days following hospital admission. In-hospital mortality was considerably lower in patients assigned to tocilizumab (28% versus 36%; median adjusted OR 1.64, 95% credible interval 1.14–2.35), as was 90-day mortality.</p><p>The RECOVERY group conducted the largest RCT of tocilizumab in COVID-19 to date<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 19" title="RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397, 1637–1645 (2021)." href="/articles/s41581-022-00642-4#ref-CR19" id="ref-link-section-d17524587e1442">19</a></sup>. A total of 4,116 adult patients hospitalized at 131 sites in the UK were randomly assigned to receive tocilizumab or usual care. Tocilizumab was administered at a median of 2 days following hospital admission. Mortality at 28 days was lower in patients assigned to tocilizumab (31% versus 35%; RR 0.85, 95% CI 0.76–0.94).</p><p>Some investigators have raised concerns regarding the lack of blinding in these large pragmatic trials<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Normand, S. L. T. The RECOVERY platform. N. Engl. J. Med. 384, 757–758 (2021)." href="/articles/s41581-022-00642-4#ref-CR20" id="ref-link-section-d17524587e1449">20</a></sup> but the results seem to be consistent across studies. Further, the findings were concordant with the results of the WHO REACT Working Group’s meta-analysis, which included 10,930 adult patients with COVID-19 from 27 RCTs that assessed the efficacy of IL-6 antagonists. In this meta-analysis, the OR for 28-day mortality with IL-6 antagonists was 0.86 (95% CI 0.79–0.95)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 21" title="WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA 326, 499–518 (2021)." href="/articles/s41581-022-00642-4#ref-CR21" id="ref-link-section-d17524587e1453">21</a></sup>. Tocilizumab received FDA EUA for COVID-19 on 24 June 2021 and is currently under priority review by the FDA for approval (Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41581-022-00642-4#Tab1">1</a>); this treatment was approved by the EMA on 6 December 2021 (Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41581-022-00642-4#Tab1">1</a>).</p><h3 class="c-article__sub-heading" id="Sec5">Baricitinib</h3><p>Baricitinib is an oral Janus kinase 1 (JAK1) and JAK2 inhibitor with anti-inflammatory properties. An RCT conducted in 1,033 hospitalized adults found that treatment with baricitinib (4 mg daily, up to 14 days) plus the antiviral remdesivir (discussed in more detail below) was superior to remdesivir alone in reducing time to recovery<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Kalil, A. C. et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N. Engl. J. Med. 384, 795–807 (2021)." href="/articles/s41581-022-00642-4#ref-CR22" id="ref-link-section-d17524587e1471">22</a></sup>. In a subsequent phase III RCT, 1,525 adult patients hospitalized at 101 centres across 12 countries were assigned to baricitinib (4 mg daily) or placebo for up to 14 days<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Marconi, V. C. et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir. Med. 9, 1407–1418 (2021)." href="/articles/s41581-022-00642-4#ref-CR23" id="ref-link-section-d17524587e1475">23</a></sup>. Although the primary composite outcome (the proportion who progressed to high-flow oxygen, noninvasive ventilation (NIV), IMV or death by day 28) was similar between groups, 28-day mortality was notably lower in the baricitinib group than in the placebo group (8% versus 13%; hazard ratio (HR) 0.57, 95% CI 0.41–0.78). Importantly, patients receiving IMV were excluded from this study. However, a subsequent smaller RCT conducted by the same group in 101 critically ill adults with COVID-19 receiving IMV or extracorporeal membrane oxygenation (ECMO) reported a 28-day mortality benefit with baricitinib versus placebo (39% versus 58%; HR 0.54, 95% CI 0.31–0.96)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 24" title="Ely, E. W. et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respir. Med. 10, 327–336 (2022)." href="/articles/s41581-022-00642-4#ref-CR24" id="ref-link-section-d17524587e1479">24</a></sup>. In the largest RCT of baricitinib to date, the RECOVERY group randomly assigned 8,156 hospitalized adults to receive baricitinib 4 mg daily until either 10 days or hospital discharge, versus usual care. Patients who received baricitinib had lower 28-day mortality than those receiving usual care (age-adjusted RR 0.87, 95% CI 0.77–0.99)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 25" title="RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet 400, 359–368 (2022)." href="/articles/s41581-022-00642-4#ref-CR25" id="ref-link-section-d17524587e1483">25</a></sup>. Baricitinib was approved by the FDA in May 2022 and is currently under review by the EMA (Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41581-022-00642-4#Tab1">1</a>).</p><h3 class="c-article__sub-heading" id="Sec6">Relevance to patients with kidney disease</h3><p>The largest RCTs that assessed dexamethasone and tocilizumab in COVID-19 included patients with AKI, CKD and kidney failure requiring KRT, as well as kidney transplant recipients. No dose adjustments are required for the use of these agents in patients with kidney dysfunction (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41581-022-00642-4#Fig3">3</a>). By contrast, the baricitinib dose is reduced to 2 mg daily in patients with estimated glomerular filtration rate (eGFR) 30–59 ml/min/1.73 m<sup>2</sup>, and to 1 mg daily in patients with eGFR 15–29 ml/min/1.73 m<sup>2</sup> (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41581-022-00642-4#Fig3">3</a>). Whether the magnitude of benefit of anti-inflammatory therapies in patients with COVID-19 differs according to the level of kidney function at baseline has not been assessed.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-3" data-title="Anti-inflammatory and antiviral agents for COVID-19 including dose adjustment for kidney function impairment."><figure><figcaption><b id="Fig3" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 3: Anti-inflammatory and antiviral agents for COVID-19 including dose adjustment for kidney function impairment.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41581-022-00642-4/figures/3" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41581-022-00642-4/MediaObjects/41581_2022_642_Fig3_HTML.png?as=webp"><img aria-describedby="Fig3" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41581-022-00642-4/MediaObjects/41581_2022_642_Fig3_HTML.png" alt="figure 3" loading="lazy" width="685" height="274"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-3-desc"><p>The immunosuppressive therapies dexamethasone and tocilizumab can be used without dose adjustments in patients with kidney disease, including those with kidney failure. However, the anti-inflammatory agent baricitinib must be administered at reduced doses in patients with estimated glomerular filtration rate (eGFR) &lt;60 ml/min/1.73 m<sup>2</sup>. In the case of antivirals used to treat SARS-CoV-2 infection, molnupiravir can be used without dose adjustments and remdesivir, although currently not recommended for use in patients with eGFR &lt; 30 ml/min/1.73 m<sup>2</sup>, has been reportedly used in patients across the spectrum of kidney dysfunction, including in patients with kidney failure who require kidney replacement therapy (KRT). By contrast, nirmatrelvir–ritonavir is contraindicated in patients with eGFR &lt;30 ml/min/1.73 m<sup>2</sup> and, given its potential to increase exposure to calcineurin inhibitors (CNIs) and mammalian target of rapamycin (mTOR) inhibitors, must be used with extreme caution in recipients of solid organ transplants, and only if CNI and/or mTOR levels can be monitored closely. The asterisk indicates that in patients with eGFR 30–59 ml/min/1.73 m<sup>2</sup>, the dose of nirmatrelvir is reduced by 50% but the ritonavir dose remains unchanged.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41581-022-00642-4/figures/3" data-track-dest="link:Figure3 Full size image" aria-label="Full size image figure 3" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>The use of anti-inflammatory agents such as tocilizumab or dexamethasone could potentially increase the risk of secondary infection, especially in patients with kidney failure or in kidney transplant recipients. Of note, although the aforementioned RCTs of tocilizumab did not report an increased risk of secondary infection<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with covid-19. N. Engl. J. Med. 384, 1491–1502 (2021)." href="/articles/s41581-022-00642-4#ref-CR18" id="ref-link-section-d17524587e1540">18</a></sup>, solid organ transplant recipients might have been under-represented in these trials.</p><p>Finally, whether glucocorticoids, IL-6 antagonists and other anti-inflammatory therapies reduce the risk of AKI in patients with COVID-19 has not been rigorously examined. However, the effect of dexamethasone and tocilizumab on the most severe form of AKI (that is, AKI requiring KRT) was assessed by the RECOVERY group trials of these agents and, in both cases, treatment reduced the incidence of KRT considerably<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 11" title="RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 384, 693–704 (2021)." href="/articles/s41581-022-00642-4#ref-CR11" id="ref-link-section-d17524587e1547">11</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 19" title="RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397, 1637–1645 (2021)." href="/articles/s41581-022-00642-4#ref-CR19" id="ref-link-section-d17524587e1550">19</a></sup>.</p></div></div></section><section data-title="Antiviral therapies"><div class="c-article-section" id="Sec7-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec7">Antiviral therapies</h2><div class="c-article-section__content" id="Sec7-content"><p>At the outset of the COVID-19 pandemic, no antiviral agents were licensed for the treatment of this disease. Consequently, numerous repurposed therapies with in vitro antiviral activity entered clinical use and were tested in clinical trials. However, many widely used agents such as hydroxychloroquine, lopinavir or ritonavir, and ivermectin were shown to be ineffective COVID-19 therapies when studied in adequately powered RCTs<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Axfors, C. et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat. Commun. 12, 2349 (2021)." href="#ref-CR26" id="ref-link-section-d17524587e1563">26</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Arabi, Y. M. et al. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Med. 47, 867–886 (2021)." href="#ref-CR27" id="ref-link-section-d17524587e1563_1">27</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Reis, G. et al. Effect of early treatment with ivermectin among patients with Covid-19. N. Engl. J. Med. 386, 1721–1731 (2022)." href="/articles/s41581-022-00642-4#ref-CR28" id="ref-link-section-d17524587e1566">28</a></sup>; more effective antivirals are now available.</p><h3 class="c-article__sub-heading" id="Sec8">Remdesivir</h3><p>Remdesivir is a prodrug nucleoside analogue — its active metabolite reduces genome replication by inhibiting RNA-dependent RNA polymerase — and has antiviral activity against many RNA viruses in vitro, including SARS-CoV-2 (refs. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 29" title="Sheahan, T. P. et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl Med. 9, eaal3653 (2017)." href="/articles/s41581-022-00642-4#ref-CR29" id="ref-link-section-d17524587e1577">29</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 30" title="Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, 269–271 (2020)." href="/articles/s41581-022-00642-4#ref-CR30" id="ref-link-section-d17524587e1580">30</a></sup>). Remdesivir has been studied in patients with COVID-19 in both the outpatient and inpatient settings. In the PINETREE study, a 3-day course of i.v. remdesivir among unvaccinated outpatients with COVID-19 at a high risk of disease progression reduced 28-day hospitalization or death by 87% compared with placebo (0.7% versus 5.3%; HR 0.13, 95% CI 0.03–0.59)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 31" title="Gottlieb, R. L. et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N. Engl. J. Med. 386, 305–315 (2022)." href="/articles/s41581-022-00642-4#ref-CR31" id="ref-link-section-d17524587e1584">31</a></sup>. By contrast, remdesivir’s magnitude of benefit was modest among hospitalized patients. The pivotal ACTT-1 trial, which enrolled 1,062 patients, showed that the time to recovery was shorter with remdesivir than with placebo (10 days versus 15 days), and there was a trend towards lower 29-day mortality (11.4% versus 15.2%; HR 0.73, 95% CI 0.52–1.03)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 32" title="Beigel, J. H. et al. Remdesivir for the treatment of Covid-19 — final report. N. Engl. J. Med. 383, 1813–1826 (2020)." href="/articles/s41581-022-00642-4#ref-CR32" id="ref-link-section-d17524587e1588">32</a></sup>. The WHO Solidarity trial, which is the largest RCT of remdesivir to date, randomly assigned 8,275 hospitalized patients to remdesivir or no study drug. Overall, treatment with remdesivir did not affect hospital mortality compared with control (14.5% versus 15.6%; RR 0.91, 95% CI 0.82–1.02), although it reduced hospital mortality modestly in patients who were not ventilated at study entry (11.9% versus 13.5%; RR 0.86, 95% CI 0.76–0.98); there was no benefit in patients who were already ventilated at the start of treatment<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 33" title="WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet 399, 1941–1953 (2022)." href="/articles/s41581-022-00642-4#ref-CR33" id="ref-link-section-d17524587e1592">33</a></sup>. Remdesivir was approved by the FDA on 22 October 2020 and by the EMA on 3 July 2020 (Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41581-022-00642-4#Tab1">1</a>).</p><h3 class="c-article__sub-heading" id="Sec9">Nirmatrelvir–ritonavir</h3><p>Nirmatrelvir–ritonavir (also known as Paxlovid) is a combination therapy consisting of nirmatrelvir, an oral 3C-like protease inhibitor that is active against the main viral protease that cleaves SARS-CoV-2 polyproteins during viral replication, and ritonavir, a strong cytochrome P450 3A4 (CYP3A4) inhibitor and pharmacokinetic boosting agent<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 34" title="Owen, D. R. et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science 374, 1586–1593 (2021)." href="/articles/s41581-022-00642-4#ref-CR34" id="ref-link-section-d17524587e1607">34</a></sup>. In the EPIC-HR trial, which enrolled 2,246 unvaccinated adult outpatients with COVID-19 at a high risk of disease progression, nirmatrelvir–ritonavir reduced the risk of 28-day hospitalization or death by 89% compared with placebo (0.7% versus 6.5%; difference of −6.32 percentage points, 95% CI −9.04 to −3.59)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 35" title="Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N. Engl. J. Med. 386, 1397–1408 (2022)." href="/articles/s41581-022-00642-4#ref-CR35" id="ref-link-section-d17524587e1611">35</a></sup>. Nirmatrelvir–ritonavir received EUA from the FDA on 22 December 2021, and approval from the EMA on 28 January 2022 (Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41581-022-00642-4#Tab1">1</a>).</p><h3 class="c-article__sub-heading" id="Sec10">Molnupiravir</h3><p>Molnupiravir is an oral pro-drug of β-<span class="u-small-caps">d</span>-N4-hydroxycytidine (NHC), which is a cytidine analogue that has broad-spectrum antiviral activity against SARS-CoV-2 in vitro<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 36" title="Sheahan, T. P. et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl Med. 12, eabb5883 (2020)." href="/articles/s41581-022-00642-4#ref-CR36" id="ref-link-section-d17524587e1629">36</a></sup>. NHC is incorporated into new RNA strands of the SARS-CoV-2 genome as they are synthesized, causing an accumulation of deleterious mutations that is termed lethal mutagenesis. In the MOVe-OUT trial, which enrolled 1,433 adult outpatients with mild-to-moderate COVID-19, molnupiravir reduced 29-day hospitalization or death by approximately one-third compared with placebo (6.8% versus 9.7%; HR 0.69, 95% CI 0.48–1.01), which was an effect of lesser magnitude than that observed with other antivirals<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 37" title="Jayk Bernal, A. et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N. Engl. J. Med. 386, 509–520 (2022)." href="/articles/s41581-022-00642-4#ref-CR37" id="ref-link-section-d17524587e1633">37</a></sup>.</p><h3 class="c-article__sub-heading" id="Sec11">Relevance to patients with kidney disease</h3><p>Most RCTs of remdesivir excluded patients with an eGFR &lt;30 ml/min/1.73 m<sup>2</sup> (refs. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Gottlieb, R. L. et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N. Engl. J. Med. 386, 305–315 (2022)." href="#ref-CR31" id="ref-link-section-d17524587e1648">31</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Beigel, J. H. et al. Remdesivir for the treatment of Covid-19 — final report. N. Engl. J. Med. 383, 1813–1826 (2020)." href="#ref-CR32" id="ref-link-section-d17524587e1648_1">32</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 33" title="WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet 399, 1941–1953 (2022)." href="/articles/s41581-022-00642-4#ref-CR33" id="ref-link-section-d17524587e1651">33</a></sup>). Remdesivir is formulated with sulfobutylether β-cyclodextrin sodium, which is a solubility enhancer that is eliminated by the kidney and is nephrotoxic in rats at high doses<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 38" title="Hoover, R. K. et al. Clinical pharmacokinetics of sulfobutylether-β-cyclodextrin in patients with varying degrees of renal impairment. J. Clin. Pharmacol. 58, 814–822 (2018)." href="/articles/s41581-022-00642-4#ref-CR38" id="ref-link-section-d17524587e1655">38</a></sup>. However, whether the doses of sulfobutylether β-cyclodextrin sodium administered during short courses of remdesivir represent a substantial safety concern is unclear, and remdesivir use in patients with severely impaired kidney function has been reported<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Estiverne, C. et al. Remdesivir in patients with estimated GFR <30 ml/min per 1.73 m2 or on renal replacement therapy. Kidney Int. Rep. 6, 835–838 (2021)." href="#ref-CR39" id="ref-link-section-d17524587e1659">39</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Thakare, S. et al. Safety of remdesivir in patients with acute kidney injury or CKD. Kidney Int. Rep. 6, 206–210 (2021)." href="#ref-CR40" id="ref-link-section-d17524587e1659_1">40</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Pettit, N. N. et al. Remdesivir use in the setting of severe renal impairment: a theoretical concern or real risk? Clin. Infect. Dis. 73, e3990–e3995 (2021)." href="#ref-CR41" id="ref-link-section-d17524587e1659_2">41</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Sukeishi, A. et al. Population pharmacokinetic modeling of GS-441524, the active metabolite of remdesivir, in Japanese COVID-19 patients with renal dysfunction. CPT Pharmacomet. Syst. Pharmacol. 11, 94–103 (2022)." href="#ref-CR42" id="ref-link-section-d17524587e1659_3">42</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 43" title="Seethapathy, R., Zhao, S., Long, J. D., Strohbehn, I. A. &amp; Sise, M. E. A propensity score-matched observational study of remdesivir in patients with COVID-19 and severe kidney disease. Kidney360 3, 269–278 (2022)." href="/articles/s41581-022-00642-4#ref-CR43" id="ref-link-section-d17524587e1662">43</a></sup>. Nonetheless, remdesivir is not currently recommended in patients with eGFR &lt;30 ml/min/1.73 m<sup>2</sup> (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41581-022-00642-4#Fig3">3</a>), although a phase III RCT is ongoing to evaluate its efficacy and safety in that population<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 44" title="US National Library of Medicine. ClinicalTrials.gov &#xA;                  https://clinicaltrials.gov/ct2/show/NCT04745351&#xA;                  &#xA;                 (2022)." href="/articles/s41581-022-00642-4#ref-CR44" id="ref-link-section-d17524587e1672">44</a></sup>.</p><p>The EPIC-HR trial of nirmatrelvir–ritonavir described above excluded patients with an eGFR &lt;45 ml/min/1.73 m<sup>2</sup> (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 35" title="Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N. Engl. J. Med. 386, 1397–1408 (2022)." href="/articles/s41581-022-00642-4#ref-CR35" id="ref-link-section-d17524587e1681">35</a></sup>). Nonetheless, nirmatrelvir–ritonavir can be used in patients with moderate CKD — a 50% dose reduction of nirmatrelvir is recommended in patients with an eGFR 30–59 ml/min/1.73 m<sup>2</sup> (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 45" title="US Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for paxlovid. FDA &#xA;                  https://www.fda.gov/media/155050/download&#xA;                  &#xA;                 (2022)." href="/articles/s41581-022-00642-4#ref-CR45" id="ref-link-section-d17524587e1687">45</a></sup>) (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41581-022-00642-4#Fig3">3</a>). Nirmatrelvir–ritonavir is contraindicated in patients with eGFR &lt;30 ml/min/1.73 m<sup>2</sup>, as well as in those with severe hepatic impairment. Importantly, ritonavir is a potent inhibitor of CYP3A and would therefore increase exposure to calcineurin inhibitors and mammalian target of rapamycin inhibitors, which are immunosuppressive drugs commonly used to prevent graft rejection in kidney transplant recipients. Accordingly, nirmatrelvir–ritonavir should be used with extreme caution in recipients of kidney and other solid organ transplants, and only if calcineurin inhibitors and/or mammalian target of rapamycin levels can be monitored closely<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 46" title="Salerno, D. M. et al. Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients. Am. J. Transplant. 22, 2083–2088 (2022)." href="/articles/s41581-022-00642-4#ref-CR46" id="ref-link-section-d17524587e1697">46</a></sup>.</p><p>The MOVe-OUT trial of molnupiravir excluded patients with eGFR &lt;30 ml/min/1.73 m<sup>2</sup>, and only 5.9% of participants had CKD<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 37" title="Jayk Bernal, A. et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N. Engl. J. Med. 386, 509–520 (2022)." href="/articles/s41581-022-00642-4#ref-CR37" id="ref-link-section-d17524587e1706">37</a></sup>. However, because NHC is metabolized through an endogenous pyrimidine pathway<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 47" title="Swanstrom, R. &amp; Schinazi, R. F. Lethal mutagenesis as an antiviral strategy. Science 375, 497–498 (2022)." href="/articles/s41581-022-00642-4#ref-CR47" id="ref-link-section-d17524587e1710">47</a></sup>, the EUA for molnupiravir does not restrict its use in patients with advanced CKD or kidney failure requiring KRT, and no dose adjustment is required for patients with kidney disease (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41581-022-00642-4#Fig3">3</a>).</p><p>In summary, antiviral therapy now has an established role in preventing disease progression when used for early treatment of symptomatic patients at risk of poor outcomes (for example, unvaccinated patients and those with comorbidities such as CKD). Whether the remdesivir, nirmatrelvir–ritonavir and molnupiravir RCT data can be extrapolated to vaccinated populations, patients infected with new SARS-CoV-2 variants or patients with advanced CKD is unclear. Notably, all three drugs have limitations: remdesivir requires i.v. infusion, nirmatrelvir–ritonavir has important interactions with other drugs that might restrict or complicate its use, and the efficacy of molnupiravir is modest. Evidence directly relevant to patients with CKD or kidney failure and kidney transplant recipients is scarce and eagerly awaited.</p></div></div></section><section data-title="Antithrombotic therapies"><div class="c-article-section" id="Sec12-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec12">Antithrombotic therapies</h2><div class="c-article-section__content" id="Sec12-content"><p>Hospitalized patients with COVID-19 experience relatively high rates of morbid and potentially fatal haemostatic and thrombotic complications, particularly venous thromboembolism (VTE)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 48" title="Al-Samkari, H. et al. Thrombosis, bleeding, and the observational effect of early therapeutic anticoagulation on survival in critically ill patients with COVID-19. Ann. Intern. Med. 174, 622–632 (2021)." href="/articles/s41581-022-00642-4#ref-CR48" id="ref-link-section-d17524587e1729">48</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 49" title="Al-Samkari, H. et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood 136, 489–500 (2020)." href="/articles/s41581-022-00642-4#ref-CR49" id="ref-link-section-d17524587e1732">49</a></sup>. These complications result from a state of dysfunction in the thromboinflammatory coagulation system, sometimes referred to as ‘COVID-19-associated coagulopathy’<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 50" title="Iba, T., Connors, J. M. &amp; Levy, J. H. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflamm. Res. 69, 1181–1189 (2020)." href="/articles/s41581-022-00642-4#ref-CR50" id="ref-link-section-d17524587e1736">50</a></sup>. The pathogenesis of this coagulopathy is incompletely understood and seems to be multifactorial. Contributing factors include endothelial injury (induced by the virus and/or the anti-viral immune response), a hypercoagulable state induced by elevated levels of acute-phase reactant coagulation factors (particularly fibrinogen and factor VIII) and other pro-inflammatory mechanisms, including the formation of neutrophil extracellular traps<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Al-Samkari, H. et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood 136, 489–500 (2020)." href="#ref-CR49" id="ref-link-section-d17524587e1740">49</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Iba, T., Connors, J. M. &amp; Levy, J. H. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflamm. Res. 69, 1181–1189 (2020)." href="#ref-CR50" id="ref-link-section-d17524587e1740_1">50</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Goshua, G. et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol. 7, e575–e582 (2020)." href="#ref-CR51" id="ref-link-section-d17524587e1740_2">51</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 52" title="Al-Samkari, H., Song, F., Van Cott, E. M., Kuter, D. J. &amp; Rosovsky, R. Evaluation of the prothrombin fragment 1.2 in patients with coronavirus disease 2019 (COVID-19). Am. J. Hematol. 95, 1479–1485 (2020)." href="/articles/s41581-022-00642-4#ref-CR52" id="ref-link-section-d17524587e1743">52</a></sup>. Consequently, empirical use of antithrombotic therapies, including empirical administration of anticoagulant or antiplatelet agents in the absence of a standard clinical indication, and empirical dose escalation to a dose higher than that otherwise indicated in patients who would typically receive prophylactic dosing, has been under investigation in patients with COVID-19 since the early days of the pandemic.</p><p>Importantly, the use of antithrombotic therapies requires careful balancing of thrombotic and bleeding risks. In most patient populations, major bleeding is associated with a higher mortality risk than VTE, including in patients with COVID-19 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 48" title="Al-Samkari, H. et al. Thrombosis, bleeding, and the observational effect of early therapeutic anticoagulation on survival in critically ill patients with COVID-19. Ann. Intern. Med. 174, 622–632 (2021)." href="/articles/s41581-022-00642-4#ref-CR48" id="ref-link-section-d17524587e1750">48</a></sup>). The risks of both bleeding and thrombosis escalate with worsening illness, but not always in equal proportions, and the relative contribution of thrombotic injury to morbidity might depend on the phase of illness<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 53" title="ATTACC Investigators, ACTIV-4a Investigators &amp; REMAP-CAP Investigators. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N. Engl. J. Med. 385, 790–802 (2021)." href="/articles/s41581-022-00642-4#ref-CR53" id="ref-link-section-d17524587e1754">53</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 54" title="REMAP-CAP Investigators, ACTIV-4a Investigators &amp; ATTACC Investigators. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N. Engl. J. Med. 385, 777–789 (2021)." href="/articles/s41581-022-00642-4#ref-CR54" id="ref-link-section-d17524587e1757">54</a></sup>. The potential benefit of empirical use or dose-escalation of anticoagulation or antiplatelet therapy in COVID-19 has been evaluated across different phases of illness (that is, in critically ill inpatients, non-critically ill inpatients, and outpatients) and at varying dose levels, particularly for anticoagulation (prophylactic, intermediate and therapeutic doses)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 55" title="Al-Samkari, H. Finding the optimal thromboprophylaxis dose in patients with COVID-19. JAMA 325, 1613–1615 (2021)." href="/articles/s41581-022-00642-4#ref-CR55" id="ref-link-section-d17524587e1761">55</a></sup> (Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41581-022-00642-4#Tab2">2</a>); several clinical trials are ongoing. Patients with COVID-19 and an existing indication for therapeutic anticoagulation (for example, VTE) or antiplatelet therapy (for example, coronary artery disease) should receive antithrombotic therapy as indicated by American Society of Hematology guidelines<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 56" title="Cuker, A. et al. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Adv. 5, 872–888 (2021)." href="/articles/s41581-022-00642-4#ref-CR56" id="ref-link-section-d17524587e1768">56</a></sup>.</p><div class="c-article-table" data-test="inline-table" data-container-section="table" id="table-2"><figure><figcaption class="c-article-table__figcaption"><b id="Tab2" data-test="table-caption">Table 2 Summary of evidence from major RCTs evaluating the use of empirical antithrombotic therapy in COVID-19</b></figcaption><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="table-link" data-track="click" data-track-action="view table" data-track-label="button" rel="nofollow" href="/articles/s41581-022-00642-4/tables/2" aria-label="Full size table 2"><span>Full size table</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>At present, the accumulated body of evidence suggests that antithrombotic management of patients with COVID-19 should not differ substantially from that of other populations with similar degrees of illness. However, where no contraindications exist, all hospitalized patients with COVID-19 should receive pharmacological thromboprophylaxis (in contrast to mechanical thromboprophylaxis alone)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 56" title="Cuker, A. et al. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Adv. 5, 872–888 (2021)." href="/articles/s41581-022-00642-4#ref-CR56" id="ref-link-section-d17524587e2053">56</a></sup>, and empirical therapeutic anticoagulation can be considered in non-critically ill hospitalized patients, particularly in those with a high thrombosis risk (that is, patients with elevated D-dimer levels) and a low bleeding risk<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 57" title="National Institutes of Health. COVID-19 treatment guidelines: antithrombotic therapy in patients with COVID-19. NIH &#xA;                  https://www.covid19treatmentguidelines.nih.gov/therapies/antithrombotic-therapy/&#xA;                  &#xA;                 (2022)." href="/articles/s41581-022-00642-4#ref-CR57" id="ref-link-section-d17524587e2057">57</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 58" title="American Society of Hematology. ASH clinical practice guidelines on venous thromboembolism. ASH &#xA;                  https://www.hematology.org/education/clinicians/guidelines-and-quality-care/clinical-practice-guidelines/venous-thromboembolism-guidelines/ash-guidelines-on-use-of-anticoagulation-in-patients-with-covid-19&#xA;                  &#xA;                 (2022)." href="/articles/s41581-022-00642-4#ref-CR58" id="ref-link-section-d17524587e2060">58</a></sup>. Importantly, although two large RCTs reported a benefit for therapeutic anticoagulation in non-critically ill hospitalized patients<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 53" title="ATTACC Investigators, ACTIV-4a Investigators &amp; REMAP-CAP Investigators. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N. Engl. J. Med. 385, 790–802 (2021)." href="/articles/s41581-022-00642-4#ref-CR53" id="ref-link-section-d17524587e2064">53</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 59" title="Spyropoulos, A. C. et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA Intern. Med. 181, 1612–1620 (2021)." href="/articles/s41581-022-00642-4#ref-CR59" id="ref-link-section-d17524587e2067">59</a></sup>, two others did not report a beneficial effect<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 60" title="Sholzberg, M. et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ 375, n2400 (2021)." href="/articles/s41581-022-00642-4#ref-CR60" id="ref-link-section-d17524587e2071">60</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 61" title="Lopes, R. D. et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet 397, 2253–2263 (2021)." href="/articles/s41581-022-00642-4#ref-CR61" id="ref-link-section-d17524587e2074">61</a></sup>. However, of the two trials that did not find a benefit, one was stopped early owing to feasibility (although data showed that therapeutic anticoagulation significantly reduced 28-day mortality compared with prophylactic anticoagulation)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 60" title="Sholzberg, M. et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ 375, n2400 (2021)." href="/articles/s41581-022-00642-4#ref-CR60" id="ref-link-section-d17524587e2078">60</a></sup>, and the other investigated rivaroxaban, which is a factor Xa inhibitor<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 61" title="Lopes, R. D. et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet 397, 2253–2263 (2021)." href="/articles/s41581-022-00642-4#ref-CR61" id="ref-link-section-d17524587e2083">61</a></sup> (whereas other RCTs evaluated the use of unfractionated or low-molecular-weight heparin (LMWH)). Finally, patients at high risk of VTE might benefit from post-discharge pharmacological thromboprophylaxis<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 62" title="Giannis, D. et al. Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry. Blood 137, 2838–2847 (2021)." href="/articles/s41581-022-00642-4#ref-CR62" id="ref-link-section-d17524587e2087">62</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 63" title="Ramacciotti, E. et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet 399, 50–59 (2022)." href="/articles/s41581-022-00642-4#ref-CR63" id="ref-link-section-d17524587e2090">63</a></sup>, which also applies to patients who were hospitalized without COVID-19 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 64" title="Spyropoulos, A. C. et al. Post-discharge prophylaxis with rivaroxaban reduces fatal and major thromboembolic events in medically ill patients. J. Am. Coll. Cardiol. 75, 3140–3147 (2020)." href="/articles/s41581-022-00642-4#ref-CR64" id="ref-link-section-d17524587e2094">64</a></sup>).</p><p>In contrast to therapeutic anticoagulation, empirical antiplatelet therapy does not seem to be beneficial at any stage of COVID-19 (refs. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 399, 143–151 (2022)." href="#ref-CR65" id="ref-link-section-d17524587e2101">65</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Connors, J. M. et al. Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial. JAMA 326, 1703–1712 (2021)." href="#ref-CR66" id="ref-link-section-d17524587e2101_1">66</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 67" title="REMAP-CAP Writing Committee for the REMAP-CAP Investigators. Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA 327, 1247–1259 (2022)." href="/articles/s41581-022-00642-4#ref-CR67" id="ref-link-section-d17524587e2104">67</a></sup>), including the RECOVERY trial of aspirin versus usual care in 14,892 hospitalized patients<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 65" title="RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 399, 143–151 (2022)." href="/articles/s41581-022-00642-4#ref-CR65" id="ref-link-section-d17524587e2108">65</a></sup>, which is the largest trial of any agent in patients with COVID-19 to date. One trial found a reduction in 90-day mortality with antiplatelet therapy (aspirin or a P2Y12 inhibitor) in critically ill patients with COVID-19 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 67" title="REMAP-CAP Writing Committee for the REMAP-CAP Investigators. Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA 327, 1247–1259 (2022)." href="/articles/s41581-022-00642-4#ref-CR67" id="ref-link-section-d17524587e2112">67</a></sup>), although this was a secondary end point and additional trials are ongoing to address this question<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 68" title="US National Library of Medicine. ClinicalTrials.gov &#xA;                  https://clinicaltrials.gov/ct2/show/NCT04505774&#xA;                  &#xA;                 (2022)." href="/articles/s41581-022-00642-4#ref-CR68" id="ref-link-section-d17524587e2116">68</a></sup>. Conversely, several trials have reported increased rates of major bleeding in patients treated with empirical antiplatelet versus no antiplatelet therapy, and in patients treated with therapeutic- versus prophylactic-dose anticoagulation therapy<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 53" title="ATTACC Investigators, ACTIV-4a Investigators &amp; REMAP-CAP Investigators. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N. Engl. J. Med. 385, 790–802 (2021)." href="/articles/s41581-022-00642-4#ref-CR53" id="ref-link-section-d17524587e2120">53</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 54" title="REMAP-CAP Investigators, ACTIV-4a Investigators &amp; ATTACC Investigators. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N. Engl. J. Med. 385, 777–789 (2021)." href="/articles/s41581-022-00642-4#ref-CR54" id="ref-link-section-d17524587e2123">54</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 61" title="Lopes, R. D. et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet 397, 2253–2263 (2021)." href="/articles/s41581-022-00642-4#ref-CR61" id="ref-link-section-d17524587e2126">61</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 67" title="REMAP-CAP Writing Committee for the REMAP-CAP Investigators. Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA 327, 1247–1259 (2022)." href="/articles/s41581-022-00642-4#ref-CR67" id="ref-link-section-d17524587e2129">67</a></sup>. Importantly, given the substantial contribution of inflammation to COVID-19-associated coagulopathy, the development of anti-inflammatory therapies to treat COVID-19 might attenuate or nullify any potential benefit of escalated anticoagulation, leaving only elevated bleeding risk. This risk is particularly important to consider when assessing trials of antithrombotic therapies conducted before the routine use of anti-inflammatory therapies.</p><h3 class="c-article__sub-heading" id="Sec13">Relevance to patients with kidney disease</h3><p>In general, the aforementioned conclusions regarding antithrombotic therapies apply to patients with advanced kidney disease, with slight modifications. Patients with CKD or kidney failure requiring KRT are at an increased risk of both bleeding<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 69" title="Kaw, D. &amp; Malhotra, D. Platelet dysfunction and end-stage renal disease. Semin. Dial. 19, 317–322 (2006)." href="/articles/s41581-022-00642-4#ref-CR69" id="ref-link-section-d17524587e2141">69</a></sup> and clotting<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 70" title="Wattanakit, K., Cushman, M., Stehman-Breen, C., Heckbert, S. R. &amp; Folsom, A. R. Chronic kidney disease increases risk for venous thromboembolism. J. Am. Soc. Nephrol. 19, 135–140 (2008)." href="/articles/s41581-022-00642-4#ref-CR70" id="ref-link-section-d17524587e2145">70</a></sup> at baseline compared with patients with normal kidney function. These risks must be considered when evaluating non-critically ill patients for empirical therapeutic-dose anticoagulation and when evaluating hospitalized patients for post-discharge pharmacological thromboprophylaxis. Most major trials of anticoagulation in hospitalized patients with COVID-19 enrolled patients with advanced kidney disease, but dose-reduced LMWH or mandated the use of unfractionated heparin rather than LMWH in these patients. Although LMWH is usually preferred over unfractionated heparin, given its much lower risk of heparin-induced thrombocytopenia<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 71" title="Martel, N., Lee, J. &amp; Wells, P. S. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 106, 2710–2715 (2005)." href="/articles/s41581-022-00642-4#ref-CR71" id="ref-link-section-d17524587e2149">71</a></sup> and ease of administration, LMWH must be used with caution and at lower doses in patients with advanced kidney disease owing to the potential increased risk of bleeding given that LMWH is excreted in the kidney<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 72" title="Garcia, D. A., Baglin, T. P., Weitz, J. I. &amp; Samama, M. M. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141, e24S–e43S (2012)." href="/articles/s41581-022-00642-4#ref-CR72" id="ref-link-section-d17524587e2153">72</a></sup>. Finally, although empirical dose escalation of prophylactic anticoagulation does not seem to be beneficial in critically ill patients with COVID-19 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 54" title="REMAP-CAP Investigators, ACTIV-4a Investigators &amp; ATTACC Investigators. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N. Engl. J. Med. 385, 777–789 (2021)." href="/articles/s41581-022-00642-4#ref-CR54" id="ref-link-section-d17524587e2157">54</a></sup>), patients receiving continuous KRT who experience recurrent clotting of the circuit filter might benefit from therapeutic-dose anticoagulation to prevent further clotting<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 73" title="Endres, P. et al. Filter clotting with continuous renal replacement therapy in COVID-19. J. Thromb. Thrombolysis 51, 966–970 (2021)." href="/articles/s41581-022-00642-4#ref-CR73" id="ref-link-section-d17524587e2162">73</a></sup>. Of note, some small studies suggest that argatroban, which is a direct thrombin inhibitor, might be useful to prevent circuit filter thrombosis in these patients<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 74" title="Arnold, F. et al. Comparison of different anticoagulation strategies for renal replacement therapy in critically ill patients with COVID-19: a cohort study. BMC Nephrol. 21, 486 (2020)." href="/articles/s41581-022-00642-4#ref-CR74" id="ref-link-section-d17524587e2166">74</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 75" title="Seshadri, M., Ahamed, J. &amp; Laurence, J. Intervention in COVID-19 linked hypercoagulable states characterized by circuit thrombosis utilizing a direct thrombin inhibitor. Thrombosis Update 1, 100009 (2020)." href="/articles/s41581-022-00642-4#ref-CR75" id="ref-link-section-d17524587e2169">75</a></sup> but high-level evidence to support its use is lacking. Importantly, in any critically ill patient with multi-organ system failure, acquired antithrombin deficiency might render heparin ineffective. This effect can be countered with either antithrombin repletion or a switch to a direct thrombin inhibitor, which would act independently of antithrombin<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 76" title="Rahbar, E., Cotton, B. A., Wade, C. E. &amp; Cardenas, J. C. Acquired antithrombin deficiency is a risk factor for venous thromboembolism after major trauma. Thromb. Res. 204, 9–12 (2021)." href="/articles/s41581-022-00642-4#ref-CR76" id="ref-link-section-d17524587e2173">76</a></sup>.</p><p>Finally, whether therapeutic anticoagulation can attenuate the risk of COVID-19-associated AKI is unknown. The pathophysiology of AKI in COVID-19 is complex and involves inflammation, endothelial injury, and microvascular thrombosis<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 77" title="Legrand, M. et al. Pathophysiology of COVID-19-associated acute kidney injury. Nat. Rev. Nephrol. 17, 751–764 (2021)." href="/articles/s41581-022-00642-4#ref-CR77" id="ref-link-section-d17524587e2180">77</a></sup>. Although acute tubular injury is the most common finding at autopsy in patients with COVID-19-associated AKI, platelet-rich peritubular fibrin microthrombi in the kidney microcirculation have also been reported<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 78" title="Rapkiewicz, A. V. et al. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series. EClinicalMedicine 24, 100434 (2020)." href="/articles/s41581-022-00642-4#ref-CR78" id="ref-link-section-d17524587e2184">78</a></sup>. Therapeutic anticoagulation with heparin might mitigate microvascular thrombosis and attenuate ischaemia–reperfusion injury<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 79" title="Hisama, N. et al. Anticoagulant pretreatment attenuates production of cytokine-induced neutrophil chemoattractant following ischemia-reperfusion of rat liver. Dig. Dis. Sci. 41, 1481–1486 (1996)." href="/articles/s41581-022-00642-4#ref-CR79" id="ref-link-section-d17524587e2188">79</a></sup> thereby preventing AKI, but supporting clinical trial data are lacking.</p></div></div></section><section data-title="Therapies for acute respiratory failure"><div class="c-article-section" id="Sec14-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec14">Therapies for acute respiratory failure</h2><div class="c-article-section__content" id="Sec14-content"><p>COVID-19 might cause critical illness through a variety of mechanisms, but acute hypoxaemic respiratory failure remains the leading cause<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 7" title="Gupta, S. et al. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern. Med. 180, 1436–1447 (2020)." href="/articles/s41581-022-00642-4#ref-CR7" id="ref-link-section-d17524587e2201">7</a></sup>. In addition to decisions regarding the use of antivirals, immunomodulators and anticoagulants, which might benefit patients across the spectrum of illness, the treatment of COVID-19-induced respiratory failure requires special consideration of the method of oxygen delivery, timing of intubation, and the use of prone positioning or of adjuvant therapies for refractory hypoxaemia.</p><h3 class="c-article__sub-heading" id="Sec15">Oxygen delivery</h3><p>Three noninvasive methods of oxygen delivery can be used in patients who require more oxygen than can be delivered by a standard nasal cannula — conventional oxygen therapy (usually a mask with an oxygen reservoir, termed a ‘non-rebreather mask’), a high-flow nasal cannula (HFNC), which delivers warmed and humidified oxygen through large-bore nasal cannulas at flow rates that exceed the patient’s peak inspiratory flow rate, or NIV, whereby a tight-fitting mask connected to a noninvasive ventilation machine provides continuous positive airway pressure or bilevel positive airway pressure.</p><p>Initially, concerns surrounding the use of HFNC or NIV included a potential increase in the risk to health-care workers owing to aerosolization of SARS-CoV-2 and potential exacerbation of lung injury owing to increased transpulmonary pressures from vigorous respiratory effort (so-called patient self-induced lung injury), which might be avoided with intubation and sedation<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 80" title="Marini, J. J. &amp; Gattinoni, L. Management of COVID-19 respiratory distress. JAMA 323, 2329–2330 (2020)." href="/articles/s41581-022-00642-4#ref-CR80" id="ref-link-section-d17524587e2215">80</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 81" title="Papoutsi, E., Giannakoulis, V. G., Xourgia, E., Routsi, C. &amp; Kotanidou, A. Siempos II. Effect of timing of intubation on clinical outcomes of critically ill patients with COVID-19: a systematic review and meta-analysis of non-randomized cohort studies. Crit. Care 25, 121 (2021)." href="/articles/s41581-022-00642-4#ref-CR81" id="ref-link-section-d17524587e2218">81</a></sup>. During the first wave of COVID-19, these concerns led to the intubation of patients who had only moderate hypoxaemia<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 82" title="Ziehr, D. R. et al. Respiratory pathophysiology of mechanically ventilated patients with COVID-19: a cohort study. Am. J. Respir. Crit. Care Med. 201, 1560–1564 (2020)." href="/articles/s41581-022-00642-4#ref-CR82" id="ref-link-section-d17524587e2222">82</a></sup>. Earlier intubation, however, potentially exposes patients to other risks, such as ventilator-induced lung injury and sedation-associated delirium. Accordingly, some studies showed that the outcomes of hospitalized patients improved as the use of HFNC and NIV became more liberal, and the approach to intubation became more conservative<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 83" title="Anesi, G. L. et al. Characteristics, outcomes, and trends of patients with COVID-19-related critical illness at a learning health system in the United States. Ann. Intern. Med. 174, 613–621 (2021)." href="/articles/s41581-022-00642-4#ref-CR83" id="ref-link-section-d17524587e2226">83</a></sup>. Furthermore, the availability of highly effective vaccines and research suggesting that HFNC and NIV do not significantly increase aerosolization of virus particles have allayed concerns regarding the risk to health care workers<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 84" title="Gaeckle, N. T. et al. Aerosol generation from the respiratory tract with various modes of oxygen delivery. Am. J. Respir. Crit. Care Med. 202, 1115–1124 (2020)." href="/articles/s41581-022-00642-4#ref-CR84" id="ref-link-section-d17524587e2230">84</a></sup>.</p><p>Although the use of HFNC and NIV are now more common in the treatment of COVID-19 than earlier in the pandemic, their relative effectiveness remains unclear. The RECOVERY-RS trial compared available methods for oxygen delivery by randomly assigning 1,237 hospitalized adults with COVID-19-related acute hypoxaemic respiratory failure to conventional oxygen therapy, HFNC or NIV (specifically, continuous positive airway pressure). The study found that NIV led to lower rates of intubation than conventional oxygen delivery or HFNC, but mortality was not significantly different among the three groups. However, the interpretation of the study is complicated by a high rate of crossover between groups<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 85" title="Perkins, G. D. et al. Effect of noninvasive respiratory strategies on intubation or mortality among patients with acute hypoxemic respiratory failure and COVID-19: the RECOVERY-RS randomized clinical trial. JAMA 327, 546–558 (2022)." href="/articles/s41581-022-00642-4#ref-CR85" id="ref-link-section-d17524587e2237">85</a></sup>.</p><h3 class="c-article__sub-heading" id="Sec16">Prone positioning</h3><p>Prone positioning is one of the few interventions shown to reduce mortality among patients intubated for non-COVID-19 ARDS<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 86" title="Guérin, C. et al. Prone positioning in severe acute respiratory distress syndrome. N. Engl. J. Med. 368, 2159–2168 (2013)." href="/articles/s41581-022-00642-4#ref-CR86" id="ref-link-section-d17524587e2249">86</a></sup>. However, adoption of proning in patients with COVID-19 ARDS has been incomplete based on ongoing concerns regarding its effectiveness, resource utilization and the risk of dislodging support devices; reports show wide inter-hospital variation in the use of proning<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 7" title="Gupta, S. et al. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern. Med. 180, 1436–1447 (2020)." href="/articles/s41581-022-00642-4#ref-CR7" id="ref-link-section-d17524587e2253">7</a></sup>. No RCT has evaluated proning in patients intubated owing to COVID-19 but observational studies suggest that early proning of these patients is associated with reduced mortality<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 87" title="Mathews, K. S. et al. Prone positioning and survival in mechanically ventilated patients with coronavirus disease 2019-related respiratory failure. Crit. Care Med. 49, 1026–1037 (2021)." href="/articles/s41581-022-00642-4#ref-CR87" id="ref-link-section-d17524587e2257">87</a></sup>.</p><p>Since the early days of the pandemic, some experts have proposed extending the use of proning to non-intubated spontaneously breathing patients (that is, awake proning). However, results of trials evaluating the use of awake proning have been mixed — some showed benefit<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 88" title="Ehrmann, S. et al. Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial. Lancet Respir. Med. 9, 1387–1395 (2021)." href="/articles/s41581-022-00642-4#ref-CR88" id="ref-link-section-d17524587e2264">88</a></sup>, whereas others showed no effect<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 89" title="Alhazzani, W. et al. Effect of awake prone positioning on endotracheal intubation in patients with COVID-19 and acute respiratory failure: a randomized clinical trial. JAMA 327, 2104–2113 (2022)." href="/articles/s41581-022-00642-4#ref-CR89" id="ref-link-section-d17524587e2268">89</a></sup> or even potential harm<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 90" title="Qian, E. T. et al. Assessment of awake prone positioning in hospitalized adults with COVID-19: a nonrandomized controlled trial. JAMA Intern. Med. 182, 612–621 (2022)." href="/articles/s41581-022-00642-4#ref-CR90" id="ref-link-section-d17524587e2272">90</a></sup>.</p><h3 class="c-article__sub-heading" id="Sec17">Adjunctive therapy for hypoxemia</h3><p>In the years leading up to the COVID-19 pandemic, the use of neuromuscular blockade in ARDS had been hotly debated. The Reevaluation of Systemic Early Neuromuscular Blockade (ROSE) trial, reported in 2019, showed that 48 h of neuromuscular blockade in patients with a partial pressure of arterial oxygen (PaO<sub>2</sub>) to fraction of inspired oxygen (FiO<sub>2</sub>) ratio &lt;150 mmHg did not improve 90-day mortality<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 91" title="National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, Moss, M. et al. Early neuromuscular blockade in the acute respiratory distress syndrome. N. Engl. J. Med. 380, 1997–2008 (2019)." href="/articles/s41581-022-00642-4#ref-CR91" id="ref-link-section-d17524587e2288">91</a></sup>. No trials have specifically evaluated neuromuscular blockade in patients with COVID-19 but, based on the results of the ROSE trial, no major medical society has recommended the routine use of neuromuscular blockade. However, many patients with COVID-19 develop refractory hypoxaemia despite maximal ventilatory support, and both neuromuscular blockade and inhaled pulmonary vasodilators are routinely used in this setting despite a lack of evidence that they affect clinical outcomes in either COVID-19 or non-COVID-19 ARDS.</p><h3 class="c-article__sub-heading" id="Sec18">ECMO</h3><p>For patients with refractory hypoxaemia despite maximal ventilatory support, proning, neuromuscular blockade, and inhaled pulmonary vasodilators, ECMO might be a life-saving therapy<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 92" title="Shaefi, S. et al. Extracorporeal membrane oxygenation in patients with severe respiratory failure from COVID-19. Intensive Care Med. 47, 208–221 (2021)." href="/articles/s41581-022-00642-4#ref-CR92" id="ref-link-section-d17524587e2301">92</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 93" title="Urner, M. et al. Venovenous extracorporeal membrane oxygenation in patients with acute covid-19 associated respiratory failure: comparative effectiveness study. BMJ 377, e068723 (2022)." href="/articles/s41581-022-00642-4#ref-CR93" id="ref-link-section-d17524587e2304">93</a></sup>. The ECMO to Rescue Lung Injury in Severe ARDS (EOLIA) trial, published in 2018, suggested a mortality benefit in patients with non-COVID-19 ARDS with severe hypoxaemia<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 94" title="Goligher, E. C. et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome and posterior probability of mortality benefit in a post hoc Bayesian analysis of a randomized clinical trial. JAMA 320, 2251–2259 (2018)." href="/articles/s41581-022-00642-4#ref-CR94" id="ref-link-section-d17524587e2308">94</a></sup>, and the use of ECMO increased dramatically during the COVID-19 pandemic.</p><p>No RCTs have evaluated the efficacy of ECMO in patients with COVID-19 ARDS. However, two <a data-track="click" data-track-label="link" data-track-action="" href="/articles/s41581-022-00642-4#Glos1">target trial emulation analyses</a>, as well as a <a data-track="click" data-track-label="link" data-track-action="" href="/articles/s41581-022-00642-4#Glos2">pseudo-randomized study</a> that used a period of resource limitation as a natural experiment, suggested a robust mortality benefit from ECMO in patients with COVID-19 (refs. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 92" title="Shaefi, S. et al. Extracorporeal membrane oxygenation in patients with severe respiratory failure from COVID-19. Intensive Care Med. 47, 208–221 (2021)." href="/articles/s41581-022-00642-4#ref-CR92" id="ref-link-section-d17524587e2321">92</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 93" title="Urner, M. et al. Venovenous extracorporeal membrane oxygenation in patients with acute covid-19 associated respiratory failure: comparative effectiveness study. BMJ 377, e068723 (2022)." href="/articles/s41581-022-00642-4#ref-CR93" id="ref-link-section-d17524587e2324">93</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 95" title="Gannon, W. D. et al. Association between availability of ECMO and mortality in COVID-19 patients eligible for ECMO: a natural experiment. Am. J. Respir. Crit. Care Med. 205, 1354–1357 (2022)." href="/articles/s41581-022-00642-4#ref-CR95" id="ref-link-section-d17524587e2327">95</a></sup>). In one target trial analysis, which used data from 55 geographically diverse sites from across the USA, patients with severe hypoxaemia (defined as PaO<sub>2</sub> to FiO<sub>2</sub> ratio &lt;100 mmHg while receiving IMV) in whom ECMO was initiated within 7 days following intensive care unit admission, had a considerably lower mortality than similarly ill patients at ECMO-capable centres who were not treated with ECMO (34.6% versus 47.4%; HR 0.55, 95% CI 0.41–0.74)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 92" title="Shaefi, S. et al. Extracorporeal membrane oxygenation in patients with severe respiratory failure from COVID-19. Intensive Care Med. 47, 208–221 (2021)." href="/articles/s41581-022-00642-4#ref-CR92" id="ref-link-section-d17524587e2336">92</a></sup>. Similar findings were observed in a larger subsequent study, which used data from 7,345 adults admitted to intensive care units in 30 countries<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 93" title="Urner, M. et al. Venovenous extracorporeal membrane oxygenation in patients with acute covid-19 associated respiratory failure: comparative effectiveness study. BMJ 377, e068723 (2022)." href="/articles/s41581-022-00642-4#ref-CR93" id="ref-link-section-d17524587e2340">93</a></sup>. In the pseudo-randomized study, mortality among patients who qualified for ECMO but did not receive it owing to resource limitations was ~90%, compared with 43% among patients for whom those resources were available<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 95" title="Gannon, W. D. et al. Association between availability of ECMO and mortality in COVID-19 patients eligible for ECMO: a natural experiment. Am. J. Respir. Crit. Care Med. 205, 1354–1357 (2022)." href="/articles/s41581-022-00642-4#ref-CR95" id="ref-link-section-d17524587e2344">95</a></sup>. Although the data from these observational studies are compelling, they should nonetheless be interpreted cautiously, as they might have been affected by residual confounding (for example, disease severity and mortality risk might have affected treatment selection).</p><h3 class="c-article__sub-heading" id="Sec19">Relevance to patients with kidney disease</h3><p>ARDS is independently associated with a higher risk of AKI in critically ill patients, and the combination of both syndromes portends a particularly poor prognosis in both COVID-19 and non-COVID-19 settings<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 7" title="Gupta, S. et al. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern. Med. 180, 1436–1447 (2020)." href="/articles/s41581-022-00642-4#ref-CR7" id="ref-link-section-d17524587e2356">7</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 96" title="Darmon, M. et al. Acute respiratory distress syndrome and risk of AKI among critically ill patients. Clin. J. Am. Soc. Nephrol. 9, 1347–1353 (2014)." href="/articles/s41581-022-00642-4#ref-CR96" id="ref-link-section-d17524587e2359">96</a></sup>. Crosstalk between injured lungs and kidneys has been well recognized in both animal models and human studies, and multiple mechanisms have been proposed to explain this pathophysiology (reviewed previously<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 97" title="Teixeira, J. P., Ambruso, S., Griffin, B. R. &amp; Faubel, S. Pulmonary consequences of acute kidney injury. Semin. Nephrol. 39, 3–16 (2019)." href="/articles/s41581-022-00642-4#ref-CR97" id="ref-link-section-d17524587e2363">97</a></sup>).</p></div></div></section><section data-title="Neutralizing antibody therapies"><div class="c-article-section" id="Sec20-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec20">Neutralizing antibody therapies</h2><div class="c-article-section__content" id="Sec20-content"><p>Antibodies have a key role in the adaptive immune response and are crucial to protecting the host from pathogens. Passive administration of pathogen-specific polyclonal or monoclonal antibodies (mAbs) has been used to control viral infections, with the goal of neutralizing a target virus by targeting it for elimination and preventing its entry into host cells, thereby eliminating the infection-associated disease<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 98" title="Pantaleo, G., Correia, B., Fenwick, C., Joo, V. S. &amp; Perez, L. Antibodies to combat viral infections: development strategies and progress. Nat. Rev. Drug Discov. 21, 676–696 (2022)." href="/articles/s41581-022-00642-4#ref-CR98" id="ref-link-section-d17524587e2377">98</a></sup>. Pathogen-specific neutralizing antibodies can either be transferred from patients who have recovered from a viral infection (that is, convalescent plasma) or synthesized as recombinant neutralizing mAbs through established molecular engineering techniques.</p><p>The use of convalescent plasma was rapidly implemented in the early phase of the pandemic in the absence of alternative treatment options<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 99" title="Janiaud, P. et al. Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA 325, 1185–1195 (2021)." href="/articles/s41581-022-00642-4#ref-CR99" id="ref-link-section-d17524587e2384">99</a></sup>; since then, several studies have investigated the efficacy of this therapy. Multicentre, open-label RCTs repeatedly demonstrated a lack of benefit for convalescent plasma in hospitalized patients with COVID-19 (refs. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Bégin, P. et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nat. Med. 27, 2012–2024 (2021)." href="#ref-CR100" id="ref-link-section-d17524587e2388">100</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet 397, 2049–2059 (2021)." href="#ref-CR101" id="ref-link-section-d17524587e2388_1">101</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 102" title="Writing Committee for the REMAP-CAP Investigators. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA 326, 1690–1702 (2021)." href="/articles/s41581-022-00642-4#ref-CR102" id="ref-link-section-d17524587e2391">102</a></sup>). In non-hospitalized and mostly unvaccinated adults, a double-blind RCT of convalescent plasma versus control plasma administered within 8 days of symptom onset reduced hospitalization (2.9% versus 6.3%; absolute risk reduction, 3.4 percentage points, 95% CI 1.0–5.8)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 103" title="Sullivan, D. J. et al. Early outpatient treatment for Covid-19 with convalescent plasma. N. Engl. J. Med. 386, 1700–1711 (2022)." href="/articles/s41581-022-00642-4#ref-CR103" id="ref-link-section-d17524587e2395">103</a></sup>. Similarly, in non-hospitalized unvaccinated older adults with mild COVID-19 symptoms, a double-blind RCT of convalescent plasma versus placebo administered within 72 hours of symptom onset reduced the progression of COVID-19 (ref.  <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 104" title="Libster, R. et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N. Engl. J. Med. 384, 610–618 (2021)." href="/articles/s41581-022-00642-4#ref-CR104" id="ref-link-section-d17524587e2399">104</a></sup>). By contrast, two RCTs in adult patients with mild or moderate COVID-19 symptoms for less than 1 week<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 105" title="Alemany, A. et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respir. Med. 10, 278–288 (2022)." href="/articles/s41581-022-00642-4#ref-CR105" id="ref-link-section-d17524587e2403">105</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 106" title="Korley, F. K. et al. Early convalescent plasma for high-risk outpatients with Covid-19. N. Engl. J. Med. 385, 1951–1960 (2021)." href="/articles/s41581-022-00642-4#ref-CR106" id="ref-link-section-d17524587e2406">106</a></sup> or failed to demonstrate any benefit from the administration of convalescent plasma. Lack of efficacy of convalescent plasma for adult patients with mild to moderate COVID-19 was further confirmed by a patient-level meta-analysis of 782 patients from two RCTs<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 107" title="Millat-Martinez, P. et al. Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients. Nat. Commun. 13, 2583 (2022)." href="/articles/s41581-022-00642-4#ref-CR107" id="ref-link-section-d17524587e2411">107</a></sup>. The emergence of new variants of SARS-CoV-2 added further uncertainty to the potential benefit of convalescent plasma therapy. Currently, the use of convalescent plasma collected prior to the Omicron (B1.1.529/BA1 and BA2) surge is not recommended by the FDA<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 108" title="National Institutes of Health. Anti-SARS-CoV-2 antibody products summary recommendations: COVID-19 treatment guidelines. NIH &#xA;                  https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/summary-recommendations/&#xA;                  &#xA;                 (2022)." href="/articles/s41581-022-00642-4#ref-CR108" id="ref-link-section-d17524587e2415">108</a></sup> and has not been considered by the EMA.</p><p>Recombinant neutralizing mAbs have been the focus of a large number of studies<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 109" title="Taylor, P. C. et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat. Rev. Immunol. 21, 382–393 (2021)." href="/articles/s41581-022-00642-4#ref-CR109" id="ref-link-section-d17524587e2422">109</a></sup>. These neutralizing mAbs are developed to target the receptor-binding spike protein of SARS-CoV-2, which mediates viral entry into host cells by binding to angiotensin-converting enzyme 2 (ACE2). Five mAb agents are currently available in the USA under EUA: bamlanivimab plus etesevimab, casirivimab plus imdevimab, sotrovimab, bebtelovimab, and tixagevimab plus cilgavimab (Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41581-022-00642-4#Tab1">1</a>). One large RCT found that casirivimab plus imdevimab reduced 28-day mortality in hospitalized patients who were seronegative at baseline compared with standard of care (24% versus 30%; RR 0.79, 95% CI 0.69–0.91)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 110" title="RECOVERY Collaborative Group. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 399, 665–676 (2022)." href="/articles/s41581-022-00642-4#ref-CR110" id="ref-link-section-d17524587e2429">110</a></sup>. Furthermore, several RCTs in non-hospitalized adults from high-risk groups with mild or moderate COVID-19 demonstrated that early treatment with recombinant neutralizing mAbs reduced the risk of hospitalization or death, particularly in patients who were seronegative<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Dougan, M. et al. A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load. Clin. Infect. Dis. 75, e440–e449 (2021)." href="#ref-CR111" id="ref-link-section-d17524587e2433">111</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Gupta, A. et al. Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial. JAMA 327, 1236–1246 (2022)." href="#ref-CR112" id="ref-link-section-d17524587e2433_1">112</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 113" title="Weinreich, D. M. et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N. Engl. J. Med. 385, e81 (2021)." href="/articles/s41581-022-00642-4#ref-CR113" id="ref-link-section-d17524587e2436">113</a></sup>. Recombinant mAbs are highly effective at preventing hospitalization when given early but they are highly susceptible to loss of neutralizing activity as novel virus variants emerge<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 114" title="Takashita, E. et al. Efficacy of antibodies and antiviral drugs against Covid-19 Omicron variant. N. Engl. J. Med. 386, 995–998 (2022)." href="/articles/s41581-022-00642-4#ref-CR114" id="ref-link-section-d17524587e2440">114</a></sup>. Currently, in the USA, only bebtelovimab is recommended in non-hospitalized adult patients with COVID-19 at risk of disease progression when antiviral treatment is unavailable or contraindicated<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 108" title="National Institutes of Health. Anti-SARS-CoV-2 antibody products summary recommendations: COVID-19 treatment guidelines. NIH &#xA;                  https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/summary-recommendations/&#xA;                  &#xA;                 (2022)." href="/articles/s41581-022-00642-4#ref-CR108" id="ref-link-section-d17524587e2445">108</a></sup>.</p><p>The NIH COVID-19 treatment guideline panel recommends pre-exposure prophylaxis with tixagevimab plus cilgavimab (Evusheld) in moderately to severely immunocompromised adults without active SARS-CoV-2 infection<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 108" title="National Institutes of Health. Anti-SARS-CoV-2 antibody products summary recommendations: COVID-19 treatment guidelines. NIH &#xA;                  https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/summary-recommendations/&#xA;                  &#xA;                 (2022)." href="/articles/s41581-022-00642-4#ref-CR108" id="ref-link-section-d17524587e2452">108</a></sup>. These specific recombinant neutralizing mAbs carry a modification of the fragment crystallizable (Fc) region that prolongs their half-life and hence their potential protective effect for up to 6 months. A double-blind RCT conducted in 5,197 patients at a high risk of severe outcomes demonstrated that tixagevimab plus cilgavimab reduced the incidence of COVID-19 infection (0.2%) compared with placebo (1.0%) (relative risk reduction 76.7%; 95% CI 46.0–90.0)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 115" title="Levin, M. J. et al. Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19. N. Engl. J. Med. 386, 2188–2200 (2022)." href="/articles/s41581-022-00642-4#ref-CR115" id="ref-link-section-d17524587e2456">115</a></sup>. Of note, tixagevimab plus cilgavimab have neutralizing activity against Omicron sub-variants BA1.1.529 (refs. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 114" title="Takashita, E. et al. Efficacy of antibodies and antiviral drugs against Covid-19 Omicron variant. N. Engl. J. Med. 386, 995–998 (2022)." href="/articles/s41581-022-00642-4#ref-CR114" id="ref-link-section-d17524587e2460">114</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 115" title="Levin, M. J. et al. Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19. N. Engl. J. Med. 386, 2188–2200 (2022)." href="/articles/s41581-022-00642-4#ref-CR115" id="ref-link-section-d17524587e2463">115</a></sup>).</p><p>Overall, based on these pharmacological, epidemiological and clinical trial data, recommendations for the use of convalescent plasma and recombinant neutralizing mAbs for COVID-19 treatment or prevention are necessarily fluid, as they require frequent updates depending on the resistance patterns of prevalent virus variants and the results of ongoing research.</p><h3 class="c-article__sub-heading" id="Sec21">Relevance to patients with kidney disease</h3><p>Kidney transplant recipients and patients with CKD or kidney failure requiring KRT are at a high risk of progression to severe illness and death from COVID-19 (refs. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 2" title="Flythe, J. E. et al. Characteristics and outcomes of individuals with pre-existing kidney disease and COVID-19 admitted to intensive care units in the United States. Am. J. Kidney Dis. 77, 190–203.e1 (2021)." href="/articles/s41581-022-00642-4#ref-CR2" id="ref-link-section-d17524587e2478">2</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 116" title="Molnar, M. Z. et al. Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States. Am. J. Transpl. 20, 3061–3071 (2020)." href="/articles/s41581-022-00642-4#ref-CR116" id="ref-link-section-d17524587e2481">116</a></sup>) and could theoretically benefit from early treatment with convalescent plasma or recombinant neutralizing mAbs. Convalescent plasma has been examined in these populations and, although several observational studies suggested some benefit<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Cristelli, M. P. et al. Efficacy of convalescent plasma to treat mild to moderate COVID-19 in kidney transplant patients: a propensity score matching analysis. Transplantation 106, e92–e94 (2022)." href="#ref-CR117" id="ref-link-section-d17524587e2485">117</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Kluger, M. A. et al. Convalescent plasma treatment for early post-kidney transplant acquired COVID-19. Transpl. Infect. Dis. 23, e13685 (2021)." href="#ref-CR118" id="ref-link-section-d17524587e2485_1">118</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Rodionov, R. N. et al. Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19. Lancet Microbe 2, e138 (2021)." href="#ref-CR119" id="ref-link-section-d17524587e2485_2">119</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 120" title="Thompson, M. A. et al. Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19. JAMA Oncol. 7, 1167–1175 (2021)." href="/articles/s41581-022-00642-4#ref-CR120" id="ref-link-section-d17524587e2488">120</a></sup>, clinical trial data to support the routine use of convalescent plasma in patients with COVID-19 with underlying kidney disease are lacking. Similarly, no high-grade evidence supports the use of convalescent plasma as pre-exposure prophylaxis in these populations.</p><p>Of note, small observational studies suggested that early treatment with recombinant neutralizing mAbs might be beneficial in patients with kidney failure requiring KRT or in kidney transplant recipients with mild COVID-19 (refs. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 121" title="Arikawa, S. et al. Effectiveness of neutralizing antibody cocktail in hemodialysis patients: a case series of 20 patients treated with or without REGN-COV2. Clin. Exp. Nephrol. 26, 476–485 (2022)." href="/articles/s41581-022-00642-4#ref-CR121" id="ref-link-section-d17524587e2495">121</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 122" title="Gueguen, J. et al. Early administration of anti-SARS-CoV-2 monoclonal antibodies prevents severe Covid-19 in kidney transplant patients. Kidney Int. Rep. 7, 1241–1247 (2022)." href="/articles/s41581-022-00642-4#ref-CR122" id="ref-link-section-d17524587e2498">122</a></sup>). Additionally, data from several observational studies suggested that kidney transplant recipients might benefit from pre-exposure prophylaxis with tixagevimab plus cilgavimab<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 123" title="Bertrand, D. et al. Efficacy of anti-SARS-CoV-2 monoclonal antibody prophylaxis and vaccination on the Omicron variant of COVID-19 in kidney transplant recipients. Kidney Int. 102, 440–442 (2022)." href="/articles/s41581-022-00642-4#ref-CR123" id="ref-link-section-d17524587e2502">123</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 124" title="Al Jurdi, A. et al. Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave. Am. J. Transplant. &#xA;                  https://doi.org/10.1111/ajt.17128&#xA;                  &#xA;                 (2022)." href="/articles/s41581-022-00642-4#ref-CR124" id="ref-link-section-d17524587e2505">124</a></sup>. Importantly, given that mAbs are metabolized via target-mediated elimination, no dose adjustment is required in patients with kidney impairment (Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41581-022-00642-4#Tab1">1</a>). However, conclusive data from RCTs conducted in this patient population are lacking and the existing studies were conducted before the emergence of the Omicron variant, which was resistant to most neutralizing mAbs<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="US Food and Drug Administration. Fact sheet for health care providers emergency use authorization (EUA) of bamlanivimab and etesevimab. FDA &#xA;                  https://www.fda.gov/media/145802/download&#xA;                  &#xA;                 (2020)." href="#ref-CR125" id="ref-link-section-d17524587e2512">125</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="US Food and Drug Administration. Fact sheet for health care providers emergency use authorization (EUA) of REGEN-COV. FDA &#xA;                  https://www.fda.gov/media/145611/download&#xA;                  &#xA;                 (2020)." href="#ref-CR126" id="ref-link-section-d17524587e2512_1">126</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 127" title="US Food and Drug Administration. Fact sheet for healthcare providers emergency use authorization (EUA) of sotrovimab. FDA &#xA;                  https://www.fda.gov/media/149534/download&#xA;                  &#xA;                 (2020)." href="/articles/s41581-022-00642-4#ref-CR127" id="ref-link-section-d17524587e2515">127</a></sup>.</p></div></div></section><section data-title="Therapies targeting the RAAS"><div class="c-article-section" id="Sec22-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec22">Therapies targeting the RAAS</h2><div class="c-article-section__content" id="Sec22-content"><p>Interest in the effects of SARS-CoV-2 on the host RAAS emerged early in the pandemic<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 128" title="Vaduganathan, M. et al. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N. Engl. J. Med. 382, 1653–1659 (2020)." href="/articles/s41581-022-00642-4#ref-CR128" id="ref-link-section-d17524587e2528">128</a></sup>. The RAAS has key roles in the regulation of vascular tone, electrolyte balance, inflammation, thrombosis and response to injury, and might be dysregulated in COVID-19 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 129" title="Sfera, A. et al. Intoxication with endogenous angiotensin II: a COVID-19 hypothesis. Front. Immunol. 11, 1472 (2020)." href="/articles/s41581-022-00642-4#ref-CR129" id="ref-link-section-d17524587e2532">129</a></sup>). Moreover, ACE2, which converts angiotensin II into angiotensin (1–7), is the functional host receptor for SARS-CoV-2 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 130" title="Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280.e8 (2020)." href="/articles/s41581-022-00642-4#ref-CR130" id="ref-link-section-d17524587e2536">130</a></sup>). ACE2 is abundantly expressed on the surface of nasopharyngeal and lung alveolar epithelial cells, and throughout the vascular endothelium; soluble ACE2 is also present in the circulation<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 131" title="Hamming, I. et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 203, 631–637 (2004)." href="/articles/s41581-022-00642-4#ref-CR131" id="ref-link-section-d17524587e2540">131</a></sup>. Angiotensin II increases vascular tone, upregulates inflammation, increases capillary permeability and activates clotting and profibrotic responses, whereas angiotensin (1–7) provides counter-regulatory functions to angiotensin II<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 132" title="Jiang, F. et al. Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets. Nat. Rev. Cardiol. 11, 413–426 (2014)." href="/articles/s41581-022-00642-4#ref-CR132" id="ref-link-section-d17524587e2544">132</a></sup>.</p><p>COVID-19 might disrupt ACE2 homeostasis via several mechanisms, and lead to a maladaptive increase in angiotensin II and a reduction of protective angiotensin (1–7). These mechanisms include direct binding to virus particles, which might reduce the bioavailability of ACE2, as well as COVID-19-mediated destruction of alveolar epithelial cells, which are a primary source of ACE2 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 133" title="Imai, Y. et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436, 112–116 (2005)." href="/articles/s41581-022-00642-4#ref-CR133" id="ref-link-section-d17524587e2551">133</a></sup>). These observations led to the hypothesis that attenuating angiotensin II activity and augmenting angiotensin (1–7) might be beneficial in COVID-19. Therapies being evaluated in RCTs include those that inhibit angiotensin II production (ACE inhibitors), inhibit angiotensin II binding to the angiotensin type I receptor (angiotensin II receptor blockers (ARBs)), accelerate conversion of angiotensin II to angiotensin (1–7) (recombinant ACE2) or activate angiotensin (1–7) signalling (investigational drugs, including TRV-027 and TXA-127). Recombinant ACE2 might confer the additional advantage of serving as a decoy for SARS-CoV-2, potentially limiting viral invasion<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 134" title="Zhang, H., Penninger, J. M., Li, Y., Zhong, N. &amp; Slutsky, A. S. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 46, 586–590 (2020)." href="/articles/s41581-022-00642-4#ref-CR134" id="ref-link-section-d17524587e2555">134</a></sup>.</p><p>These hypotheses are supported by observations that ACE inhibitors or ARBs mitigate the severity of acute lung injury in experimental models of COVID-19 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 135" title="Rysz, S. et al. COVID-19 pathophysiology may be driven by an imbalance in the renin-angiotensin-aldosterone system. Nat. Commun. 12, 2417 (2021)." href="/articles/s41581-022-00642-4#ref-CR135" id="ref-link-section-d17524587e2562">135</a></sup>), as well as models of acute lung injury induced by sepsis, chemical aspiration, SARS-CoV-1 or ventilation<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 136" title="Lawler, P. R., Derde, L. P. G., Mc Verry, B., Russell, J. A. &amp; van de Veerdonk, F. The renin-angiotensin system in acute lung injury. Crit. Care Med. 50, 1411–1415 (2022)." href="/articles/s41581-022-00642-4#ref-CR136" id="ref-link-section-d17524587e2566">136</a></sup>. Observational studies suggested that the use of ACE inhibitors and ARBs is associated with improved outcomes in pneumonia<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 137" title="Caldeira, D., Alarcão, J., Vaz-Carneiro, A. &amp; Costa, J. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ 345, e4260 (2012)." href="/articles/s41581-022-00642-4#ref-CR137" id="ref-link-section-d17524587e2570">137</a></sup>, influenza<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 138" title="Chung, S. C., Providencia, R. &amp; Sofat, R. Association between angiotensin blockade and incidence of influenza in the United Kingdom. N. Engl. J. Med. 383, 397–400 (2020)." href="/articles/s41581-022-00642-4#ref-CR138" id="ref-link-section-d17524587e2574">138</a></sup> and sepsis<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 139" title="Kim, J. et al. Effect of antihypertensive medications on sepsis-related outcomes: a population-based cohort study. Crit. Care Med. 47, e386–e393 (2019)." href="/articles/s41581-022-00642-4#ref-CR139" id="ref-link-section-d17524587e2578">139</a></sup>. Among patients with COVID-19, a meta-analysis of 52 observational studies found that antecedent ACE inhibitor or ARB use was associated with improved survival<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 140" title="Baral, R. et al. Association between renin-angiotensin-aldosterone system inhibitors and clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA Netw. Open 4, e213594 (2021)." href="/articles/s41581-022-00642-4#ref-CR140" id="ref-link-section-d17524587e2583">140</a></sup>. By contrast, an RCT in 659 hypertensive adults hospitalized for mild or moderate COVID-19 who were already taking an ACE inhibitor or an ARB prior to hospitalization found that continuation of ACE inhibitors and ARBs resulted in a similar number of hospital-free days compared with discontinuation<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 141" title="Lopes, R. D. et al. Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial. JAMA 325, 254–264 (2021)." href="/articles/s41581-022-00642-4#ref-CR141" id="ref-link-section-d17524587e2587">141</a></sup>. However, whether initiating RAAS modulators in the setting of acute COVID-19 is beneficial is unclear and is being evaluated in several RCTs. Notably, as with other COVID-19 treatments, the risk–benefit balance might depend on the stage and/or severity of COVID-19, as the potential for these agents to cause or worsen hypotension, hyperkalaemia and/or kidney impairment might increase with greater illness severity. The benefits of these therapies remain uncertain owing to the limited number of published RCTs and their modest sample sizes<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 142" title="Duarte, M. et al. Telmisartan for treatment of Covid-19 patients: an open multicenter randomized clinical trial. EClinicalMedicine 37, 100962 (2021)." href="/articles/s41581-022-00642-4#ref-CR142" id="ref-link-section-d17524587e2591">142</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 143" title="Puskarich, M. A. et al. A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19. EClinicalMedicine 37, 100957 (2021)." href="/articles/s41581-022-00642-4#ref-CR143" id="ref-link-section-d17524587e2594">143</a></sup>. Therefore, initiating these treatments in patients with COVID-19 who do not have accepted clinical indications is not recommended outside of RCT settings.</p></div></div></section><section data-title="Vitamin supplements"><div class="c-article-section" id="Sec23-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec23">Vitamin supplements</h2><div class="c-article-section__content" id="Sec23-content"><p>In addition to the COVID-19 therapeutics discussed above, the potential benefits of several vitamin and nutritional supplements — including vitamin D, nicotinamide and vitamin C — have been investigated.</p><p>Biologically active vitamin D (1,25-dihydroxyvitamin D (1,25D)) exerts immunomodulatory effects by binding to the cytoplasmic vitamin D receptor (VDR) that is expressed in T, B, and antigen-presenting cells. The 1,25D–VDR complex translocates to the nucleus, where it binds to DNA sequence elements in vitamin D-responsive genes<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 144" title="Ramagopalan, S. V. et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res. 20, 1352–1360 (2010)." href="/articles/s41581-022-00642-4#ref-CR144" id="ref-link-section-d17524587e2609">144</a></sup>. Over 200 vitamin D target genes have been identified, including genes that encode antimicrobial peptides (for example, cathelicidin) with broad activity against a range of bacteria and viruses<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 145" title="Liu, P. T. et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311, 1770–1773 (2006)." href="/articles/s41581-022-00642-4#ref-CR145" id="ref-link-section-d17524587e2613">145</a></sup>.</p><p>This established biological process, in combination with the epidemiological data linking vitamin D deficiency to adverse health outcomes across multiple clinical settings, generated enthusiasm for a potential therapeutic role for vitamin D long before the COVID-19 pandemic. However, two RCTs found that administration of high-dose vitamin D<sub>3</sub> did not reduce hospital length of stay or mortality compared with placebo in non-COVID-19 critically ill patients with vitamin D deficiency<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 146" title="National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, Ginde, A. A. et al. Early high-dose vitamin D3 for critically ill, vitamin D-deficient patients. N. Engl. J. Med. 381, 2529–2540 (2019)." href="/articles/s41581-022-00642-4#ref-CR146" id="ref-link-section-d17524587e2622">146</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 147" title="Amrein, K. et al. Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency: the VITdAL-ICU randomized clinical trial. JAMA 312, 1520–1530 (2014)." href="/articles/s41581-022-00642-4#ref-CR147" id="ref-link-section-d17524587e2625">147</a></sup>. In patients with COVID-19, an RCT conducted in 240 hospitalized adults with moderate to severe illness found that a single dose of vitamin D<sub>3</sub> (200,000 IU) had no effect on the length of hospital stay compared with placebo<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 148" title="Murai, I. H. et al. Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial. JAMA 325, 1053–1060 (2021)." href="/articles/s41581-022-00642-4#ref-CR148" id="ref-link-section-d17524587e2631">148</a></sup>. Of note, the study had several important limitations, including being underpowered<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 149" title="Leaf, D. E. &amp; Ginde, A. A. Vitamin D3 to treat COVID-19: different disease, same answer. JAMA 325, 1047–1048 (2021)." href="/articles/s41581-022-00642-4#ref-CR149" id="ref-link-section-d17524587e2635">149</a></sup>. The Vitamin D for COVID Trial (VIVID) is an ongoing phase III RCT that will enrol 1,880 outpatients with newly diagnosed COVID-19 to assess whether a 28-day course of vitamin D<sub>3</sub> improves outcomes compared with placebo<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 150" title="US National Library of Medicine. ClinicalTrials.gov &#xA;                  https://clinicaltrials.gov/ct2/show/NCT04536298&#xA;                  &#xA;                 (2022)." href="/articles/s41581-022-00642-4#ref-CR150" id="ref-link-section-d17524587e2642">150</a></sup>.</p><p>Nicotinamide is a vitamin B<sub>3</sub> analogue that attenuates AKI in preclinical models through its effects on mitochondrial oxidation and prostaglandin production<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 151" title="Tran, M. T. et al. PGC1α drives NAD biosynthesis linking oxidative metabolism to renal protection. Nature 531, 528–532 (2016)." href="/articles/s41581-022-00642-4#ref-CR151" id="ref-link-section-d17524587e2651">151</a></sup>, and also attenuated AKI in a pilot RCT in adults undergoing cardiac surgery<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 152" title="Poyan Mehr, A. et al. De novo NAD+ biosynthetic impairment in acute kidney injury in humans. Nat. Med. 24, 1351–1359 (2018)." href="/articles/s41581-022-00642-4#ref-CR152" id="ref-link-section-d17524587e2655">152</a></sup>. Several RCTs are currently ongoing to investigate nicotinamide for AKI prevention in various non-COVID-19 settings, including in patients undergoing aortic aneurysm repair<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 153" title="US National Library of Medicine. ClinicalTrials.gov &#xA;                  https://clinicaltrials.gov/ct2/show/NCT04342975&#xA;                  &#xA;                 (2022)." href="/articles/s41581-022-00642-4#ref-CR153" id="ref-link-section-d17524587e2659">153</a></sup> and those with septic shock<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 154" title="US National Library of Medicine. ClinicalTrials.gov &#xA;                  https://clinicaltrials.gov/ct2/show/NCT04589546&#xA;                  &#xA;                 (2021)." href="/articles/s41581-022-00642-4#ref-CR154" id="ref-link-section-d17524587e2663">154</a></sup>. In patients with COVID-19, data are more limited, although a prospective cohort study conducted in 201 hospitalized adults with COVID-19 found that administration of nicotinamide was associated with a lower risk of KRT or death compared with control individuals (HR 0.64, 95% CI 0.40–1.00)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 155" title="Raines, N. H. et al. Niacinamide may be associated with improved outcomes in COVID-19-related acute kidney injury: an observational study. Kidney360 2, 33–41 (2021)." href="/articles/s41581-022-00642-4#ref-CR155" id="ref-link-section-d17524587e2668">155</a></sup>. Ongoing RCTs of nicotinamide in patients with COVID-19 are investigating several outcomes, including AKI<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 156" title="US National Library of Medicine. ClinicalTrials.gov &#xA;                  https://clinicaltrials.gov/ct2/show/NCT05038488&#xA;                  &#xA;                 (2021)." href="/articles/s41581-022-00642-4#ref-CR156" id="ref-link-section-d17524587e2672">156</a></sup> and cognitive function<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 157" title="US National Library of Medicine. ClinicalTrials.gov &#xA;                  https://clinicaltrials.gov/ct2/show/NCT04809974&#xA;                  &#xA;                 (2022)." href="/articles/s41581-022-00642-4#ref-CR157" id="ref-link-section-d17524587e2676">157</a></sup>.</p><p>Administration of vitamin C (ascorbic acid) has been investigated in several non-COVID-19 clinical settings, including in critically ill patients with sepsis or septic shock, given its antioxidant, anti-inflammatory and free radical scavenging properties. However, a meta-analysis of 11 RCTs concluded that use of high-dose i.v. vitamin C does not improve survival in patients with sepsis<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 158" title="Sato, R. et al. Effect of IV high-dose vitamin c on mortality in patients with sepsis: a systematic review and meta-analysis of randomized controlled trials. Crit. Care Med. 49, 2121–2130 (2021)." href="/articles/s41581-022-00642-4#ref-CR158" id="ref-link-section-d17524587e2684">158</a></sup>. Furthermore, the 2022 LOVIT trial found that administration of i.v. vitamin C in critically ill patients with sepsis who were receiving vasopressor therapy increased the risk of death or persistent organ dysfunction at 28 days compared with placebo<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 159" title="Lamontagne, F. et al. Intravenous vitamin C in adults with sepsis in the intensive care unit. N. Engl. J. Med. 386, 2387–2398 (2022)." href="/articles/s41581-022-00642-4#ref-CR159" id="ref-link-section-d17524587e2688">159</a></sup>. In the setting of COVID-19, an open-label 2 × 2 factorial RCT tested the efficacy of a 10-day course of oral vitamin C (8,000 mg) and zinc gluconate (50 mg) in non-hospitalized adults. The study was stopped early for futility after enrolling 214 patients<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 160" title="Thomas, S. et al. Effect of high-dose zinc and ascorbic acid supplementation vs usual care on symptom length and reduction among ambulatory patients with SARS-CoV-2 infection: the COVID A to Z randomized clinical trial. JAMA Netw. Open 4, e210369 (2021)." href="/articles/s41581-022-00642-4#ref-CR160" id="ref-link-section-d17524587e2692">160</a></sup>. Moreover, a pilot trial conducted in China randomly assigned 56 critically ill patients with COVID-19 to receive 24 g vitamin C daily for 7 days or placebo but the study was terminated early and found no effect of vitamin C on mortality or duration of IMV<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 161" title="Zhang, J. et al. Pilot trial of high-dose vitamin C in critically ill COVID-19 patients. Ann. Intensive Care 11, 5 (2021)." href="/articles/s41581-022-00642-4#ref-CR161" id="ref-link-section-d17524587e2696">161</a></sup>. In summary, despite the interest in several vitamin supplements for the treatment of COVID-19, data to support their efficacy are currently lacking, although several RCTs are ongoing.</p></div></div></section><section data-title="Conclusions"><div class="c-article-section" id="Sec24-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec24">Conclusions</h2><div class="c-article-section__content" id="Sec24-content"><p>Multiple effective and safe therapeutics for COVID-19 have been developed during the past 2 years, with several agents now having been approved for use across the spectrum of disease severity. The extraordinarily rapid pace of drug development for this disease represents an incredible feat for the global scientific community. In addition to the development of direct antiviral agents and recombinant neutralizing mAbs with activity against SARS-CoV-2, anti-inflammatory, immunomodulatory, and antithrombotic agents that target the host immune response to COVID-19 have also been introduced and have a crucial role in preventing severe illness and death. Indeed, although few direct comparisons have been performed, anti-inflammatory therapies appear to be among the most effective in improving outcomes, at least among hospitalized patients. Efforts to develop effective therapies to treat emerging novel variants of SARS-CoV-2 are also underway. In combination with mass vaccination campaigns, the development of highly efficacious therapies to treat COVID-19 has undoubtedly contributed to the lower rates of hospitalization, critical illness and death that are observed today compared with earlier stages of the pandemic<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 162" title="Johns Hopkins University &amp; Medicine. Coronavirus Resource Center. JHU &#xA;                  https://coronavirus.jhu.edu/&#xA;                  &#xA;                 (2022)." href="/articles/s41581-022-00642-4#ref-CR162" id="ref-link-section-d17524587e2708">162</a></sup>.</p><p>Despite these impressive therapeutic advances for the general population, patients with kidney disease, including CKD or kidney failure, and kidney transplant recipients, are often excluded or under-represented in clinical trials. This patient population is immunocompromised and often has multiple comorbidities, such as hypertension, diabetes mellitus, coronary artery disease and cancer, and is therefore at a high risk of developing severe COVID-19 and death. Accordingly, greater efforts are needed to include these high-risk populations in RCTs of COVID-19 therapeutics. Additionally, more studies are needed to understand the impact of novel and repurposed agents on the prevention and treatment of COVID-19-associated AKI, which is linked to high mortality<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5" title="Gupta, S. et al. AKI treated with renal replacement therapy in critically ill patients with COVID-19. J. Am. Soc. Nephrol. 32, 161–176 (2021)." href="/articles/s41581-022-00642-4#ref-CR5" id="ref-link-section-d17524587e2715">5</a></sup>. Many of the larger RCTs investigating COVID-19 therapeutics failed to collect or report data on AKI, or only recorded whether patients received KRT (Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41581-022-00642-4#Tab3">3</a>), which represents a missed opportunity.</p><div class="c-article-table" data-test="inline-table" data-container-section="table" id="table-3"><figure><figcaption class="c-article-table__figcaption"><b id="Tab3" data-test="table-caption">Table 3 Major COVID-19 RCTs that assessed AKI outcomes</b></figcaption><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="table-link" data-track="click" data-track-action="view table" data-track-label="button" rel="nofollow" href="/articles/s41581-022-00642-4/tables/3" aria-label="Full size table 3"><span>Full size table</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div></div></div></section>
                </div>
            

            <div>
                <section data-title="Change history"><div class="c-article-section" id="change-history-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="change-history">Change history</h2><div class="c-article-section__content" id="change-history-content"><ul class="c-article-change-list"><li class="c-article-change-list__item u-mb-24" id="chg1"><ins datetime="2023-02-06"><h3 class="c-article-change-list__heading u-h3 u-pr-8 u-display-inline">06 February 2023</h3><div class="c-article-change-list__details"><p>A Correction to this paper has been published: <a href="https://doi.org/10.1038/s41581-023-00686-0">https://doi.org/10.1038/s41581-023-00686-0</a></p></div></ins></li></ul></div></div></section><div id="MagazineFulltextArticleBodySuffix"><section aria-labelledby="Bib1" data-title="References"><div class="c-article-section" id="Bib1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Bib1">References</h2><div class="c-article-section__content" id="Bib1-content"><div data-container-section="references"><ol class="c-article-references" data-track-component="outbound reference"><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="1."><p class="c-article-references__text" id="ref-CR1">Karim, S. S. A. &amp; Karim, Q. A. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. <i>Lancet</i> <b>398</b>, 2126–2128 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/S0140-6736(21)02758-6" data-track-action="article reference" href="https://doi.org/10.1016%2FS0140-6736%2821%2902758-6" aria-label="Article reference 1" data-doi="10.1016/S0140-6736(21)02758-6">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXis1yhsrfN" aria-label="CAS reference 1">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34871545" aria-label="PubMed reference 1">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640673" aria-label="PubMed Central reference 1">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 1" href="http://scholar.google.com/scholar_lookup?&amp;title=Omicron%20SARS-CoV-2%20variant%3A%20a%20new%20chapter%20in%20the%20COVID-19%20pandemic&amp;journal=Lancet&amp;doi=10.1016%2FS0140-6736%2821%2902758-6&amp;volume=398&amp;pages=2126-2128&amp;publication_year=2021&amp;author=Karim%2CSSA&amp;author=Karim%2CQA">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="2."><p class="c-article-references__text" id="ref-CR2">Flythe, J. E. et al. Characteristics and outcomes of individuals with pre-existing kidney disease and COVID-19 admitted to intensive care units in the United States. <i>Am. J. Kidney Dis.</i> <b>77</b>, 190–203.e1 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1053/j.ajkd.2020.09.003" data-track-action="article reference" href="https://doi.org/10.1053%2Fj.ajkd.2020.09.003" aria-label="Article reference 2" data-doi="10.1053/j.ajkd.2020.09.003">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXisVerurfF" aria-label="CAS reference 2">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32961244" aria-label="PubMed reference 2">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 2" href="http://scholar.google.com/scholar_lookup?&amp;title=Characteristics%20and%20outcomes%20of%20individuals%20with%20pre-existing%20kidney%20disease%20and%20COVID-19%20admitted%20to%20intensive%20care%20units%20in%20the%20United%20States&amp;journal=Am.%20J.%20Kidney%20Dis.&amp;doi=10.1053%2Fj.ajkd.2020.09.003&amp;volume=77&amp;pages=190-203.e1&amp;publication_year=2021&amp;author=Flythe%2CJE">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="3."><p class="c-article-references__text" id="ref-CR3">Massie, A. B. et al. Quantifying excess deaths among solid organ transplant recipients in the COVID-19 era. <i>Am. J. Transplant.</i> <b>22</b>, 2077–2082 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1111/ajt.17036" data-track-action="article reference" href="https://doi.org/10.1111%2Fajt.17036" aria-label="Article reference 3" data-doi="10.1111/ajt.17036">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XhsFShu7%2FI" aria-label="CAS reference 3">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35294799" aria-label="PubMed reference 3">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 3" href="http://scholar.google.com/scholar_lookup?&amp;title=Quantifying%20excess%20deaths%20among%20solid%20organ%20transplant%20recipients%20in%20the%20COVID-19%20era&amp;journal=Am.%20J.%20Transplant.&amp;doi=10.1111%2Fajt.17036&amp;volume=22&amp;pages=2077-2082&amp;publication_year=2022&amp;author=Massie%2CAB">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="4."><p class="c-article-references__text" id="ref-CR4">Chan, L. et al. AKI in hospitalized patients with COVID-19. <i>J. Am. Soc. Nephrol.</i> <b>32</b>, 151–160 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1681/ASN.2020050615" data-track-action="article reference" href="https://doi.org/10.1681%2FASN.2020050615" aria-label="Article reference 4" data-doi="10.1681/ASN.2020050615">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXkvFGrsbw%3D" aria-label="CAS reference 4">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32883700" aria-label="PubMed reference 4">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 4" href="http://scholar.google.com/scholar_lookup?&amp;title=AKI%20in%20hospitalized%20patients%20with%20COVID-19&amp;journal=J.%20Am.%20Soc.%20Nephrol.&amp;doi=10.1681%2FASN.2020050615&amp;volume=32&amp;pages=151-160&amp;publication_year=2021&amp;author=Chan%2CL">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="5."><p class="c-article-references__text" id="ref-CR5">Gupta, S. et al. AKI treated with renal replacement therapy in critically ill patients with COVID-19. <i>J. Am. Soc. Nephrol.</i> <b>32</b>, 161–176 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1681/ASN.2020060897" data-track-action="article reference" href="https://doi.org/10.1681%2FASN.2020060897" aria-label="Article reference 5" data-doi="10.1681/ASN.2020060897">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXkvFGrsLg%3D" aria-label="CAS reference 5">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33067383" aria-label="PubMed reference 5">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 5" href="http://scholar.google.com/scholar_lookup?&amp;title=AKI%20treated%20with%20renal%20replacement%20therapy%20in%20critically%20ill%20patients%20with%20COVID-19&amp;journal=J.%20Am.%20Soc.%20Nephrol.&amp;doi=10.1681%2FASN.2020060897&amp;volume=32&amp;pages=161-176&amp;publication_year=2021&amp;author=Gupta%2CS">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="6."><p class="c-article-references__text" id="ref-CR6">Mehta, P. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. <i>Lancet</i> <b>395</b>, 1033–1034 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/S0140-6736(20)30628-0" data-track-action="article reference" href="https://doi.org/10.1016%2FS0140-6736%2820%2930628-0" aria-label="Article reference 6" data-doi="10.1016/S0140-6736(20)30628-0">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXltFCjsb8%3D" aria-label="CAS reference 6">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32192578" aria-label="PubMed reference 6">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270045" aria-label="PubMed Central reference 6">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 6" href="http://scholar.google.com/scholar_lookup?&amp;title=COVID-19%3A%20consider%20cytokine%20storm%20syndromes%20and%20immunosuppression&amp;journal=Lancet&amp;doi=10.1016%2FS0140-6736%2820%2930628-0&amp;volume=395&amp;pages=1033-1034&amp;publication_year=2020&amp;author=Mehta%2CP">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="7."><p class="c-article-references__text" id="ref-CR7">Gupta, S. et al. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. <i>JAMA Intern. Med.</i> <b>180</b>, 1436–1447 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1001/jamainternmed.2020.3596" data-track-action="article reference" href="https://doi.org/10.1001%2Fjamainternmed.2020.3596" aria-label="Article reference 7" data-doi="10.1001/jamainternmed.2020.3596">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXit1Kntb%2FM" aria-label="CAS reference 7">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32667668" aria-label="PubMed reference 7">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 7" href="http://scholar.google.com/scholar_lookup?&amp;title=Factors%20associated%20with%20death%20in%20critically%20ill%20patients%20with%20coronavirus%20disease%202019%20in%20the%20US&amp;journal=JAMA%20Intern.%20Med.&amp;doi=10.1001%2Fjamainternmed.2020.3596&amp;volume=180&amp;pages=1436-1447&amp;publication_year=2020&amp;author=Gupta%2CS">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="8."><p class="c-article-references__text" id="ref-CR8">Del Valle, D. M. et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. <i>Nat. Med.</i> <b>26</b>, 1636–1643 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/s41591-020-1051-9" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41591-020-1051-9" aria-label="Article reference 8" data-doi="10.1038/s41591-020-1051-9">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32839624" aria-label="PubMed reference 8">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869028" aria-label="PubMed Central reference 8">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 8" href="http://scholar.google.com/scholar_lookup?&amp;title=An%20inflammatory%20cytokine%20signature%20predicts%20COVID-19%20severity%20and%20survival&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-020-1051-9&amp;volume=26&amp;pages=1636-1643&amp;publication_year=2020&amp;author=Valle%2CDM">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="9."><p class="c-article-references__text" id="ref-CR9">Short, S. A. P. et al. d-dimer and death in critically ill patients with coronavirus disease 2019. <i>Crit. Care Med.</i> <b>49</b>, e500–e511 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1097/CCM.0000000000004917" data-track-action="article reference" href="https://doi.org/10.1097%2FCCM.0000000000004917" aria-label="Article reference 9" data-doi="10.1097/CCM.0000000000004917">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXpvVOjtrs%3D" aria-label="CAS reference 9">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33591017" aria-label="PubMed reference 9">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275993" aria-label="PubMed Central reference 9">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 9" href="http://scholar.google.com/scholar_lookup?&amp;title=d-dimer%20and%20death%20in%20critically%20ill%20patients%20with%20coronavirus%20disease%202019&amp;journal=Crit.%20Care%20Med.&amp;doi=10.1097%2FCCM.0000000000004917&amp;volume=49&amp;pages=e500-e511&amp;publication_year=2021&amp;author=Short%2CSAP">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="10."><p class="c-article-references__text" id="ref-CR10">Wilson, J. G. et al. Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis. <i>JCI Insight</i> <b>5</b>, 140289 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1172/jci.insight.140289" data-track-action="article reference" href="https://doi.org/10.1172%2Fjci.insight.140289" aria-label="Article reference 10" data-doi="10.1172/jci.insight.140289">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32706339" aria-label="PubMed reference 10">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 10" href="http://scholar.google.com/scholar_lookup?&amp;title=Cytokine%20profile%20in%20plasma%20of%20severe%20COVID-19%20does%20not%20differ%20from%20ARDS%20and%20sepsis&amp;journal=JCI%20Insight&amp;doi=10.1172%2Fjci.insight.140289&amp;volume=5&amp;publication_year=2020&amp;author=Wilson%2CJG">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="11."><p class="c-article-references__text" id="ref-CR11">RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. <i>N. Engl. J. Med.</i> <b>384</b>, 693–704 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMoa2021436" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa2021436" aria-label="Article reference 11" data-doi="10.1056/NEJMoa2021436">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 11" href="http://scholar.google.com/scholar_lookup?&amp;title=Dexamethasone%20in%20hospitalized%20patients%20with%20Covid-19&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa2021436&amp;volume=384&amp;pages=693-704&amp;publication_year=2021">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="12."><p class="c-article-references__text" id="ref-CR12">WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. <i>JAMA</i> <b>324</b>, 1330–1341 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1001/jama.2020.17023" data-track-action="article reference" href="https://doi.org/10.1001%2Fjama.2020.17023" aria-label="Article reference 12" data-doi="10.1001/jama.2020.17023">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 12" href="http://scholar.google.com/scholar_lookup?&amp;title=Association%20between%20administration%20of%20systemic%20corticosteroids%20and%20mortality%20among%20critically%20ill%20patients%20with%20COVID-19%3A%20a%20meta-analysis&amp;journal=JAMA&amp;doi=10.1001%2Fjama.2020.17023&amp;volume=324&amp;pages=1330-1341&amp;publication_year=2020">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="13."><p class="c-article-references__text" id="ref-CR13">Gupta, S. et al. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. <i>JAMA Intern. Med.</i> <b>181</b>, 41–51 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1001/jamainternmed.2020.6252" data-track-action="article reference" href="https://doi.org/10.1001%2Fjamainternmed.2020.6252" aria-label="Article reference 13" data-doi="10.1001/jamainternmed.2020.6252">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXitl2gs7w%3D" aria-label="CAS reference 13">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33080002" aria-label="PubMed reference 13">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 13" href="http://scholar.google.com/scholar_lookup?&amp;title=Association%20between%20early%20treatment%20with%20tocilizumab%20and%20mortality%20among%20critically%20ill%20patients%20with%20COVID-19&amp;journal=JAMA%20Intern.%20Med.&amp;doi=10.1001%2Fjamainternmed.2020.6252&amp;volume=181&amp;pages=41-51&amp;publication_year=2021&amp;author=Gupta%2CS">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="14."><p class="c-article-references__text" id="ref-CR14">Guaraldi, G. et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. <i>Lancet Rheumatol.</i> <b>2</b>, e474–e484 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/S2665-9913(20)30173-9" data-track-action="article reference" href="https://doi.org/10.1016%2FS2665-9913%2820%2930173-9" aria-label="Article reference 14" data-doi="10.1016/S2665-9913(20)30173-9">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32835257" aria-label="PubMed reference 14">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7314456" aria-label="PubMed Central reference 14">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 14" href="http://scholar.google.com/scholar_lookup?&amp;title=Tocilizumab%20in%20patients%20with%20severe%20COVID-19%3A%20a%20retrospective%20cohort%20study&amp;journal=Lancet%20Rheumatol.&amp;doi=10.1016%2FS2665-9913%2820%2930173-9&amp;volume=2&amp;pages=e474-e484&amp;publication_year=2020&amp;author=Guaraldi%2CG">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="15."><p class="c-article-references__text" id="ref-CR15">Stone, J. H. et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. <i>N. Engl. J. Med.</i> <b>383</b>, 2333–2344 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMoa2028836" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa2028836" aria-label="Article reference 15" data-doi="10.1056/NEJMoa2028836">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXisF2kur7J" aria-label="CAS reference 15">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33085857" aria-label="PubMed reference 15">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 15" href="http://scholar.google.com/scholar_lookup?&amp;title=Efficacy%20of%20tocilizumab%20in%20patients%20hospitalized%20with%20Covid-19&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa2028836&amp;volume=383&amp;pages=2333-2344&amp;publication_year=2020&amp;author=Stone%2CJH">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="16."><p class="c-article-references__text" id="ref-CR16">Salvarani, C. et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. <i>JAMA Intern. Med.</i> <b>181</b>, 24–31 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1001/jamainternmed.2020.6615" data-track-action="article reference" href="https://doi.org/10.1001%2Fjamainternmed.2020.6615" aria-label="Article reference 16" data-doi="10.1001/jamainternmed.2020.6615">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXitl2gs7o%3D" aria-label="CAS reference 16">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33080005" aria-label="PubMed reference 16">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 16" href="http://scholar.google.com/scholar_lookup?&amp;title=Effect%20of%20tocilizumab%20vs%20standard%20care%20on%20clinical%20worsening%20in%20patients%20hospitalized%20with%20COVID-19%20pneumonia%3A%20a%20randomized%20clinical%20trial&amp;journal=JAMA%20Intern.%20Med.&amp;doi=10.1001%2Fjamainternmed.2020.6615&amp;volume=181&amp;pages=24-31&amp;publication_year=2021&amp;author=Salvarani%2CC">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="17."><p class="c-article-references__text" id="ref-CR17">Leaf, D. E., Gupta, S. &amp; Wang, W. Tocilizumab in covid-19. <i>N. Engl. J. Med.</i> <b>384</b>, 86–87 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMc2032911" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMc2032911" aria-label="Article reference 17" data-doi="10.1056/NEJMc2032911">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXotFSjtg%3D%3D" aria-label="CAS reference 17">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33356049" aria-label="PubMed reference 17">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 17" href="http://scholar.google.com/scholar_lookup?&amp;title=Tocilizumab%20in%20covid-19&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMc2032911&amp;volume=384&amp;pages=86-87&amp;publication_year=2021&amp;author=Leaf%2CDE&amp;author=Gupta%2CS&amp;author=Wang%2CW">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="18."><p class="c-article-references__text" id="ref-CR18">REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with covid-19. <i>N. Engl. J. Med.</i> <b>384</b>, 1491–1502 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMoa2100433" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa2100433" aria-label="Article reference 18" data-doi="10.1056/NEJMoa2100433">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 18" href="http://scholar.google.com/scholar_lookup?&amp;title=Interleukin-6%20receptor%20antagonists%20in%20critically%20ill%20patients%20with%20covid-19&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa2100433&amp;volume=384&amp;pages=1491-1502&amp;publication_year=2021">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="19."><p class="c-article-references__text" id="ref-CR19">RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet</i> <b>397</b>, 1637–1645 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/S0140-6736(21)00676-0" data-track-action="article reference" href="https://doi.org/10.1016%2FS0140-6736%2821%2900676-0" aria-label="Article reference 19" data-doi="10.1016/S0140-6736(21)00676-0">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 19" href="http://scholar.google.com/scholar_lookup?&amp;title=Tocilizumab%20in%20patients%20admitted%20to%20hospital%20with%20COVID-19%20%28RECOVERY%29%3A%20a%20randomised%2C%20controlled%2C%20open-label%2C%20platform%20trial&amp;journal=Lancet&amp;doi=10.1016%2FS0140-6736%2821%2900676-0&amp;volume=397&amp;pages=1637-1645&amp;publication_year=2021">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="20."><p class="c-article-references__text" id="ref-CR20">Normand, S. L. T. The RECOVERY platform. <i>N. Engl. J. Med.</i> <b>384</b>, 757–758 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMe2025674" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMe2025674" aria-label="Article reference 20" data-doi="10.1056/NEJMe2025674">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXlt1Kgs7Y%3D" aria-label="CAS reference 20">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32706531" aria-label="PubMed reference 20">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 20" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20RECOVERY%20platform&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMe2025674&amp;volume=384&amp;pages=757-758&amp;publication_year=2021&amp;author=Normand%2CSLT">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="21."><p class="c-article-references__text" id="ref-CR21">WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. <i>JAMA</i> <b>326</b>, 499–518 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1001/jama.2021.11330" data-track-action="article reference" href="https://doi.org/10.1001%2Fjama.2021.11330" aria-label="Article reference 21" data-doi="10.1001/jama.2021.11330">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 21" href="http://scholar.google.com/scholar_lookup?&amp;title=Association%20between%20administration%20of%20IL-6%20antagonists%20and%20mortality%20among%20patients%20hospitalized%20for%20COVID-19%3A%20a%20meta-analysis&amp;journal=JAMA&amp;doi=10.1001%2Fjama.2021.11330&amp;volume=326&amp;pages=499-518&amp;publication_year=2021">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="22."><p class="c-article-references__text" id="ref-CR22">Kalil, A. C. et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. <i>N. Engl. J. Med.</i> <b>384</b>, 795–807 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMoa2031994" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa2031994" aria-label="Article reference 22" data-doi="10.1056/NEJMoa2031994">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXlvFCksrw%3D" aria-label="CAS reference 22">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33306283" aria-label="PubMed reference 22">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 22" href="http://scholar.google.com/scholar_lookup?&amp;title=Baricitinib%20plus%20remdesivir%20for%20hospitalized%20adults%20with%20Covid-19&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa2031994&amp;volume=384&amp;pages=795-807&amp;publication_year=2021&amp;author=Kalil%2CAC">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="23."><p class="c-article-references__text" id="ref-CR23">Marconi, V. C. et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. <i>Lancet Respir. Med.</i> <b>9</b>, 1407–1418 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/S2213-2600(21)00331-3" data-track-action="article reference" href="https://doi.org/10.1016%2FS2213-2600%2821%2900331-3" aria-label="Article reference 23" data-doi="10.1016/S2213-2600(21)00331-3">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXhvFyjsLrP" aria-label="CAS reference 23">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34480861" aria-label="PubMed reference 23">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409066" aria-label="PubMed Central reference 23">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 23" href="http://scholar.google.com/scholar_lookup?&amp;title=Efficacy%20and%20safety%20of%20baricitinib%20for%20the%20treatment%20of%20hospitalised%20adults%20with%20COVID-19%20%28COV-BARRIER%29%3A%20a%20randomised%2C%20double-blind%2C%20parallel-group%2C%20placebo-controlled%20phase%203%20trial&amp;journal=Lancet%20Respir.%20Med.&amp;doi=10.1016%2FS2213-2600%2821%2900331-3&amp;volume=9&amp;pages=1407-1418&amp;publication_year=2021&amp;author=Marconi%2CVC">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="24."><p class="c-article-references__text" id="ref-CR24">Ely, E. W. et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. <i>Lancet Respir. Med.</i> <b>10</b>, 327–336 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/S2213-2600(22)00006-6" data-track-action="article reference" href="https://doi.org/10.1016%2FS2213-2600%2822%2900006-6" aria-label="Article reference 24" data-doi="10.1016/S2213-2600(22)00006-6">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XjtV2rsbk%3D" aria-label="CAS reference 24">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35123660" aria-label="PubMed reference 24">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813065" aria-label="PubMed Central reference 24">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 24" href="http://scholar.google.com/scholar_lookup?&amp;title=Efficacy%20and%20safety%20of%20baricitinib%20plus%20standard%20of%20care%20for%20the%20treatment%20of%20critically%20ill%20hospitalised%20adults%20with%20COVID-19%20on%20invasive%20mechanical%20ventilation%20or%20extracorporeal%20membrane%20oxygenation%3A%20an%20exploratory%2C%20randomised%2C%20placebo-controlled%20trial&amp;journal=Lancet%20Respir.%20Med.&amp;doi=10.1016%2FS2213-2600%2822%2900006-6&amp;volume=10&amp;pages=327-336&amp;publication_year=2022&amp;author=Ely%2CEW">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="25."><p class="c-article-references__text" id="ref-CR25">RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. <i>Lancet</i> <b>400</b>, 359–368 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/S0140-6736(22)01109-6" data-track-action="article reference" href="https://doi.org/10.1016%2FS0140-6736%2822%2901109-6" aria-label="Article reference 25" data-doi="10.1016/S0140-6736(22)01109-6">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 25" href="http://scholar.google.com/scholar_lookup?&amp;title=Baricitinib%20in%20patients%20admitted%20to%20hospital%20with%20COVID-19%20%28RECOVERY%29%3A%20a%20randomised%2C%20controlled%2C%20open-label%2C%20platform%20trial%20and%20updated%20meta-analysis&amp;journal=Lancet&amp;doi=10.1016%2FS0140-6736%2822%2901109-6&amp;volume=400&amp;pages=359-368&amp;publication_year=2022">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="26."><p class="c-article-references__text" id="ref-CR26">Axfors, C. et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. <i>Nat. Commun.</i> <b>12</b>, 2349 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/s41467-021-22446-z" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41467-021-22446-z" aria-label="Article reference 26" data-doi="10.1038/s41467-021-22446-z">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXptFOqsb4%3D" aria-label="CAS reference 26">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33859192" aria-label="PubMed reference 26">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050319" aria-label="PubMed Central reference 26">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 26" href="http://scholar.google.com/scholar_lookup?&amp;title=Mortality%20outcomes%20with%20hydroxychloroquine%20and%20chloroquine%20in%20COVID-19%20from%20an%20international%20collaborative%20meta-analysis%20of%20randomized%20trials&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fs41467-021-22446-z&amp;volume=12&amp;publication_year=2021&amp;author=Axfors%2CC">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="27."><p class="c-article-references__text" id="ref-CR27">Arabi, Y. M. et al. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. <i>Intensive Care Med.</i> <b>47</b>, 867–886 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="noopener" data-track-label="10.1007/s00134-021-06448-5" data-track-action="article reference" href="https://link.springer.com/doi/10.1007/s00134-021-06448-5" aria-label="Article reference 27" data-doi="10.1007/s00134-021-06448-5">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXhsFGqsbnO" aria-label="CAS reference 27">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34251506" aria-label="PubMed reference 27">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274471" aria-label="PubMed Central reference 27">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 27" href="http://scholar.google.com/scholar_lookup?&amp;title=Lopinavir-ritonavir%20and%20hydroxychloroquine%20for%20critically%20ill%20patients%20with%20COVID-19%3A%20REMAP-CAP%20randomized%20controlled%20trial&amp;journal=Intensive%20Care%20Med.&amp;doi=10.1007%2Fs00134-021-06448-5&amp;volume=47&amp;pages=867-886&amp;publication_year=2021&amp;author=Arabi%2CYM">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="28."><p class="c-article-references__text" id="ref-CR28">Reis, G. et al. Effect of early treatment with ivermectin among patients with Covid-19. <i>N. Engl. J. Med.</i> <b>386</b>, 1721–1731 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMoa2115869" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa2115869" aria-label="Article reference 28" data-doi="10.1056/NEJMoa2115869">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38Xht1OrtL%2FF" aria-label="CAS reference 28">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35353979" aria-label="PubMed reference 28">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 28" href="http://scholar.google.com/scholar_lookup?&amp;title=Effect%20of%20early%20treatment%20with%20ivermectin%20among%20patients%20with%20Covid-19&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa2115869&amp;volume=386&amp;pages=1721-1731&amp;publication_year=2022&amp;author=Reis%2CG">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="29."><p class="c-article-references__text" id="ref-CR29">Sheahan, T. P. et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. <i>Sci. Transl Med.</i> <b>9</b>, eaal3653 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1126/scitranslmed.aal3653" data-track-action="article reference" href="https://doi.org/10.1126%2Fscitranslmed.aal3653" aria-label="Article reference 29" data-doi="10.1126/scitranslmed.aal3653">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28659436" aria-label="PubMed reference 29">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567817" aria-label="PubMed Central reference 29">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 29" href="http://scholar.google.com/scholar_lookup?&amp;title=Broad-spectrum%20antiviral%20GS-5734%20inhibits%20both%20epidemic%20and%20zoonotic%20coronaviruses&amp;journal=Sci.%20Transl%20Med.&amp;doi=10.1126%2Fscitranslmed.aal3653&amp;volume=9&amp;publication_year=2017&amp;author=Sheahan%2CTP">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="30."><p class="c-article-references__text" id="ref-CR30">Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. <i>Cell Res.</i> <b>30</b>, 269–271 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/s41422-020-0282-0" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41422-020-0282-0" aria-label="Article reference 30" data-doi="10.1038/s41422-020-0282-0">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXkt1Ciu7k%3D" aria-label="CAS reference 30">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32020029" aria-label="PubMed reference 30">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054408" aria-label="PubMed Central reference 30">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 30" href="http://scholar.google.com/scholar_lookup?&amp;title=Remdesivir%20and%20chloroquine%20effectively%20inhibit%20the%20recently%20emerged%20novel%20coronavirus%20%282019-nCoV%29%20in%20vitro&amp;journal=Cell%20Res.&amp;doi=10.1038%2Fs41422-020-0282-0&amp;volume=30&amp;pages=269-271&amp;publication_year=2020&amp;author=Wang%2CM">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="31."><p class="c-article-references__text" id="ref-CR31">Gottlieb, R. L. et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. <i>N. Engl. J. Med.</i> <b>386</b>, 305–315 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMoa2116846" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa2116846" aria-label="Article reference 31" data-doi="10.1056/NEJMoa2116846">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XisFSksr0%3D" aria-label="CAS reference 31">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34937145" aria-label="PubMed reference 31">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 31" href="http://scholar.google.com/scholar_lookup?&amp;title=Early%20remdesivir%20to%20prevent%20progression%20to%20severe%20Covid-19%20in%20outpatients&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa2116846&amp;volume=386&amp;pages=305-315&amp;publication_year=2022&amp;author=Gottlieb%2CRL">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="32."><p class="c-article-references__text" id="ref-CR32">Beigel, J. H. et al. Remdesivir for the treatment of Covid-19 — final report. <i>N. Engl. J. Med.</i> <b>383</b>, 1813–1826 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMoa2007764" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa2007764" aria-label="Article reference 32" data-doi="10.1056/NEJMoa2007764">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXit1yltL7O" aria-label="CAS reference 32">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32445440" aria-label="PubMed reference 32">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 32" href="http://scholar.google.com/scholar_lookup?&amp;title=Remdesivir%20for%20the%20treatment%20of%20Covid-19%20%E2%80%94%20final%20report&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa2007764&amp;volume=383&amp;pages=1813-1826&amp;publication_year=2020&amp;author=Beigel%2CJH">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="33."><p class="c-article-references__text" id="ref-CR33">WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. <i>Lancet</i> <b>399</b>, 1941–1953 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/S0140-6736(22)00519-0" data-track-action="article reference" href="https://doi.org/10.1016%2FS0140-6736%2822%2900519-0" aria-label="Article reference 33" data-doi="10.1016/S0140-6736(22)00519-0">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9060606" aria-label="PubMed Central reference 33">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 33" href="http://scholar.google.com/scholar_lookup?&amp;title=Remdesivir%20and%20three%20other%20drugs%20for%20hospitalised%20patients%20with%20COVID-19%3A%20final%20results%20of%20the%20WHO%20Solidarity%20randomised%20trial%20and%20updated%20meta-analyses&amp;journal=Lancet&amp;doi=10.1016%2FS0140-6736%2822%2900519-0&amp;volume=399&amp;pages=1941-1953&amp;publication_year=2022">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="34."><p class="c-article-references__text" id="ref-CR34">Owen, D. R. et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. <i>Science</i> <b>374</b>, 1586–1593 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1126/science.abl4784" data-track-action="article reference" href="https://doi.org/10.1126%2Fscience.abl4784" aria-label="Article reference 34" data-doi="10.1126/science.abl4784">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XhsFygt70%3D" aria-label="CAS reference 34">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34726479" aria-label="PubMed reference 34">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 34" href="http://scholar.google.com/scholar_lookup?&amp;title=An%20oral%20SARS-CoV-2%20Mpro%20inhibitor%20clinical%20candidate%20for%20the%20treatment%20of%20COVID-19&amp;journal=Science&amp;doi=10.1126%2Fscience.abl4784&amp;volume=374&amp;pages=1586-1593&amp;publication_year=2021&amp;author=Owen%2CDR">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="35."><p class="c-article-references__text" id="ref-CR35">Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. <i>N. Engl. J. Med.</i> <b>386</b>, 1397–1408 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMoa2118542" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa2118542" aria-label="Article reference 35" data-doi="10.1056/NEJMoa2118542">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XhtFShu73O" aria-label="CAS reference 35">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35172054" aria-label="PubMed reference 35">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 35" href="http://scholar.google.com/scholar_lookup?&amp;title=Oral%20nirmatrelvir%20for%20high-risk%2C%20nonhospitalized%20adults%20with%20Covid-19&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa2118542&amp;volume=386&amp;pages=1397-1408&amp;publication_year=2022&amp;author=Hammond%2CJ">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="36."><p class="c-article-references__text" id="ref-CR36">Sheahan, T. P. et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. <i>Sci. Transl Med.</i> <b>12</b>, eabb5883 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1126/scitranslmed.abb5883" data-track-action="article reference" href="https://doi.org/10.1126%2Fscitranslmed.abb5883" aria-label="Article reference 36" data-doi="10.1126/scitranslmed.abb5883">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXotl2qtrg%3D" aria-label="CAS reference 36">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32253226" aria-label="PubMed reference 36">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 36" href="http://scholar.google.com/scholar_lookup?&amp;title=An%20orally%20bioavailable%20broad-spectrum%20antiviral%20inhibits%20SARS-CoV-2%20in%20human%20airway%20epithelial%20cell%20cultures%20and%20multiple%20coronaviruses%20in%20mice&amp;journal=Sci.%20Transl%20Med.&amp;doi=10.1126%2Fscitranslmed.abb5883&amp;volume=12&amp;publication_year=2020&amp;author=Sheahan%2CTP">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="37."><p class="c-article-references__text" id="ref-CR37">Jayk Bernal, A. et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. <i>N. Engl. J. Med.</i> <b>386</b>, 509–520 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMoa2116044" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa2116044" aria-label="Article reference 37" data-doi="10.1056/NEJMoa2116044">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34914868" aria-label="PubMed reference 37">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 37" href="http://scholar.google.com/scholar_lookup?&amp;title=Molnupiravir%20for%20oral%20treatment%20of%20Covid-19%20in%20nonhospitalized%20patients&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa2116044&amp;volume=386&amp;pages=509-520&amp;publication_year=2022&amp;author=Jayk%20Bernal%2CA">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="38."><p class="c-article-references__text" id="ref-CR38">Hoover, R. K. et al. Clinical pharmacokinetics of sulfobutylether-β-cyclodextrin in patients with varying degrees of renal impairment. <i>J. Clin. Pharmacol.</i> <b>58</b>, 814–822 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1002/jcph.1077" data-track-action="article reference" href="https://doi.org/10.1002%2Fjcph.1077" aria-label="Article reference 38" data-doi="10.1002/jcph.1077">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXhtVCgt7%2FM" aria-label="CAS reference 38">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29578585" aria-label="PubMed reference 38">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718009" aria-label="PubMed Central reference 38">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 38" href="http://scholar.google.com/scholar_lookup?&amp;title=Clinical%20pharmacokinetics%20of%20sulfobutylether-%CE%B2-cyclodextrin%20in%20patients%20with%20varying%20degrees%20of%20renal%20impairment&amp;journal=J.%20Clin.%20Pharmacol.&amp;doi=10.1002%2Fjcph.1077&amp;volume=58&amp;pages=814-822&amp;publication_year=2018&amp;author=Hoover%2CRK">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="39."><p class="c-article-references__text" id="ref-CR39">Estiverne, C. et al. Remdesivir in patients with estimated GFR &lt;30 ml/min per 1.73 m<sup>2</sup> or on renal replacement therapy. <i>Kidney Int. Rep.</i> <b>6</b>, 835–838 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.ekir.2020.11.025" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.ekir.2020.11.025" aria-label="Article reference 39" data-doi="10.1016/j.ekir.2020.11.025">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33263094" aria-label="PubMed reference 39">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 39" href="http://scholar.google.com/scholar_lookup?&amp;title=Remdesivir%20in%20patients%20with%20estimated%20GFR%20%3C30%20ml%2Fmin%20per%201.73%20m2%20or%20on%20renal%20replacement%20therapy&amp;journal=Kidney%20Int.%20Rep.&amp;doi=10.1016%2Fj.ekir.2020.11.025&amp;volume=6&amp;pages=835-838&amp;publication_year=2021&amp;author=Estiverne%2CC">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="40."><p class="c-article-references__text" id="ref-CR40">Thakare, S. et al. Safety of remdesivir in patients with acute kidney injury or CKD. <i>Kidney Int. Rep.</i> <b>6</b>, 206–210 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.ekir.2020.10.005" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.ekir.2020.10.005" aria-label="Article reference 40" data-doi="10.1016/j.ekir.2020.10.005">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33073066" aria-label="PubMed reference 40">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 40" href="http://scholar.google.com/scholar_lookup?&amp;title=Safety%20of%20remdesivir%20in%20patients%20with%20acute%20kidney%20injury%20or%20CKD&amp;journal=Kidney%20Int.%20Rep.&amp;doi=10.1016%2Fj.ekir.2020.10.005&amp;volume=6&amp;pages=206-210&amp;publication_year=2021&amp;author=Thakare%2CS">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="41."><p class="c-article-references__text" id="ref-CR41">Pettit, N. N. et al. Remdesivir use in the setting of severe renal impairment: a theoretical concern or real risk? <i>Clin. Infect. Dis.</i> <b>73</b>, e3990–e3995 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1093/cid/ciaa1851" data-track-action="article reference" href="https://doi.org/10.1093%2Fcid%2Fciaa1851" aria-label="Article reference 41" data-doi="10.1093/cid/ciaa1851">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XnslCmsQ%3D%3D" aria-label="CAS reference 41">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33315065" aria-label="PubMed reference 41">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 41" href="http://scholar.google.com/scholar_lookup?&amp;title=Remdesivir%20use%20in%20the%20setting%20of%20severe%20renal%20impairment%3A%20a%20theoretical%20concern%20or%20real%20risk%3F&amp;journal=Clin.%20Infect.%20Dis.&amp;doi=10.1093%2Fcid%2Fciaa1851&amp;volume=73&amp;pages=e3990-e3995&amp;publication_year=2021&amp;author=Pettit%2CNN">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="42."><p class="c-article-references__text" id="ref-CR42">Sukeishi, A. et al. Population pharmacokinetic modeling of GS-441524, the active metabolite of remdesivir, in Japanese COVID-19 patients with renal dysfunction. <i>CPT Pharmacomet. Syst. Pharmacol.</i> <b>11</b>, 94–103 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1002/psp4.12736" data-track-action="article reference" href="https://doi.org/10.1002%2Fpsp4.12736" aria-label="Article reference 42" data-doi="10.1002/psp4.12736">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXisFGjsL7L" aria-label="CAS reference 42">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 42" href="http://scholar.google.com/scholar_lookup?&amp;title=Population%20pharmacokinetic%20modeling%20of%20GS-441524%2C%20the%20active%20metabolite%20of%20remdesivir%2C%20in%20Japanese%20COVID-19%20patients%20with%20renal%20dysfunction&amp;journal=CPT%20Pharmacomet.%20Syst.%20Pharmacol.&amp;doi=10.1002%2Fpsp4.12736&amp;volume=11&amp;pages=94-103&amp;publication_year=2022&amp;author=Sukeishi%2CA">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="43."><p class="c-article-references__text" id="ref-CR43">Seethapathy, R., Zhao, S., Long, J. D., Strohbehn, I. A. &amp; Sise, M. E. A propensity score-matched observational study of remdesivir in patients with COVID-19 and severe kidney disease. <i>Kidney360</i> <b>3</b>, 269–278 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.34067/KID.0006152021" data-track-action="article reference" href="https://doi.org/10.34067%2FKID.0006152021" aria-label="Article reference 43" data-doi="10.34067/KID.0006152021">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35373125" aria-label="PubMed reference 43">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 43" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20propensity%20score-matched%20observational%20study%20of%20remdesivir%20in%20patients%20with%20COVID-19%20and%20severe%20kidney%20disease&amp;journal=Kidney360&amp;doi=10.34067%2FKID.0006152021&amp;volume=3&amp;pages=269-278&amp;publication_year=2022&amp;author=Seethapathy%2CR&amp;author=Zhao%2CS&amp;author=Long%2CJD&amp;author=Strohbehn%2CIA&amp;author=Sise%2CME">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="44."><p class="c-article-references__text" id="ref-CR44">US National Library of Medicine. <i>ClinicalTrials.gov</i> <a href="https://clinicaltrials.gov/ct2/show/NCT04745351" data-track="click" data-track-action="external reference" data-track-label="https://clinicaltrials.gov/ct2/show/NCT04745351">https://clinicaltrials.gov/ct2/show/NCT04745351</a> (2022).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="45."><p class="c-article-references__text" id="ref-CR45">US Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for paxlovid. <i>FDA</i> <a href="https://www.fda.gov/media/155050/download" data-track="click" data-track-action="external reference" data-track-label="https://www.fda.gov/media/155050/download">https://www.fda.gov/media/155050/download</a> (2022).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="46."><p class="c-article-references__text" id="ref-CR46">Salerno, D. M. et al. Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients. <i>Am. J. Transplant.</i> <b>22</b>, 2083–2088 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1111/ajt.17027" data-track-action="article reference" href="https://doi.org/10.1111%2Fajt.17027" aria-label="Article reference 46" data-doi="10.1111/ajt.17027">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XhsVWgt7vF" aria-label="CAS reference 46">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35278260" aria-label="PubMed reference 46">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 46" href="http://scholar.google.com/scholar_lookup?&amp;title=Early%20clinical%20experience%20with%20nirmatrelvir%2Fritonavir%20for%20the%20treatment%20of%20COVID-19%20in%20solid%20organ%20transplant%20recipients&amp;journal=Am.%20J.%20Transplant.&amp;doi=10.1111%2Fajt.17027&amp;volume=22&amp;pages=2083-2088&amp;publication_year=2022&amp;author=Salerno%2CDM">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="47."><p class="c-article-references__text" id="ref-CR47">Swanstrom, R. &amp; Schinazi, R. F. Lethal mutagenesis as an antiviral strategy. <i>Science</i> <b>375</b>, 497–498 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1126/science.abn0048" data-track-action="article reference" href="https://doi.org/10.1126%2Fscience.abn0048" aria-label="Article reference 47" data-doi="10.1126/science.abn0048">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XjtlyqurY%3D" aria-label="CAS reference 47">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35113690" aria-label="PubMed reference 47">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 47" href="http://scholar.google.com/scholar_lookup?&amp;title=Lethal%20mutagenesis%20as%20an%20antiviral%20strategy&amp;journal=Science&amp;doi=10.1126%2Fscience.abn0048&amp;volume=375&amp;pages=497-498&amp;publication_year=2022&amp;author=Swanstrom%2CR&amp;author=Schinazi%2CRF">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="48."><p class="c-article-references__text" id="ref-CR48">Al-Samkari, H. et al. Thrombosis, bleeding, and the observational effect of early therapeutic anticoagulation on survival in critically ill patients with COVID-19. <i>Ann. Intern. Med.</i> <b>174</b>, 622–632 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.7326/M20-6739" data-track-action="article reference" href="https://doi.org/10.7326%2FM20-6739" aria-label="Article reference 48" data-doi="10.7326/M20-6739">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33493012" aria-label="PubMed reference 48">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 48" href="http://scholar.google.com/scholar_lookup?&amp;title=Thrombosis%2C%20bleeding%2C%20and%20the%20observational%20effect%20of%20early%20therapeutic%20anticoagulation%20on%20survival%20in%20critically%20ill%20patients%20with%20COVID-19&amp;journal=Ann.%20Intern.%20Med.&amp;doi=10.7326%2FM20-6739&amp;volume=174&amp;pages=622-632&amp;publication_year=2021&amp;author=Al-Samkari%2CH">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="49."><p class="c-article-references__text" id="ref-CR49">Al-Samkari, H. et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. <i>Blood</i> <b>136</b>, 489–500 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1182/blood.2020006520" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood.2020006520" aria-label="Article reference 49" data-doi="10.1182/blood.2020006520">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXhs1SnurfK" aria-label="CAS reference 49">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32492712" aria-label="PubMed reference 49">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 49" href="http://scholar.google.com/scholar_lookup?&amp;title=COVID-19%20and%20coagulation%3A%20bleeding%20and%20thrombotic%20manifestations%20of%20SARS-CoV-2%20infection&amp;journal=Blood&amp;doi=10.1182%2Fblood.2020006520&amp;volume=136&amp;pages=489-500&amp;publication_year=2020&amp;author=Al-Samkari%2CH">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="50."><p class="c-article-references__text" id="ref-CR50">Iba, T., Connors, J. M. &amp; Levy, J. H. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. <i>Inflamm. Res.</i> <b>69</b>, 1181–1189 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="noopener" data-track-label="10.1007/s00011-020-01401-6" data-track-action="article reference" href="https://link.springer.com/doi/10.1007/s00011-020-01401-6" aria-label="Article reference 50" data-doi="10.1007/s00011-020-01401-6">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXhvVOrtrfM" aria-label="CAS reference 50">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32918567" aria-label="PubMed reference 50">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486586" aria-label="PubMed Central reference 50">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 50" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20coagulopathy%2C%20endotheliopathy%2C%20and%20vasculitis%20of%20COVID-19&amp;journal=Inflamm.%20Res.&amp;doi=10.1007%2Fs00011-020-01401-6&amp;volume=69&amp;pages=1181-1189&amp;publication_year=2020&amp;author=Iba%2CT&amp;author=Connors%2CJM&amp;author=Levy%2CJH">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="51."><p class="c-article-references__text" id="ref-CR51">Goshua, G. et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. <i>Lancet Haematol.</i> <b>7</b>, e575–e582 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/S2352-3026(20)30216-7" data-track-action="article reference" href="https://doi.org/10.1016%2FS2352-3026%2820%2930216-7" aria-label="Article reference 51" data-doi="10.1016/S2352-3026(20)30216-7">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32619411" aria-label="PubMed reference 51">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326446" aria-label="PubMed Central reference 51">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 51" href="http://scholar.google.com/scholar_lookup?&amp;title=Endotheliopathy%20in%20COVID-19-associated%20coagulopathy%3A%20evidence%20from%20a%20single-centre%2C%20cross-sectional%20study&amp;journal=Lancet%20Haematol.&amp;doi=10.1016%2FS2352-3026%2820%2930216-7&amp;volume=7&amp;pages=e575-e582&amp;publication_year=2020&amp;author=Goshua%2CG">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="52."><p class="c-article-references__text" id="ref-CR52">Al-Samkari, H., Song, F., Van Cott, E. M., Kuter, D. J. &amp; Rosovsky, R. Evaluation of the prothrombin fragment 1.2 in patients with coronavirus disease 2019 (COVID-19). <i>Am. J. Hematol.</i> <b>95</b>, 1479–1485 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1002/ajh.25962" data-track-action="article reference" href="https://doi.org/10.1002%2Fajh.25962" aria-label="Article reference 52" data-doi="10.1002/ajh.25962">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXitlGlt73L" aria-label="CAS reference 52">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32780525" aria-label="PubMed reference 52">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7436379" aria-label="PubMed Central reference 52">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 52" href="http://scholar.google.com/scholar_lookup?&amp;title=Evaluation%20of%20the%20prothrombin%20fragment%201.2%20in%20patients%20with%20coronavirus%20disease%202019%20%28COVID-19%29&amp;journal=Am.%20J.%20Hematol.&amp;doi=10.1002%2Fajh.25962&amp;volume=95&amp;pages=1479-1485&amp;publication_year=2020&amp;author=Al-Samkari%2CH&amp;author=Song%2CF&amp;author=Cott%2CEM&amp;author=Kuter%2CDJ&amp;author=Rosovsky%2CR">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="53."><p class="c-article-references__text" id="ref-CR53">ATTACC Investigators, ACTIV-4a Investigators &amp; REMAP-CAP Investigators. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. <i>N. Engl. J. Med.</i> <b>385</b>, 790–802 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMoa2105911" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa2105911" aria-label="Article reference 53" data-doi="10.1056/NEJMoa2105911">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 53" href="http://scholar.google.com/scholar_lookup?&amp;title=Therapeutic%20anticoagulation%20with%20heparin%20in%20noncritically%20ill%20patients%20with%20Covid-19&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa2105911&amp;volume=385&amp;pages=790-802&amp;publication_year=2021">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="54."><p class="c-article-references__text" id="ref-CR54">REMAP-CAP Investigators, ACTIV-4a Investigators &amp; ATTACC Investigators. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. <i>N. Engl. J. Med.</i> <b>385</b>, 777–789 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMoa2103417" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa2103417" aria-label="Article reference 54" data-doi="10.1056/NEJMoa2103417">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 54" href="http://scholar.google.com/scholar_lookup?&amp;title=Therapeutic%20anticoagulation%20with%20heparin%20in%20critically%20ill%20patients%20with%20Covid-19&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa2103417&amp;volume=385&amp;pages=777-789&amp;publication_year=2021">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="55."><p class="c-article-references__text" id="ref-CR55">Al-Samkari, H. Finding the optimal thromboprophylaxis dose in patients with COVID-19. <i>JAMA</i> <b>325</b>, 1613–1615 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1001/jama.2021.4295" data-track-action="article reference" href="https://doi.org/10.1001%2Fjama.2021.4295" aria-label="Article reference 55" data-doi="10.1001/jama.2021.4295">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXhtVWns77E" aria-label="CAS reference 55">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33734290" aria-label="PubMed reference 55">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 55" href="http://scholar.google.com/scholar_lookup?&amp;title=Finding%20the%20optimal%20thromboprophylaxis%20dose%20in%20patients%20with%20COVID-19&amp;journal=JAMA&amp;doi=10.1001%2Fjama.2021.4295&amp;volume=325&amp;pages=1613-1615&amp;publication_year=2021&amp;author=Al-Samkari%2CH">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="56."><p class="c-article-references__text" id="ref-CR56">Cuker, A. et al. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. <i>Blood Adv.</i> <b>5</b>, 872–888 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1182/bloodadvances.2020003763" data-track-action="article reference" href="https://doi.org/10.1182%2Fbloodadvances.2020003763" aria-label="Article reference 56" data-doi="10.1182/bloodadvances.2020003763">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXktlWrsbc%3D" aria-label="CAS reference 56">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33560401" aria-label="PubMed reference 56">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869684" aria-label="PubMed Central reference 56">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 56" href="http://scholar.google.com/scholar_lookup?&amp;title=American%20Society%20of%20Hematology%202021%20guidelines%20on%20the%20use%20of%20anticoagulation%20for%20thromboprophylaxis%20in%20patients%20with%20COVID-19&amp;journal=Blood%20Adv.&amp;doi=10.1182%2Fbloodadvances.2020003763&amp;volume=5&amp;pages=872-888&amp;publication_year=2021&amp;author=Cuker%2CA">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="57."><p class="c-article-references__text" id="ref-CR57">National Institutes of Health. COVID-19 treatment guidelines: antithrombotic therapy in patients with COVID-19. <i>NIH</i> <a href="https://www.covid19treatmentguidelines.nih.gov/therapies/antithrombotic-therapy/" data-track="click" data-track-action="external reference" data-track-label="https://www.covid19treatmentguidelines.nih.gov/therapies/antithrombotic-therapy/">https://www.covid19treatmentguidelines.nih.gov/therapies/antithrombotic-therapy/</a> (2022).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="58."><p class="c-article-references__text" id="ref-CR58">American Society of Hematology. ASH clinical practice guidelines on venous thromboembolism. <i>ASH</i> <a href="https://www.hematology.org/education/clinicians/guidelines-and-quality-care/clinical-practice-guidelines/venous-thromboembolism-guidelines/ash-guidelines-on-use-of-anticoagulation-in-patients-with-covid-19" data-track="click" data-track-action="external reference" data-track-label="https://www.hematology.org/education/clinicians/guidelines-and-quality-care/clinical-practice-guidelines/venous-thromboembolism-guidelines/ash-guidelines-on-use-of-anticoagulation-in-patients-with-covid-19">https://www.hematology.org/education/clinicians/guidelines-and-quality-care/clinical-practice-guidelines/venous-thromboembolism-guidelines/ash-guidelines-on-use-of-anticoagulation-in-patients-with-covid-19</a> (2022).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="59."><p class="c-article-references__text" id="ref-CR59">Spyropoulos, A. C. et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. <i>JAMA Intern. Med.</i> <b>181</b>, 1612–1620 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1001/jamainternmed.2021.6203" data-track-action="article reference" href="https://doi.org/10.1001%2Fjamainternmed.2021.6203" aria-label="Article reference 59" data-doi="10.1001/jamainternmed.2021.6203">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XnvVWrsg%3D%3D" aria-label="CAS reference 59">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34617959" aria-label="PubMed reference 59">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8498934" aria-label="PubMed Central reference 59">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 59" href="http://scholar.google.com/scholar_lookup?&amp;title=Efficacy%20and%20safety%20of%20therapeutic-dose%20heparin%20vs%20standard%20prophylactic%20or%20intermediate-dose%20heparins%20for%20thromboprophylaxis%20in%20high-risk%20hospitalized%20patients%20with%20COVID-19%3A%20the%20HEP-COVID%20randomized%20clinical%20trial&amp;journal=JAMA%20Intern.%20Med.&amp;doi=10.1001%2Fjamainternmed.2021.6203&amp;volume=181&amp;pages=1612-1620&amp;publication_year=2021&amp;author=Spyropoulos%2CAC">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="60."><p class="c-article-references__text" id="ref-CR60">Sholzberg, M. et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. <i>BMJ</i> <b>375</b>, n2400 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1136/bmj.n2400" data-track-action="article reference" href="https://doi.org/10.1136%2Fbmj.n2400" aria-label="Article reference 60" data-doi="10.1136/bmj.n2400">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34649864" aria-label="PubMed reference 60">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 60" href="http://scholar.google.com/scholar_lookup?&amp;title=Effectiveness%20of%20therapeutic%20heparin%20versus%20prophylactic%20heparin%20on%20death%2C%20mechanical%20ventilation%2C%20or%20intensive%20care%20unit%20admission%20in%20moderately%20ill%20patients%20with%20covid-19%20admitted%20to%20hospital%3A%20RAPID%20randomised%20clinical%20trial&amp;journal=BMJ&amp;doi=10.1136%2Fbmj.n2400&amp;volume=375&amp;publication_year=2021&amp;author=Sholzberg%2CM">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="61."><p class="c-article-references__text" id="ref-CR61">Lopes, R. D. et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. <i>Lancet</i> <b>397</b>, 2253–2263 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/S0140-6736(21)01203-4" data-track-action="article reference" href="https://doi.org/10.1016%2FS0140-6736%2821%2901203-4" aria-label="Article reference 61" data-doi="10.1016/S0140-6736(21)01203-4">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXht12jtrjL" aria-label="CAS reference 61">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34097856" aria-label="PubMed reference 61">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177770" aria-label="PubMed Central reference 61">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 61" href="http://scholar.google.com/scholar_lookup?&amp;title=Therapeutic%20versus%20prophylactic%20anticoagulation%20for%20patients%20admitted%20to%20hospital%20with%20COVID-19%20and%20elevated%20D-dimer%20concentration%20%28ACTION%29%3A%20an%20open-label%2C%20multicentre%2C%20randomised%2C%20controlled%20trial&amp;journal=Lancet&amp;doi=10.1016%2FS0140-6736%2821%2901203-4&amp;volume=397&amp;pages=2253-2263&amp;publication_year=2021&amp;author=Lopes%2CRD">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="62."><p class="c-article-references__text" id="ref-CR62">Giannis, D. et al. Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry. <i>Blood</i> <b>137</b>, 2838–2847 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1182/blood.2020010529" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood.2020010529" aria-label="Article reference 62" data-doi="10.1182/blood.2020010529">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXhsFaiu7zP" aria-label="CAS reference 62">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33824972" aria-label="PubMed reference 62">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032474" aria-label="PubMed Central reference 62">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 62" href="http://scholar.google.com/scholar_lookup?&amp;title=Postdischarge%20thromboembolic%20outcomes%20and%20mortality%20of%20hospitalized%20patients%20with%20COVID-19%3A%20the%20CORE-19%20registry&amp;journal=Blood&amp;doi=10.1182%2Fblood.2020010529&amp;volume=137&amp;pages=2838-2847&amp;publication_year=2021&amp;author=Giannis%2CD">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="63."><p class="c-article-references__text" id="ref-CR63">Ramacciotti, E. et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. <i>Lancet</i> <b>399</b>, 50–59 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/S0140-6736(21)02392-8" data-track-action="article reference" href="https://doi.org/10.1016%2FS0140-6736%2821%2902392-8" aria-label="Article reference 63" data-doi="10.1016/S0140-6736(21)02392-8">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXislygtbrM" aria-label="CAS reference 63">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34921756" aria-label="PubMed reference 63">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 63" href="http://scholar.google.com/scholar_lookup?&amp;title=Rivaroxaban%20versus%20no%20anticoagulation%20for%20post-discharge%20thromboprophylaxis%20after%20hospitalisation%20for%20COVID-19%20%28MICHELLE%29%3A%20an%20open-label%2C%20multicentre%2C%20randomised%2C%20controlled%20trial&amp;journal=Lancet&amp;doi=10.1016%2FS0140-6736%2821%2902392-8&amp;volume=399&amp;pages=50-59&amp;publication_year=2022&amp;author=Ramacciotti%2CE">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="64."><p class="c-article-references__text" id="ref-CR64">Spyropoulos, A. C. et al. Post-discharge prophylaxis with rivaroxaban reduces fatal and major thromboembolic events in medically ill patients. <i>J. Am. Coll. Cardiol.</i> <b>75</b>, 3140–3147 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.jacc.2020.04.071" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.jacc.2020.04.071" aria-label="Article reference 64" data-doi="10.1016/j.jacc.2020.04.071">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXht1CjtbjJ" aria-label="CAS reference 64">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32586587" aria-label="PubMed reference 64">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308003" aria-label="PubMed Central reference 64">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 64" href="http://scholar.google.com/scholar_lookup?&amp;title=Post-discharge%20prophylaxis%20with%20rivaroxaban%20reduces%20fatal%20and%20major%20thromboembolic%20events%20in%20medically%20ill%20patients&amp;journal=J.%20Am.%20Coll.%20Cardiol.&amp;doi=10.1016%2Fj.jacc.2020.04.071&amp;volume=75&amp;pages=3140-3147&amp;publication_year=2020&amp;author=Spyropoulos%2CAC">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="65."><p class="c-article-references__text" id="ref-CR65">RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet</i> <b>399</b>, 143–151 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/S0140-6736(21)01825-0" data-track-action="article reference" href="https://doi.org/10.1016%2FS0140-6736%2821%2901825-0" aria-label="Article reference 65" data-doi="10.1016/S0140-6736(21)01825-0">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 65" href="http://scholar.google.com/scholar_lookup?&amp;title=Aspirin%20in%20patients%20admitted%20to%20hospital%20with%20COVID-19%20%28RECOVERY%29%3A%20a%20randomised%2C%20controlled%2C%20open-label%2C%20platform%20trial&amp;journal=Lancet&amp;doi=10.1016%2FS0140-6736%2821%2901825-0&amp;volume=399&amp;pages=143-151&amp;publication_year=2022">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="66."><p class="c-article-references__text" id="ref-CR66">Connors, J. M. et al. Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial. <i>JAMA</i> <b>326</b>, 1703–1712 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1001/jama.2021.17272" data-track-action="article reference" href="https://doi.org/10.1001%2Fjama.2021.17272" aria-label="Article reference 66" data-doi="10.1001/jama.2021.17272">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXisValtbnK" aria-label="CAS reference 66">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34633405" aria-label="PubMed reference 66">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 66" href="http://scholar.google.com/scholar_lookup?&amp;title=Effect%20of%20antithrombotic%20therapy%20on%20clinical%20outcomes%20in%20outpatients%20with%20clinically%20stable%20symptomatic%20COVID-19%3A%20the%20ACTIV-4B%20randomized%20clinical%20trial&amp;journal=JAMA&amp;doi=10.1001%2Fjama.2021.17272&amp;volume=326&amp;pages=1703-1712&amp;publication_year=2021&amp;author=Connors%2CJM">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="67."><p class="c-article-references__text" id="ref-CR67">REMAP-CAP Writing Committee for the REMAP-CAP Investigators. Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. <i>JAMA</i> <b>327</b>, 1247–1259 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1001/jama.2022.2910" data-track-action="article reference" href="https://doi.org/10.1001%2Fjama.2022.2910" aria-label="Article reference 67" data-doi="10.1001/jama.2022.2910">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941448" aria-label="PubMed Central reference 67">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 67" href="http://scholar.google.com/scholar_lookup?&amp;title=Effect%20of%20antiplatelet%20therapy%20on%20survival%20and%20organ%20support-free%20days%20in%20critically%20ill%20patients%20with%20COVID-19%3A%20a%20randomized%20clinical%20trial&amp;journal=JAMA&amp;doi=10.1001%2Fjama.2022.2910&amp;volume=327&amp;pages=1247-1259&amp;publication_year=2022">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="68."><p class="c-article-references__text" id="ref-CR68">US National Library of Medicine. <i>ClinicalTrials.gov</i> <a href="https://clinicaltrials.gov/ct2/show/NCT04505774" data-track="click" data-track-action="external reference" data-track-label="https://clinicaltrials.gov/ct2/show/NCT04505774">https://clinicaltrials.gov/ct2/show/NCT04505774</a> (2022).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="69."><p class="c-article-references__text" id="ref-CR69">Kaw, D. &amp; Malhotra, D. Platelet dysfunction and end-stage renal disease. <i>Semin. Dial.</i> <b>19</b>, 317–322 (2006).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1111/j.1525-139X.2006.00179.x" data-track-action="article reference" href="https://doi.org/10.1111%2Fj.1525-139X.2006.00179.x" aria-label="Article reference 69" data-doi="10.1111/j.1525-139X.2006.00179.x">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16893410" aria-label="PubMed reference 69">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 69" href="http://scholar.google.com/scholar_lookup?&amp;title=Platelet%20dysfunction%20and%20end-stage%20renal%20disease&amp;journal=Semin.%20Dial.&amp;doi=10.1111%2Fj.1525-139X.2006.00179.x&amp;volume=19&amp;pages=317-322&amp;publication_year=2006&amp;author=Kaw%2CD&amp;author=Malhotra%2CD">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="70."><p class="c-article-references__text" id="ref-CR70">Wattanakit, K., Cushman, M., Stehman-Breen, C., Heckbert, S. R. &amp; Folsom, A. R. Chronic kidney disease increases risk for venous thromboembolism. <i>J. Am. Soc. Nephrol.</i> <b>19</b>, 135–140 (2008).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1681/ASN.2007030308" data-track-action="article reference" href="https://doi.org/10.1681%2FASN.2007030308" aria-label="Article reference 70" data-doi="10.1681/ASN.2007030308">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18032796" aria-label="PubMed reference 70">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2391038" aria-label="PubMed Central reference 70">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 70" href="http://scholar.google.com/scholar_lookup?&amp;title=Chronic%20kidney%20disease%20increases%20risk%20for%20venous%20thromboembolism&amp;journal=J.%20Am.%20Soc.%20Nephrol.&amp;doi=10.1681%2FASN.2007030308&amp;volume=19&amp;pages=135-140&amp;publication_year=2008&amp;author=Wattanakit%2CK&amp;author=Cushman%2CM&amp;author=Stehman-Breen%2CC&amp;author=Heckbert%2CSR&amp;author=Folsom%2CAR">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="71."><p class="c-article-references__text" id="ref-CR71">Martel, N., Lee, J. &amp; Wells, P. S. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. <i>Blood</i> <b>106</b>, 2710–2715 (2005).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1182/blood-2005-04-1546" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood-2005-04-1546" aria-label="Article reference 71" data-doi="10.1182/blood-2005-04-1546">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD2MXhtFantbjE" aria-label="CAS reference 71">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15985543" aria-label="PubMed reference 71">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 71" href="http://scholar.google.com/scholar_lookup?&amp;title=Risk%20for%20heparin-induced%20thrombocytopenia%20with%20unfractionated%20and%20low-molecular-weight%20heparin%20thromboprophylaxis%3A%20a%20meta-analysis&amp;journal=Blood&amp;doi=10.1182%2Fblood-2005-04-1546&amp;volume=106&amp;pages=2710-2715&amp;publication_year=2005&amp;author=Martel%2CN&amp;author=Lee%2CJ&amp;author=Wells%2CPS">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="72."><p class="c-article-references__text" id="ref-CR72">Garcia, D. A., Baglin, T. P., Weitz, J. I. &amp; Samama, M. M. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> <b>141</b>, e24S–e43S (2012).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1378/chest.11-2291" data-track-action="article reference" href="https://doi.org/10.1378%2Fchest.11-2291" aria-label="Article reference 72" data-doi="10.1378/chest.11-2291">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC38XnsVOrt7k%3D" aria-label="CAS reference 72">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22315264" aria-label="PubMed reference 72">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278070" aria-label="PubMed Central reference 72">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 72" href="http://scholar.google.com/scholar_lookup?&amp;title=Parenteral%20anticoagulants%3A%20antithrombotic%20therapy%20and%20prevention%20of%20thrombosis%2C%209th%20ed%3A%20American%20College%20of%20Chest%20Physicians%20Evidence-Based%20Clinical%20Practice%20Guidelines&amp;journal=Chest&amp;doi=10.1378%2Fchest.11-2291&amp;volume=141&amp;pages=e24S-e43S&amp;publication_year=2012&amp;author=Garcia%2CDA&amp;author=Baglin%2CTP&amp;author=Weitz%2CJI&amp;author=Samama%2CMM">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="73."><p class="c-article-references__text" id="ref-CR73">Endres, P. et al. Filter clotting with continuous renal replacement therapy in COVID-19. <i>J. Thromb. Thrombolysis</i> <b>51</b>, 966–970 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="noopener" data-track-label="10.1007/s11239-020-02301-6" data-track-action="article reference" href="https://link.springer.com/doi/10.1007/s11239-020-02301-6" aria-label="Article reference 73" data-doi="10.1007/s11239-020-02301-6">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXitVKksbzL" aria-label="CAS reference 73">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33026569" aria-label="PubMed reference 73">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 73" href="http://scholar.google.com/scholar_lookup?&amp;title=Filter%20clotting%20with%20continuous%20renal%20replacement%20therapy%20in%20COVID-19&amp;journal=J.%20Thromb.%20Thrombolysis&amp;doi=10.1007%2Fs11239-020-02301-6&amp;volume=51&amp;pages=966-970&amp;publication_year=2021&amp;author=Endres%2CP">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="74."><p class="c-article-references__text" id="ref-CR74">Arnold, F. et al. Comparison of different anticoagulation strategies for renal replacement therapy in critically ill patients with COVID-19: a cohort study. <i>BMC Nephrol.</i> <b>21</b>, 486 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="noopener" data-track-label="10.1186/s12882-020-02150-8" data-track-action="article reference" href="https://link.springer.com/doi/10.1186/s12882-020-02150-8" aria-label="Article reference 74" data-doi="10.1186/s12882-020-02150-8">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXisVSgt7jI" aria-label="CAS reference 74">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33198670" aria-label="PubMed reference 74">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668013" aria-label="PubMed Central reference 74">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 74" href="http://scholar.google.com/scholar_lookup?&amp;title=Comparison%20of%20different%20anticoagulation%20strategies%20for%20renal%20replacement%20therapy%20in%20critically%20ill%20patients%20with%20COVID-19%3A%20a%20cohort%20study&amp;journal=BMC%20Nephrol.&amp;doi=10.1186%2Fs12882-020-02150-8&amp;volume=21&amp;publication_year=2020&amp;author=Arnold%2CF">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="75."><p class="c-article-references__text" id="ref-CR75">Seshadri, M., Ahamed, J. &amp; Laurence, J. Intervention in COVID-19 linked hypercoagulable states characterized by circuit thrombosis utilizing a direct thrombin inhibitor. <i>Thrombosis Update</i> <b>1</b>, 100009 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.tru.2020.100009" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.tru.2020.100009" aria-label="Article reference 75" data-doi="10.1016/j.tru.2020.100009">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476895" aria-label="PubMed Central reference 75">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 75" href="http://scholar.google.com/scholar_lookup?&amp;title=Intervention%20in%20COVID-19%20linked%20hypercoagulable%20states%20characterized%20by%20circuit%20thrombosis%20utilizing%20a%20direct%20thrombin%20inhibitor&amp;journal=Thrombosis%20Update&amp;doi=10.1016%2Fj.tru.2020.100009&amp;volume=1&amp;publication_year=2020&amp;author=Seshadri%2CM&amp;author=Ahamed%2CJ&amp;author=Laurence%2CJ">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="76."><p class="c-article-references__text" id="ref-CR76">Rahbar, E., Cotton, B. A., Wade, C. E. &amp; Cardenas, J. C. Acquired antithrombin deficiency is a risk factor for venous thromboembolism after major trauma. <i>Thromb. Res.</i> <b>204</b>, 9–12 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.thromres.2021.05.015" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.thromres.2021.05.015" aria-label="Article reference 76" data-doi="10.1016/j.thromres.2021.05.015">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXht1KhurzF" aria-label="CAS reference 76">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34091120" aria-label="PubMed reference 76">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653093" aria-label="PubMed Central reference 76">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 76" href="http://scholar.google.com/scholar_lookup?&amp;title=Acquired%20antithrombin%20deficiency%20is%20a%20risk%20factor%20for%20venous%20thromboembolism%20after%20major%20trauma&amp;journal=Thromb.%20Res.&amp;doi=10.1016%2Fj.thromres.2021.05.015&amp;volume=204&amp;pages=9-12&amp;publication_year=2021&amp;author=Rahbar%2CE&amp;author=Cotton%2CBA&amp;author=Wade%2CCE&amp;author=Cardenas%2CJC">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="77."><p class="c-article-references__text" id="ref-CR77">Legrand, M. et al. Pathophysiology of COVID-19-associated acute kidney injury. <i>Nat. Rev. Nephrol.</i> <b>17</b>, 751–764 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/s41581-021-00452-0" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41581-021-00452-0" aria-label="Article reference 77" data-doi="10.1038/s41581-021-00452-0">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXhsFSns7%2FN" aria-label="CAS reference 77">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34226718" aria-label="PubMed reference 77">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256398" aria-label="PubMed Central reference 77">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 77" href="http://scholar.google.com/scholar_lookup?&amp;title=Pathophysiology%20of%20COVID-19-associated%20acute%20kidney%20injury&amp;journal=Nat.%20Rev.%20Nephrol.&amp;doi=10.1038%2Fs41581-021-00452-0&amp;volume=17&amp;pages=751-764&amp;publication_year=2021&amp;author=Legrand%2CM">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="78."><p class="c-article-references__text" id="ref-CR78">Rapkiewicz, A. V. et al. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series. <i>EClinicalMedicine</i> <b>24</b>, 100434 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.eclinm.2020.100434" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.eclinm.2020.100434" aria-label="Article reference 78" data-doi="10.1016/j.eclinm.2020.100434">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32766543" aria-label="PubMed reference 78">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316051" aria-label="PubMed Central reference 78">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 78" href="http://scholar.google.com/scholar_lookup?&amp;title=Megakaryocytes%20and%20platelet-fibrin%20thrombi%20characterize%20multi-organ%20thrombosis%20at%20autopsy%20in%20COVID-19%3A%20a%20case%20series&amp;journal=EClinicalMedicine&amp;doi=10.1016%2Fj.eclinm.2020.100434&amp;volume=24&amp;publication_year=2020&amp;author=Rapkiewicz%2CAV">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="79."><p class="c-article-references__text" id="ref-CR79">Hisama, N. et al. Anticoagulant pretreatment attenuates production of cytokine-induced neutrophil chemoattractant following ischemia-reperfusion of rat liver. <i>Dig. Dis. Sci.</i> <b>41</b>, 1481–1486 (1996).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="noopener" data-track-label="10.1007/BF02088576" data-track-action="article reference" href="https://link.springer.com/doi/10.1007/BF02088576" aria-label="Article reference 79" data-doi="10.1007/BF02088576">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DyaK28XltF2itL8%3D" aria-label="CAS reference 79">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=8689928" aria-label="PubMed reference 79">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 79" href="http://scholar.google.com/scholar_lookup?&amp;title=Anticoagulant%20pretreatment%20attenuates%20production%20of%20cytokine-induced%20neutrophil%20chemoattractant%20following%20ischemia-reperfusion%20of%20rat%20liver&amp;journal=Dig.%20Dis.%20Sci.&amp;doi=10.1007%2FBF02088576&amp;volume=41&amp;pages=1481-1486&amp;publication_year=1996&amp;author=Hisama%2CN">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="80."><p class="c-article-references__text" id="ref-CR80">Marini, J. J. &amp; Gattinoni, L. Management of COVID-19 respiratory distress. <i>JAMA</i> <b>323</b>, 2329–2330 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1001/jama.2020.6825" data-track-action="article reference" href="https://doi.org/10.1001%2Fjama.2020.6825" aria-label="Article reference 80" data-doi="10.1001/jama.2020.6825">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32329799" aria-label="PubMed reference 80">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 80" href="http://scholar.google.com/scholar_lookup?&amp;title=Management%20of%20COVID-19%20respiratory%20distress&amp;journal=JAMA&amp;doi=10.1001%2Fjama.2020.6825&amp;volume=323&amp;pages=2329-2330&amp;publication_year=2020&amp;author=Marini%2CJJ&amp;author=Gattinoni%2CL">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="81."><p class="c-article-references__text" id="ref-CR81">Papoutsi, E., Giannakoulis, V. G., Xourgia, E., Routsi, C. &amp; Kotanidou, A. Siempos II. Effect of timing of intubation on clinical outcomes of critically ill patients with COVID-19: a systematic review and meta-analysis of non-randomized cohort studies. <i>Crit. Care</i> <b>25</b>, 121 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="noopener" data-track-label="10.1186/s13054-021-03540-6" data-track-action="article reference" href="https://link.springer.com/doi/10.1186/s13054-021-03540-6" aria-label="Article reference 81" data-doi="10.1186/s13054-021-03540-6">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33766109" aria-label="PubMed reference 81">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993905" aria-label="PubMed Central reference 81">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 81" href="http://scholar.google.com/scholar_lookup?&amp;title=Siempos%20II.%20Effect%20of%20timing%20of%20intubation%20on%20clinical%20outcomes%20of%20critically%20ill%20patients%20with%20COVID-19%3A%20a%20systematic%20review%20and%20meta-analysis%20of%20non-randomized%20cohort%20studies&amp;journal=Crit.%20Care&amp;doi=10.1186%2Fs13054-021-03540-6&amp;volume=25&amp;publication_year=2021&amp;author=Papoutsi%2CE&amp;author=Giannakoulis%2CVG&amp;author=Xourgia%2CE&amp;author=Routsi%2CC&amp;author=Kotanidou%2CA">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="82."><p class="c-article-references__text" id="ref-CR82">Ziehr, D. R. et al. Respiratory pathophysiology of mechanically ventilated patients with COVID-19: a cohort study. <i>Am. J. Respir. Crit. Care Med.</i> <b>201</b>, 1560–1564 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1164/rccm.202004-1163LE" data-track-action="article reference" href="https://doi.org/10.1164%2Frccm.202004-1163LE" aria-label="Article reference 82" data-doi="10.1164/rccm.202004-1163LE">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXhvFOmtrrL" aria-label="CAS reference 82">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32348678" aria-label="PubMed reference 82">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301734" aria-label="PubMed Central reference 82">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 82" href="http://scholar.google.com/scholar_lookup?&amp;title=Respiratory%20pathophysiology%20of%20mechanically%20ventilated%20patients%20with%20COVID-19%3A%20a%20cohort%20study&amp;journal=Am.%20J.%20Respir.%20Crit.%20Care%20Med.&amp;doi=10.1164%2Frccm.202004-1163LE&amp;volume=201&amp;pages=1560-1564&amp;publication_year=2020&amp;author=Ziehr%2CDR">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="83."><p class="c-article-references__text" id="ref-CR83">Anesi, G. L. et al. Characteristics, outcomes, and trends of patients with COVID-19-related critical illness at a learning health system in the United States. <i>Ann. Intern. Med.</i> <b>174</b>, 613–621 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.7326/M20-5327" data-track-action="article reference" href="https://doi.org/10.7326%2FM20-5327" aria-label="Article reference 83" data-doi="10.7326/M20-5327">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33460330" aria-label="PubMed reference 83">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 83" href="http://scholar.google.com/scholar_lookup?&amp;title=Characteristics%2C%20outcomes%2C%20and%20trends%20of%20patients%20with%20COVID-19-related%20critical%20illness%20at%20a%20learning%20health%20system%20in%20the%20United%20States&amp;journal=Ann.%20Intern.%20Med.&amp;doi=10.7326%2FM20-5327&amp;volume=174&amp;pages=613-621&amp;publication_year=2021&amp;author=Anesi%2CGL">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="84."><p class="c-article-references__text" id="ref-CR84">Gaeckle, N. T. et al. Aerosol generation from the respiratory tract with various modes of oxygen delivery. <i>Am. J. Respir. Crit. Care Med.</i> <b>202</b>, 1115–1124 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1164/rccm.202006-2309OC" data-track-action="article reference" href="https://doi.org/10.1164%2Frccm.202006-2309OC" aria-label="Article reference 84" data-doi="10.1164/rccm.202006-2309OC">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXisFKiu7%2FK" aria-label="CAS reference 84">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32822208" aria-label="PubMed reference 84">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7560792" aria-label="PubMed Central reference 84">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 84" href="http://scholar.google.com/scholar_lookup?&amp;title=Aerosol%20generation%20from%20the%20respiratory%20tract%20with%20various%20modes%20of%20oxygen%20delivery&amp;journal=Am.%20J.%20Respir.%20Crit.%20Care%20Med.&amp;doi=10.1164%2Frccm.202006-2309OC&amp;volume=202&amp;pages=1115-1124&amp;publication_year=2020&amp;author=Gaeckle%2CNT">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="85."><p class="c-article-references__text" id="ref-CR85">Perkins, G. D. et al. Effect of noninvasive respiratory strategies on intubation or mortality among patients with acute hypoxemic respiratory failure and COVID-19: the RECOVERY-RS randomized clinical trial. <i>JAMA</i> <b>327</b>, 546–558 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1001/jama.2022.0028" data-track-action="article reference" href="https://doi.org/10.1001%2Fjama.2022.0028" aria-label="Article reference 85" data-doi="10.1001/jama.2022.0028">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XktFSgs7g%3D" aria-label="CAS reference 85">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35072713" aria-label="PubMed reference 85">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787685" aria-label="PubMed Central reference 85">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 85" href="http://scholar.google.com/scholar_lookup?&amp;title=Effect%20of%20noninvasive%20respiratory%20strategies%20on%20intubation%20or%20mortality%20among%20patients%20with%20acute%20hypoxemic%20respiratory%20failure%20and%20COVID-19%3A%20the%20RECOVERY-RS%20randomized%20clinical%20trial&amp;journal=JAMA&amp;doi=10.1001%2Fjama.2022.0028&amp;volume=327&amp;pages=546-558&amp;publication_year=2022&amp;author=Perkins%2CGD">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="86."><p class="c-article-references__text" id="ref-CR86">Guérin, C. et al. Prone positioning in severe acute respiratory distress syndrome. <i>N. Engl. J. Med.</i> <b>368</b>, 2159–2168 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1214103" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1214103" aria-label="Article reference 86" data-doi="10.1056/NEJMoa1214103">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23688302" aria-label="PubMed reference 86">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 86" href="http://scholar.google.com/scholar_lookup?&amp;title=Prone%20positioning%20in%20severe%20acute%20respiratory%20distress%20syndrome&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1214103&amp;volume=368&amp;pages=2159-2168&amp;publication_year=2013&amp;author=Gu%C3%A9rin%2CC">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="87."><p class="c-article-references__text" id="ref-CR87">Mathews, K. S. et al. Prone positioning and survival in mechanically ventilated patients with coronavirus disease 2019-related respiratory failure. <i>Crit. Care Med.</i> <b>49</b>, 1026–1037 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXhtl2lsr7P" aria-label="CAS reference 87">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33595960" aria-label="PubMed reference 87">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277560" aria-label="PubMed Central reference 87">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 87" href="http://scholar.google.com/scholar_lookup?&amp;title=Prone%20positioning%20and%20survival%20in%20mechanically%20ventilated%20patients%20with%20coronavirus%20disease%202019-related%20respiratory%20failure&amp;journal=Crit.%20Care%20Med.&amp;volume=49&amp;pages=1026-1037&amp;publication_year=2021&amp;author=Mathews%2CKS">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="88."><p class="c-article-references__text" id="ref-CR88">Ehrmann, S. et al. Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial. <i>Lancet Respir. Med.</i> <b>9</b>, 1387–1395 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/S2213-2600(21)00356-8" data-track-action="article reference" href="https://doi.org/10.1016%2FS2213-2600%2821%2900356-8" aria-label="Article reference 88" data-doi="10.1016/S2213-2600(21)00356-8">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXhvVKnsb%2FE" aria-label="CAS reference 88">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34425070" aria-label="PubMed reference 88">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378833" aria-label="PubMed Central reference 88">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 88" href="http://scholar.google.com/scholar_lookup?&amp;title=Awake%20prone%20positioning%20for%20COVID-19%20acute%20hypoxaemic%20respiratory%20failure%3A%20a%20randomised%2C%20controlled%2C%20multinational%2C%20open-label%20meta-trial&amp;journal=Lancet%20Respir.%20Med.&amp;doi=10.1016%2FS2213-2600%2821%2900356-8&amp;volume=9&amp;pages=1387-1395&amp;publication_year=2021&amp;author=Ehrmann%2CS">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="89."><p class="c-article-references__text" id="ref-CR89">Alhazzani, W. et al. Effect of awake prone positioning on endotracheal intubation in patients with COVID-19 and acute respiratory failure: a randomized clinical trial. <i>JAMA</i> <b>327</b>, 2104–2113 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1001/jama.2022.7993" data-track-action="article reference" href="https://doi.org/10.1001%2Fjama.2022.7993" aria-label="Article reference 89" data-doi="10.1001/jama.2022.7993">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XhsVyqsrnJ" aria-label="CAS reference 89">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35569448" aria-label="PubMed reference 89">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108999" aria-label="PubMed Central reference 89">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 89" href="http://scholar.google.com/scholar_lookup?&amp;title=Effect%20of%20awake%20prone%20positioning%20on%20endotracheal%20intubation%20in%20patients%20with%20COVID-19%20and%20acute%20respiratory%20failure%3A%20a%20randomized%20clinical%20trial&amp;journal=JAMA&amp;doi=10.1001%2Fjama.2022.7993&amp;volume=327&amp;pages=2104-2113&amp;publication_year=2022&amp;author=Alhazzani%2CAW">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="90."><p class="c-article-references__text" id="ref-CR90">Qian, E. T. et al. Assessment of awake prone positioning in hospitalized adults with COVID-19: a nonrandomized controlled trial. <i>JAMA Intern. Med.</i> <b>182</b>, 612–621 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1001/jamainternmed.2022.1070" data-track-action="article reference" href="https://doi.org/10.1001%2Fjamainternmed.2022.1070" aria-label="Article reference 90" data-doi="10.1001/jamainternmed.2022.1070">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XhslCgu7bN" aria-label="CAS reference 90">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35435937" aria-label="PubMed reference 90">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016608" aria-label="PubMed Central reference 90">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 90" href="http://scholar.google.com/scholar_lookup?&amp;title=Assessment%20of%20awake%20prone%20positioning%20in%20hospitalized%20adults%20with%20COVID-19%3A%20a%20nonrandomized%20controlled%20trial&amp;journal=JAMA%20Intern.%20Med.&amp;doi=10.1001%2Fjamainternmed.2022.1070&amp;volume=182&amp;pages=612-621&amp;publication_year=2022&amp;author=Qian%2CET">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="91."><p class="c-article-references__text" id="ref-CR91">National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, Moss, M. et al. Early neuromuscular blockade in the acute respiratory distress syndrome. <i>N. Engl. J. Med.</i> <b>380</b>, 1997–2008 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1901686" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1901686" aria-label="Article reference 91" data-doi="10.1056/NEJMoa1901686">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 91" href="http://scholar.google.com/scholar_lookup?&amp;title=Early%20neuromuscular%20blockade%20in%20the%20acute%20respiratory%20distress%20syndrome&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1901686&amp;volume=380&amp;pages=1997-2008&amp;publication_year=2019&amp;author=Moss%2CM">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="92."><p class="c-article-references__text" id="ref-CR92">Shaefi, S. et al. Extracorporeal membrane oxygenation in patients with severe respiratory failure from COVID-19. <i>Intensive Care Med.</i> <b>47</b>, 208–221 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="noopener" data-track-label="10.1007/s00134-020-06331-9" data-track-action="article reference" href="https://link.springer.com/doi/10.1007/s00134-020-06331-9" aria-label="Article reference 92" data-doi="10.1007/s00134-020-06331-9">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXjsFGhtb4%3D" aria-label="CAS reference 92">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33528595" aria-label="PubMed reference 92">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851810" aria-label="PubMed Central reference 92">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 92" href="http://scholar.google.com/scholar_lookup?&amp;title=Extracorporeal%20membrane%20oxygenation%20in%20patients%20with%20severe%20respiratory%20failure%20from%20COVID-19&amp;journal=Intensive%20Care%20Med.&amp;doi=10.1007%2Fs00134-020-06331-9&amp;volume=47&amp;pages=208-221&amp;publication_year=2021&amp;author=Shaefi%2CS">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="93."><p class="c-article-references__text" id="ref-CR93">Urner, M. et al. Venovenous extracorporeal membrane oxygenation in patients with acute covid-19 associated respiratory failure: comparative effectiveness study. <i>BMJ</i> <b>377</b>, e068723 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1136/bmj-2021-068723" data-track-action="article reference" href="https://doi.org/10.1136%2Fbmj-2021-068723" aria-label="Article reference 93" data-doi="10.1136/bmj-2021-068723">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35508314" aria-label="PubMed reference 93">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 93" href="http://scholar.google.com/scholar_lookup?&amp;title=Venovenous%20extracorporeal%20membrane%20oxygenation%20in%20patients%20with%20acute%20covid-19%20associated%20respiratory%20failure%3A%20comparative%20effectiveness%20study&amp;journal=BMJ&amp;doi=10.1136%2Fbmj-2021-068723&amp;volume=377&amp;publication_year=2022&amp;author=Urner%2CM">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="94."><p class="c-article-references__text" id="ref-CR94">Goligher, E. C. et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome and posterior probability of mortality benefit in a post hoc Bayesian analysis of a randomized clinical trial. <i>JAMA</i> <b>320</b>, 2251–2259 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1001/jama.2018.14276" data-track-action="article reference" href="https://doi.org/10.1001%2Fjama.2018.14276" aria-label="Article reference 94" data-doi="10.1001/jama.2018.14276">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30347031" aria-label="PubMed reference 94">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 94" href="http://scholar.google.com/scholar_lookup?&amp;title=Extracorporeal%20membrane%20oxygenation%20for%20severe%20acute%20respiratory%20distress%20syndrome%20and%20posterior%20probability%20of%20mortality%20benefit%20in%20a%20post%20hoc%20Bayesian%20analysis%20of%20a%20randomized%20clinical%20trial&amp;journal=JAMA&amp;doi=10.1001%2Fjama.2018.14276&amp;volume=320&amp;pages=2251-2259&amp;publication_year=2018&amp;author=Goligher%2CEC">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="95."><p class="c-article-references__text" id="ref-CR95">Gannon, W. D. et al. Association between availability of ECMO and mortality in COVID-19 patients eligible for ECMO: a natural experiment. <i>Am. J. Respir. Crit. Care Med.</i> <b>205</b>, 1354–1357 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1164/rccm.202110-2399LE" data-track-action="article reference" href="https://doi.org/10.1164%2Frccm.202110-2399LE" aria-label="Article reference 95" data-doi="10.1164/rccm.202110-2399LE">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XhvVOls7nE" aria-label="CAS reference 95">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35212255" aria-label="PubMed reference 95">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873115" aria-label="PubMed Central reference 95">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 95" href="http://scholar.google.com/scholar_lookup?&amp;title=Association%20between%20availability%20of%20ECMO%20and%20mortality%20in%20COVID-19%20patients%20eligible%20for%20ECMO%3A%20a%20natural%20experiment&amp;journal=Am.%20J.%20Respir.%20Crit.%20Care%20Med.&amp;doi=10.1164%2Frccm.202110-2399LE&amp;volume=205&amp;pages=1354-1357&amp;publication_year=2022&amp;author=Gannon%2CWD">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="96."><p class="c-article-references__text" id="ref-CR96">Darmon, M. et al. Acute respiratory distress syndrome and risk of AKI among critically ill patients. <i>Clin. J. Am. Soc. Nephrol.</i> <b>9</b>, 1347–1353 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.2215/CJN.08300813" data-track-action="article reference" href="https://doi.org/10.2215%2FCJN.08300813" aria-label="Article reference 96" data-doi="10.2215/CJN.08300813">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2cXhs1GnurbN" aria-label="CAS reference 96">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24875195" aria-label="PubMed reference 96">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123396" aria-label="PubMed Central reference 96">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 96" href="http://scholar.google.com/scholar_lookup?&amp;title=Acute%20respiratory%20distress%20syndrome%20and%20risk%20of%20AKI%20among%20critically%20ill%20patients&amp;journal=Clin.%20J.%20Am.%20Soc.%20Nephrol.&amp;doi=10.2215%2FCJN.08300813&amp;volume=9&amp;pages=1347-1353&amp;publication_year=2014&amp;author=Darmon%2CM">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="97."><p class="c-article-references__text" id="ref-CR97">Teixeira, J. P., Ambruso, S., Griffin, B. R. &amp; Faubel, S. Pulmonary consequences of acute kidney injury. <i>Semin. Nephrol.</i> <b>39</b>, 3–16 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.semnephrol.2018.10.001" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.semnephrol.2018.10.001" aria-label="Article reference 97" data-doi="10.1016/j.semnephrol.2018.10.001">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30606405" aria-label="PubMed reference 97">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 97" href="http://scholar.google.com/scholar_lookup?&amp;title=Pulmonary%20consequences%20of%20acute%20kidney%20injury&amp;journal=Semin.%20Nephrol.&amp;doi=10.1016%2Fj.semnephrol.2018.10.001&amp;volume=39&amp;pages=3-16&amp;publication_year=2019&amp;author=Teixeira%2CJP&amp;author=Ambruso%2CS&amp;author=Griffin%2CBR&amp;author=Faubel%2CS">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="98."><p class="c-article-references__text" id="ref-CR98">Pantaleo, G., Correia, B., Fenwick, C., Joo, V. S. &amp; Perez, L. Antibodies to combat viral infections: development strategies and progress. <i>Nat. Rev. Drug Discov.</i> <b>21</b>, 676–696 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/s41573-022-00495-3" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41573-022-00495-3" aria-label="Article reference 98" data-doi="10.1038/s41573-022-00495-3">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XhsFGhsLrN" aria-label="CAS reference 98">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35725925" aria-label="PubMed reference 98">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207876" aria-label="PubMed Central reference 98">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 98" href="http://scholar.google.com/scholar_lookup?&amp;title=Antibodies%20to%20combat%20viral%20infections%3A%20development%20strategies%20and%20progress&amp;journal=Nat.%20Rev.%20Drug%20Discov.&amp;doi=10.1038%2Fs41573-022-00495-3&amp;volume=21&amp;pages=676-696&amp;publication_year=2022&amp;author=Pantaleo%2CG&amp;author=Correia%2CB&amp;author=Fenwick%2CC&amp;author=Joo%2CVS&amp;author=Perez%2CL">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="99."><p class="c-article-references__text" id="ref-CR99">Janiaud, P. et al. Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. <i>JAMA</i> <b>325</b>, 1185–1195 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1001/jama.2021.2747" data-track-action="article reference" href="https://doi.org/10.1001%2Fjama.2021.2747" aria-label="Article reference 99" data-doi="10.1001/jama.2021.2747">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXntlWru7Y%3D" aria-label="CAS reference 99">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33635310" aria-label="PubMed reference 99">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 99" href="http://scholar.google.com/scholar_lookup?&amp;title=Association%20of%20convalescent%20plasma%20treatment%20with%20clinical%20outcomes%20in%20patients%20with%20COVID-19%3A%20a%20systematic%20review%20and%20meta-analysis&amp;journal=JAMA&amp;doi=10.1001%2Fjama.2021.2747&amp;volume=325&amp;pages=1185-1195&amp;publication_year=2021&amp;author=Janiaud%2CP">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="100."><p class="c-article-references__text" id="ref-CR100">Bégin, P. et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. <i>Nat. Med.</i> <b>27</b>, 2012–2024 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/s41591-021-01488-2" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41591-021-01488-2" aria-label="Article reference 100" data-doi="10.1038/s41591-021-01488-2">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34504336" aria-label="PubMed reference 100">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604729" aria-label="PubMed Central reference 100">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 100" href="http://scholar.google.com/scholar_lookup?&amp;title=Convalescent%20plasma%20for%20hospitalized%20patients%20with%20COVID-19%3A%20an%20open-label%2C%20randomized%20controlled%20trial&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-021-01488-2&amp;volume=27&amp;pages=2012-2024&amp;publication_year=2021&amp;author=B%C3%A9gin%2CP">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="101."><p class="c-article-references__text" id="ref-CR101">RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. <i>Lancet</i> <b>397</b>, 2049–2059 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/S0140-6736(21)00897-7" data-track-action="article reference" href="https://doi.org/10.1016%2FS0140-6736%2821%2900897-7" aria-label="Article reference 101" data-doi="10.1016/S0140-6736(21)00897-7">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 101" href="http://scholar.google.com/scholar_lookup?&amp;title=Convalescent%20plasma%20in%20patients%20admitted%20to%20hospital%20with%20COVID-19%20%28RECOVERY%29%3A%20a%20randomised%20controlled%2C%20open-label%2C%20platform%20trial&amp;journal=Lancet&amp;doi=10.1016%2FS0140-6736%2821%2900897-7&amp;volume=397&amp;pages=2049-2059&amp;publication_year=2021">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="102."><p class="c-article-references__text" id="ref-CR102">Writing Committee for the REMAP-CAP Investigators. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. <i>JAMA</i> <b>326</b>, 1690–1702 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1001/jama.2021.18178" data-track-action="article reference" href="https://doi.org/10.1001%2Fjama.2021.18178" aria-label="Article reference 102" data-doi="10.1001/jama.2021.18178">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491132" aria-label="PubMed Central reference 102">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 102" href="http://scholar.google.com/scholar_lookup?&amp;title=Effect%20of%20convalescent%20plasma%20on%20organ%20support-free%20days%20in%20critically%20ill%20patients%20with%20COVID-19%3A%20a%20randomized%20clinical%20trial&amp;journal=JAMA&amp;doi=10.1001%2Fjama.2021.18178&amp;volume=326&amp;pages=1690-1702&amp;publication_year=2021">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="103."><p class="c-article-references__text" id="ref-CR103">Sullivan, D. J. et al. Early outpatient treatment for Covid-19 with convalescent plasma. <i>N. Engl. J. Med.</i> <b>386</b>, 1700–1711 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMoa2119657" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa2119657" aria-label="Article reference 103" data-doi="10.1056/NEJMoa2119657">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38Xht1OrtLzM" aria-label="CAS reference 103">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35353960" aria-label="PubMed reference 103">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 103" href="http://scholar.google.com/scholar_lookup?&amp;title=Early%20outpatient%20treatment%20for%20Covid-19%20with%20convalescent%20plasma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa2119657&amp;volume=386&amp;pages=1700-1711&amp;publication_year=2022&amp;author=Sullivan%2CDJ">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="104."><p class="c-article-references__text" id="ref-CR104">Libster, R. et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. <i>N. Engl. J. Med.</i> <b>384</b>, 610–618 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMoa2033700" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa2033700" aria-label="Article reference 104" data-doi="10.1056/NEJMoa2033700">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXkvVGhurs%3D" aria-label="CAS reference 104">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33406353" aria-label="PubMed reference 104">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 104" href="http://scholar.google.com/scholar_lookup?&amp;title=Early%20high-titer%20plasma%20therapy%20to%20prevent%20severe%20Covid-19%20in%20older%20adults&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa2033700&amp;volume=384&amp;pages=610-618&amp;publication_year=2021&amp;author=Libster%2CR">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="105."><p class="c-article-references__text" id="ref-CR105">Alemany, A. et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. <i>Lancet Respir. Med.</i> <b>10</b>, 278–288 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/S2213-2600(21)00545-2" data-track-action="article reference" href="https://doi.org/10.1016%2FS2213-2600%2821%2900545-2" aria-label="Article reference 105" data-doi="10.1016/S2213-2600(21)00545-2">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XjsFCgtrg%3D" aria-label="CAS reference 105">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35150610" aria-label="PubMed reference 105">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828369" aria-label="PubMed Central reference 105">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 105" href="http://scholar.google.com/scholar_lookup?&amp;title=High-titre%20methylene%20blue-treated%20convalescent%20plasma%20as%20an%20early%20treatment%20for%20outpatients%20with%20COVID-19%3A%20a%20randomised%2C%20placebo-controlled%20trial&amp;journal=Lancet%20Respir.%20Med.&amp;doi=10.1016%2FS2213-2600%2821%2900545-2&amp;volume=10&amp;pages=278-288&amp;publication_year=2022&amp;author=Alemany%2CA">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="106."><p class="c-article-references__text" id="ref-CR106">Korley, F. K. et al. Early convalescent plasma for high-risk outpatients with Covid-19. <i>N. Engl. J. Med.</i> <b>385</b>, 1951–1960 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMoa2103784" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa2103784" aria-label="Article reference 106" data-doi="10.1056/NEJMoa2103784">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXisFCku7bL" aria-label="CAS reference 106">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34407339" aria-label="PubMed reference 106">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 106" href="http://scholar.google.com/scholar_lookup?&amp;title=Early%20convalescent%20plasma%20for%20high-risk%20outpatients%20with%20Covid-19&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa2103784&amp;volume=385&amp;pages=1951-1960&amp;publication_year=2021&amp;author=Korley%2CFK">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="107."><p class="c-article-references__text" id="ref-CR107">Millat-Martinez, P. et al. Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients. <i>Nat. Commun.</i> <b>13</b>, 2583 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/s41467-022-29911-3" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41467-022-29911-3" aria-label="Article reference 107" data-doi="10.1038/s41467-022-29911-3">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38Xht1OitbfE" aria-label="CAS reference 107">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35546145" aria-label="PubMed reference 107">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095637" aria-label="PubMed Central reference 107">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 107" href="http://scholar.google.com/scholar_lookup?&amp;title=Prospective%20individual%20patient%20data%20meta-analysis%20of%20two%20randomized%20trials%20on%20convalescent%20plasma%20for%20COVID-19%20outpatients&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fs41467-022-29911-3&amp;volume=13&amp;publication_year=2022&amp;author=Millat-Martinez%2CP">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="108."><p class="c-article-references__text" id="ref-CR108">National Institutes of Health. Anti-SARS-CoV-2 antibody products summary recommendations: COVID-19 treatment guidelines. <i>NIH</i> <a href="https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/summary-recommendations/" data-track="click" data-track-action="external reference" data-track-label="https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/summary-recommendations/">https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/summary-recommendations/</a> (2022).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="109."><p class="c-article-references__text" id="ref-CR109">Taylor, P. C. et al. Neutralizing monoclonal antibodies for treatment of COVID-19. <i>Nat. Rev. Immunol.</i> <b>21</b>, 382–393 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/s41577-021-00542-x" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41577-021-00542-x" aria-label="Article reference 109" data-doi="10.1038/s41577-021-00542-x">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXptFWit7c%3D" aria-label="CAS reference 109">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33875867" aria-label="PubMed reference 109">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054133" aria-label="PubMed Central reference 109">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 109" href="http://scholar.google.com/scholar_lookup?&amp;title=Neutralizing%20monoclonal%20antibodies%20for%20treatment%20of%20COVID-19&amp;journal=Nat.%20Rev.%20Immunol.&amp;doi=10.1038%2Fs41577-021-00542-x&amp;volume=21&amp;pages=382-393&amp;publication_year=2021&amp;author=Taylor%2CPC">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="110."><p class="c-article-references__text" id="ref-CR110">RECOVERY Collaborative Group. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet</i> <b>399</b>, 665–676 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/S0140-6736(22)00163-5" data-track-action="article reference" href="https://doi.org/10.1016%2FS0140-6736%2822%2900163-5" aria-label="Article reference 110" data-doi="10.1016/S0140-6736(22)00163-5">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 110" href="http://scholar.google.com/scholar_lookup?&amp;title=Casirivimab%20and%20imdevimab%20in%20patients%20admitted%20to%20hospital%20with%20COVID-19%20%28RECOVERY%29%3A%20a%20randomised%2C%20controlled%2C%20open-label%2C%20platform%20trial&amp;journal=Lancet&amp;doi=10.1016%2FS0140-6736%2822%2900163-5&amp;volume=399&amp;pages=665-676&amp;publication_year=2022">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="111."><p class="c-article-references__text" id="ref-CR111">Dougan, M. et al. A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load. <i>Clin. Infect. Dis.</i> <b>75</b>, e440–e449 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1093/cid/ciab912" data-track-action="article reference" href="https://doi.org/10.1093%2Fcid%2Fciab912" aria-label="Article reference 111" data-doi="10.1093/cid/ciab912">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402688" aria-label="PubMed Central reference 111">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 111" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20randomized%2C%20placebo-controlled%20clinical%20trial%20of%20bamlanivimab%20and%20etesevimab%20together%20in%20high-risk%20ambulatory%20patients%20with%20COVID-19%20and%20validation%20of%20the%20prognostic%20value%20of%20persistently%20high%20viral%20load&amp;journal=Clin.%20Infect.%20Dis.&amp;doi=10.1093%2Fcid%2Fciab912&amp;volume=75&amp;pages=e440-e449&amp;publication_year=2021&amp;author=Dougan%2CM">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="112."><p class="c-article-references__text" id="ref-CR112">Gupta, A. et al. Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial. <i>JAMA</i> <b>327</b>, 1236–1246 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1001/jama.2022.2832" data-track-action="article reference" href="https://doi.org/10.1001%2Fjama.2022.2832" aria-label="Article reference 112" data-doi="10.1001/jama.2022.2832">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XpsFGqtrY%3D" aria-label="CAS reference 112">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35285853" aria-label="PubMed reference 112">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922199" aria-label="PubMed Central reference 112">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 112" href="http://scholar.google.com/scholar_lookup?&amp;title=Effect%20of%20sotrovimab%20on%20hospitalization%20or%20death%20among%20high-risk%20patients%20with%20mild%20to%20moderate%20COVID-19%3A%20a%20randomized%20clinical%20trial&amp;journal=JAMA&amp;doi=10.1001%2Fjama.2022.2832&amp;volume=327&amp;pages=1236-1246&amp;publication_year=2022&amp;author=Gupta%2CA">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="113."><p class="c-article-references__text" id="ref-CR113">Weinreich, D. M. et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. <i>N. Engl. J. Med.</i> <b>385</b>, e81 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMoa2108163" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa2108163" aria-label="Article reference 113" data-doi="10.1056/NEJMoa2108163">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXislCntrrN" aria-label="CAS reference 113">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34587383" aria-label="PubMed reference 113">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 113" href="http://scholar.google.com/scholar_lookup?&amp;title=REGEN-COV%20antibody%20combination%20and%20outcomes%20in%20outpatients%20with%20Covid-19&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa2108163&amp;volume=385&amp;publication_year=2021&amp;author=Weinreich%2CDM">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="114."><p class="c-article-references__text" id="ref-CR114">Takashita, E. et al. Efficacy of antibodies and antiviral drugs against Covid-19 Omicron variant. <i>N. Engl. J. Med.</i> <b>386</b>, 995–998 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMc2119407" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMc2119407" aria-label="Article reference 114" data-doi="10.1056/NEJMc2119407">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35081300" aria-label="PubMed reference 114">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 114" href="http://scholar.google.com/scholar_lookup?&amp;title=Efficacy%20of%20antibodies%20and%20antiviral%20drugs%20against%20Covid-19%20Omicron%20variant&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMc2119407&amp;volume=386&amp;pages=995-998&amp;publication_year=2022&amp;author=Takashita%2CE">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="115."><p class="c-article-references__text" id="ref-CR115">Levin, M. J. et al. Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19. <i>N. Engl. J. Med.</i> <b>386</b>, 2188–2200 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMoa2116620" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa2116620" aria-label="Article reference 115" data-doi="10.1056/NEJMoa2116620">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38Xit1ersLbJ" aria-label="CAS reference 115">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35443106" aria-label="PubMed reference 115">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 115" href="http://scholar.google.com/scholar_lookup?&amp;title=Intramuscular%20AZD7442%20%28tixagevimab-cilgavimab%29%20for%20prevention%20of%20Covid-19&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa2116620&amp;volume=386&amp;pages=2188-2200&amp;publication_year=2022&amp;author=Levin%2CMJ">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="116."><p class="c-article-references__text" id="ref-CR116">Molnar, M. Z. et al. Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States. <i>Am. J. Transpl.</i> <b>20</b>, 3061–3071 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1111/ajt.16280" data-track-action="article reference" href="https://doi.org/10.1111%2Fajt.16280" aria-label="Article reference 116" data-doi="10.1111/ajt.16280">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXit1KitbjK" aria-label="CAS reference 116">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 116" href="http://scholar.google.com/scholar_lookup?&amp;title=Outcomes%20of%20critically%20ill%20solid%20organ%20transplant%20patients%20with%20COVID-19%20in%20the%20United%20States&amp;journal=Am.%20J.%20Transpl.&amp;doi=10.1111%2Fajt.16280&amp;volume=20&amp;pages=3061-3071&amp;publication_year=2020&amp;author=Molnar%2CMZ">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="117."><p class="c-article-references__text" id="ref-CR117">Cristelli, M. P. et al. Efficacy of convalescent plasma to treat mild to moderate COVID-19 in kidney transplant patients: a propensity score matching analysis. <i>Transplantation</i> <b>106</b>, e92–e94 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1097/TP.0000000000003962" data-track-action="article reference" href="https://doi.org/10.1097%2FTP.0000000000003962" aria-label="Article reference 117" data-doi="10.1097/TP.0000000000003962">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXislaqtLbJ" aria-label="CAS reference 117">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34581314" aria-label="PubMed reference 117">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 117" href="http://scholar.google.com/scholar_lookup?&amp;title=Efficacy%20of%20convalescent%20plasma%20to%20treat%20mild%20to%20moderate%20COVID-19%20in%20kidney%20transplant%20patients%3A%20a%20propensity%20score%20matching%20analysis&amp;journal=Transplantation&amp;doi=10.1097%2FTP.0000000000003962&amp;volume=106&amp;pages=e92-e94&amp;publication_year=2022&amp;author=Cristelli%2CMP">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="118."><p class="c-article-references__text" id="ref-CR118">Kluger, M. A. et al. Convalescent plasma treatment for early post-kidney transplant acquired COVID-19. <i>Transpl. Infect. Dis.</i> <b>23</b>, e13685 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1111/tid.13685" data-track-action="article reference" href="https://doi.org/10.1111%2Ftid.13685" aria-label="Article reference 118" data-doi="10.1111/tid.13685">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXit1yktrrL" aria-label="CAS reference 118">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34251081" aria-label="PubMed reference 118">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420349" aria-label="PubMed Central reference 118">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 118" href="http://scholar.google.com/scholar_lookup?&amp;title=Convalescent%20plasma%20treatment%20for%20early%20post-kidney%20transplant%20acquired%20COVID-19&amp;journal=Transpl.%20Infect.%20Dis.&amp;doi=10.1111%2Ftid.13685&amp;volume=23&amp;publication_year=2021&amp;author=Kluger%2CMA">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="119."><p class="c-article-references__text" id="ref-CR119">Rodionov, R. N. et al. Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19. <i>Lancet Microbe</i> <b>2</b>, e138 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/S2666-5247(21)00030-6" data-track-action="article reference" href="https://doi.org/10.1016%2FS2666-5247%2821%2900030-6" aria-label="Article reference 119" data-doi="10.1016/S2666-5247(21)00030-6">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXosVWhs7k%3D" aria-label="CAS reference 119">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33817676" aria-label="PubMed reference 119">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009633" aria-label="PubMed Central reference 119">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 119" href="http://scholar.google.com/scholar_lookup?&amp;title=Potential%20benefit%20of%20convalescent%20plasma%20transfusions%20in%20immunocompromised%20patients%20with%20COVID-19&amp;journal=Lancet%20Microbe&amp;doi=10.1016%2FS2666-5247%2821%2900030-6&amp;volume=2&amp;publication_year=2021&amp;author=Rodionov%2CRN">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="120."><p class="c-article-references__text" id="ref-CR120">Thompson, M. A. et al. Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19. <i>JAMA Oncol.</i> <b>7</b>, 1167–1175 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1001/jamaoncol.2021.1799" data-track-action="article reference" href="https://doi.org/10.1001%2Fjamaoncol.2021.1799" aria-label="Article reference 120" data-doi="10.1001/jamaoncol.2021.1799">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34137799" aria-label="PubMed reference 120">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377563" aria-label="PubMed Central reference 120">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 120" href="http://scholar.google.com/scholar_lookup?&amp;title=Association%20of%20convalescent%20plasma%20therapy%20with%20survival%20in%20patients%20with%20hematologic%20cancers%20and%20COVID-19&amp;journal=JAMA%20Oncol.&amp;doi=10.1001%2Fjamaoncol.2021.1799&amp;volume=7&amp;pages=1167-1175&amp;publication_year=2021&amp;author=Thompson%2CMA">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="121."><p class="c-article-references__text" id="ref-CR121">Arikawa, S. et al. Effectiveness of neutralizing antibody cocktail in hemodialysis patients: a case series of 20 patients treated with or without REGN-COV2. <i>Clin. Exp. Nephrol.</i> <b>26</b>, 476–485 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="noopener" data-track-label="10.1007/s10157-021-02151-3" data-track-action="article reference" href="https://link.springer.com/doi/10.1007/s10157-021-02151-3" aria-label="Article reference 121" data-doi="10.1007/s10157-021-02151-3">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XksVWns7k%3D" aria-label="CAS reference 121">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35182277" aria-label="PubMed reference 121">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856930" aria-label="PubMed Central reference 121">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 121" href="http://scholar.google.com/scholar_lookup?&amp;title=Effectiveness%20of%20neutralizing%20antibody%20cocktail%20in%20hemodialysis%20patients%3A%20a%20case%20series%20of%2020%20patients%20treated%20with%20or%20without%20REGN-COV2&amp;journal=Clin.%20Exp.%20Nephrol.&amp;doi=10.1007%2Fs10157-021-02151-3&amp;volume=26&amp;pages=476-485&amp;publication_year=2022&amp;author=Arikawa%2CS">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="122."><p class="c-article-references__text" id="ref-CR122">Gueguen, J. et al. Early administration of anti-SARS-CoV-2 monoclonal antibodies prevents severe Covid-19 in kidney transplant patients. <i>Kidney Int. Rep.</i> <b>7</b>, 1241–1247 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.ekir.2022.03.020" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.ekir.2022.03.020" aria-label="Article reference 122" data-doi="10.1016/j.ekir.2022.03.020">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35372734" aria-label="PubMed reference 122">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957354" aria-label="PubMed Central reference 122">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 122" href="http://scholar.google.com/scholar_lookup?&amp;title=Early%20administration%20of%20anti-SARS-CoV-2%20monoclonal%20antibodies%20prevents%20severe%20Covid-19%20in%20kidney%20transplant%20patients&amp;journal=Kidney%20Int.%20Rep.&amp;doi=10.1016%2Fj.ekir.2022.03.020&amp;volume=7&amp;pages=1241-1247&amp;publication_year=2022&amp;author=Gueguen%2CJ">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="123."><p class="c-article-references__text" id="ref-CR123">Bertrand, D. et al. Efficacy of anti-SARS-CoV-2 monoclonal antibody prophylaxis and vaccination on the Omicron variant of COVID-19 in kidney transplant recipients. <i>Kidney Int.</i> <b>102</b>, 440–442 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.kint.2022.05.007" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.kint.2022.05.007" aria-label="Article reference 123" data-doi="10.1016/j.kint.2022.05.007">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XhsFyrs7vJ" aria-label="CAS reference 123">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35618097" aria-label="PubMed reference 123">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125992" aria-label="PubMed Central reference 123">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 123" href="http://scholar.google.com/scholar_lookup?&amp;title=Efficacy%20of%20anti-SARS-CoV-2%20monoclonal%20antibody%20prophylaxis%20and%20vaccination%20on%20the%20Omicron%20variant%20of%20COVID-19%20in%20kidney%20transplant%20recipients&amp;journal=Kidney%20Int.&amp;doi=10.1016%2Fj.kint.2022.05.007&amp;volume=102&amp;pages=440-442&amp;publication_year=2022&amp;author=Bertrand%2CD">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="124."><p class="c-article-references__text" id="ref-CR124">Al Jurdi, A. et al. Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave. <i>Am. J. Transplant.</i> <a href="https://doi.org/10.1111/ajt.17128" data-track="click" data-track-action="external reference" data-track-label="10.1111/ajt.17128">https://doi.org/10.1111/ajt.17128</a> (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1111/ajt.17128" data-track-action="article reference" href="https://doi.org/10.1111%2Fajt.17128" aria-label="Article reference 124" data-doi="10.1111/ajt.17128">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35727916" aria-label="PubMed reference 124">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 124" href="http://scholar.google.com/scholar_lookup?&amp;title=Tixagevimab%2Fcilgavimab%20pre-exposure%20prophylaxis%20is%20associated%20with%20lower%20breakthrough%20infection%20risk%20in%20vaccinated%20solid%20organ%20transplant%20recipients%20during%20the%20omicron%20wave&amp;journal=Am.%20J.%20Transplant.&amp;doi=10.1111%2Fajt.17128&amp;publication_year=2022&amp;author=Al%20Jurdi%2CA">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="125."><p class="c-article-references__text" id="ref-CR125">US Food and Drug Administration. Fact sheet for health care providers emergency use authorization (EUA) of bamlanivimab and etesevimab. <i>FDA</i> <a href="https://www.fda.gov/media/145802/download" data-track="click" data-track-action="external reference" data-track-label="https://www.fda.gov/media/145802/download">https://www.fda.gov/media/145802/download</a> (2020).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="126."><p class="c-article-references__text" id="ref-CR126">US Food and Drug Administration. Fact sheet for health care providers emergency use authorization (EUA) of REGEN-COV. <i>FDA</i> <a href="https://www.fda.gov/media/145611/download" data-track="click" data-track-action="external reference" data-track-label="https://www.fda.gov/media/145611/download">https://www.fda.gov/media/145611/download</a> (2020).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="127."><p class="c-article-references__text" id="ref-CR127">US Food and Drug Administration. Fact sheet for healthcare providers emergency use authorization (EUA) of sotrovimab. <i>FDA</i> <a href="https://www.fda.gov/media/149534/download" data-track="click" data-track-action="external reference" data-track-label="https://www.fda.gov/media/149534/download">https://www.fda.gov/media/149534/download</a> (2020).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="128."><p class="c-article-references__text" id="ref-CR128">Vaduganathan, M. et al. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. <i>N. Engl. J. Med.</i> <b>382</b>, 1653–1659 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMsr2005760" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMsr2005760" aria-label="Article reference 128" data-doi="10.1056/NEJMsr2005760">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXot1Klsrs%3D" aria-label="CAS reference 128">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32227760" aria-label="PubMed reference 128">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 128" href="http://scholar.google.com/scholar_lookup?&amp;title=Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMsr2005760&amp;volume=382&amp;pages=1653-1659&amp;publication_year=2020&amp;author=Vaduganathan%2CM">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="129."><p class="c-article-references__text" id="ref-CR129">Sfera, A. et al. Intoxication with endogenous angiotensin II: a COVID-19 hypothesis. <i>Front. Immunol.</i> <b>11</b>, 1472 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.3389/fimmu.2020.01472" data-track-action="article reference" href="https://doi.org/10.3389%2Ffimmu.2020.01472" aria-label="Article reference 129" data-doi="10.3389/fimmu.2020.01472">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXitVWgu7nP" aria-label="CAS reference 129">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32655579" aria-label="PubMed reference 129">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325923" aria-label="PubMed Central reference 129">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 129" href="http://scholar.google.com/scholar_lookup?&amp;title=Intoxication%20with%20endogenous%20angiotensin%20II%3A%20a%20COVID-19%20hypothesis&amp;journal=Front.%20Immunol.&amp;doi=10.3389%2Ffimmu.2020.01472&amp;volume=11&amp;publication_year=2020&amp;author=Sfera%2CA">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="130."><p class="c-article-references__text" id="ref-CR130">Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. <i>Cell</i> <b>181</b>, 271–280.e8 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.cell.2020.02.052" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.cell.2020.02.052" aria-label="Article reference 130" data-doi="10.1016/j.cell.2020.02.052">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXktl2qtb8%3D" aria-label="CAS reference 130">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32142651" aria-label="PubMed reference 130">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102627" aria-label="PubMed Central reference 130">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 130" href="http://scholar.google.com/scholar_lookup?&amp;title=SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2020.02.052&amp;volume=181&amp;pages=271-280.e8&amp;publication_year=2020&amp;author=Hoffmann%2CM">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="131."><p class="c-article-references__text" id="ref-CR131">Hamming, I. et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. <i>J. Pathol.</i> <b>203</b>, 631–637 (2004).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1002/path.1570" data-track-action="article reference" href="https://doi.org/10.1002%2Fpath.1570" aria-label="Article reference 131" data-doi="10.1002/path.1570">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD2cXlsVWktbY%3D" aria-label="CAS reference 131">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15141377" aria-label="PubMed reference 131">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167720" aria-label="PubMed Central reference 131">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 131" href="http://scholar.google.com/scholar_lookup?&amp;title=Tissue%20distribution%20of%20ACE2%20protein%2C%20the%20functional%20receptor%20for%20SARS%20coronavirus.%20A%20first%20step%20in%20understanding%20SARS%20pathogenesis&amp;journal=J.%20Pathol.&amp;doi=10.1002%2Fpath.1570&amp;volume=203&amp;pages=631-637&amp;publication_year=2004&amp;author=Hamming%2CI">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="132."><p class="c-article-references__text" id="ref-CR132">Jiang, F. et al. Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets. <i>Nat. Rev. Cardiol.</i> <b>11</b>, 413–426 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/nrcardio.2014.59" data-track-action="article reference" href="https://doi.org/10.1038%2Fnrcardio.2014.59" aria-label="Article reference 132" data-doi="10.1038/nrcardio.2014.59">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2cXnslGitLs%3D" aria-label="CAS reference 132">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24776703" aria-label="PubMed reference 132">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097196" aria-label="PubMed Central reference 132">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 132" href="http://scholar.google.com/scholar_lookup?&amp;title=Angiotensin-converting%20enzyme%202%20and%20angiotensin%201-7%3A%20novel%20therapeutic%20targets&amp;journal=Nat.%20Rev.%20Cardiol.&amp;doi=10.1038%2Fnrcardio.2014.59&amp;volume=11&amp;pages=413-426&amp;publication_year=2014&amp;author=Jiang%2CF">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="133."><p class="c-article-references__text" id="ref-CR133">Imai, Y. et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. <i>Nature</i> <b>436</b>, 112–116 (2005).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/nature03712" data-track-action="article reference" href="https://doi.org/10.1038%2Fnature03712" aria-label="Article reference 133" data-doi="10.1038/nature03712">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD2MXlvVGiu7Y%3D" aria-label="CAS reference 133">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16001071" aria-label="PubMed reference 133">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094998" aria-label="PubMed Central reference 133">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 133" href="http://scholar.google.com/scholar_lookup?&amp;title=Angiotensin-converting%20enzyme%202%20protects%20from%20severe%20acute%20lung%20failure&amp;journal=Nature&amp;doi=10.1038%2Fnature03712&amp;volume=436&amp;pages=112-116&amp;publication_year=2005&amp;author=Imai%2CY">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="134."><p class="c-article-references__text" id="ref-CR134">Zhang, H., Penninger, J. M., Li, Y., Zhong, N. &amp; Slutsky, A. S. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. <i>Intensive Care Med.</i> <b>46</b>, 586–590 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="noopener" data-track-label="10.1007/s00134-020-05985-9" data-track-action="article reference" href="https://link.springer.com/doi/10.1007/s00134-020-05985-9" aria-label="Article reference 134" data-doi="10.1007/s00134-020-05985-9">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXkt1erurY%3D" aria-label="CAS reference 134">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32125455" aria-label="PubMed reference 134">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079879" aria-label="PubMed Central reference 134">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 134" href="http://scholar.google.com/scholar_lookup?&amp;title=Angiotensin-converting%20enzyme%202%20%28ACE2%29%20as%20a%20SARS-CoV-2%20receptor%3A%20molecular%20mechanisms%20and%20potential%20therapeutic%20target&amp;journal=Intensive%20Care%20Med.&amp;doi=10.1007%2Fs00134-020-05985-9&amp;volume=46&amp;pages=586-590&amp;publication_year=2020&amp;author=Zhang%2CH&amp;author=Penninger%2CJM&amp;author=Li%2CY&amp;author=Zhong%2CN&amp;author=Slutsky%2CAS">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="135."><p class="c-article-references__text" id="ref-CR135">Rysz, S. et al. COVID-19 pathophysiology may be driven by an imbalance in the renin-angiotensin-aldosterone system. <i>Nat. Commun.</i> <b>12</b>, 2417 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/s41467-021-22713-z" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41467-021-22713-z" aria-label="Article reference 135" data-doi="10.1038/s41467-021-22713-z">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXpsl2kt7c%3D" aria-label="CAS reference 135">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33893295" aria-label="PubMed reference 135">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065208" aria-label="PubMed Central reference 135">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 135" href="http://scholar.google.com/scholar_lookup?&amp;title=COVID-19%20pathophysiology%20may%20be%20driven%20by%20an%20imbalance%20in%20the%20renin-angiotensin-aldosterone%20system&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fs41467-021-22713-z&amp;volume=12&amp;publication_year=2021&amp;author=Rysz%2CS">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="136."><p class="c-article-references__text" id="ref-CR136">Lawler, P. R., Derde, L. P. G., Mc Verry, B., Russell, J. A. &amp; van de Veerdonk, F. The renin-angiotensin system in acute lung injury. <i>Crit. Care Med.</i> <b>50</b>, 1411–1415 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1097/CCM.0000000000005567" data-track-action="article reference" href="https://doi.org/10.1097%2FCCM.0000000000005567" aria-label="Article reference 136" data-doi="10.1097/CCM.0000000000005567">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XitFGiu7%2FI" aria-label="CAS reference 136">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35984058" aria-label="PubMed reference 136">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 136" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20renin-angiotensin%20system%20in%20acute%20lung%20injury&amp;journal=Crit.%20Care%20Med.&amp;doi=10.1097%2FCCM.0000000000005567&amp;volume=50&amp;pages=1411-1415&amp;publication_year=2022&amp;author=Lawler%2CPR&amp;author=Derde%2CLPG&amp;author=Verry%2CB&amp;author=Russell%2CJA&amp;author=Veerdonk%2CF">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="137."><p class="c-article-references__text" id="ref-CR137">Caldeira, D., Alarcão, J., Vaz-Carneiro, A. &amp; Costa, J. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. <i>BMJ</i> <b>345</b>, e4260 (2012).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1136/bmj.e4260" data-track-action="article reference" href="https://doi.org/10.1136%2Fbmj.e4260" aria-label="Article reference 137" data-doi="10.1136/bmj.e4260">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22786934" aria-label="PubMed reference 137">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394697" aria-label="PubMed Central reference 137">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 137" href="http://scholar.google.com/scholar_lookup?&amp;title=Risk%20of%20pneumonia%20associated%20with%20use%20of%20angiotensin%20converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers%3A%20systematic%20review%20and%20meta-analysis&amp;journal=BMJ&amp;doi=10.1136%2Fbmj.e4260&amp;volume=345&amp;publication_year=2012&amp;author=Caldeira%2CD&amp;author=Alarc%C3%A3o%2CJ&amp;author=Vaz-Carneiro%2CA&amp;author=Costa%2CJ">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="138."><p class="c-article-references__text" id="ref-CR138">Chung, S. C., Providencia, R. &amp; Sofat, R. Association between angiotensin blockade and incidence of influenza in the United Kingdom. <i>N. Engl. J. Med.</i> <b>383</b>, 397–400 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMc2005396" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMc2005396" aria-label="Article reference 138" data-doi="10.1056/NEJMc2005396">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32383830" aria-label="PubMed reference 138">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 138" href="http://scholar.google.com/scholar_lookup?&amp;title=Association%20between%20angiotensin%20blockade%20and%20incidence%20of%20influenza%20in%20the%20United%20Kingdom&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMc2005396&amp;volume=383&amp;pages=397-400&amp;publication_year=2020&amp;author=Chung%2CSC&amp;author=Providencia%2CR&amp;author=Sofat%2CR">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="139."><p class="c-article-references__text" id="ref-CR139">Kim, J. et al. Effect of antihypertensive medications on sepsis-related outcomes: a population-based cohort study. <i>Crit. Care Med.</i> <b>47</b>, e386–e393 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1097/CCM.0000000000003654" data-track-action="article reference" href="https://doi.org/10.1097%2FCCM.0000000000003654" aria-label="Article reference 139" data-doi="10.1097/CCM.0000000000003654">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXnt1ers78%3D" aria-label="CAS reference 139">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30688717" aria-label="PubMed reference 139">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 139" href="http://scholar.google.com/scholar_lookup?&amp;title=Effect%20of%20antihypertensive%20medications%20on%20sepsis-related%20outcomes%3A%20a%20population-based%20cohort%20study&amp;journal=Crit.%20Care%20Med.&amp;doi=10.1097%2FCCM.0000000000003654&amp;volume=47&amp;pages=e386-e393&amp;publication_year=2019&amp;author=Kim%2CJ">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="140."><p class="c-article-references__text" id="ref-CR140">Baral, R. et al. Association between renin-angiotensin-aldosterone system inhibitors and clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. <i>JAMA Netw. Open</i> <b>4</b>, e213594 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1001/jamanetworkopen.2021.3594" data-track-action="article reference" href="https://doi.org/10.1001%2Fjamanetworkopen.2021.3594" aria-label="Article reference 140" data-doi="10.1001/jamanetworkopen.2021.3594">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33787911" aria-label="PubMed reference 140">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8013817" aria-label="PubMed Central reference 140">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 140" href="http://scholar.google.com/scholar_lookup?&amp;title=Association%20between%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20clinical%20outcomes%20in%20patients%20with%20COVID-19%3A%20a%20systematic%20review%20and%20meta-analysis&amp;journal=JAMA%20Netw.%20Open&amp;doi=10.1001%2Fjamanetworkopen.2021.3594&amp;volume=4&amp;publication_year=2021&amp;author=Baral%2CR">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="141."><p class="c-article-references__text" id="ref-CR141">Lopes, R. D. et al. Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial. <i>JAMA</i> <b>325</b>, 254–264 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1001/jama.2020.25864" data-track-action="article reference" href="https://doi.org/10.1001%2Fjama.2020.25864" aria-label="Article reference 141" data-doi="10.1001/jama.2020.25864">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXhvVGht7w%3D" aria-label="CAS reference 141">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33464336" aria-label="PubMed reference 141">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816106" aria-label="PubMed Central reference 141">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 141" href="http://scholar.google.com/scholar_lookup?&amp;title=Effect%20of%20discontinuing%20vs%20continuing%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20II%20receptor%20blockers%20on%20days%20alive%20and%20out%20of%20the%20hospital%20in%20patients%20admitted%20with%20COVID-19%3A%20a%20randomized%20clinical%20trial&amp;journal=JAMA&amp;doi=10.1001%2Fjama.2020.25864&amp;volume=325&amp;pages=254-264&amp;publication_year=2021&amp;author=Lopes%2CRD">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="142."><p class="c-article-references__text" id="ref-CR142">Duarte, M. et al. Telmisartan for treatment of Covid-19 patients: an open multicenter randomized clinical trial. <i>EClinicalMedicine</i> <b>37</b>, 100962 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.eclinm.2021.100962" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.eclinm.2021.100962" aria-label="Article reference 142" data-doi="10.1016/j.eclinm.2021.100962">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34189447" aria-label="PubMed reference 142">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225700" aria-label="PubMed Central reference 142">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 142" href="http://scholar.google.com/scholar_lookup?&amp;title=Telmisartan%20for%20treatment%20of%20Covid-19%20patients%3A%20an%20open%20multicenter%20randomized%20clinical%20trial&amp;journal=EClinicalMedicine&amp;doi=10.1016%2Fj.eclinm.2021.100962&amp;volume=37&amp;publication_year=2021&amp;author=Duarte%2CM">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="143."><p class="c-article-references__text" id="ref-CR143">Puskarich, M. A. et al. A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19. <i>EClinicalMedicine</i> <b>37</b>, 100957 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.eclinm.2021.100957" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.eclinm.2021.100957" aria-label="Article reference 143" data-doi="10.1016/j.eclinm.2021.100957">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34195577" aria-label="PubMed reference 143">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225661" aria-label="PubMed Central reference 143">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 143" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20multi-center%20phase%20II%20randomized%20clinical%20trial%20of%20losartan%20on%20symptomatic%20outpatients%20with%20COVID-19&amp;journal=EClinicalMedicine&amp;doi=10.1016%2Fj.eclinm.2021.100957&amp;volume=37&amp;publication_year=2021&amp;author=Puskarich%2CMA">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="144."><p class="c-article-references__text" id="ref-CR144">Ramagopalan, S. V. et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. <i>Genome Res.</i> <b>20</b>, 1352–1360 (2010).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1101/gr.107920.110" data-track-action="article reference" href="https://doi.org/10.1101%2Fgr.107920.110" aria-label="Article reference 144" data-doi="10.1101/gr.107920.110">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3cXht12jsrnN" aria-label="CAS reference 144">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20736230" aria-label="PubMed reference 144">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945184" aria-label="PubMed Central reference 144">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 144" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20ChIP-seq%20defined%20genome-wide%20map%20of%20vitamin%20D%20receptor%20binding%3A%20associations%20with%20disease%20and%20evolution&amp;journal=Genome%20Res.&amp;doi=10.1101%2Fgr.107920.110&amp;volume=20&amp;pages=1352-1360&amp;publication_year=2010&amp;author=Ramagopalan%2CSV">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="145."><p class="c-article-references__text" id="ref-CR145">Liu, P. T. et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. <i>Science</i> <b>311</b>, 1770–1773 (2006).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1126/science.1123933" data-track-action="article reference" href="https://doi.org/10.1126%2Fscience.1123933" aria-label="Article reference 145" data-doi="10.1126/science.1123933">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD28Xis1eqtbk%3D" aria-label="CAS reference 145">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16497887" aria-label="PubMed reference 145">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 145" href="http://scholar.google.com/scholar_lookup?&amp;title=Toll-like%20receptor%20triggering%20of%20a%20vitamin%20D-mediated%20human%20antimicrobial%20response&amp;journal=Science&amp;doi=10.1126%2Fscience.1123933&amp;volume=311&amp;pages=1770-1773&amp;publication_year=2006&amp;author=Liu%2CPT">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="146."><p class="c-article-references__text" id="ref-CR146">National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, Ginde, A. A. et al. Early high-dose vitamin D3 for critically ill, vitamin D-deficient patients. <i>N. Engl. J. Med.</i> <b>381</b>, 2529–2540 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1911124" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1911124" aria-label="Article reference 146" data-doi="10.1056/NEJMoa1911124">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 146" href="http://scholar.google.com/scholar_lookup?&amp;title=Early%20high-dose%20vitamin%20D3%20for%20critically%20ill%2C%20vitamin%20D-deficient%20patients&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1911124&amp;volume=381&amp;pages=2529-2540&amp;publication_year=2019&amp;author=Ginde%2CAA">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="147."><p class="c-article-references__text" id="ref-CR147">Amrein, K. et al. Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency: the VITdAL-ICU randomized clinical trial. <i>JAMA</i> <b>312</b>, 1520–1530 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1001/jama.2014.13204" data-track-action="article reference" href="https://doi.org/10.1001%2Fjama.2014.13204" aria-label="Article reference 147" data-doi="10.1001/jama.2014.13204">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25268295" aria-label="PubMed reference 147">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 147" href="http://scholar.google.com/scholar_lookup?&amp;title=Effect%20of%20high-dose%20vitamin%20D3%20on%20hospital%20length%20of%20stay%20in%20critically%20ill%20patients%20with%20vitamin%20D%20deficiency%3A%20the%20VITdAL-ICU%20randomized%20clinical%20trial&amp;journal=JAMA&amp;doi=10.1001%2Fjama.2014.13204&amp;volume=312&amp;pages=1520-1530&amp;publication_year=2014&amp;author=Amrein%2CK">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="148."><p class="c-article-references__text" id="ref-CR148">Murai, I. H. et al. Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial. <i>JAMA</i> <b>325</b>, 1053–1060 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1001/jama.2020.26848" data-track-action="article reference" href="https://doi.org/10.1001%2Fjama.2020.26848" aria-label="Article reference 148" data-doi="10.1001/jama.2020.26848">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXntVWisb8%3D" aria-label="CAS reference 148">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33595634" aria-label="PubMed reference 148">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 148" href="http://scholar.google.com/scholar_lookup?&amp;title=Effect%20of%20a%20single%20high%20dose%20of%20vitamin%20D3%20on%20hospital%20length%20of%20stay%20in%20patients%20with%20moderate%20to%20severe%20COVID-19%3A%20a%20randomized%20clinical%20trial&amp;journal=JAMA&amp;doi=10.1001%2Fjama.2020.26848&amp;volume=325&amp;pages=1053-1060&amp;publication_year=2021&amp;author=Murai%2CIH">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="149."><p class="c-article-references__text" id="ref-CR149">Leaf, D. E. &amp; Ginde, A. A. Vitamin D3 to treat COVID-19: different disease, same answer. <i>JAMA</i> <b>325</b>, 1047–1048 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1001/jama.2020.26850" data-track-action="article reference" href="https://doi.org/10.1001%2Fjama.2020.26850" aria-label="Article reference 149" data-doi="10.1001/jama.2020.26850">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXntVWisLY%3D" aria-label="CAS reference 149">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33595641" aria-label="PubMed reference 149">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8412177" aria-label="PubMed Central reference 149">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 149" href="http://scholar.google.com/scholar_lookup?&amp;title=Vitamin%20D3%20to%20treat%20COVID-19%3A%20different%20disease%2C%20same%20answer&amp;journal=JAMA&amp;doi=10.1001%2Fjama.2020.26850&amp;volume=325&amp;pages=1047-1048&amp;publication_year=2021&amp;author=Leaf%2CDE&amp;author=Ginde%2CAA">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="150."><p class="c-article-references__text" id="ref-CR150">US National Library of Medicine. <i>ClinicalTrials.gov</i> <a href="https://clinicaltrials.gov/ct2/show/NCT04536298" data-track="click" data-track-action="external reference" data-track-label="https://clinicaltrials.gov/ct2/show/NCT04536298">https://clinicaltrials.gov/ct2/show/NCT04536298</a> (2022).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="151."><p class="c-article-references__text" id="ref-CR151">Tran, M. T. et al. PGC1α drives NAD biosynthesis linking oxidative metabolism to renal protection. <i>Nature</i> <b>531</b>, 528–532 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/nature17184" data-track-action="article reference" href="https://doi.org/10.1038%2Fnature17184" aria-label="Article reference 151" data-doi="10.1038/nature17184">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XksVKksro%3D" aria-label="CAS reference 151">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26982719" aria-label="PubMed reference 151">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909121" aria-label="PubMed Central reference 151">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 151" href="http://scholar.google.com/scholar_lookup?&amp;title=PGC1%CE%B1%20drives%20NAD%20biosynthesis%20linking%20oxidative%20metabolism%20to%20renal%20protection&amp;journal=Nature&amp;doi=10.1038%2Fnature17184&amp;volume=531&amp;pages=528-532&amp;publication_year=2016&amp;author=Tran%2CMT">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="152."><p class="c-article-references__text" id="ref-CR152">Poyan Mehr, A. et al. De novo NAD<sup>+</sup> biosynthetic impairment in acute kidney injury in humans. <i>Nat. Med.</i> <b>24</b>, 1351–1359 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/s41591-018-0138-z" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41591-018-0138-z" aria-label="Article reference 152" data-doi="10.1038/s41591-018-0138-z">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXhsFGjurzJ" aria-label="CAS reference 152">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30127395" aria-label="PubMed reference 152">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 152" href="http://scholar.google.com/scholar_lookup?&amp;title=De%20novo%20NAD%2B%20biosynthetic%20impairment%20in%20acute%20kidney%20injury%20in%20humans&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-018-0138-z&amp;volume=24&amp;pages=1351-1359&amp;publication_year=2018&amp;author=Poyan%20Mehr%2CA">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="153."><p class="c-article-references__text" id="ref-CR153">US National Library of Medicine. <i>ClinicalTrials.gov</i> <a href="https://clinicaltrials.gov/ct2/show/NCT04342975" data-track="click" data-track-action="external reference" data-track-label="https://clinicaltrials.gov/ct2/show/NCT04342975">https://clinicaltrials.gov/ct2/show/NCT04342975</a> (2022).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="154."><p class="c-article-references__text" id="ref-CR154">US National Library of Medicine. <i>ClinicalTrials.gov</i> <a href="https://clinicaltrials.gov/ct2/show/NCT04589546" data-track="click" data-track-action="external reference" data-track-label="https://clinicaltrials.gov/ct2/show/NCT04589546">https://clinicaltrials.gov/ct2/show/NCT04589546</a> (2021).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="155."><p class="c-article-references__text" id="ref-CR155">Raines, N. H. et al. Niacinamide may be associated with improved outcomes in COVID-19-related acute kidney injury: an observational study. <i>Kidney360</i> <b>2</b>, 33–41 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.34067/KID.0006452020" data-track-action="article reference" href="https://doi.org/10.34067%2FKID.0006452020" aria-label="Article reference 155" data-doi="10.34067/KID.0006452020">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35368823" aria-label="PubMed reference 155">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 155" href="http://scholar.google.com/scholar_lookup?&amp;title=Niacinamide%20may%20be%20associated%20with%20improved%20outcomes%20in%20COVID-19-related%20acute%20kidney%20injury%3A%20an%20observational%20study&amp;journal=Kidney360&amp;doi=10.34067%2FKID.0006452020&amp;volume=2&amp;pages=33-41&amp;publication_year=2021&amp;author=Raines%2CNH">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="156."><p class="c-article-references__text" id="ref-CR156">US National Library of Medicine. ClinicalTrials.gov <a href="https://clinicaltrials.gov/ct2/show/NCT05038488" data-track="click" data-track-action="external reference" data-track-label="https://clinicaltrials.gov/ct2/show/NCT05038488">https://clinicaltrials.gov/ct2/show/NCT05038488</a> (2021).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="157."><p class="c-article-references__text" id="ref-CR157">US National Library of Medicine. <i>ClinicalTrials.gov</i> <a href="https://clinicaltrials.gov/ct2/show/NCT04809974" data-track="click" data-track-action="external reference" data-track-label="https://clinicaltrials.gov/ct2/show/NCT04809974">https://clinicaltrials.gov/ct2/show/NCT04809974</a> (2022).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="158."><p class="c-article-references__text" id="ref-CR158">Sato, R. et al. Effect of IV high-dose vitamin c on mortality in patients with sepsis: a systematic review and meta-analysis of randomized controlled trials. <i>Crit. Care Med.</i> <b>49</b>, 2121–2130 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXisFWitbfL" aria-label="CAS reference 158">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34495877" aria-label="PubMed reference 158">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 158" href="http://scholar.google.com/scholar_lookup?&amp;title=Effect%20of%20IV%20high-dose%20vitamin%20c%20on%20mortality%20in%20patients%20with%20sepsis%3A%20a%20systematic%20review%20and%20meta-analysis%20of%20randomized%20controlled%20trials&amp;journal=Crit.%20Care%20Med.&amp;volume=49&amp;pages=2121-2130&amp;publication_year=2021&amp;author=Sato%2CR">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="159."><p class="c-article-references__text" id="ref-CR159">Lamontagne, F. et al. Intravenous vitamin C in adults with sepsis in the intensive care unit. <i>N. Engl. J. Med.</i> <b>386</b>, 2387–2398 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMoa2200644" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa2200644" aria-label="Article reference 159" data-doi="10.1056/NEJMoa2200644">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38Xit1ersL3P" aria-label="CAS reference 159">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35704292" aria-label="PubMed reference 159">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 159" href="http://scholar.google.com/scholar_lookup?&amp;title=Intravenous%20vitamin%20C%20in%20adults%20with%20sepsis%20in%20the%20intensive%20care%20unit&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa2200644&amp;volume=386&amp;pages=2387-2398&amp;publication_year=2022&amp;author=Lamontagne%2CF">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="160."><p class="c-article-references__text" id="ref-CR160">Thomas, S. et al. Effect of high-dose zinc and ascorbic acid supplementation vs usual care on symptom length and reduction among ambulatory patients with SARS-CoV-2 infection: the COVID A to Z randomized clinical trial. <i>JAMA Netw. Open</i> <b>4</b>, e210369 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1001/jamanetworkopen.2021.0369" data-track-action="article reference" href="https://doi.org/10.1001%2Fjamanetworkopen.2021.0369" aria-label="Article reference 160" data-doi="10.1001/jamanetworkopen.2021.0369">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33576820" aria-label="PubMed reference 160">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881357" aria-label="PubMed Central reference 160">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 160" href="http://scholar.google.com/scholar_lookup?&amp;title=Effect%20of%20high-dose%20zinc%20and%20ascorbic%20acid%20supplementation%20vs%20usual%20care%20on%20symptom%20length%20and%20reduction%20among%20ambulatory%20patients%20with%20SARS-CoV-2%20infection%3A%20the%20COVID%20A%20to%20Z%20randomized%20clinical%20trial&amp;journal=JAMA%20Netw.%20Open&amp;doi=10.1001%2Fjamanetworkopen.2021.0369&amp;volume=4&amp;publication_year=2021&amp;author=Thomas%2CS">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="161."><p class="c-article-references__text" id="ref-CR161">Zhang, J. et al. Pilot trial of high-dose vitamin C in critically ill COVID-19 patients. <i>Ann. Intensive Care</i> <b>11</b>, 5 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="noopener" data-track-label="10.1186/s13613-020-00792-3" data-track-action="article reference" href="https://link.springer.com/doi/10.1186/s13613-020-00792-3" aria-label="Article reference 161" data-doi="10.1186/s13613-020-00792-3">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXhslSqtrk%3D" aria-label="CAS reference 161">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33420963" aria-label="PubMed reference 161">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794643" aria-label="PubMed Central reference 161">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 161" href="http://scholar.google.com/scholar_lookup?&amp;title=Pilot%20trial%20of%20high-dose%20vitamin%20C%20in%20critically%20ill%20COVID-19%20patients&amp;journal=Ann.%20Intensive%20Care&amp;doi=10.1186%2Fs13613-020-00792-3&amp;volume=11&amp;publication_year=2021&amp;author=Zhang%2CJ">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="162."><p class="c-article-references__text" id="ref-CR162">Johns Hopkins University &amp; Medicine. Coronavirus Resource Center. <i>JHU</i> <a href="https://coronavirus.jhu.edu/" data-track="click" data-track-action="external reference" data-track-label="https://coronavirus.jhu.edu/">https://coronavirus.jhu.edu/</a> (2022).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="163."><p class="c-article-references__text" id="ref-CR163">INSPIRATION Investigators. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. <i>JAMA</i> <b>325</b>, 1620–1630 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1001/jama.2021.4152" data-track-action="article reference" href="https://doi.org/10.1001%2Fjama.2021.4152" aria-label="Article reference 163" data-doi="10.1001/jama.2021.4152">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 163" href="http://scholar.google.com/scholar_lookup?&amp;title=Effect%20of%20intermediate-dose%20vs%20standard-dose%20prophylactic%20anticoagulation%20on%20thrombotic%20events%2C%20extracorporeal%20membrane%20oxygenation%20treatment%2C%20or%20mortality%20among%20patients%20with%20COVID-19%20admitted%20to%20the%20intensive%20care%20unit%3A%20the%20INSPIRATION%20randomized%20clinical%20trial&amp;journal=JAMA&amp;doi=10.1001%2Fjama.2021.4152&amp;volume=325&amp;pages=1620-1630&amp;publication_year=2021">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="164."><p class="c-article-references__text" id="ref-CR164">ACTIV-3/TICO LY-CoV555 Study Group. A neutralizing monoclonal antibody for hospitalized patients with Covid-19. <i>N. Engl. J. Med.</i> <b>384</b>, 905–914 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMoa2033130" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa2033130" aria-label="Article reference 164" data-doi="10.1056/NEJMoa2033130">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 164" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20neutralizing%20monoclonal%20antibody%20for%20hospitalized%20patients%20with%20Covid-19&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa2033130&amp;volume=384&amp;pages=905-914&amp;publication_year=2021">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="165."><p class="c-article-references__text" id="ref-CR165">Dougan, M. et al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. <i>N. Engl. J. Med.</i> <b>385</b>, 1382–1392 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click" rel="nofollow noopener" data-track-label="10.1056/NEJMoa2102685" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa2102685" aria-label="Article reference 165" data-doi="10.1056/NEJMoa2102685">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXit1SgurbM" aria-label="CAS reference 165">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34260849" aria-label="PubMed reference 165">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 165" href="http://scholar.google.com/scholar_lookup?&amp;title=Bamlanivimab%20plus%20etesevimab%20in%20mild%20or%20moderate%20Covid-19&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa2102685&amp;volume=385&amp;pages=1382-1392&amp;publication_year=2021&amp;author=Dougan%2CM">
                    Google Scholar</a> 
                </p></li></ol><p class="c-article-references__download u-hide-print"><a data-track="click" data-track-action="download citation references" data-track-label="link" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41581-022-00642-4?format=refman&amp;flavour=references">Download references<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p></div></div></div></section></div><section aria-labelledby="author-information" data-title="Author information"><div class="c-article-section" id="author-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="author-information">Author information</h2><div class="c-article-section__content" id="author-information-content"><h3 class="c-article__sub-heading" id="affiliations">Authors and Affiliations</h3><ol class="c-article-author-affiliation__list"><li id="Aff1"><p class="c-article-author-affiliation__address">Division of Renal Medicine, Brigham and Women’s Hospital, Boston, MA, USA</p><p class="c-article-author-affiliation__authors-list">Naoka Murakami, Robert Hayden &amp; David E. Leaf</p></li><li id="Aff2"><p class="c-article-author-affiliation__address">Harvard Medical School, Boston, MA, USA</p><p class="c-article-author-affiliation__authors-list">Naoka Murakami, Robert Hayden, Hanny Al-Samkari, Meghan E. Sise &amp; David E. Leaf</p></li><li id="Aff3"><p class="c-article-author-affiliation__address">Medical Research Institute of New Zealand, Wellington, New Zealand</p><p class="c-article-author-affiliation__authors-list">Thomas Hills</p></li><li id="Aff4"><p class="c-article-author-affiliation__address">Auckland District Health Board, Auckland, New Zealand</p><p class="c-article-author-affiliation__authors-list">Thomas Hills</p></li><li id="Aff5"><p class="c-article-author-affiliation__address">Division of Hematology, Massachusetts General Hospital, Boston, MA, USA</p><p class="c-article-author-affiliation__authors-list">Hanny Al-Samkari</p></li><li id="Aff6"><p class="c-article-author-affiliation__address">Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA</p><p class="c-article-author-affiliation__authors-list">Jonathan Casey</p></li><li id="Aff7"><p class="c-article-author-affiliation__address">Department of Medicine, University Health Network, Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada</p><p class="c-article-author-affiliation__authors-list">Lorenzo Del Sorbo &amp; Patrick R. Lawler</p></li><li id="Aff8"><p class="c-article-author-affiliation__address">Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada</p><p class="c-article-author-affiliation__authors-list">Patrick R. Lawler</p></li><li id="Aff9"><p class="c-article-author-affiliation__address">Division of Nephrology, Massachusetts General Hospital, Boston, MA, USA</p><p class="c-article-author-affiliation__authors-list">Meghan E. Sise</p></li></ol><div class="u-js-hide u-hide-print" data-test="author-info"><span class="c-article__sub-heading">Authors</span><ol class="c-article-authors-search u-list-reset"><li id="auth-Naoka-Murakami-Aff1-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Naoka Murakami</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Naoka%20Murakami" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in
                        <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Naoka%20Murakami" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Naoka%20Murakami%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Robert-Hayden-Aff1-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Robert Hayden</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Robert%20Hayden" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in
                        <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Robert%20Hayden" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Robert%20Hayden%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Thomas-Hills-Aff3-Aff4"><span class="c-article-authors-search__title u-h3 js-search-name">Thomas Hills</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Thomas%20Hills" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in
                        <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Thomas%20Hills" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Thomas%20Hills%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Hanny-Al_Samkari-Aff2-Aff5"><span class="c-article-authors-search__title u-h3 js-search-name">Hanny Al-Samkari</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Hanny%20Al-Samkari" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in
                        <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Hanny%20Al-Samkari" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Hanny%20Al-Samkari%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Jonathan-Casey-Aff6"><span class="c-article-authors-search__title u-h3 js-search-name">Jonathan Casey</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Jonathan%20Casey" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in
                        <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Jonathan%20Casey" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Jonathan%20Casey%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Lorenzo-Sorbo-Aff7"><span class="c-article-authors-search__title u-h3 js-search-name">Lorenzo Del Sorbo</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Lorenzo%20Del%20Sorbo" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in
                        <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Lorenzo%20Del%20Sorbo" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Lorenzo%20Del%20Sorbo%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Patrick_R_-Lawler-Aff7-Aff8"><span class="c-article-authors-search__title u-h3 js-search-name">Patrick R. Lawler</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Patrick%20R.%20Lawler" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in
                        <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Patrick%20R.%20Lawler" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Patrick%20R.%20Lawler%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Meghan_E_-Sise-Aff2-Aff9"><span class="c-article-authors-search__title u-h3 js-search-name">Meghan E. Sise</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Meghan%20E.%20Sise" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in
                        <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Meghan%20E.%20Sise" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Meghan%20E.%20Sise%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-David_E_-Leaf-Aff1-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">David E. Leaf</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=David%20E.%20Leaf" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in
                        <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=David%20E.%20Leaf" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22David%20E.%20Leaf%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li></ol></div><h3 class="c-article__sub-heading" id="contributions">Contributions</h3><p>All authors researched data for the article, made substantial contributions to discussions of the content and wrote, reviewed or edited the manuscript before submission.</p><h3 class="c-article__sub-heading" id="corresponding-author">Corresponding author</h3><p id="corresponding-author-list">Correspondence to
                <a id="corresp-c1" href="mailto:deleaf@bwh.harvard.edu">David E. Leaf</a>.</p></div></div></section><section data-title="Ethics declarations"><div class="c-article-section" id="ethics-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="ethics">Ethics declarations</h2><div class="c-article-section__content" id="ethics-content">
              
                <h3 class="c-article__sub-heading" id="FPar2">Competing interests</h3>
                <p>H.A.-S. reports no disclosures relevant to the manuscript; universal disclosures include consultancy (Agios, Dova/Sobi, argenx, Rigel, Novartis, Forma, Moderna) and research funding (Agios, Dova/Sobi, Amgen). P.R.L. is an investigator in the REMAP-CAP ACE2 RAS Domain, which is investigating renin–angiotensin–system-modulating treatments for COVID-19, is supported by a Heart and Stroke Foundation of Canada National New Investigator Award, and has received unrelated consulting honoraria from Novartis, CorEvitas, and Brigham and Women’s Hospital (Boston, MA, USA), as well as unrelated royalties from McGraw-Hill Publishing. L.D.S. is inventor of a patent licensed to SQI Diagnostic and has received unrelated research funding from the Canadian Institutes of Health Research. M.E.S. has received research funding from Gilead Sciences awarded to her institution; additional, unrelated disclosures include research funding from AbbVie, Merck, EMD-Serono, Angion and serving as a scientific advisory board member for Travere and Mallinckrodt. The other authors declare no competing interests.</p>
              
            </div></div></section><section data-title="Peer review"><div class="c-article-section" id="peer-review-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="peer-review">Peer review</h2><div class="c-article-section__content" id="peer-review-content">
              
              
                <h3 class="c-article__sub-heading" id="FPar1">Peer review information</h3>
                <p><i>Nature Reviews Nephrology</i> thanks L. Forni, R. Haynes and W. Karsan for their contribution to the peer review of this work.</p>
              
            </div></div></section><section data-title="Additional information"><div class="c-article-section" id="additional-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="additional-information">Additional information</h2><div class="c-article-section__content" id="additional-information-content"><p><b>Publisher’s note</b> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div></div></section><section data-title="Glossary"><div class="c-article-section" id="glossary-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="glossary">Glossary</h2><div class="c-article-section__content" id="glossary-content"><dl class="c-description-list"><dt class="c-description-list__term u-text-bold" id="Glos2">Pseudo-randomized study</dt><dd class="c-description-list__description u-pl-32">
                  <p>The use of naturally occurring variation in an exposure to identify its effect on an outcome of interest; also known as a natural experiment.</p>
                </dd><dt class="c-description-list__term u-text-bold" id="Glos1">Target trial emulation analyses</dt><dd class="c-description-list__description u-pl-32">
                  <p>The application of principles from randomized clinical trials to observational studies.</p>
                </dd></dl></div></div></section><section data-title="Rights and permissions"><div class="c-article-section" id="rightslink-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="rightslink">Rights and permissions</h2><div class="c-article-section__content" id="rightslink-content"><p>Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</p><p class="c-article-rights"><a data-track="click" data-track-action="view rights and permissions" data-track-label="link" href="https://s100.copyright.com/AppDispatchServlet?title=Therapeutic%20advances%20in%20COVID-19&amp;author=Naoka%20Murakami%20et%20al&amp;contentID=10.1038%2Fs41581-022-00642-4&amp;copyright=Springer%20Nature%20Limited&amp;publication=1759-5061&amp;publicationDate=2022-10-17&amp;publisherName=SpringerNature&amp;orderBeanReset=true">Reprints and permissions</a></p></div></div></section><section aria-labelledby="article-info" data-title="About this article"><div class="c-article-section" id="article-info-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="article-info">About this article</h2><div class="c-article-section__content" id="article-info-content"><div class="c-bibliographic-information"><div class="u-hide-print c-bibliographic-information__column c-bibliographic-information__column--border"><a data-crossmark="10.1038/s41581-022-00642-4" target="_blank" rel="noopener" href="https://crossmark.crossref.org/dialog/?doi=10.1038/s41581-022-00642-4" data-track="click" data-track-action="Click Crossmark" data-track-label="link" data-test="crossmark"><img loading="lazy" width="57" height="81" alt="Check for updates. Verify currency and authenticity via CrossMark" src="data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>"></a></div><div class="c-bibliographic-information__column"><h3 class="c-article__sub-heading" id="citeas">Cite this article</h3><p class="c-bibliographic-information__citation">Murakami, N., Hayden, R., Hills, T. <i>et al.</i> Therapeutic advances in COVID-19.
                    <i>Nat Rev Nephrol</i> <b>19</b>, 38–52 (2023). https://doi.org/10.1038/s41581-022-00642-4</p><p class="c-bibliographic-information__download-citation u-hide-print"><a data-test="citation-link" data-track="click" data-track-action="download article citation" data-track-label="link" data-track-external="" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41581-022-00642-4?format=refman&amp;flavour=citation">Download citation<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p><ul class="c-bibliographic-information__list" data-test="publication-history"><li class="c-bibliographic-information__list-item"><p>Accepted<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2022-09-21">21 September 2022</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Published<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2022-10-17">17 October 2022</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Issue Date<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2023-01">January 2023</time></span></p></li><li class="c-bibliographic-information__list-item c-bibliographic-information__list-item--full-width"><p><abbr title="Digital Object Identifier">DOI</abbr><span class="u-hide">: </span><span class="c-bibliographic-information__value">https://doi.org/10.1038/s41581-022-00642-4</span></p></li></ul><div data-component="share-box"><div class="c-article-share-box u-display-none" hidden=""><h3 class="c-article__sub-heading">Share this article</h3><p class="c-article-share-box__description">Anyone you share the following link with will be able to read this content:</p><button class="js-get-share-url c-article-share-box__button" type="button" id="get-share-url" data-track="click" data-track-label="button" data-track-external="" data-track-action="get shareable link">Get shareable link</button><div class="js-no-share-url-container u-display-none" hidden=""><p class="js-c-article-share-box__no-sharelink-info c-article-share-box__no-sharelink-info">Sorry, a shareable link is not currently available for this article.</p></div><div class="js-share-url-container u-display-none" hidden=""><p class="js-share-url c-article-share-box__only-read-input" id="share-url" data-track="click" data-track-label="button" data-track-action="select share url"></p><button class="js-copy-share-url c-article-share-box__button--link-like" type="button" id="copy-share-url" data-track="click" data-track-label="button" data-track-action="copy share url" data-track-external="">Copy to clipboard</button></div><p class="js-c-article-share-box__additional-info c-article-share-box__additional-info">
                            Provided by the Springer Nature SharedIt content-sharing initiative
                        </p></div></div><div data-component="article-info-list"></div></div></div></div></div></section>
            </div>

            
        <section>
            <div class="c-article-section js-article-section" id="further-reading-section">
                <h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="further-reading">This article is cited by</h2>
                <div class="c-article-section__content js-collapsible-section" id="further-reading-content">
                    <ul class="c-article-further-reading__list" id="further-reading-list">
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article"
                                       data-track-label="link:Habitual salt preference worsens blood pressure in hospitalized hypertensive patients with omicron infection under epidemic-related stress" href="https://doi.org/10.1186/s12889-023-17633-0">
                                        Habitual salt preference worsens blood pressure in hospitalized hypertensive patients with omicron infection under epidemic-related stress
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="c-author-list c-author-list--compact c-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Chenyi Wang</li><li>Wanhong Tan</li><li>Qiang Li</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>BMC Public Health</i> (2024)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article"
                                       data-track-label="link:Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge" href="https://doi.org/10.1038/s41598-024-56195-y">
                                        Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="c-author-list c-author-list--compact c-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Supavit Chesdachai</li><li>Christina G. Rivera</li><li>Raymund R. Razonable</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Scientific Reports</i> (2024)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article"
                                       data-track-label="link:Reply to ‘Use of convalescent plasma in the treatment of COVID-19’" href="https://doi.org/10.1038/s41581-023-00691-3">
                                        Reply to ‘Use of convalescent plasma in the treatment of COVID-19’
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="c-author-list c-author-list--compact c-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Naoka Murakami</li><li>Robert Hayden</li><li>David E. Leaf</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Nature Reviews Nephrology</i> (2023)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article"
                                       data-track-label="link:Use of convalescent plasma in the treatment of COVID-19" href="https://doi.org/10.1038/s41581-023-00690-4">
                                        Use of convalescent plasma in the treatment of COVID-19
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="c-author-list c-author-list--compact u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Michael J. Joyner</li><li>Nigel Paneth</li><li>Arturo Casadevall</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Nature Reviews Nephrology</i> (2023)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article"
                                       data-track-label="link:Epigenetic perspectives associated with COVID-19 infection and related cytokine storm: an updated review" href="https://doi.org/10.1007/s15010-023-02017-8">
                                        Epigenetic perspectives associated with COVID-19 infection and related cytokine storm: an updated review
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="c-author-list c-author-list--compact c-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Amit Dey</li><li>K. Vaishak</li><li>Antara Banerjee</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Infection</i> (2023)</p>
                            </li>
                        
                    </ul>
                </div>
            </div>
        </section>
    

            
        </div>
</article>
</main>

<aside class="c-article-extras u-hide-print" aria-label="Article navigation" data-component-reading-companion data-container-type="reading-companion" data-track-component="reading companion">
    <div class="js-context-bar-sticky-point-desktop">
        

        
            
                
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41581-022-00642-4.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="click" data-track-action="download pdf" data-track-label="link" data-track-external download>
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"/></svg>
            </a>
        </div>
    

            
        
    </div>

    
        
    

    
    
        <div class="c-article-associated-content__container">
            <section>
                <h2 class="c-article-associated-content__title u-mb-24">Associated content</h2>
                
                    
                        <div class="c-article-associated-content__collection series u-mb-24">
                            <section>
                                <p class="c-article-associated-content__collection-label u-sans-serif u-text-bold u-mb-8">Series</p>
                                <h3 class="c-article-associated-content__collection-title u-h3 u-mb-8">
                                    <a href="https://www.nature.com/collections/gggidgechf"
                                       class="u-link-inherit"
                                       data-track="click"
                                       data-track-action="view series"
                                       data-track-category="associated content"
                                       data-track-label="series"
                                       data-test="collection-link">COVID-19 and nephrology</a>
                                </h3>
                            </section>
                        </div>
                    
                    
                        <div class="u-full-height u-mb-24">
                            
    <article class="u-full-height c-card c-card--flush">
        <div class="c-card__layout u-full-height">
            <div class="c-card__body">
                <h3 class="c-card__title">
                    <a href="https://www.nature.com/articles/s41581-023-00690-4"
                       class="c-card__link u-link-inherit"
                       data-track="click"
                       data-track-action="view article"
                       data-track-category="associated content"
                       
                       data-track-label="correspondence">Use of convalescent plasma in the treatment of COVID-19</a>
                </h3>
                
<ul data-test="author-list" class="c-author-list c-author-list--compact">
    <li>Michael J. Joyner</li><li>Nigel Paneth</li><li>Arturo Casadevall</li>
</ul>

                
    <div class="c-card__section c-meta">
        
            <span class="c-meta__item">Nature Reviews Nephrology</span>
        
        <span class="c-meta__item" data-test="article.type"><span class="c-meta__type">Correspondence</span></span>
        
        
            <time class="c-meta__item" datetime="2023-02-17">17 Feb 2023</time>
        
    </div>

            </div>
        </div>
    </article>


                        </div>
                    
                        <div class="u-full-height u-mb-24">
                            
    <article class="u-full-height c-card c-card--flush">
        <div class="c-card__layout u-full-height">
            <div class="c-card__body">
                <h3 class="c-card__title">
                    <a href="https://www.nature.com/articles/s41581-023-00691-3"
                       class="c-card__link u-link-inherit"
                       data-track="click"
                       data-track-action="view article"
                       data-track-category="associated content"
                       
                       data-track-label="correspondence">Reply to ‘Use of convalescent plasma in the treatment of COVID-19’</a>
                </h3>
                
<ul data-test="author-list" class="c-author-list c-author-list--compact c-author-list--truncated">
    <li>Naoka Murakami</li><li>Robert Hayden</li><li>David E. Leaf</li>
</ul>

                
    <div class="c-card__section c-meta">
        
            <span class="c-meta__item">Nature Reviews Nephrology</span>
        
        <span class="c-meta__item" data-test="article.type"><span class="c-meta__type">Correspondence</span></span>
        
        
            <time class="c-meta__item" datetime="2023-02-17">17 Feb 2023</time>
        
    </div>

            </div>
        </div>
    </article>


                        </div>
                    
                
            </section>
        </div>
        <script>
            window.dataLayer = window.dataLayer || [];
            window.dataLayer[0] = window.dataLayer[0] || {};
            window.dataLayer[0].content = window.dataLayer[0].content || {};
            window.dataLayer[0].content.associatedContentTypes = "series;correspondence;correspondence;";
        </script>
    

    

    <div class="c-reading-companion">
        <div class="c-reading-companion__sticky" data-component="reading-companion-sticky" data-test="reading-companion-sticky">
            <div class="c-reading-companion__panel c-reading-companion__sections c-reading-companion__panel--active" id="tabpanel-sections">
                <div class="u-lazy-ad-wrapper u-mt-16 u-hide" data-component-mpu>
                    <div class="c-ad c-ad--300x250">
                        <div class="c-ad__inner">
                            <p class="c-ad__label">Advertisement</p>
                            
    <div id="div-gpt-ad-right-2"
         class="div-gpt-ad advert medium-rectangle js-ad text-center hide-print grade-c-hide"
         data-ad-type="right"
         data-test="right-ad"
         data-pa11y-ignore
         data-gpt
         data-gpt-unitpath="/285/naturereviews.nephrology/article"
         data-gpt-sizes="300x250"
         data-gpt-targeting="type=article;pos=right;artid=s41581-022-00642-4;doi=10.1038/s41581-022-00642-4;subjmeta=104,1436,1585,1586,2185,326,402,4022,4130,545,565,576,596,631,692,700;kwrd=End-stage+renal+disease,Molecularly+targeted+therapy,Organ+transplantation,SARS-CoV-2">
        <noscript>
            <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/285/naturereviews.nephrology/article&amp;sz=300x250&amp;c=-2038039283&amp;t=pos%3Dright%26type%3Darticle%26artid%3Ds41581-022-00642-4%26doi%3D10.1038/s41581-022-00642-4%26subjmeta%3D104,1436,1585,1586,2185,326,402,4022,4130,545,565,576,596,631,692,700%26kwrd%3DEnd-stage+renal+disease,Molecularly+targeted+therapy,Organ+transplantation,SARS-CoV-2">
                <img data-test="gpt-advert-fallback-img"
                     src="//pubads.g.doubleclick.net/gampad/ad?iu=/285/naturereviews.nephrology/article&amp;sz=300x250&amp;c=-2038039283&amp;t=pos%3Dright%26type%3Darticle%26artid%3Ds41581-022-00642-4%26doi%3D10.1038/s41581-022-00642-4%26subjmeta%3D104,1436,1585,1586,2185,326,402,4022,4130,545,565,576,596,631,692,700%26kwrd%3DEnd-stage+renal+disease,Molecularly+targeted+therapy,Organ+transplantation,SARS-CoV-2"
                     alt="Advertisement"
                     width="300"
                     height="250"></a>
        </noscript>
    </div>

                        </div>
                    </div>
                </div>
            </div>
            <div class="c-reading-companion__panel c-reading-companion__figures c-reading-companion__panel--full-width" id="tabpanel-figures"></div>
            <div class="c-reading-companion__panel c-reading-companion__references c-reading-companion__panel--full-width" id="tabpanel-references"></div>
        </div>
    </div>
</aside>
</div>


    
        <nav class="c-header__dropdown" aria-labelledby="Explore-content" data-test="Explore-content" id="explore" data-track-component="nature-150-split-header">
            <div class="c-header__container">
                <h2 id="Explore-content" class="c-header__heading c-header__heading--js-hide">Explore content</h2>
                <ul class="c-header__list c-header__list--js-stack">
                    
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nrneph/research-articles"
                                   data-track="click"
                                   data-track-action="research articles"
                                   data-track-label="link"
                                   data-test="explore-nav-item">
                                    Research articles
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nrneph/reviews-and-analysis"
                                   data-track="click"
                                   data-track-action="reviews &amp; analysis"
                                   data-track-label="link"
                                   data-test="explore-nav-item">
                                    Reviews &amp; Analysis
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nrneph/news-and-comment"
                                   data-track="click"
                                   data-track-action="news &amp; comment"
                                   data-track-label="link"
                                   data-test="explore-nav-item">
                                    News &amp; Comment
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nrneph/current-issue"
                                   data-track="click"
                                   data-track-action="current issue"
                                   data-track-label="link"
                                   data-test="explore-nav-item">
                                    Current issue
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nrneph/collections"
                                   data-track="click"
                                   data-track-action="collections"
                                   data-track-label="link"
                                   data-test="explore-nav-item">
                                    Collections
                                </a>
                            </li>
                        
                    
                </ul>
                <ul class="c-header__list c-header__list--js-stack">
                    
                        <li class="c-header__item">
                            <a class="c-header__link"
                               href="https://www.facebook.com/NatureReviews"
                               data-track="click"
                               data-track-action="facebook"
                               data-track-label="link">Follow us on Facebook
                            </a>
                        </li>
                    
                    
                        <li class="c-header__item">
                            <a class="c-header__link"
                               href="https://twitter.com/NatRevNeph"
                               data-track="click"
                               data-track-action="twitter"
                               data-track-label="link">Follow us on Twitter
                            </a>
                        </li>
                    
                    
                    
                        <li class="c-header__item c-header__item--hide-lg">
                            <a class="c-header__link"
                               href="https://www.nature.com/my-account/alerts/subscribe-journal?list-id&#x3D;110"
                               rel="nofollow"
                               data-track="click"
                               data-track-action="Sign up for alerts"
                               data-track-external
                               data-track-label="link (mobile dropdown)">Sign up for alerts<svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill="#fff"/></svg>
                            </a>
                        </li>
                    
                    
                        <li class="c-header__item c-header__item--hide-lg">
                            <a class="c-header__link"
                               href="https://www.nature.com/nrneph.rss"
                               data-track="click"
                               data-track-action="rss feed"
                               data-track-label="link">
                                <span>RSS feed</span>
                            </a>
                        </li>
                    
                </ul>
            </div>
        </nav>
    
    
        
            <nav class="c-header__dropdown" aria-labelledby="About-the-journal" id="about-the-journal" data-test="about-the-journal" data-track-component="nature-150-split-header">
                <div class="c-header__container">
                    <h2 id="About-the-journal" class="c-header__heading c-header__heading--js-hide">About the journal</h2>
                    <ul class="c-header__list c-header__list--js-stack">
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nrneph/aims"
                                   data-track="click"
                                   data-track-action="aims &amp; scope"
                                   data-track-label="link">
                                    Aims &amp; Scope
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nrneph/journal-information"
                                   data-track="click"
                                   data-track-action="journal information"
                                   data-track-label="link">
                                    Journal Information
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nrneph/editors"
                                   data-track="click"
                                   data-track-action="about the editors"
                                   data-track-label="link">
                                    About the Editors
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nrneph/journal-credits"
                                   data-track="click"
                                   data-track-action="journal credits"
                                   data-track-label="link">
                                    Journal Credits
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nrneph/editorial-input-and-checks"
                                   data-track="click"
                                   data-track-action="editorial input and checks"
                                   data-track-label="link">
                                    Editorial input and checks
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nrneph/editorial-values-statement"
                                   data-track="click"
                                   data-track-action="editorial values statement"
                                   data-track-label="link">
                                    Editorial Values Statement
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nrneph/journal-impact"
                                   data-track="click"
                                   data-track-action="journal metrics"
                                   data-track-label="link">
                                    Journal Metrics
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nrneph/publishing-model"
                                   data-track="click"
                                   data-track-action="publishing model"
                                   data-track-label="link">
                                    Publishing model
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nrneph/editorial-policies"
                                   data-track="click"
                                   data-track-action="editorial policies"
                                   data-track-label="link">
                                    Editorial policies
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nrneph/web-feeds"
                                   data-track="click"
                                   data-track-action="web feeds"
                                   data-track-label="link">
                                    Web Feeds
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nrneph/posters"
                                   data-track="click"
                                   data-track-action="posters"
                                   data-track-label="link">
                                    Posters
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nrneph/contact"
                                   data-track="click"
                                   data-track-action="contact"
                                   data-track-label="link">
                                    Contact
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nrneph/reviews-cross-journal-editorial-team"
                                   data-track="click"
                                   data-track-action="reviews cross-journal editorial team"
                                   data-track-label="link">
                                    Reviews Cross-Journal Editorial Team
                                </a>
                            </li>
                        
                    </ul>
                </div>
            </nav>
        

        
            <nav class="c-header__dropdown" aria-labelledby="Publish-with-us-label" id="publish-with-us" data-test="publish-with-us" data-track-component="nature-150-split-header">
                <div class="c-header__container">
                    <h2 id="Publish-with-us-label" class="c-header__heading c-header__heading--js-hide">Publish with us</h2>
                    <ul class="c-header__list c-header__list--js-stack">
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nrneph/for-authors"
                                   data-track="click"
                                   data-track-action="for authors"
                                   data-track-label="link">
                                    For Authors
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nrneph/for-referees"
                                   data-track="click"
                                   data-track-action="for referees"
                                   data-track-label="link">
                                    For Referees
                                </a>
                            </li>
                        
                        
                        
                            <li class="c-header__item c-header__item--keyline">
                                <a class="c-header__link"
                                   href="https://mts-nrneph.nature.com/cgi-bin/main.plex"
                                   data-track="click"
                                   data-track-action="submit manuscript"
                                   data-track-label="link (publish with us dropdown menu)"
                                   data-track-external>Submit manuscript<svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m15 0c1.1045695 0 2 .8954305 2 2v5.5c0 .27614237-.2238576.5-.5.5s-.5-.22385763-.5-.5v-5.5c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-9v3c0 1.1045695-.8954305 2-2 2h-3v10c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h7.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-7.5c-1.1045695 0-2-.8954305-2-2v-10.17157288c0-.53043297.21071368-1.0391408.58578644-1.41421356l3.82842712-3.82842712c.37507276-.37507276.88378059-.58578644 1.41421356-.58578644zm-.5442863 8.18867991 3.3545404 3.35454039c.2508994.2508994.2538696.6596433.0035959.909917-.2429543.2429542-.6561449.2462671-.9065387-.0089489l-2.2609825-2.3045251.0010427 7.2231989c0 .3569916-.2898381.6371378-.6473715.6371378-.3470771 0-.6473715-.2852563-.6473715-.6371378l-.0010428-7.2231995-2.2611222 2.3046654c-.2531661.2580415-.6562868.2592444-.9065605.0089707-.24295423-.2429542-.24865597-.6576651.0036132-.9099343l3.3546673-3.35466731c.2509089-.25090888.6612706-.25227691.9135302-.00001728zm-.9557137-3.18867991c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm-8.5-3.587-3.587 3.587h2.587c.55228475 0 1-.44771525 1-1zm8.5 1.587c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill="#fff"/></svg>
                                </a>
                            </li>
                        
                    </ul>
                </div>
            </nav>
        
    


<div id="search-menu" class="c-header__dropdown c-header__dropdown--full-width" data-track-component="nature-150-split-header">
    <div class="c-header__container">
        <h2 class="c-header__visually-hidden">Search</h2>
        <form class="c-header__search-form" action="/search" method="get" role="search" autocomplete="off" data-test="inline-search">
            <label class="c-header__heading" for="keywords">Search articles by subject, keyword or author</label>
            <div class="c-header__search-layout c-header__search-layout--max-width">
                <div>
                    <input type="text" required="" class="c-header__input" id="keywords" name="q" value="">
                </div>
                <div class="c-header__search-layout">
                    <div>
                        <label for="results-from" class="c-header__visually-hidden">Show results from</label>
                        <select id="results-from" name="journal" class="c-header__select">
                            
                                
                                    <option value="" selected>All journals</option>
                                    <option value="nrneph">This journal</option>
                                
                            
                        </select>
                    </div>
                    <div>
                        <button type="submit" class="c-header__search-button">Search</button>
                    </div>
                </div>

            </div>
        </form>

        <div class="c-header__flush">
            <a class="c-header__link" href="/search/advanced"
               data-track="click" data-track-action="advanced search" data-track-label="link">
                Advanced search
            </a>
        </div>

        <h3 class="c-header__heading c-header__heading--keyline">Quick links</h3>
        <ul class="c-header__list">
            <li><a class="c-header__link" href="/subjects" data-track="click" data-track-action="explore articles by subject" data-track-label="link">Explore articles by subject</a></li>
            <li><a class="c-header__link" href="/naturecareers" data-track="click" data-track-action="find a job" data-track-label="link">Find a job</a></li>
            <li><a class="c-header__link" href="/authors/index.html" data-track="click" data-track-action="guide to authors" data-track-label="link">Guide to authors</a></li>
            <li><a class="c-header__link" href="/authors/editorial_policies/" data-track="click" data-track-action="editorial policies" data-track-label="link">Editorial policies</a></li>
        </ul>
    </div>
</div>

<footer class="composite-layer" itemscope itemtype="http://schema.org/Periodical">
        <meta itemprop="publisher" content="Springer Nature">
        

        <div class="u-mt-16 u-mb-16">
    <div class="u-container">
        <div class="u-display-flex u-flex-wrap u-justify-content-space-between">
            

            <p class="c-meta u-ma-0 u-flex-shrink">
                <span class="c-meta__item">
                    Nature Reviews Nephrology (<i>Nat Rev Nephrol</i>)
                </span>
                
    
    <span class="c-meta__item">
        <abbr title="International Standard Serial Number">ISSN</abbr> <span itemprop="onlineIssn">1759-507X</span> (online)
    </span>
    


                
    
    <span class="c-meta__item">
        <abbr title="International Standard Serial Number">ISSN</abbr> <span itemprop="printIssn">1759-5061</span> (print)
    </span>
    

            </p>
        </div>
    </div>
</div>

    <div class="c-footer">
        <div class="u-hide-print" data-track-component="footer">
    <h2 class="u-visually-hidden">nature.com sitemap</h2>
    <div class="c-footer__container">
        <div class="c-footer__grid c-footer__group--separator">
            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">About Nature Portfolio</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://www.nature.com/npg_/company_info/index.html"
                                                  data-track="click" data-track-action="about us"
                                                  data-track-label="link">About us</a></li>
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://www.nature.com/npg_/press_room/press_releases.html"
                                                  data-track="click" data-track-action="press releases"
                                                  data-track-label="link">Press releases</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://press.nature.com/"
                                                  data-track="click" data-track-action="press office"
                                                  data-track-label="link">Press office</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://support.nature.com/support/home"
                                                  data-track="click" data-track-action="contact us"
                                                  data-track-label="link">Contact us</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Discover content</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/siteindex"
                                                  data-track="click" data-track-action="journals a-z"
                                                  data-track-label="link">Journals A-Z</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/subjects"
                                                  data-track="click" data-track-action="article by subject"
                                                  data-track-label="link">Articles by subject</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/protocolexchange/"
                                                  data-track="click" data-track-action="protocol exchange"
                                                  data-track-label="link">Protocol Exchange</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.natureindex.com/"
                                                  data-track="click" data-track-action="nature index"
                                                  data-track-label="link">Nature Index</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Publishing policies</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://www.nature.com/authors/editorial_policies"
                                                  data-track="click" data-track-action="Nature portfolio policies"
                                                  data-track-label="link">Nature portfolio policies</a></li>
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://www.nature.com/nature-research/open-access"
                                                  data-track="click" data-track-action="open access"
                                                  data-track-label="link">Open access</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Author &amp; Researcher services</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/reprints"
                                                  data-track="click" data-track-action="reprints and permissions"
                                                  data-track-label="link">Reprints &amp; permissions</a></li>
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://www.springernature.com/gp/authors/research-data"
                                                  data-track="click" data-track-action="data research service"
                                                  data-track-label="link">Research data</a></li>
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://authorservices.springernature.com/language-editing/"
                                                  data-track="click" data-track-action="language editing"
                                                  data-track-label="link">Language editing</a></li>
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://authorservices.springernature.com/scientific-editing/"
                                                  data-track="click" data-track-action="scientific editing"
                                                  data-track-label="link">Scientific editing</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://masterclasses.nature.com/"
                                                  data-track="click" data-track-action="nature masterclasses"
                                                  data-track-label="link">Nature Masterclasses</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://solutions.springernature.com/"
                                                  data-track="click" data-track-action="research solutions"
                                                  data-track-label="link">Research Solutions</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Libraries &amp; institutions</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://www.springernature.com/gp/librarians/tools-services"
                                                  data-track="click" data-track-action="librarian service and tools"
                                                  data-track-label="link">Librarian service &amp; tools</a></li>
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://www.springernature.com/gp/librarians/manage-your-account/librarianportal"
                                                  data-track="click" data-track-action="librarian portal"
                                                  data-track-label="link">Librarian portal</a></li>
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://www.nature.com/openresearch/about-open-access/information-for-institutions"
                                                  data-track="click" data-track-action="open research"
                                                  data-track-label="link">Open research</a></li>
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://www.springernature.com/gp/librarians/recommend-to-your-library"
                                                  data-track="click" data-track-action="Recommend to library"
                                                  data-track-label="link">Recommend to library</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Advertising &amp; partnerships</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://partnerships.nature.com/product/digital-advertising/"
                                                  data-track="click" data-track-action="advertising"
                                                  data-track-label="link">Advertising</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/"
                                                  data-track="click" data-track-action="partnerships and services"
                                                  data-track-label="link">Partnerships &amp; Services</a></li>
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://partnerships.nature.com/media-kits/" data-track="click"
                                                  data-track-action="media kits" data-track-label="link">Media kits</a>
                    </li>
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://partnerships.nature.com/product/branded-content-native-advertising/"
                                                  data-track-action="branded content" data-track-label="link">Branded
                        content</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Professional development</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/naturecareers/"
                                                  data-track="click" data-track-action="nature careers"
                                                  data-track-label="link">Nature Careers</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://conferences.nature.com"
                                                  data-track="click" data-track-action="nature conferences"
                                                  data-track-label="link">Nature<span class="u-visually-hidden"> </span>
                        Conferences</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Regional websites</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/natafrica"
                                                  data-track="click" data-track-action="nature africa"
                                                  data-track-label="link">Nature Africa</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="http://www.naturechina.com"
                                                  data-track="click" data-track-action="nature china"
                                                  data-track-label="link">Nature China</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nindia"
                                                  data-track="click" data-track-action="nature india"
                                                  data-track-label="link">Nature India</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/natitaly"
                                                  data-track="click" data-track-action="nature Italy"
                                                  data-track-label="link">Nature Italy</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.natureasia.com/ja-jp"
                                                  data-track="click" data-track-action="nature japan"
                                                  data-track-label="link">Nature Japan</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.natureasia.com/ko-kr"
                                                  data-track="click" data-track-action="nature korea"
                                                  data-track-label="link">Nature Korea</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nmiddleeast"
                                                  data-track="click" data-track-action="nature middle east"
                                                  data-track-label="link">Nature Middle East</a></li>
                </ul>
            </div>

        </div>
    </div>
    <div class="c-footer__container">
        <ul class="c-footer__links">
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/privacy"
                                          data-track="click" data-track-action="privacy policy" data-track-label="link">Privacy
                Policy</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/cookies"
                                          data-track="click" data-track-action="use of cookies" data-track-label="link">Use
                of cookies</a></li>
            <li class="c-footer__item">
                <button class="optanon-toggle-display c-footer__link" onclick="javascript:;"
                        data-cc-action="preferences" data-track="click" data-track-action="manage cookies"
                        data-track-label="link">Your privacy choices/Manage cookies
                </button>
            </li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/legal-notice"
                                          data-track="click" data-track-action="legal notice" data-track-label="link">Legal
                notice</a></li>
            <li class="c-footer__item"><a class="c-footer__link"
                                          href="https://www.nature.com/info/accessibility-statement" data-track="click"
                                          data-track-action="accessibility statement" data-track-label="link">Accessibility
                statement</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/terms-and-conditions"
                                          data-track="click" data-track-action="terms and conditions"
                                          data-track-label="link">Terms &amp; Conditions</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/ccpa"
                                          data-track="click" data-track-action="california privacy statement"
                                          data-track-label="link">Your US state privacy rights</a></li>
            
        </ul>
    </div>
</div>


        <div class="c-footer__container">
    <a href="https://www.springernature.com/" class="c-footer__link">
        <img src="/static/images/logos/sn-logo-white-ea63208b81.svg" alt="Springer Nature" loading="lazy" width="200" height="20"/>
    </a>
    <p class="c-footer__legal" data-test="copyright">&copy; 2024 Springer Nature Limited</p>
</div>

    </div>
    <div class="u-visually-hidden" aria-hidden="true">
    
    <?xml version="1.0" encoding="UTF-8"?><!DOCTYPE svg PUBLIC "-//W3C//DTD SVG 1.1//EN" "http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><defs><path id="a" d="M0 .74h56.72v55.24H0z"/></defs><symbol id="icon-access" viewBox="0 0 18 18"><path d="m14 8c.5522847 0 1 .44771525 1 1v7h2.5c.2761424 0 .5.2238576.5.5v1.5h-18v-1.5c0-.2761424.22385763-.5.5-.5h2.5v-7c0-.55228475.44771525-1 1-1s1 .44771525 1 1v6.9996556h8v-6.9996556c0-.55228475.4477153-1 1-1zm-8 0 2 1v5l-2 1zm6 0v7l-2-1v-5zm-2.42653766-7.59857636 7.03554716 4.92488299c.4162533.29137735.5174853.86502537.226108 1.28127873-.1721584.24594054-.4534847.39241464-.7536934.39241464h-14.16284822c-.50810197 0-.92-.41189803-.92-.92 0-.30020869.1464741-.58153499.39241464-.75369337l7.03554714-4.92488299c.34432015-.2410241.80260453-.2410241 1.14692468 0zm-.57346234 2.03988748-3.65526982 2.55868888h7.31053962z" fill-rule="evenodd"/></symbol><symbol id="icon-account" viewBox="0 0 18 18"><path d="m10.2379028 16.9048051c1.3083556-.2032362 2.5118471-.7235183 3.5294683-1.4798399-.8731327-2.5141501-2.0638925-3.935978-3.7673711-4.3188248v-1.27684611c1.1651924-.41183641 2-1.52307546 2-2.82929429 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.30621883.83480763 2.41745788 2 2.82929429v1.27684611c-1.70347856.3828468-2.89423845 1.8046747-3.76737114 4.3188248 1.01762123.7563216 2.22111275 1.2766037 3.52946833 1.4798399.40563808.0629726.81921174.0951949 1.23790281.0951949s.83226473-.0322223 1.2379028-.0951949zm4.3421782-2.1721994c1.4927655-1.4532925 2.419919-3.484675 2.419919-5.7326057 0-4.418278-3.581722-8-8-8s-8 3.581722-8 8c0 2.2479307.92715352 4.2793132 2.41991895 5.7326057.75688473-2.0164459 1.83949951-3.6071894 3.48926591-4.3218837-1.14534283-.70360829-1.90918486-1.96796271-1.90918486-3.410722 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.44275929-.763842 2.70711371-1.9091849 3.410722 1.6497664.7146943 2.7323812 2.3054378 3.4892659 4.3218837zm-5.580081 3.2673943c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"/></symbol><symbol id="icon-alert" viewBox="0 0 18 18"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-broad" viewBox="0 0 16 16"><path d="m6.10307866 2.97190702v7.69043288l2.44965196-2.44676915c.38776071-.38730439 1.0088052-.39493524 1.38498697-.01919617.38609051.38563612.38643641 1.01053024-.00013864 1.39665039l-4.12239817 4.11754683c-.38616704.3857126-1.01187344.3861062-1.39846576-.0000311l-4.12258206-4.11773056c-.38618426-.38572979-.39254614-1.00476697-.01636437-1.38050605.38609047-.38563611 1.01018509-.38751562 1.4012233.00306241l2.44985644 2.4469734v-8.67638639c0-.54139983.43698413-.98042709.98493125-.98159081l7.89910522-.0043627c.5451687 0 .9871152.44142642.9871152.98595351s-.4419465.98595351-.9871152.98595351z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 14 15)"/></symbol><symbol id="icon-arrow-down" viewBox="0 0 16 16"><path d="m3.28337502 11.5302405 4.03074001 4.176208c.37758093.3912076.98937525.3916069 1.367372-.0000316l4.03091977-4.1763942c.3775978-.3912252.3838182-1.0190815.0160006-1.4001736-.3775061-.39113013-.9877245-.39303641-1.3700683.003106l-2.39538585 2.4818345v-11.6147896l-.00649339-.11662112c-.055753-.49733869-.46370161-.88337888-.95867408-.88337888-.49497246 0-.90292107.38604019-.95867408.88337888l-.00649338.11662112v11.6147896l-2.39518594-2.4816273c-.37913917-.39282218-.98637524-.40056175-1.35419292-.0194697-.37750607.3911302-.37784433 1.0249269.00013556 1.4165479z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-left" viewBox="0 0 16 16"><path d="m4.46975946 3.28337502-4.17620792 4.03074001c-.39120768.37758093-.39160691.98937525.0000316 1.367372l4.1763942 4.03091977c.39122514.3775978 1.01908149.3838182 1.40017357.0160006.39113012-.3775061.3930364-.9877245-.00310603-1.3700683l-2.48183446-2.39538585h11.61478958l.1166211-.00649339c.4973387-.055753.8833789-.46370161.8833789-.95867408 0-.49497246-.3860402-.90292107-.8833789-.95867408l-.1166211-.00649338h-11.61478958l2.4816273-2.39518594c.39282216-.37913917.40056173-.98637524.01946965-1.35419292-.39113012-.37750607-1.02492687-.37784433-1.41654791.00013556z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-right" viewBox="0 0 16 16"><path d="m11.5302405 12.716625 4.176208-4.03074003c.3912076-.37758093.3916069-.98937525-.0000316-1.367372l-4.1763942-4.03091981c-.3912252-.37759778-1.0190815-.38381821-1.4001736-.01600053-.39113013.37750607-.39303641.98772445.003106 1.37006824l2.4818345 2.39538588h-11.6147896l-.11662112.00649339c-.49733869.055753-.88337888.46370161-.88337888.95867408 0 .49497246.38604019.90292107.88337888.95867408l.11662112.00649338h11.6147896l-2.4816273 2.39518592c-.39282218.3791392-.40056175.9863753-.0194697 1.3541929.3911302.3775061 1.0249269.3778444 1.4165479-.0001355z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-sub" viewBox="0 0 16 16"><path d="m7.89692134 4.97190702v7.69043288l-2.44965196-2.4467692c-.38776071-.38730434-1.0088052-.39493519-1.38498697-.0191961-.38609047.3856361-.38643643 1.0105302.00013864 1.3966504l4.12239817 4.1175468c.38616704.3857126 1.01187344.3861062 1.39846576-.0000311l4.12258202-4.1177306c.3861843-.3857298.3925462-1.0047669.0163644-1.380506-.3860905-.38563612-1.0101851-.38751563-1.4012233.0030624l-2.44985643 2.4469734v-8.67638639c0-.54139983-.43698413-.98042709-.98493125-.98159081l-7.89910525-.0043627c-.54516866 0-.98711517.44142642-.98711517.98595351s.44194651.98595351.98711517.98595351z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-up" viewBox="0 0 16 16"><path d="m12.716625 4.46975946-4.03074003-4.17620792c-.37758093-.39120768-.98937525-.39160691-1.367372.0000316l-4.03091981 4.1763942c-.37759778.39122514-.38381821 1.01908149-.01600053 1.40017357.37750607.39113012.98772445.3930364 1.37006824-.00310603l2.39538588-2.48183446v11.61478958l.00649339.1166211c.055753.4973387.46370161.8833789.95867408.8833789.49497246 0 .90292107-.3860402.95867408-.8833789l.00649338-.1166211v-11.61478958l2.39518592 2.4816273c.3791392.39282216.9863753.40056173 1.3541929.01946965.3775061-.39113012.3778444-1.02492687-.0001355-1.41654791z" fill-rule="evenodd"/></symbol><symbol id="icon-article" viewBox="0 0 18 18"><path d="m13 15v-12.9906311c0-.0073595-.0019884-.0093689.0014977-.0093689l-11.00158888.00087166v13.00506804c0 .5482678.44615281.9940603.99415146.9940603h10.27350412c-.1701701-.2941734-.2675644-.6357129-.2675644-1zm-12 .0059397v-13.00506804c0-.5562408.44704472-1.00087166.99850233-1.00087166h11.00299537c.5510129 0 .9985023.45190985.9985023 1.0093689v2.9906311h3v9.9914698c0 1.1065798-.8927712 2.0085302-1.9940603 2.0085302h-12.01187942c-1.09954652 0-1.99406028-.8927712-1.99406028-1.9940603zm13-9.0059397v9c0 .5522847.4477153 1 1 1s1-.4477153 1-1v-9zm-10-2h7v4h-7zm1 1v2h5v-2zm-1 4h7v1h-7zm0 2h7v1h-7zm0 2h7v1h-7z" fill-rule="evenodd"/></symbol><symbol id="icon-audio" viewBox="0 0 18 18"><path d="m13.0957477 13.5588459c-.195279.1937043-.5119137.193729-.7072234.0000551-.1953098-.193674-.1953346-.5077061-.0000556-.7014104 1.0251004-1.0168342 1.6108711-2.3905226 1.6108711-3.85745208 0-1.46604976-.5850634-2.83898246-1.6090736-3.85566829-.1951894-.19379323-.1950192-.50782531.0003802-.70141028.1953993-.19358497.512034-.19341614.7072234.00037709 1.2094886 1.20083761 1.901635 2.8250555 1.901635 4.55670148 0 1.73268608-.6929822 3.35779608-1.9037571 4.55880738zm2.1233994 2.1025159c-.195234.193749-.5118687.1938462-.7072235.0002171-.1953548-.1936292-.1954528-.5076613-.0002189-.7014104 1.5832215-1.5711805 2.4881302-3.6939808 2.4881302-5.96012998 0-2.26581266-.9046382-4.3883241-2.487443-5.95944795-.1952117-.19377107-.1950777-.50780316.0002993-.70141031s.5120117-.19347426.7072234.00029682c1.7683321 1.75528196 2.7800854 4.12911258 2.7800854 6.66056144 0 2.53182498-1.0120556 4.90597838-2.7808529 6.66132328zm-14.21898205-3.6854911c-.5523759 0-1.00016505-.4441085-1.00016505-.991944v-3.96777631c0-.54783558.44778915-.99194407 1.00016505-.99194407h2.0003301l5.41965617-3.8393633c.44948677-.31842296 1.07413994-.21516983 1.39520191.23062232.12116339.16823446.18629727.36981184.18629727.57655577v12.01603479c0 .5478356-.44778914.9919441-1.00016505.9919441-.20845738 0-.41170538-.0645985-.58133413-.184766l-5.41965617-3.8393633zm0-.991944h2.32084805l5.68047235 4.0241292v-12.01603479l-5.68047235 4.02412928h-2.32084805z" fill-rule="evenodd"/></symbol><symbol id="icon-block" viewBox="0 0 24 24"><path d="m0 0h24v24h-24z" fill-rule="evenodd"/></symbol><symbol id="icon-book" viewBox="0 0 18 18"><path d="m4 13v-11h1v11h11v-11h-13c-.55228475 0-1 .44771525-1 1v10.2675644c.29417337-.1701701.63571286-.2675644 1-.2675644zm12 1h-13c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1h13zm0 3h-13c-1.1045695 0-2-.8954305-2-2v-12c0-1.1045695.8954305-2 2-2h13c.5522847 0 1 .44771525 1 1v14c0 .5522847-.4477153 1-1 1zm-8.5-13h6c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1 2h4c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-4c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"/></symbol><symbol id="icon-broad" viewBox="0 0 24 24"><path d="m9.18274226 7.81v7.7999954l2.48162734-2.4816273c.3928221-.3928221 1.0219731-.4005617 1.4030652-.0194696.3911301.3911301.3914806 1.0249268-.0001404 1.4165479l-4.17620796 4.1762079c-.39120769.3912077-1.02508144.3916069-1.41671995-.0000316l-4.1763942-4.1763942c-.39122514-.3912251-.39767006-1.0190815-.01657798-1.4001736.39113012-.3911301 1.02337106-.3930364 1.41951349.0031061l2.48183446 2.4818344v-8.7999954c0-.54911294.4426881-.99439484.99778758-.99557515l8.00221246-.00442485c.5522847 0 1 .44771525 1 1s-.4477153 1-1 1z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 20.182742 24.805206)"/></symbol><symbol id="icon-calendar" viewBox="0 0 18 18"><path d="m12.5 0c.2761424 0 .5.21505737.5.49047852v.50952148h2c1.1072288 0 2 .89451376 2 2v12c0 1.1072288-.8945138 2-2 2h-12c-1.1072288 0-2-.8945138-2-2v-12c0-1.1072288.89451376-2 2-2h1v1h-1c-.55393837 0-1 .44579254-1 1v3h14v-3c0-.55393837-.4457925-1-1-1h-2v1.50952148c0 .27088381-.2319336.49047852-.5.49047852-.2761424 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.2319336-.49047852.5-.49047852zm3.5 7h-14v8c0 .5539384.44579254 1 1 1h12c.5539384 0 1-.4457925 1-1zm-11 6v1h-1v-1zm3 0v1h-1v-1zm3 0v1h-1v-1zm-6-2v1h-1v-1zm3 0v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-3-2v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-5.5-9c.27614237 0 .5.21505737.5.49047852v.50952148h5v1h-5v1.50952148c0 .27088381-.23193359.49047852-.5.49047852-.27614237 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.23193359-.49047852.5-.49047852z" fill-rule="evenodd"/></symbol><symbol id="icon-cart" viewBox="0 0 18 18"><path d="m5 14c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm10 0c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm-10 1c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1 1-.4477153 1-1-.44771525-1-1-1zm10 0c-.5522847 0-1 .4477153-1 1s.4477153 1 1 1 1-.4477153 1-1-.4477153-1-1-1zm-12.82032249-15c.47691417 0 .88746157.33678127.98070211.80449199l.23823144 1.19501025 13.36277974.00045554c.5522847.00001882.9999659.44774934.9999659 1.00004222 0 .07084994-.0075361.14150708-.022474.2107727l-1.2908094 5.98534344c-.1007861.46742419-.5432548.80388386-1.0571651.80388386h-10.24805106c-.59173366 0-1.07142857.4477153-1.07142857 1 0 .5128358.41361449.9355072.94647737.9932723l.1249512.0067277h10.35933776c.2749512 0 .4979349.2228539.4979349.4978051 0 .2749417-.2227336.4978951-.4976753.4980063l-10.35959736.0041886c-1.18346732 0-2.14285714-.8954305-2.14285714-2 0-.6625717.34520317-1.24989198.87690425-1.61383592l-1.63768102-8.19004794c-.01312273-.06561364-.01950005-.131011-.0196107-.19547395l-1.71961253-.00064219c-.27614237 0-.5-.22385762-.5-.5 0-.27614237.22385763-.5.5-.5zm14.53193359 2.99950224h-13.11300004l1.20580469 6.02530174c.11024034-.0163252.22327998-.02480398.33844139-.02480398h10.27064786z"/></symbol><symbol id="icon-chevron-less" viewBox="0 0 10 10"><path d="m5.58578644 4-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 -1 -1 0 9 9)"/></symbol><symbol id="icon-chevron-more" viewBox="0 0 10 10"><path d="m5.58578644 6-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4.00000002c-.39052429.3905243-1.02368927.3905243-1.41421356 0s-.39052429-1.02368929 0-1.41421358z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"/></symbol><symbol id="icon-chevron-right" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"/></symbol><symbol id="icon-circle-fill" viewBox="0 0 16 16"><path d="m8 14c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"/></symbol><symbol id="icon-circle" viewBox="0 0 16 16"><path d="m8 12c2.209139 0 4-1.790861 4-4s-1.790861-4-4-4-4 1.790861-4 4 1.790861 4 4 4zm0 2c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"/></symbol><symbol id="icon-citation" viewBox="0 0 18 18"><path d="m8.63593473 5.99995183c2.20913897 0 3.99999997 1.79084375 3.99999997 3.99996146 0 1.40730761-.7267788 2.64486871-1.8254829 3.35783281 1.6240224.6764218 2.8754442 2.0093871 3.4610603 3.6412466l-1.0763845.000006c-.5310008-1.2078237-1.5108121-2.1940153-2.7691712-2.7181346l-.79002167-.329052v-1.023992l.63016577-.4089232c.8482885-.5504661 1.3698342-1.4895187 1.3698342-2.51898361 0-1.65683828-1.3431457-2.99996146-2.99999997-2.99996146-1.65685425 0-3 1.34312318-3 2.99996146 0 1.02946491.52154569 1.96851751 1.36983419 2.51898361l.63016581.4089232v1.023992l-.79002171.329052c-1.25835905.5241193-2.23817037 1.5103109-2.76917113 2.7181346l-1.07638453-.000006c.58561612-1.6318595 1.8370379-2.9648248 3.46106024-3.6412466-1.09870405-.7129641-1.82548287-1.9505252-1.82548287-3.35783281 0-2.20911771 1.790861-3.99996146 4-3.99996146zm7.36897597-4.99995183c1.1018574 0 1.9950893.89353404 1.9950893 2.00274083v5.994422c0 1.10608317-.8926228 2.00274087-1.9950893 2.00274087l-3.0049107-.0009037v-1l3.0049107.00091329c.5490631 0 .9950893-.44783123.9950893-1.00275046v-5.994422c0-.55646537-.4450595-1.00275046-.9950893-1.00275046h-14.00982141c-.54906309 0-.99508929.44783123-.99508929 1.00275046v5.9971821c0 .66666024.33333333.99999036 1 .99999036l2-.00091329v1l-2 .0009037c-1 0-2-.99999041-2-1.99998077v-5.9971821c0-1.10608322.8926228-2.00274083 1.99508929-2.00274083zm-8.5049107 2.9999711c.27614237 0 .5.22385547.5.5 0 .2761349-.22385763.5-.5.5h-4c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm3 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-1c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm4 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238651-.5-.5 0-.27614453.2238576-.5.5-.5z" fill-rule="evenodd"/></symbol><symbol id="icon-close" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"/></symbol><symbol id="icon-collections" viewBox="0 0 18 18"><path d="m15 4c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2h1c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-1v-1zm-4-3c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2v-9c0-1.1045695.8954305-2 2-2zm0 1h-8c-.51283584 0-.93550716.38604019-.99327227.88337887l-.00672773.11662113v9c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227zm-1.5 7c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"/></symbol><symbol id="icon-compare" viewBox="0 0 18 18"><path d="m12 3c3.3137085 0 6 2.6862915 6 6s-2.6862915 6-6 6c-1.0928452 0-2.11744941-.2921742-2.99996061-.8026704-.88181407.5102749-1.90678042.8026704-3.00003939.8026704-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6c1.09325897 0 2.11822532.29239547 3.00096303.80325037.88158756-.51107621 1.90619177-.80325037 2.99903697-.80325037zm-6 1c-2.76142375 0-5 2.23857625-5 5 0 2.7614237 2.23857625 5 5 5 .74397391 0 1.44999672-.162488 2.08451611-.4539116-1.27652344-1.1000812-2.08451611-2.7287264-2.08451611-4.5460884s.80799267-3.44600721 2.08434391-4.5463015c-.63434719-.29121054-1.34037-.4536985-2.08434391-.4536985zm6 0c-.7439739 0-1.4499967.16248796-2.08451611.45391156 1.27652341 1.10008123 2.08451611 2.72872644 2.08451611 4.54608844s-.8079927 3.4460072-2.08434391 4.5463015c.63434721.2912105 1.34037001.4536985 2.08434391.4536985 2.7614237 0 5-2.2385763 5-5 0-2.76142375-2.2385763-5-5-5zm-1.4162763 7.0005324h-3.16744736c.15614659.3572676.35283837.6927622.58425872 1.0006671h1.99892988c.23142036-.3079049.42811216-.6433995.58425876-1.0006671zm.4162763-2.0005324h-4c0 .34288501.0345146.67770871.10025909 1.0011864h3.79948181c.0657445-.32347769.1002591-.65830139.1002591-1.0011864zm-.4158423-1.99953894h-3.16831543c-.13859957.31730812-.24521946.651783-.31578599.99935097h3.79988742c-.0705665-.34756797-.1771864-.68204285-.315786-.99935097zm-1.58295822-1.999926-.08316107.06199199c-.34550042.27081213-.65446126.58611297-.91825862.93727862h2.00044041c-.28418626-.37830727-.6207872-.71499149-.99902072-.99927061z" fill-rule="evenodd"/></symbol><symbol id="icon-download-file" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.5046024 4c.27614237 0 .5.21637201.5.49209595v6.14827645l1.7462789-1.77990922c.1933927-.1971171.5125222-.19455839.7001689-.0069117.1932998.19329992.1910058.50899492-.0027774.70277812l-2.59089271 2.5908927c-.19483374.1948337-.51177825.1937771-.70556873-.0000133l-2.59099079-2.5909908c-.19484111-.1948411-.19043735-.5151448-.00279066-.70279146.19329987-.19329987.50465175-.19237083.70018565.00692852l1.74638684 1.78001764v-6.14827695c0-.27177709.23193359-.49209595.5-.49209595z" fill-rule="evenodd"/></symbol><symbol id="icon-download" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"/></symbol><symbol id="icon-editors" viewBox="0 0 18 18"><path d="m8.72592184 2.54588137c-.48811714-.34391207-1.08343326-.54588137-1.72592184-.54588137-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400182l-.79002171.32905522c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274v.9009805h-1v-.9009805c0-2.5479714 1.54557359-4.79153984 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4 1.09079823 0 2.07961816.43662103 2.80122451 1.1446278-.37707584.09278571-.7373238.22835063-1.07530267.40125357zm-2.72592184 14.45411863h-1v-.9009805c0-2.5479714 1.54557359-4.7915398 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.40732121-.7267788 2.64489414-1.8254829 3.3578652 2.2799093.9496145 3.8254829 3.1931829 3.8254829 5.7411543v.9009805h-1v-.9009805c0-2.1155483-1.2760206-4.0125067-3.2099783-4.8180274l-.7900217-.3290552v-1.02400184l.6301658-.40892721c.8482885-.55047139 1.3698342-1.489533 1.3698342-2.51900785 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400184l-.79002171.3290552c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274z" fill-rule="evenodd"/></symbol><symbol id="icon-email" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-.0049107 2.55749512v1.44250488l-7 4-7-4v-1.44250488l7 4z" fill-rule="evenodd"/></symbol><symbol id="icon-error" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm2.8630343 4.71100931-2.8630343 2.86303426-2.86303426-2.86303426c-.39658757-.39658757-1.03281091-.39438847-1.4265779-.00062147-.39651227.39651226-.39348876 1.03246767.00062147 1.4265779l2.86303426 2.86303426-2.86303426 2.8630343c-.39658757.3965875-.39438847 1.0328109-.00062147 1.4265779.39651226.3965122 1.03246767.3934887 1.4265779-.0006215l2.86303426-2.8630343 2.8630343 2.8630343c.3965875.3965876 1.0328109.3943885 1.4265779.0006215.3965122-.3965123.3934887-1.0324677-.0006215-1.4265779l-2.8630343-2.8630343 2.8630343-2.86303426c.3965876-.39658757.3943885-1.03281091.0006215-1.4265779-.3965123-.39651227-1.0324677-.39348876-1.4265779.00062147z" fill-rule="evenodd"/></symbol><symbol id="icon-ethics" viewBox="0 0 18 18"><path d="m6.76384967 1.41421356.83301651-.8330165c.77492941-.77492941 2.03133823-.77492941 2.80626762 0l.8330165.8330165c.3750728.37507276.8837806.58578644 1.4142136.58578644h1.3496361c1.1045695 0 2 .8954305 2 2v1.34963611c0 .53043298.2107137 1.03914081.5857864 1.41421356l.8330165.83301651c.7749295.77492941.7749295 2.03133823 0 2.80626762l-.8330165.8330165c-.3750727.3750728-.5857864.8837806-.5857864 1.4142136v1.3496361c0 1.1045695-.8954305 2-2 2h-1.3496361c-.530433 0-1.0391408.2107137-1.4142136.5857864l-.8330165.8330165c-.77492939.7749295-2.03133821.7749295-2.80626762 0l-.83301651-.8330165c-.37507275-.3750727-.88378058-.5857864-1.41421356-.5857864h-1.34963611c-1.1045695 0-2-.8954305-2-2v-1.3496361c0-.530433-.21071368-1.0391408-.58578644-1.4142136l-.8330165-.8330165c-.77492941-.77492939-.77492941-2.03133821 0-2.80626762l.8330165-.83301651c.37507276-.37507275.58578644-.88378058.58578644-1.41421356v-1.34963611c0-1.1045695.8954305-2 2-2h1.34963611c.53043298 0 1.03914081-.21071368 1.41421356-.58578644zm-1.41421356 1.58578644h-1.34963611c-.55228475 0-1 .44771525-1 1v1.34963611c0 .79564947-.31607052 1.55871121-.87867966 2.12132034l-.8330165.83301651c-.38440512.38440512-.38440512 1.00764896 0 1.39205408l.8330165.83301646c.56260914.5626092.87867966 1.3256709.87867966 2.1213204v1.3496361c0 .5522847.44771525 1 1 1h1.34963611c.79564947 0 1.55871121.3160705 2.12132034.8786797l.83301651.8330165c.38440512.3844051 1.00764896.3844051 1.39205408 0l.83301646-.8330165c.5626092-.5626092 1.3256709-.8786797 2.1213204-.8786797h1.3496361c.5522847 0 1-.4477153 1-1v-1.3496361c0-.7956495.3160705-1.5587112.8786797-2.1213204l.8330165-.83301646c.3844051-.38440512.3844051-1.00764896 0-1.39205408l-.8330165-.83301651c-.5626092-.56260913-.8786797-1.32567087-.8786797-2.12132034v-1.34963611c0-.55228475-.4477153-1-1-1h-1.3496361c-.7956495 0-1.5587112-.31607052-2.1213204-.87867966l-.83301646-.8330165c-.38440512-.38440512-1.00764896-.38440512-1.39205408 0l-.83301651.8330165c-.56260913.56260914-1.32567087.87867966-2.12132034.87867966zm3.58698944 11.4960218c-.02081224.002155-.04199226.0030286-.06345763.002542-.98766446-.0223875-1.93408568-.3063547-2.75885125-.8155622-.23496767-.1450683-.30784554-.4531483-.16277726-.688116.14506827-.2349677.45314827-.3078455.68811595-.1627773.67447084.4164161 1.44758575.6483839 2.25617384.6667123.01759529.0003988.03495764.0017019.05204365.0038639.01713363-.0017748.03452416-.0026845.05212715-.0026845 2.4852814 0 4.5-2.0147186 4.5-4.5 0-1.04888973-.3593547-2.04134635-1.0074477-2.83787157-.1742817-.21419731-.1419238-.5291218.0722736-.70340353.2141973-.17428173.5291218-.14192375.7034035.07227357.7919032.97327203 1.2317706 2.18808682 1.2317706 3.46900153 0 3.0375661-2.4624339 5.5-5.5 5.5-.02146768 0-.04261937-.0013529-.06337445-.0039782zm1.57975095-10.78419583c.2654788.07599731.419084.35281842.3430867.61829728-.0759973.26547885-.3528185.419084-.6182973.3430867-.37560116-.10752146-.76586237-.16587951-1.15568824-.17249193-2.5587807-.00064534-4.58547766 2.00216524-4.58547766 4.49928198 0 .62691557.12797645 1.23496.37274865 1.7964426.11035133.2531347-.0053975.5477984-.25853224.6581497-.25313473.1103514-.54779841-.0053975-.65814974-.2585322-.29947131-.6869568-.45606667-1.43097603-.45606667-2.1960601 0-3.05211432 2.47714695-5.50006595 5.59399617-5.49921198.48576182.00815502.96289603.0795037 1.42238033.21103795zm-1.9766658 6.41091303 2.69835-2.94655317c.1788432-.21040373.4943901-.23598862.7047939-.05714545.2104037.17884318.2359886.49439014.0571454.70479387l-3.01637681 3.34277395c-.18039088.1999106-.48669547.2210637-.69285412.0478478l-1.93095347-1.62240047c-.21213845-.17678204-.24080048-.49206439-.06401844-.70420284.17678204-.21213844.49206439-.24080048.70420284-.06401844z" fill-rule="evenodd"/></symbol><symbol id="icon-expand"><path d="M7.498 11.918a.997.997 0 0 0-.003-1.411.995.995 0 0 0-1.412-.003l-4.102 4.102v-3.51A1 1 0 0 0 .98 10.09.992.992 0 0 0 0 11.092V17c0 .554.448 1.002 1.002 1.002h5.907c.554 0 1.002-.45 1.002-1.003 0-.539-.45-.978-1.006-.978h-3.51zm3.005-5.835a.997.997 0 0 0 .003 1.412.995.995 0 0 0 1.411.003l4.103-4.103v3.51a1 1 0 0 0 1.001 1.006A.992.992 0 0 0 18 6.91V1.002A1 1 0 0 0 17 0h-5.907a1.003 1.003 0 0 0-1.002 1.003c0 .539.45.978 1.006.978h3.51z" fill-rule="evenodd"/></symbol><symbol id="icon-explore" viewBox="0 0 18 18"><path d="m9 17c4.418278 0 8-3.581722 8-8s-3.581722-8-8-8-8 3.581722-8 8 3.581722 8 8 8zm0 1c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9zm0-2.5c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5c2.969509 0 5.400504-2.3575119 5.497023-5.31714844.0090007-.27599565.2400359-.49243782.5160315-.48343711.2759957.0090007.4924378.2400359.4834371.51603155-.114093 3.4985237-2.9869632 6.284554-6.4964916 6.284554zm-.29090657-12.99359748c.27587424-.01216621.50937715.20161139.52154336.47748563.01216621.27587423-.20161139.50937715-.47748563.52154336-2.93195733.12930094-5.25315116 2.54886451-5.25315116 5.49456849 0 .27614237-.22385763.5-.5.5s-.5-.22385763-.5-.5c0-3.48142406 2.74307146-6.34074398 6.20909343-6.49359748zm1.13784138 8.04763908-1.2004882-1.20048821c-.19526215-.19526215-.19526215-.51184463 0-.70710678s.51184463-.19526215.70710678 0l1.20048821 1.2004882 1.6006509-4.00162734-4.50670359 1.80268144-1.80268144 4.50670359zm4.10281269-6.50378907-2.6692597 6.67314927c-.1016411.2541026-.3029834.4554449-.557086.557086l-6.67314927 2.6692597 2.66925969-6.67314926c.10164107-.25410266.30298336-.45544495.55708602-.55708602z" fill-rule="evenodd"/></symbol><symbol id="icon-filter" viewBox="0 0 16 16"><path d="m14.9738641 0c.5667192 0 1.0261359.4477136 1.0261359 1 0 .24221858-.0902161.47620768-.2538899.65849851l-5.6938314 6.34147206v5.49997973c0 .3147562-.1520673.6111434-.4104543.7999971l-2.05227171 1.4999945c-.45337535.3313696-1.09655869.2418269-1.4365902-.1999993-.13321514-.1730955-.20522717-.3836284-.20522717-.5999978v-6.99997423l-5.69383133-6.34147206c-.3731872-.41563511-.32996891-1.0473954.09653074-1.41107611.18705584-.15950448.42716133-.2474224.67571519-.2474224zm-5.9218641 8.5h-2.105v6.491l.01238459.0070843.02053271.0015705.01955278-.0070558 2.0532976-1.4990996zm-8.02585008-7.5-.01564945.00240169 5.83249953 6.49759831h2.313l5.836-6.499z"/></symbol><symbol id="icon-home" viewBox="0 0 18 18"><path d="m9 5-6 6v5h4v-4h4v4h4v-5zm7 6.5857864v4.4142136c0 .5522847-.4477153 1-1 1h-5v-4h-2v4h-5c-.55228475 0-1-.4477153-1-1v-4.4142136c-.25592232 0-.51184464-.097631-.70710678-.2928932l-.58578644-.5857864c-.39052429-.3905243-.39052429-1.02368929 0-1.41421358l8.29289322-8.29289322 8.2928932 8.29289322c.3905243.39052429.3905243 1.02368928 0 1.41421358l-.5857864.5857864c-.1952622.1952622-.4511845.2928932-.7071068.2928932zm-7-9.17157284-7.58578644 7.58578644.58578644.5857864 7-6.99999996 7 6.99999996.5857864-.5857864z" fill-rule="evenodd"/></symbol><symbol id="icon-image" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm-3.49645283 10.1752453-3.89407257 6.7495552c.11705545.048464.24538859.0751995.37998328.0751995h10.60290092l-2.4329715-4.2154691-1.57494129 2.7288098zm8.49779013 6.8247547c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v13.98991071l4.50814957-7.81026689 3.08089884 5.33809539 1.57494129-2.7288097 3.5875735 6.2159812zm-3.0059397-11c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm0 1c-.5522847 0-1 .44771525-1 1s.4477153 1 1 1 1-.44771525 1-1-.4477153-1-1-1z" fill-rule="evenodd"/></symbol><symbol id="icon-info" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"/></symbol><symbol id="icon-institution" viewBox="0 0 18 18"><path d="m7 16.9998189v-2.0003623h4v2.0003623h2v-3.0005434h-8v3.0005434zm-3-10.00181122h-1.52632364c-.27614237 0-.5-.22389817-.5-.50009056 0-.13995446.05863589-.27350497.16166338-.36820841l1.23156713-1.13206327h-2.36690687v12.00217346h3v-2.0003623h-3v-1.0001811h3v-1.0001811h1v-4.00072448h-1zm10 0v2.00036224h-1v4.00072448h1v1.0001811h3v1.0001811h-3v2.0003623h3v-12.00217346h-2.3695309l1.2315671 1.13206327c.2033191.186892.2166633.50325042.0298051.70660631-.0946863.10304615-.2282126.16169266-.3681417.16169266zm3-3.00054336c.5522847 0 1 .44779634 1 1.00018112v13.00235456h-18v-13.00235456c0-.55238478.44771525-1.00018112 1-1.00018112h3.45499992l4.20535144-3.86558216c.19129876-.17584288.48537447-.17584288.67667324 0l4.2053514 3.86558216zm-4 3.00054336h-8v1.00018112h8zm-2 6.00108672h1v-4.00072448h-1zm-1 0v-4.00072448h-2v4.00072448zm-3 0v-4.00072448h-1v4.00072448zm8-4.00072448c.5522847 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.4477153-1.00018112 1-1.00018112zm-12 0c.55228475 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.44771525-1.00018112 1-1.00018112zm5.99868798-7.81907007-5.24205601 4.81852671h10.48411203zm.00131202 3.81834559c-.55228475 0-1-.44779634-1-1.00018112s.44771525-1.00018112 1-1.00018112 1 .44779634 1 1.00018112-.44771525 1.00018112-1 1.00018112zm-1 11.00199236v1.0001811h2v-1.0001811z" fill-rule="evenodd"/></symbol><symbol id="icon-location" viewBox="0 0 18 18"><path d="m9.39521328 16.2688008c.79596342-.7770119 1.59208152-1.6299956 2.33285652-2.5295081 1.4020032-1.7024324 2.4323601-3.3624519 2.9354918-4.871847.2228715-.66861448.3364384-1.29323246.3364384-1.8674457 0-3.3137085-2.6862915-6-6-6-3.36356866 0-6 2.60156856-6 6 0 .57421324.11356691 1.19883122.3364384 1.8674457.50313169 1.5093951 1.53348863 3.1694146 2.93549184 4.871847.74077492.8995125 1.53689309 1.7524962 2.33285648 2.5295081.13694479.1336842.26895677.2602648.39521328.3793207.12625651-.1190559.25826849-.2456365.39521328-.3793207zm-.39521328 1.7311992s-7-6-7-11c0-4 3.13400675-7 7-7 3.8659932 0 7 3.13400675 7 7 0 5-7 11-7 11zm0-8c-1.65685425 0-3-1.34314575-3-3s1.34314575-3 3-3c1.6568542 0 3 1.34314575 3 3s-1.3431458 3-3 3zm0-1c1.1045695 0 2-.8954305 2-2s-.8954305-2-2-2-2 .8954305-2 2 .8954305 2 2 2z" fill-rule="evenodd"/></symbol><symbol id="icon-minus" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"/></symbol><symbol id="icon-newsletter" viewBox="0 0 18 18"><path d="m9 11.8482489 2-1.1428571v-1.7053918h-4v1.7053918zm-3-1.7142857v-2.1339632h6v2.1339632l3-1.71428574v-6.41967746h-12v6.41967746zm10-5.3839632 1.5299989.95624934c.2923814.18273835.4700011.50320827.4700011.8479983v8.44575236c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-8.44575236c0-.34479003.1776197-.66525995.47000106-.8479983l1.52999894-.95624934v-2.75c0-.55228475.44771525-1 1-1h12c.5522847 0 1 .44771525 1 1zm0 1.17924764v3.07075236l-7 4-7-4v-3.07075236l-1 .625v8.44575236c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-8.44575236zm-10-1.92924764h6v1h-6zm-1 2h8v1h-8z" fill-rule="evenodd"/></symbol><symbol id="icon-orcid" viewBox="0 0 18 18"><path d="m9 1c4.418278 0 8 3.581722 8 8s-3.581722 8-8 8-8-3.581722-8-8 3.581722-8 8-8zm-2.90107518 5.2732337h-1.41865256v7.1712107h1.41865256zm4.55867178.02508949h-2.99247027v7.14612121h2.91062487c.7673039 0 1.4476365-.1483432 2.0410182-.445034s1.0511995-.7152915 1.3734671-1.2558144c.3222677-.540523.4833991-1.1603247.4833991-1.85942385 0-.68545815-.1602789-1.30270225-.4808414-1.85175082-.3205625-.54904856-.7707074-.97532211-1.3504481-1.27883343-.5797408-.30351132-1.2413173-.45526471-1.9847495-.45526471zm-.1892674 1.07933542c.7877654 0 1.4143875.22336734 1.8798852.67010873.4654977.44674138.698243 1.05546001.698243 1.82617415 0 .74343221-.2310402 1.34447791-.6931277 1.80315511-.4620874.4586773-1.0750688.6880124-1.8389625.6880124h-1.46810075v-4.98745039zm-5.08652545-3.71099194c-.21825533 0-.410525.08444276-.57681478.25333081-.16628977.16888806-.24943341.36245684-.24943341.58071218 0 .22345188.08314364.41961891.24943341.58850696.16628978.16888806.35855945.25333082.57681478.25333082.233845 0 .43390938-.08314364.60019916-.24943342.16628978-.16628977.24943342-.36375592.24943342-.59240436 0-.233845-.08314364-.43131115-.24943342-.59240437s-.36635416-.24163862-.60019916-.24163862z" fill-rule="evenodd"/></symbol><symbol id="icon-plus" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"/></symbol><symbol id="icon-print" viewBox="0 0 18 18"><path d="m16.0049107 5h-14.00982141c-.54941618 0-.99508929.4467783-.99508929.99961498v6.00077002c0 .5570958.44271433.999615.99508929.999615h1.00491071v-3h12v3h1.0049107c.5494162 0 .9950893-.4467783.9950893-.999615v-6.00077002c0-.55709576-.4427143-.99961498-.9950893-.99961498zm-2.0049107-1v-2.00208688c0-.54777062-.4519464-.99791312-1.0085302-.99791312h-7.9829396c-.55661731 0-1.0085302.44910695-1.0085302.99791312v2.00208688zm1 10v2.0018986c0 1.103521-.9019504 1.9981014-2.0085302 1.9981014h-7.9829396c-1.1092806 0-2.0085302-.8867064-2.0085302-1.9981014v-2.0018986h-1.00491071c-1.10185739 0-1.99508929-.8874333-1.99508929-1.999615v-6.00077002c0-1.10435686.8926228-1.99961498 1.99508929-1.99961498h1.00491071v-2.00208688c0-1.10341695.90195036-1.99791312 2.0085302-1.99791312h7.9829396c1.1092806 0 2.0085302.89826062 2.0085302 1.99791312v2.00208688h1.0049107c1.1018574 0 1.9950893.88743329 1.9950893 1.99961498v6.00077002c0 1.1043569-.8926228 1.999615-1.9950893 1.999615zm-1-3h-10v5.0018986c0 .5546075.44702548.9981014 1.0085302.9981014h7.9829396c.5565964 0 1.0085302-.4491701 1.0085302-.9981014zm-9 1h8v1h-8zm0 2h5v1h-5zm9-5c-.5522847 0-1-.44771525-1-1s.4477153-1 1-1 1 .44771525 1 1-.4477153 1-1 1z" fill-rule="evenodd"/></symbol><symbol id="icon-search" viewBox="0 0 22 22"><path d="M21.697 20.261a1.028 1.028 0 01.01 1.448 1.034 1.034 0 01-1.448-.01l-4.267-4.267A9.812 9.811 0 010 9.812a9.812 9.811 0 1117.43 6.182zM9.812 18.222A8.41 8.41 0 109.81 1.403a8.41 8.41 0 000 16.82z" fill-rule="evenodd"/></symbol><symbol id="icon-social-facebook" viewBox="0 0 24 24"><path d="m6.00368507 20c-1.10660471 0-2.00368507-.8945138-2.00368507-1.9940603v-12.01187942c0-1.10128908.89451376-1.99406028 1.99406028-1.99406028h12.01187942c1.1012891 0 1.9940603.89451376 1.9940603 1.99406028v12.01187942c0 1.1012891-.88679 1.9940603-2.0032184 1.9940603h-2.9570132v-6.1960818h2.0797387l.3114113-2.414723h-2.39115v-1.54164807c0-.69911803.1941355-1.1755439 1.1966615-1.1755439l1.2786739-.00055875v-2.15974763l-.2339477-.02492088c-.3441234-.03134957-.9500153-.07025255-1.6293054-.07025255-1.8435726 0-3.1057323 1.12531866-3.1057323 3.19187953v1.78079225h-2.0850778v2.414723h2.0850778v6.1960818z" fill-rule="evenodd"/></symbol><symbol id="icon-social-twitter" viewBox="0 0 24 24"><path d="m18.8767135 6.87445248c.7638174-.46908424 1.351611-1.21167363 1.6250764-2.09636345-.7135248.43394112-1.50406.74870123-2.3464594.91677702-.6695189-.73342162-1.6297913-1.19486605-2.6922204-1.19486605-2.0399895 0-3.6933555 1.69603749-3.6933555 3.78628909 0 .29642457.0314329.58673729.0942985.8617704-3.06469922-.15890802-5.78835241-1.66547825-7.60988389-3.9574208-.3174714.56076194-.49978171 1.21167363-.49978171 1.90536824 0 1.31404706.65223085 2.47224203 1.64236444 3.15218497-.60350999-.0198635-1.17401554-.1925232-1.67222562-.47366811v.04583885c0 1.83355406 1.27302891 3.36609966 2.96411421 3.71294696-.31118484.0886217-.63651445.1329326-.97441718.1329326-.2357461 0-.47149219-.0229194-.69466516-.0672303.47149219 1.5065703 1.83253297 2.6036468 3.44975116 2.632678-1.2651707 1.0160946-2.85724264 1.6196394-4.5891906 1.6196394-.29861172 0-.59093688-.0152796-.88011875-.0504227 1.63450624 1.0726291 3.57548241 1.6990934 5.66104951 1.6990934 6.79263079 0 10.50641749-5.7711113 10.50641749-10.7751859l-.0094298-.48894775c.7229547-.53478659 1.3516109-1.20250585 1.8419628-1.96190282-.6632323.30100846-1.3751855.50422736-2.1217148.59590507z" fill-rule="evenodd"/></symbol><symbol id="icon-social-youtube" viewBox="0 0 24 24"><path d="m10.1415 14.3973208-.0005625-5.19318431 4.863375 2.60554491zm9.963-7.92753362c-.6845625-.73643756-1.4518125-.73990314-1.803375-.7826454-2.518875-.18714178-6.2971875-.18714178-6.2971875-.18714178-.007875 0-3.7861875 0-6.3050625.18714178-.352125.04274226-1.1188125.04620784-1.8039375.7826454-.5394375.56084773-.7149375 1.8344515-.7149375 1.8344515s-.18 1.49597903-.18 2.99138042v1.4024082c0 1.495979.18 2.9913804.18 2.9913804s.1755 1.2736038.7149375 1.8344515c.685125.7364376 1.5845625.7133337 1.9850625.7901542 1.44.1420891 6.12.1859866 6.12.1859866s3.78225-.005776 6.301125-.1929178c.3515625-.0433198 1.1188125-.0467854 1.803375-.783223.5394375-.5608477.7155-1.8344515.7155-1.8344515s.18-1.4954014.18-2.9913804v-1.4024082c0-1.49540139-.18-2.99138042-.18-2.99138042s-.1760625-1.27360377-.7155-1.8344515z" fill-rule="evenodd"/></symbol><symbol id="icon-subject-medicine" viewBox="0 0 18 18"><path d="m12.5 8h-6.5c-1.65685425 0-3 1.34314575-3 3v1c0 1.6568542 1.34314575 3 3 3h1v-2h-.5c-.82842712 0-1.5-.6715729-1.5-1.5s.67157288-1.5 1.5-1.5h1.5 2 1 2c1.6568542 0 3-1.34314575 3-3v-1c0-1.65685425-1.3431458-3-3-3h-2v2h1.5c.8284271 0 1.5.67157288 1.5 1.5s-.6715729 1.5-1.5 1.5zm-5.5-1v-1h-3.5c-1.38071187 0-2.5-1.11928813-2.5-2.5s1.11928813-2.5 2.5-2.5h1.02786405c.46573528 0 .92507448.10843528 1.34164078.31671843l1.13382424.56691212c.06026365-1.05041141.93116291-1.88363055 1.99667093-1.88363055 1.1045695 0 2 .8954305 2 2h2c2.209139 0 4 1.790861 4 4v1c0 2.209139-1.790861 4-4 4h-2v1h2c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2h-2c0 1.1045695-.8954305 2-2 2s-2-.8954305-2-2h-1c-2.209139 0-4-1.790861-4-4v-1c0-2.209139 1.790861-4 4-4zm0-2v-2.05652691c-.14564246-.03538148-.28733393-.08714006-.42229124-.15461871l-1.15541752-.57770876c-.27771087-.13885544-.583937-.21114562-.89442719-.21114562h-1.02786405c-.82842712 0-1.5.67157288-1.5 1.5s.67157288 1.5 1.5 1.5zm4 1v1h1.5c.2761424 0 .5-.22385763.5-.5s-.2238576-.5-.5-.5zm-1 1v-5c0-.55228475-.44771525-1-1-1s-1 .44771525-1 1v5zm-2 4v5c0 .5522847.44771525 1 1 1s1-.4477153 1-1v-5zm3 2v2h2c.5522847 0 1-.4477153 1-1s-.4477153-1-1-1zm-4-1v-1h-.5c-.27614237 0-.5.2238576-.5.5s.22385763.5.5.5zm-3.5-9h1c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"/></symbol><symbol id="icon-success" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm3.4860198 4.98163161-4.71802968 5.50657859-2.62834168-2.02300024c-.42862421-.36730544-1.06564993-.30775346-1.42283677.13301307-.35718685.44076653-.29927542 1.0958383.12934879 1.46314377l3.40735508 2.7323063c.42215801.3385221 1.03700951.2798252 1.38749189-.1324571l5.38450527-6.33394549c.3613513-.43716226.3096573-1.09278382-.115462-1.46437175-.4251192-.37158792-1.0626796-.31842941-1.4240309.11873285z" fill-rule="evenodd"/></symbol><symbol id="icon-table" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587l-4.0059107-.001.001.001h-1l-.001-.001h-5l.001.001h-1l-.001-.001-3.00391071.001c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm-11.0059107 5h-3.999v6.9941413c0 .5572961.44630695 1.0058587.99508929 1.0058587h3.00391071zm6 0h-5v8h5zm5.0059107-4h-4.0059107v3h5.001v1h-5.001v7.999l4.0059107.001c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-12.5049107 9c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.22385763-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1.499-5h-5v3h5zm-6 0h-3.00391071c-.54871518 0-.99508929.44887827-.99508929 1.00585866v1.99414134h3.999z" fill-rule="evenodd"/></symbol><symbol id="icon-tick-circle" viewBox="0 0 24 24"><path d="m12 2c5.5228475 0 10 4.4771525 10 10s-4.4771525 10-10 10-10-4.4771525-10-10 4.4771525-10 10-10zm0 1c-4.97056275 0-9 4.02943725-9 9 0 4.9705627 4.02943725 9 9 9 4.9705627 0 9-4.0294373 9-9 0-4.97056275-4.0294373-9-9-9zm4.2199868 5.36606669c.3613514-.43716226.9989118-.49032077 1.424031-.11873285s.4768133 1.02720949.115462 1.46437175l-6.093335 6.94397871c-.3622945.4128716-.9897871.4562317-1.4054264.0971157l-3.89719065-3.3672071c-.42862421-.3673054-.48653564-1.0223772-.1293488-1.4631437s.99421256-.5003185 1.42283677-.1330131l3.11097438 2.6987741z" fill-rule="evenodd"/></symbol><symbol id="icon-tick" viewBox="0 0 16 16"><path d="m6.76799012 9.21106946-3.1109744-2.58349728c-.42862421-.35161617-1.06564993-.29460792-1.42283677.12733148s-.29927541 1.04903009.1293488 1.40064626l3.91576307 3.23873978c.41034319.3393961 1.01467563.2976897 1.37450571-.0948578l6.10568327-6.660841c.3613513-.41848908.3096572-1.04610608-.115462-1.4018218-.4251192-.35571573-1.0626796-.30482786-1.424031.11366122z" fill-rule="evenodd"/></symbol><symbol id="icon-update" viewBox="0 0 18 18"><path d="m1 13v1c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-1h-1v-10h-14v10zm16-1h1v2c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-2h1v-9c0-.55228475.44771525-1 1-1h14c.5522847 0 1 .44771525 1 1zm-1 0v1h-4.5857864l-1 1h-2.82842716l-1-1h-4.58578644v-1h5l1 1h2l1-1zm-13-8h12v7h-12zm1 1v5h10v-5zm1 1h4v1h-4zm0 2h4v1h-4z" fill-rule="evenodd"/></symbol><symbol id="icon-upload" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.85576936 4.14572769c.19483374-.19483375.51177826-.19377714.70556874.00001334l2.59099082 2.59099079c.1948411.19484112.1904373.51514474.0027906.70279143-.1932998.19329987-.5046517.19237083-.7001856-.00692852l-1.74638687-1.7800176v6.14827687c0 .2717771-.23193359.492096-.5.492096-.27614237 0-.5-.216372-.5-.492096v-6.14827641l-1.74627892 1.77990922c-.1933927.1971171-.51252214.19455839-.70016883.0069117-.19329987-.19329988-.19100584-.50899493.00277731-.70277808z" fill-rule="evenodd"/></symbol><symbol id="icon-video" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-8.30912922 2.24944486 4.60460462 2.73982242c.9365543.55726659.9290753 1.46522435 0 2.01804082l-4.60460462 2.7398224c-.93655425.5572666-1.69578148.1645632-1.69578148-.8937585v-5.71016863c0-1.05087579.76670616-1.446575 1.69578148-.89375851zm-.67492769.96085624v5.5750128c0 .2995102-.10753745.2442517.16578928.0847713l4.58452283-2.67497259c.3050619-.17799716.3051624-.21655446 0-.39461026l-4.58452283-2.67497264c-.26630747-.15538481-.16578928-.20699944-.16578928.08477139z" fill-rule="evenodd"/></symbol><symbol id="icon-warning" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"/></symbol><symbol id="icon-checklist-banner" viewBox="0 0 56.69 56.69"><path style="fill:none" d="M0 0h56.69v56.69H0z"/><clipPath id="b"><use xlink:href="#a" style="overflow:visible"/></clipPath><path d="M21.14 34.46c0-6.77 5.48-12.26 12.24-12.26s12.24 5.49 12.24 12.26-5.48 12.26-12.24 12.26c-6.76-.01-12.24-5.49-12.24-12.26zm19.33 10.66 10.23 9.22s1.21 1.09 2.3-.12l2.09-2.32s1.09-1.21-.12-2.3l-10.23-9.22m-19.29-5.92c0-4.38 3.55-7.94 7.93-7.94s7.93 3.55 7.93 7.94c0 4.38-3.55 7.94-7.93 7.94-4.38-.01-7.93-3.56-7.93-7.94zm17.58 12.99 4.14-4.81" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round"/><path d="M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5m14.42-5.2V4.86s0-2.93-2.93-2.93H4.13s-2.93 0-2.93 2.93v37.57s0 2.93 2.93 2.93h15.01M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round;stroke-linejoin:round"/></symbol><symbol id="icon-chevron-down" viewBox="0 0 16 16"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"/></symbol><symbol id="icon-eds-i-arrow-right-medium" viewBox="0 0 24 24"><path d="m12.728 3.293 7.98 7.99a.996.996 0 0 1 .281.561l.011.157c0 .32-.15.605-.384.788l-7.908 7.918a1 1 0 0 1-1.416-1.414L17.576 13H4a1 1 0 0 1 0-2h13.598l-6.285-6.293a1 1 0 0 1-.082-1.32l.083-.095a1 1 0 0 1 1.414.001Z"/></symbol><symbol id="icon-eds-i-chevron-down-medium" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"/></symbol><symbol id="icon-eds-i-chevron-down-small" viewBox="0 0 16 16"><path d="M13.692 5.278a1 1 0 0 1 .03 1.414L9.103 11.51a1.491 1.491 0 0 1-2.188.019L2.278 6.692a1 1 0 0 1 1.444-1.384L8 9.771l4.278-4.463a1 1 0 0 1 1.318-.111l.096.081Z"/></symbol><symbol id="icon-eds-i-chevron-right-medium" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"/></symbol><symbol id="icon-eds-i-chevron-right-small" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"/></symbol><symbol id="icon-eds-i-chevron-up-medium" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"/></symbol><symbol id="icon-eds-i-close-medium" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"/></symbol><symbol id="icon-eds-i-download-medium" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"/></symbol><symbol id="icon-eds-i-info-filled-medium" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"/></symbol><symbol id="icon-eds-i-mail-medium" viewBox="0 0 24 24"><path d="m19.462 0c1.413 0 2.538 1.184 2.538 2.619v12.762c0 1.435-1.125 2.619-2.538 2.619h-16.924c-1.413 0-2.538-1.184-2.538-2.619v-12.762c0-1.435 1.125-2.619 2.538-2.619zm.538 5.158-7.378 6.258a2.549 2.549 0 0 1 -3.253-.008l-7.369-6.248v10.222c0 .353.253.619.538.619h16.924c.285 0 .538-.266.538-.619zm-.538-3.158h-16.924c-.264 0-.5.228-.534.542l8.65 7.334c.2.165.492.165.684.007l8.656-7.342-.001-.025c-.044-.3-.274-.516-.531-.516z"/></symbol><symbol id="icon-eds-i-menu-medium" viewBox="0 0 24 24"><path d="M21 4a1 1 0 0 1 0 2H3a1 1 0 1 1 0-2h18Zm-4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2h14Zm4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2h18Z"/></symbol><symbol id="icon-eds-i-search-medium" viewBox="0 0 24 24"><path d="M11 1c5.523 0 10 4.477 10 10 0 2.4-.846 4.604-2.256 6.328l3.963 3.965a1 1 0 0 1-1.414 1.414l-3.965-3.963A9.959 9.959 0 0 1 11 21C5.477 21 1 16.523 1 11S5.477 1 11 1Zm0 2a8 8 0 1 0 0 16 8 8 0 0 0 0-16Z"/></symbol><symbol id="icon-eds-i-user-single-medium" viewBox="0 0 24 24"><path d="M12 1a5 5 0 1 1 0 10 5 5 0 0 1 0-10Zm0 2a3 3 0 1 0 0 6 3 3 0 0 0 0-6Zm-.406 9.008a8.965 8.965 0 0 1 6.596 2.494A9.161 9.161 0 0 1 21 21.025V22a1 1 0 0 1-1 1H4a1 1 0 0 1-1-1v-.985c.05-4.825 3.815-8.777 8.594-9.007Zm.39 1.992-.299.006c-3.63.175-6.518 3.127-6.678 6.775L5 21h13.998l-.009-.268a7.157 7.157 0 0 0-1.97-4.573l-.214-.213A6.967 6.967 0 0 0 11.984 14Z"/></symbol><symbol id="icon-eds-i-warning-filled-medium" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"/></symbol><symbol id="icon-expand-image" viewBox="0 0 18 18"><path d="m7.49754099 11.9178212c.38955542-.3895554.38761957-1.0207846-.00290473-1.4113089-.39324695-.3932469-1.02238878-.3918247-1.41130883-.0029047l-4.10273549 4.1027355.00055454-3.5103985c.00008852-.5603185-.44832171-1.006032-1.00155062-1.0059446-.53903074.0000852-.97857527.4487442-.97866268 1.0021075l-.00093318 5.9072465c-.00008751.553948.44841131 1.001882 1.00174994 1.0017946l5.906983-.0009331c.5539233-.0000875 1.00197907-.4486389 1.00206646-1.0018679.00008515-.5390307-.45026621-.9784332-1.00588841-.9783454l-3.51010549.0005545zm3.00571741-5.83449376c-.3895554.38955541-.3876196 1.02078454.0029047 1.41130883.393247.39324696 1.0223888.39182478 1.4113089.00290473l4.1027355-4.10273549-.0005546 3.5103985c-.0000885.56031852.4483217 1.006032 1.0015506 1.00594461.5390308-.00008516.9785753-.44874418.9786627-1.00210749l.0009332-5.9072465c.0000875-.553948-.4484113-1.00188204-1.0017499-1.00179463l-5.906983.00093313c-.5539233.00008751-1.0019791.44863892-1.0020665 1.00186784-.0000852.53903074.4502662.97843325 1.0058884.97834547l3.5101055-.00055449z" fill-rule="evenodd"/></symbol><symbol id="icon-github" viewBox="0 0 100 100"><path fill-rule="evenodd" clip-rule="evenodd" d="M48.854 0C21.839 0 0 22 0 49.217c0 21.756 13.993 40.172 33.405 46.69 2.427.49 3.316-1.059 3.316-2.362 0-1.141-.08-5.052-.08-9.127-13.59 2.934-16.42-5.867-16.42-5.867-2.184-5.704-5.42-7.17-5.42-7.17-4.448-3.015.324-3.015.324-3.015 4.934.326 7.523 5.052 7.523 5.052 4.367 7.496 11.404 5.378 14.235 4.074.404-3.178 1.699-5.378 3.074-6.6-10.839-1.141-22.243-5.378-22.243-24.283 0-5.378 1.94-9.778 5.014-13.2-.485-1.222-2.184-6.275.486-13.038 0 0 4.125-1.304 13.426 5.052a46.97 46.97 0 0 1 12.214-1.63c4.125 0 8.33.571 12.213 1.63 9.302-6.356 13.427-5.052 13.427-5.052 2.67 6.763.97 11.816.485 13.038 3.155 3.422 5.015 7.822 5.015 13.2 0 18.905-11.404 23.06-22.324 24.283 1.78 1.548 3.316 4.481 3.316 9.126 0 6.6-.08 11.897-.08 13.526 0 1.304.89 2.853 3.316 2.364 19.412-6.52 33.405-24.935 33.405-46.691C97.707 22 75.788 0 48.854 0z"/></symbol><symbol id="icon-springer-arrow-left"><path d="M15 7a1 1 0 000-2H3.385l2.482-2.482a.994.994 0 00.02-1.403 1.001 1.001 0 00-1.417 0L.294 5.292a1.001 1.001 0 000 1.416l4.176 4.177a.991.991 0 001.4.016 1 1 0 00-.003-1.42L3.385 7H15z"/></symbol><symbol id="icon-springer-arrow-right"><path d="M1 7a1 1 0 010-2h11.615l-2.482-2.482a.994.994 0 01-.02-1.403 1.001 1.001 0 011.417 0l4.176 4.177a1.001 1.001 0 010 1.416l-4.176 4.177a.991.991 0 01-1.4.016 1 1 0 01.003-1.42L12.615 7H1z"/></symbol><symbol id="icon-submit-open" viewBox="0 0 16 17"><path d="M12 0c1.10457 0 2 .895431 2 2v5c0 .276142-.223858.5-.5.5S13 7.276142 13 7V2c0-.512836-.38604-.935507-.883379-.993272L12 1H6v3c0 1.10457-.89543 2-2 2H1v8c0 .512836.38604.935507.883379.993272L2 15h6.5c.276142 0 .5.223858.5.5s-.223858.5-.5.5H2c-1.104569 0-2-.89543-2-2V5.828427c0-.530433.210714-1.039141.585786-1.414213L4.414214.585786C4.789286.210714 5.297994 0 5.828427 0H12Zm3.41 11.14c.250899.250899.250274.659726 0 .91-.242954.242954-.649606.245216-.9-.01l-1.863671-1.900337.001043 5.869492c0 .356992-.289839.637138-.647372.637138-.347077 0-.647371-.285256-.647371-.637138l-.001043-5.869492L9.5 12.04c-.253166.258042-.649726.260274-.9.01-.242954-.242954-.252269-.657731 0-.91l2.942184-2.951303c.250908-.250909.66127-.252277.91353-.000017L15.41 11.14ZM5 1.413 1.413 5H4c.552285 0 1-.447715 1-1V1.413ZM11 3c.276142 0 .5.223858.5.5s-.223858.5-.5.5H7.5c-.276142 0-.5-.223858-.5-.5s.223858-.5.5-.5H11Zm0 2c.276142 0 .5.223858.5.5s-.223858.5-.5.5H7.5c-.276142 0-.5-.223858-.5-.5s.223858-.5.5-.5H11Z" fill-rule="nonzero"/></symbol></svg>
</div>
</footer>




    

    

<div class="c-site-messages message u-hide u-hide-print c-site-messages--nature-briefing c-site-messages--nature-briefing-email-variant c-site-messages--nature-briefing-redesign-2020 sans-serif "
data-component-id="nature-briefing-banner"
data-component-expirydays="30"
data-component-trigger-scroll-percentage="15"
data-track="in-view"
data-track-action="in-view"
data-track-category="nature briefing"
data-track-label="Briefing banner visible: Flagship">

    
    <div class="c-site-messages__banner-large">

        
<div class="c-site-messages__close-container">
    <button class="c-site-messages__close"
        data-track="click"
        data-track-category="nature briefing"
        data-track-label="Briefing banner dismiss: Flagship">
        <svg width="25px" height="25px" focusable="false" aria-hidden="true" viewBox="0 0 25 25" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
            <title>Close banner</title>
            <defs></defs>
            <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd">
                <rect opacity="0" x="0" y="0" width="25" height="25"></rect>
                <path d="M6.29679575,16.2772478 C5.90020818,16.6738354 5.90240728,17.3100587 6.29617427,17.7038257 C6.69268654,18.100338 7.32864195,18.0973145 7.72275218,17.7032043 L12,13.4259564 L16.2772478,17.7032043 C16.6738354,18.0997918 17.3100587,18.0975927 17.7038257,17.7038257 C18.100338,17.3073135 18.0973145,16.671358 17.7032043,16.2772478 L13.4259564,12 L17.7032043,7.72275218 C18.0997918,7.32616461 18.0975927,6.68994127 17.7038257,6.29617427 C17.3073135,5.89966201 16.671358,5.90268552 16.2772478,6.29679575 L12,10.5740436 L7.72275218,6.29679575 C7.32616461,5.90020818 6.68994127,5.90240728 6.29617427,6.29617427 C5.89966201,6.69268654 5.90268552,7.32864195 6.29679575,7.72275218 L10.5740436,12 L6.29679575,16.2772478 Z" fill="#ffffff"></path>
            </g>
        </svg>
        <span class="visually-hidden">Close</span>
    </button>
</div>


        <div class="c-site-messages__form-container">

            <div class="grid grid-12 last">
                <div class="grid grid-4">
                    <img alt="Nature Briefing" src="/static/images/logos/nature-briefing-logo-n150-white-d81c9da3ec.svg" width="250" height="40">
                    <p class="c-site-messages--nature-briefing__strapline extra-tight-line-height">Sign up for the <em>Nature Briefing</em> newsletter — what matters in science, free to your inbox daily.</p>
                </div>
                <div class="grid grid-8 last">
                    <form action="https://www.nature.com/briefing/briefing" method="post" data-location="banner" data-track="submit||nature_briefing_sign_up" data-track-action="transmit-form" data-track-category="nature briefing" data-track-label="Briefing banner submit: Flagship">
                        <input id="briefing-banner-signup-form-input-track-originReferralPoint" type="hidden" name="track_originReferralPoint" value="MainBriefingBanner">
                        <input id="briefing-banner-signup-form-input-track-formType" type="hidden" name="track_formType" value="DirectEmailBanner">

                        <input type="hidden" value="false" name="gdpr_tick" id="gdpr_tick">
                        <input type="hidden" value="false" name="marketing" id="marketing">
                        <input type="hidden" value="false" name="marketing_tick" id="marketing_tick">
                        <input type="hidden" value="MainBriefingBanner" name="brieferEntryPoint" id="brieferEntryPoint">

                        <label class="nature-briefing-banner__email-label" for="emailAddress">Email address</label>

                        <div class="nature-briefing-banner__email-wrapper">
                            <input class="nature-briefing-banner__email-input box-sizing text14" type="email" id="emailAddress" name="emailAddress" value="" placeholder="e.g. jo.smith@university.ac.uk" required data-test-element="briefing-emailbanner-email-input">
                            
                            <input type="hidden" value="true" name="N:nature_briefing_daily" id="defaultNewsletter">
                            <button type="submit" class="nature-briefing-banner__submit-button box-sizing text14" data-test-element="briefing-emailbanner-signup-button">Sign up</button>
                        </div>

                        <div class="nature-briefing-banner__checkbox-wrapper grid grid-12 last">
                            <input class="nature-briefing-banner__checkbox-checkbox" id="gdpr-briefing-banner-checkbox" type="checkbox" name="gdpr" value="true" data-test-element="briefing-emailbanner-gdpr-checkbox" required>
                            <label class="nature-briefing-banner__checkbox-label box-sizing text13 sans-serif block tighten-line-height" for="gdpr-briefing-banner-checkbox">I agree my information will be processed in accordance with the <em>Nature</em> and Springer Nature Limited <a href="https://www.nature.com/info/privacy">Privacy Policy</a>.</label>
                        </div>
                    </form>
                </div>
            </div>

        </div>

    </div>

    
    <div class="c-site-messages__banner-small">

        
<div class="c-site-messages__close-container">
    <button class="c-site-messages__close"
        data-track="click"
        data-track-category="nature briefing"
        data-track-label="Briefing banner dismiss: Flagship">
        <svg width="25px" height="25px" focusable="false" aria-hidden="true" viewBox="0 0 25 25" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
            <title>Close banner</title>
            <defs></defs>
            <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd">
                <rect opacity="0" x="0" y="0" width="25" height="25"></rect>
                <path d="M6.29679575,16.2772478 C5.90020818,16.6738354 5.90240728,17.3100587 6.29617427,17.7038257 C6.69268654,18.100338 7.32864195,18.0973145 7.72275218,17.7032043 L12,13.4259564 L16.2772478,17.7032043 C16.6738354,18.0997918 17.3100587,18.0975927 17.7038257,17.7038257 C18.100338,17.3073135 18.0973145,16.671358 17.7032043,16.2772478 L13.4259564,12 L17.7032043,7.72275218 C18.0997918,7.32616461 18.0975927,6.68994127 17.7038257,6.29617427 C17.3073135,5.89966201 16.671358,5.90268552 16.2772478,6.29679575 L12,10.5740436 L7.72275218,6.29679575 C7.32616461,5.90020818 6.68994127,5.90240728 6.29617427,6.29617427 C5.89966201,6.69268654 5.90268552,7.32864195 6.29679575,7.72275218 L10.5740436,12 L6.29679575,16.2772478 Z" fill="#ffffff"></path>
            </g>
        </svg>
        <span class="visually-hidden">Close</span>
    </button>
</div>


        <div class="c-site-messages__content text14">
            <span class="c-site-messages--nature-briefing__strapline strong">Get the most important science stories of the day, free in your inbox.</span>
            <a class="nature-briefing__link text14 sans-serif"
                data-track="click"
                data-track-category="nature briefing"
                data-track-label="Small-screen banner CTA to site"
                data-test-element="briefing-banner-link"
                target="_blank"
                rel="noreferrer noopener"
                href="https://www.nature.com/briefing/signup/?brieferEntryPoint=MainBriefingBanner">Sign up for Nature Briefing
            </a>
        </div>

    </div>

</div>






<noscript>
    <img hidden src="https://verify.nature.com/verify/nature.png" width="0" height="0" style="display: none" alt="">
</noscript>




<script src="//content.readcube.com/ping?doi=10.1038/s41581-022-00642-4&amp;format=js&amp;last_modified=2023-02-06" async></script>
<img src="/c9rcpfjv/article/s41581-022-00642-4" width="1" height="1" alt="" class="u-visually-hidden">
</body>
</html>